Effects NNS N
of IN N
guided JJ N
imagery NN N
with IN N
relaxation NN 1_i
training NN 1_i
on IN N
anxiety NN 1_o
and CC N
quality NN 1_o
of IN 1_o
life NN 1_o
among IN N
patients NNS 1_p
with IN 1_p
inflammatory JJ 1_p
bowel NN 1_p
disease NN 1_p
. . 1_p

BACKGROUND NNP N
Inflammatory NNP N
Bowel NNP N
Disease NNP N
( ( N
IBD NNP N
) ) N
impacts VBZ N
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
. . 1_o

Psychological JJ N
factors NNS N
influence VBP N
the DT N
course NN N
of IN N
the DT N
disease NN N
and CC N
should MD N
be VB N
targeted VBN N
for IN N
intervention NN N
. . N

METHODS NNP N
Our PRP$ N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
randomised VBD N
control NN N
trial NN N
. . N

Fifty-six JJ 1_p
outpatients NNS 1_p
were VBD N
randomly RB N
chosen VBN N
and CC N
allocated VBN N
to TO N
a DT N
treatment NN N
group NN N
or CC N
a DT N
waiting-list JJ N
control NN N
group NN N
. . N

Treatment NNP N
group NN N
patients NNS N
attended VBD N
three CD N
relaxation-training JJ 1_i
sessions NNS 1_i
and CC N
received VBD N
an DT N
audio JJ N
disc NN N
for IN N
home NN N
practice NN N
. . N

Evaluations NNS N
performed VBD N
pre JJ N
and CC N
post-treatment JJ N
: : N
state NN 1_o
anxiety NN 1_o
was VBD 1_o
assessed VBN 1_o
with IN 1_o
the DT 1_o
State-Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
, , 1_o
QoL NNP 1_o
with IN 1_o
the DT 1_o
IBD NNP 1_o
Questionnaire NNP 1_o
. . 1_o

The DT 1_o
Visual NNP 1_o
Analogue NNP 1_o
Scale NNP 1_o
assessed VBD 1_o
pain NN 1_o
, , 1_o
depression NN 1_o
, , 1_o
stress NN 1_o
and CC 1_o
mood NN 1_o
. . 1_o

Patients NNS N
completed VBD N
a DT N
symptom JJ 1_o
monitoring NN 1_o
diary NN 1_o
. . 1_o

The DT N
control NN N
group NN N
's POS N
symptoms NNS N
were VBD N
monitored VBN N
without IN N
study-related JJ N
treatment NN N
. . N

RESULTS NNP N
Thirty-nine JJ 1_p
subjects NNS 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
and CC N
were VBD N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

Following VBG N
the DT N
relaxation-training JJ 1_i
intervention NN N
, , N
the DT N
treatment NN N
group NN N
's POS N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
measured VBN N
results NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
21 CD N
) ) N
( ( N
time NN N
by IN N
treatment NN N
interaction NN 1_o
) ) 1_o
: : 1_o
anxiety NN 1_o
levels NNS N
decreased VBN N
( ( 1_o
p JJ 1_o
< NNP 1_o
0.01 CD 1_o
) ) 1_o
, , 1_o
QoL NNP 1_o
and CC N
mood NN N
improved VBN N
( ( 1_o
p JJ 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
, , 1_o
while IN 1_o
levels NNS 1_o
of IN 1_o
pain NN N
and CC N
stress NN N
decreased VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Findings NNP N
indicate VBP N
IBD NNP N
patients NNS 1_i
may MD 1_i
benefit VB 1_i
from IN 1_i
relaxation NN N
training NN N
in IN N
their PRP$ N
holistic JJ N
care NN N
. . N

New NNP N
studies NNS N
as RB N
well RB N
as IN N
further JJ N
investigation NN N
of IN N
the DT N
subject NN N
are VBP N
warranted VBN N
. . N

Randomised VBN N
trial NN N
of IN N
text NN 1_i
messaging NN 1_i
on IN N
adherence NN 1_o
to TO 1_o
cardiovascular VB 1_o
preventive JJ 1_o
treatment NN 1_o
( ( N
INTERACT NNP N
trial NN N
) ) N
. . N

BACKGROUND CC N
About IN N
one CD N
third NN N
of IN N
patients NNS N
prescribed VBN N
blood JJ N
pressure NN N
or CC N
lipid-lowering JJ N
drugs NNS N
for IN N
the DT N
prevention NN N
of IN N
coronary JJ N
heart NN N
disease NN N
and CC N
stroke NN N
do VBP N
not RB N
take VB N
their PRP$ N
medication NN N
as IN N
prescribed JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
text JJ 1_i
messaging NN 1_i
as IN N
a DT N
means NN N
of IN N
improving VBG N
adherence NN 1_o
to TO 1_o
cardiovascular VB 1_o
disease NN 1_o
preventive JJ 1_o
treatment NN 1_o
. . 1_o

METHODS NNP N
303 CD 1_p
patients NNS 1_p
taking VBG 1_p
blood NN 1_p
pressure NN 1_p
and/or IN 1_p
lipid-lowering JJ 1_p
medications NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
being VBG N
sent VBN N
text NN 1_i
messages NNS 1_i
( ( 1_i
Text NNP 1_i
group NN N
, , N
151 CD N
) ) N
or CC N
not RB 1_i
being VBG 1_i
sent VBN 1_i
them PRP 1_i
( ( 1_i
No NNP 1_i
text NN 1_i
group NN N
, , N
152 CD N
) ) N
. . N

Texts NNP N
were VBD N
sent VBN N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
alternate JJ N
days NNS N
for IN N
2 CD N
weeks NNS N
and CC N
weekly JJ N
thereafter NN N
for IN N
22 CD N
weeks NNS N
( ( N
6 CD N
months NNS N
overall JJ N
) ) N
, , N
using VBG N
an DT N
automated VBN N
computer NN N
programme NN N
. . N

Patients NNS N
were VBD N
asked VBN N
to TO N
respond VB N
on IN N
whether IN N
they PRP N
had VBD N
taken VBN N
their PRP$ N
medication NN N
, , N
whether IN N
the DT N
text NN 1_i
reminded VBD N
them PRP N
to TO N
do VB N
so RB N
if IN N
they PRP N
had VBD N
forgotten VBN N
, , N
and CC N
if IN N
they PRP N
had VBD N
not RB N
taken VBN N
their PRP$ N
medication NN N
to TO N
determine VB N
if IN N
there EX N
was VBD N
a DT N
reason NN N
for IN N
not RB N
doing VBG N
so RB N
. . N

At IN N
6 CD N
months NNS N
, , N
use NN 1_o
of IN 1_o
medication NN 1_o
was VBD N
assessed VBN N
. . N

RESULTS NNP N
Two CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up NN N
, , N
providing VBG N
data NNS N
on IN N
301 CD N
for IN N
analysis NN N
. . N

In IN N
the DT N
No NNP N
text NN N
group NN N
38/151 CD N
( ( N
25 CD N
% NN N
) ) N
took VBD N
less JJR N
than IN N
80 CD N
% NN N
of IN N
the DT N
prescribed JJ 1_o
regimen NNS 1_o
( ( N
ie NN N
. . N

stopped VBD N
medication NN N
completely RB N
or CC N
took VBD N
it PRP N
on IN N
fewer JJR N
than IN N
22 CD N
of IN N
the DT N
last JJ N
28 CD N
days NNS N
of IN N
follow-up NN N
) ) N
compared VBN N
to TO N
14/150 CD N
patients NNS N
( ( N
9 CD N
% NN N
) ) N
in IN N
the DT N
Text NNP 1_i
group NN N
- : N
an DT N
improvement NN N
in IN N
adherence NN 1_o
affecting VBG N
16 CD N
per IN N
100 CD N
patients NNS N
( ( N
95 CD N
% NN N
CI NNP N
7 CD N
to TO N
24 CD N
) ) N
, , N
p JJ N
< NN N
0.001 CD N
. . N

The DT N
texts NN 1_i
reminded VBD N
98/151 CD N
patients NNS N
( ( N
65 CD N
% NN N
) ) N
to TO N
take VB N
medication NN N
on IN N
at IN N
least JJS N
one CD N
occasion NN N
and CC N
lead NN N
to TO N
20/151 CD N
( ( N
13 CD N
% NN N
) ) N
who WP N
stopped VBD 1_o
taking VBG 1_o
medication NN 1_o
because IN N
of IN N
concern NN N
over IN N
efficacy NN N
or CC N
side-effects NNS N
, , N
resuming VBG N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
taking VBG N
blood NN N
pressure NN N
or CC N
lipid-lowering JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ N
disease NN N
, , N
text NN 1_i
messaging NN 1_i
improved JJ N
medication NN 1_o
adherence NN 1_o
compared VBN N
with IN N
no DT 1_i
text NN 1_i
messaging NN 1_i
. . 1_i

TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN74757601 NNP N
. . N

[ JJ N
Effect NNP N
of IN N
liu NN 1_i
wei NN 1_i
di NN 1_i
huang NN 1_i
or CC N
jin NN 1_i
gui NN 1_i
shen NN 1_i
qi JJ 1_i
decoction NN N
as IN N
on IN N
adjuvant JJ N
treatment NN N
in IN N
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
] NNP 1_p
. . N

Eighty-three JJ 1_p
patients NNS 1_p
with IN 1_p
small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
were VBD N
randomized VBN N
with IN N
or CC N
without IN N
using VBG N
a DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP 1_i
decoction NN 1_i
( ( 1_i
Liu NNP 1_i
Wei NNP 1_i
Di NNP 1_i
Huang NNP 1_i
or CC N
Jin NNP 1_i
Gui NNP 1_i
Shen NNP 1_i
Qi NNP 1_i
medicinal JJ N
decoction NN N
) ) N
in IN N
chemotherapy NN N
or CC N
radiotherapy NN N
courses NNS N
. . N

74 CD 1_p
patients NNS 1_p
were VBD N
availble JJ N
to TO N
be VB N
analysis NN N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
well-matched JJ N
in IN N
age NN N
, , N
sex NN N
, , N
stage NN N
and CC N
performance NN N
status NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN 1_o
rate NN 1_o
and CC 1_o
the DT 1_o
median JJ 1_o
survival NN 1_o
between IN N
two CD N
groups NNS N
. . N

The DT N
overall JJ 1_o
response NN 1_o
rate NN 1_o
( ( N
CR+PR NNP N
) ) N
was VBD N
91.5 CD N
% NN N
for IN N
Chinese JJ 1_i
herb NN 1_i
group NN N
and CC N
46.9 CD N
% NN N
for IN N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
median JJ 1_o
survival NN 1_o
was VBD N
16 CD N
months NNS N
for IN N
the DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP 1_i
decoction NN 1_i
group NN N
, , N
and CC N
10 CD N
months NNS N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Survival JJ 1_o
curve NN 1_o
( ( 1_o
Kaplan-meire NNP 1_o
's POS 1_o
) ) 1_o
of IN N
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
. . N

10 CD N
patients NNS N
of IN N
Chinese JJ 1_i
herb NN 1_i
group NN N
was VBD N
alive JJ N
beyond IN N
more JJR N
than IN N
2 CD N
years NNS N
. . N

Until IN N
now RB N
, , N
4 CD N
patients NNS N
in IN N
the DT N
Chinese JJ 1_i
herb NN 1_i
group NN N
, , N
one CD N
in IN N
the DT N
control NN N
group NN N
are VBP N
still RB N
enjoying VBG N
their PRP$ N
disease-free JJ 1_o
life NN 1_o
for IN N
more JJR N
than IN N
7 CD N
years NNS N
. . N

Hematologic NNP 1_o
toxicities NNS 1_o
were VBD N
observed VBN N
much RB N
frequently RB N
in IN N
the DT N
patients NNS N
of IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
and CC N
0.01/WBC CD N
and CC N
BPC NNP N
) ) N
. . N

Results NNS N
of IN N
animal JJ N
experiments NNS N
with IN N
the DT N
same JJ N
traditional JJ N
medicinal JJ N
decoctions NNS N
as IN N
used VBN N
in IN N
clinic NN N
have VBP N
showed VBN N
immuno-enhancement JJ 1_o
activities NNS 1_o
. . 1_o

These DT N
results NNS N
have VBP N
showed VBN N
that IN N
the DT N
traditional JJ N
Chinese JJ 1_i
Kidney-tonifying NNP 1_i
decoction NN 1_i
may MD N
enhance VB N
non-specific JJ 1_o
immunology NN 1_o
activities NNS 1_o
and CC N
may MD N
be VB N
much JJ N
useful JJ N
for IN N
solid JJ 1_p
cancer NN 1_p
patients NNS 1_p
as IN N
an DT N
adjuvant JJ N
treatment NN N
. . N

Oral NNP 1_i
contraceptive NN 1_i
use NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
cardiovascular JJ 1_o
reactivity NN 1_o
in IN N
nonsmokers NNS 1_p
. . 1_p

Women NNS N
who WP N
smoke VBD N
and CC N
take VB N
oral JJ 1_i
contraceptives NNS 1_i
( ( 1_i
OCs NNP 1_i
) ) 1_i
have VBP N
significantly RB N
increased VBN N
risk NN N
of IN N
cardiovascular JJ 1_o
disease NN 1_o
, , N
but CC N
the DT N
exact JJ N
mechanismsfor VBZ N
the DT N
increased VBN N
risk NN N
are VBP N
not RB N
known VBN N
. . N

Cardiovascular JJ 1_o
reactivity NN 1_o
to TO N
psychological JJ N
stress NN N
may MD N
be VB N
one CD N
mechanism NN N
for IN N
the DT N
enhanced JJ N
risk NN N
, , N
but CC N
the DT N
small JJ N
number NN N
of IN N
studies NNS N
examining VBG N
whether IN N
OC NNP 1_i
users NNS N
who WP N
smoke VBP N
have VBP N
greater JJR N
reactivity NN N
have VBP N
produced VBN N
mixed JJ N
results NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
chronic JJ N
cigarette NN 1_i
smoking NN 1_i
, , N
acute JJ N
nicotine JJ 1_i
administration NN N
, , N
and CC N
OC NNP 1_i
use VBP N
on IN N
cardiovascular NN 1_o
and CC 1_o
lipid JJ 1_o
reactivity NN 1_o
. . 1_o

Sixty NNP 1_p
healthy JJ 1_p
women NNS 1_p
, , 1_p
half NN 1_p
of IN 1_p
whom WP 1_p
had VBD 1_p
been VBN 1_p
using VBG 1_p
OCs NNP 1_i
for IN 1_p
at IN 1_p
least JJS 1_p
the DT 1_p
previous JJ 1_p
6 CD 1_p
months NNS 1_p
, , N
participated VBN N
in IN N
the DT N
study NN N
. . N

Approximately RB N
two CD 1_p
thirds NNS 1_p
were VBD 1_p
smokers NNS 1_p
and CC N
were VBD N
randomized VBN N
to TO N
be VB N
tested VBN N
after IN N
either DT N
a DT N
12-hr JJ N
nicotine JJ 1_i
deprivation NN 1_i
or CC N
administration NN N
of IN N
nicotine JJ 1_i
gum NN N
. . N

One CD 1_p
third WDT 1_p
were VBD 1_p
nonsmokers NNS 1_p
. . 1_p

Heart NNP 1_o
rate NN 1_o
, , 1_o
blood NN 1_o
pressure NN 1_o
, , 1_o
and CC 1_o
lipid JJ 1_o
measures NNS 1_o
were VBD N
taken VBN N
at IN N
rest NN N
, , N
during IN N
a DT N
videotaped JJ N
speech NN N
task NN N
, , N
and CC N
during IN N
recovery NN N
from IN N
the DT N
task NN N
. . N

Results NNS N
indicated VBD N
that IN N
, , N
among IN N
OC NNP 1_i
nonusers NNS N
, , N
there EX N
was VBD N
no DT N
effect NN N
of IN N
smoking VBG N
status NN N
or CC N
nicotine JJ 1_i
administration NN N
on IN N
cardiovascular JJ N
reactivity NN N
. . N

However RB N
, , N
among IN N
OC NNP 1_i
users NNS N
, , N
nonsmokers NNS N
had VBD N
significantly RB N
greater JJR N
heart NN 1_o
rate NN 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
reactivity NN 1_o
to TO N
stress VB N
. . N

These DT N
data NNS N
show VBP N
that IN N
acute JJ N
nicotine JJ 1_i
administration NN N
, , N
in IN N
the DT N
form NN N
of IN N
nicotine JJ 1_i
gum NN N
, , N
has VBZ N
no DT N
effect NN N
on IN N
cardiovascular NN 1_o
or CC 1_o
lipid JJ 1_o
stress NN 1_o
reactivity NN 1_o
in IN N
women NNS 1_p
. . 1_p

However RB N
OC NNP 1_i
use NN N
among IN N
nonsmoking JJ 1_p
women NNS 1_p
is VBZ N
associated VBN N
with IN N
greater JJR N
cardiovascular JJ 1_o
reactivity NN 1_o
to TO N
stress VB N
. . N

Goal NNP 1_o
attainment NN 1_o
scaling NN 1_o
as IN N
an DT N
outcome NN N
measure NN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
psychosocial JJ 1_i
interventions NNS 1_i
in IN N
autism NN 1_p
. . 1_p

Goal NNP 1_o
attainment JJ 1_o
scaling NN 1_o
( ( 1_o
GAS NNP 1_o
) ) 1_o
holds VBZ N
promise NN N
as IN N
an DT N
idiographic JJ N
approach NN N
for IN N
measuring VBG N
outcomes NNS N
of IN N
psychosocial JJ 1_i
interventions NNS 1_i
in IN N
community NN N
settings NNS N
. . N

GAS NNP N
has VBZ N
been VBN N
criticized VBN N
for IN N
untested JJ N
assumptions NNS N
of IN N
scaling VBG 1_o
level NN 1_o
( ( N
i.e. JJ N
, , N
interval JJ N
or CC N
ordinal JJ N
) ) N
, , N
inter-individual JJ 1_o
equivalence NN 1_o
and CC N
comparability NN 1_o
, , N
and CC N
reliability NN 1_o
of IN 1_o
coding VBG 1_o
across IN 1_o
different JJ 1_o
behavioral JJ 1_o
observation NN 1_o
methods NNS 1_o
. . 1_o

We PRP N
tested VBD N
assumptions NNS 1_o
of IN 1_o
equality NN 1_o
between IN N
GAS NNP N
descriptions NNS N
for IN N
outcome JJ N
measurement NN N
in IN N
a DT N
randomized JJ N
trial NN N
( ( N
i.e. FW N
, , N
measurability NN 1_o
, , 1_o
equidistance NN 1_o
, , 1_o
level NN 1_o
of IN 1_o
difficulty NN 1_o
, , 1_o
comparability NN 1_o
of IN 1_o
behavior NN 1_o
samples NNS 1_o
collected VBN 1_o
from IN 1_o
teachers NNS 1_o
vs. FW 1_o
researchers NNS 1_o
and CC 1_o
live JJ 1_o
vs. FW 1_o
videotape NN 1_o
) ) 1_o
. . N

Results NNP N
suggest VBP N
GAS NNP 1_o
descriptions NNS N
can MD N
be VB N
evaluated VBN N
for IN N
equivalency NN N
, , N
that IN N
teacher RB N
collected VBN N
behavior NN N
samples NNS N
are VBP N
representative JJ N
, , N
and CC N
that IN N
varied JJ N
sources NNS N
of IN N
behavior NN N
samples NNS N
can MD N
be VB N
reliably RB N
coded VBN N
. . N

GAS NNP 1_o
is VBZ N
a DT N
promising JJ N
measurement NN N
approach NN N
. . N

Recommendations NNS N
are VBP N
provided VBN N
to TO N
ensure VB N
methodological JJ N
quality NN N
. . N

Clinical JJ 1_o
performance NN 1_o
of IN N
the DT N
Reichert NNP 1_i
AT550 NNP 1_i
: : 1_i
a DT N
new JJ N
non-contact JJ N
tonometer NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
level NN 1_o
of IN 1_o
accuracy NN 1_o
for IN N
measurements NNS 1_o
of IN 1_o
intra-ocular JJ 1_o
pressure NN 1_o
( ( 1_o
IOP NNP 1_o
) ) 1_o
obtained VBD N
with IN N
a DT N
new JJ N
non-contact JJ N
tonometer NN N
( ( N
NCT NNP N
) ) N
the DT N
Reichert NNP 1_i
AT550 NNP 1_i
. . 1_i

Measurements NNS N
were VBD N
compared VBN N
against IN N
those DT N
obtained VBN N
with IN N
the DT N
Reichert NNP 1_i
Xpert NNP 1_i
Plus NNP 1_i
, , 1_i
Goldmann NNP 1_i
applanation NN 1_i
tonometer NN 1_i
and CC N
Perkins NNP 1_i
tonometer NN 1_i
. . 1_i

Thirty-five JJ 1_p
university NN 1_p
students NNS 1_p
were VBD 1_p
assessed VBN 1_p
with IN N
the DT N
four CD N
tonometers NNS N
in IN N
a DT N
randomised JJ N
order NN N
, , N
with IN N
non-contact JJ N
tonometry NN N
performed VBD N
first RB N
. . N

Each DT N
of IN N
the DT N
four CD N
measurement NN N
devices NNS N
had VBD N
its PRP$ N
own JJ N
trained JJ N
clinical JJ N
observer NN N
. . N

Plots NNP N
of IN N
differences NNS N
of IN N
IOP NNP 1_o
as IN N
a DT N
function NN N
of IN N
the DT N
mean NN N
for IN N
each DT N
pair NN N
of IN N
instruments NNS N
were VBD N
obtained VBN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
when WRB N
comparing VBG N
the DT N
AT550 NNP 1_i
NCT NNP 1_i
with IN N
contact JJ N
applanation NN N
tonometry NN N
( ( N
AT NNP N
) ) N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
, , N
displaying VBG N
the DT N
closest JJS N
level NN N
of IN N
agreement NN N
( ( N
as IN N
represented VBN N
by IN N
the DT N
lowest JJS N
mean JJ N
difference NN N
and CC N
the DT N
narrowest JJS N
confidence NN N
interval NN N
) ) N
with IN N
the DT N
Goldmann NNP 1_i
tonometer NN 1_i
( ( N
limits NNS N
of IN N
agreement NN N
, , N
0.12+/-2.17 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
readings NNS N
of IN N
IOP NNP 1_o
with IN N
the DT N
AT550 NNP 1_i
NCT NNP 1_i
are VBP N
clinically RB N
comparable JJ N
with IN N
those DT N
obtained VBN N
with IN N
Goldmann NNP 1_i
tonometry NN 1_i
in IN N
a DT N
population NN N
with IN N
IOP NNP 1_o
within IN N
the DT N
normal JJ N
range NN N
. . N

Trial JJ N
design NN N
challenges NNS N
when WRB N
combining VBG N
medication NN 1_i
and CC N
parent NN 1_i
training NN 1_i
in IN N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental NN 1_p
disorders NNS 1_p
. . 1_p

This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
for IN N
a DT N
24-week JJ N
, , N
randomized JJ N
trial NN N
designed VBN N
to TO N
test VB N
whether IN N
risperidone NN 1_i
plus CC N
structured JJ 1_i
parent NN 1_i
training NN 1_i
would MD N
be VB N
superior JJ N
to TO N
risperidone VB 1_i
only RB N
on IN N
measures NNS N
of IN N
noncompliance NN 1_o
, , 1_o
irritability NN 1_o
and CC 1_o
adaptive JJ 1_o
functioning NN 1_o
. . 1_o

In IN N
this DT N
model NN N
, , N
medication NN N
reduces NNS N
tantrums NNS 1_o
, , 1_o
aggression NN 1_o
and CC 1_o
self-injury NN 1_o
; : 1_o
parent NN N
training NN N
promotes NNS N
improvement NN N
in IN N
noncompliance NN 1_o
and CC 1_o
adaptive JJ 1_o
functioning NN 1_o
. . 1_o

Thus RB N
, , N
medication NN 1_i
and CC N
parent NN 1_i
training NN 1_i
target NN N
related VBN N
, , N
but CC N
separate JJ N
, , N
outcomes RB N
. . N

At IN N
week NN N
24 CD N
, , N
the DT N
medication NN 1_i
was VBD N
gradually RB N
withdrawn VBN N
to TO N
determine VB N
whether IN N
subjects NNS N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
could MD N
be VB N
managed VBN N
on IN N
a DT N
lower JJR N
dose NN N
or CC N
off IN N
medication NN N
without IN N
relapse NN N
. . N

Both DT N
symptom JJ 1_o
reduction NN N
and CC N
functional JJ 1_o
improvement NN N
are VBP N
important JJ N
clinical JJ N
treatment NN N
targets NNS N
. . N

Thus RB N
, , N
experimental JJ N
evidence NN N
on IN N
the DT N
beneficial JJ N
effects NNS 1_o
of IN N
combining VBG N
pharmacotherapy NN N
and CC N
exportable JJ N
behavioral JJ N
interventions NNS N
is VBZ N
needed VBN N
to TO N
guide VB N
clinical JJ N
practice NN N
. . N

[ RB N
Clinical NNP N
study NN N
on IN N
treatment NN N
of IN N
endometriosis-related JJ 1_p
infertility NN 1_p
patients NNS 1_p
by IN N
laparoscopic NN 1_i
surgery NN 1_i
in IN N
combination NN N
of IN N
quyu JJ 1_i
jiedu NN 1_i
recipe NN 1_i
] NNP 1_i
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ 1_o
efficacy NN 1_o
of IN N
the DT N
laparoscopic NN 1_i
surgery NN 1_i
in IN N
combination NN N
of IN N
Quyu NNP 1_i
Jiedu NNP 1_i
Recipe NNP 1_i
( ( 1_i
QYJDR NNP 1_i
) ) 1_i
on IN N
endometriosis NN 1_p
( ( 1_p
EMs NNP 1_p
) ) 1_p
-related VBD 1_p
infertility NN 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
130 CD 1_p
EMs-related JJ 1_p
infertility NN 1_p
patients NNS 1_p
of IN 1_p
blood NN 1_p
stasis NN 1_p
and CC 1_p
toxin NN 1_p
accumulation NN 1_p
syndrome NN 1_p
diagnosed VBD 1_p
and CC 1_p
treated VBN 1_p
by IN 1_p
laparoscopic NN 1_p
surgery NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
i.e. FW N
, , N
the DT N
test NN N
group NN N
( ( N
75 CD N
cases NNS N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
55 CD N
cases NNS N
) ) N
. . N

All DT N
patients NNS N
received VBD N
routine JJ N
progesterone NN 1_i
treatment NN N
after IN N
laparoscopic NN N
surgery NN N
. . N

QYJDR NNP 1_i
was VBD N
given VBN N
to TO N
patients NNS N
in IN N
the DT N
test NN N
group NN N
after IN N
laparoscopic NN N
surgery NN N
, , N
lasting VBG N
for IN N
twelve JJ N
months NNS N
. . N

The DT N
pregnancy NN 1_o
rate NN 1_o
within IN 1_o
one CD 1_o
year NN 1_o
after IN 1_o
laparoscopic NN 1_o
surgery NN 1_o
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
Chinese JJ 1_o
medicine NN 1_o
syndrome NN 1_o
integrals NNS 1_o
, , 1_o
serum JJ 1_o
endometrium NN 1_o
antibody NN 1_o
( ( 1_o
EMAb NNP 1_o
) ) 1_o
and CC 1_o
cancer NN 1_o
antigen NN 1_o
125 CD 1_o
( ( 1_o
CA125 NNP 1_o
) ) 1_o
levels NNS 1_o
were VBD N
compared VBN N
between IN N
before RB N
drug NN N
therapy NN N
and CC N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
. . N

RESULTS VB N
The DT N
pregnancy NN 1_o
rate NN 1_o
within IN N
one CD N
year NN N
after IN N
laparoscopic NN N
surgery NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
[ VBD N
61.33 CD N
% NN N
( ( N
46/75 CD N
) ) N
vs FW N
45.45 CD N
% NN N
( ( N
25/55 CD N
) ) N
] NN N
, , N
showing VBG N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
Chinese JJ 1_o
medicine NN 1_o
syndrome JJ 1_o
integral NN 1_o
was VBD N
( ( N
16.07 CD N
+/- JJ N
6.77 CD N
) ) N
score NN N
and CC N
( ( N
7.25 CD N
+/- JJ N
3.27 CD N
) ) N
score NN N
before IN N
and CC N
3 CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
, , N
while IN N
it PRP N
was VBD N
( ( N
15.92 CD N
+/- JJ N
7.51 CD N
) ) N
score NN N
and CC N
( ( N
12.73 CD N
+/- JJ N
6.12 CD N
) ) N
score NN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
Chinese JJ 1_o
medicine NN 1_o
syndrome JJ 1_o
integral JJ 1_o
after IN N
drug NN N
therapy NN N
was VBD N
lower JJR N
than IN N
that DT N
before IN N
drug NN N
therapy NN N
in IN N
the DT N
same JJ N
group NN N
. . N

Besides IN N
, , N
the DT N
integral JJ 1_o
difference NN N
between IN N
before IN N
and CC N
after IN N
drug NN N
therapy NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
[ NNP N
( ( N
9.12 CD N
+/- JJ N
6.16 CD N
) ) N
score NN N
vs NN N
( ( N
3.48 CD N
+/- JJ N
2.06 CD N
) ) N
score NN N
) ) N
] NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
three-month JJ N
drug NN N
therapy NN N
, , N
the DT N
serum NN 1_o
EMAb NNP 1_o
negative JJ N
conversion NN N
rate NN N
was VBD N
obviously RB N
higher JJR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
44.44 CD N
% NN N
vs JJ N
15.62 CD N
% NN N
) ) N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
serum NN 1_o
CA125 NNP 1_o
level NN 1_o
was VBD N
( ( N
31.88 CD N
+/- JJ N
15.78 CD N
) ) N
U/mL NNP N
before IN N
drug NN N
therapy NN N
and CC N
( ( N
18.82 CD N
+/- JJ N
10.08 CD N
) ) N
U/mL NNP N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
, , N
while IN N
it PRP N
was VBD N
( ( N
30.63 CD N
+/- JJ N
19.28 CD N
) ) N
U/mL NN N
and CC N
( ( N
18.05 CD N
+/- JJ N
11.20 CD N
) ) N
U/mL NNP N
respectively RB N
in IN N
the DT N
control NN N
group NN N
. . N

It PRP N
was VBD N
lowered VBN N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
two CD N
groups NNS N
with IN N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
drug NN N
therapy NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
laparoscopic NN 1_i
surgery NN 1_i
in IN N
combination NN N
of IN N
QYJDR NNP 1_i
could MD N
effectively RB N
improve VB N
clinical JJ 1_o
symptoms NNS 1_o
of IN N
EMs NNP 1_p
patients NNS 1_p
of IN 1_p
blood NN 1_o
stasis NN 1_o
and CC 1_o
toxin NN 1_o
accumulation NN 1_o
syndrome NN 1_o
, , N
promote VBP N
negative JJ 1_o
conversion NN 1_o
of IN 1_o
EMAb NNP 1_o
, , N
lower JJR N
serum NN 1_o
CA125 NNP 1_o
levels NNS 1_o
, , N
and CC N
elevate VB N
the DT N
clinical JJ 1_o
pregnancy NN 1_o
rate NN 1_o
. . 1_o

QYJDR NNP 1_i
is VBZ N
an DT N
effective JJ N
formula NN N
in IN N
treatment NN N
of IN N
EMs-related JJ 1_p
infertility NN 1_p
. . 1_p

Why WRB N
were VBD N
the DT N
results NNS N
of IN N
the DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
( ( N
HOPE NNP N
) ) N
trial NN N
so IN N
astounding VBG N
? . N
The DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
( ( N
HOPE NNP N
) ) N
study NN N
was VBD N
important JJ N
because IN N
it PRP N
showed VBD N
the DT N
benefits NNS N
of IN N
ramipril NN 1_i
- : N
an DT N
angiotensin-converting JJ 1_i
enzyme NN 1_i
( ( 1_i
ACE NNP 1_i
) ) 1_i
inhibitor NN 1_i
- : N
in IN N
patients NNS 1_p
at IN 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
cardiovascular JJ 1_p
events NNS 1_p
. . 1_p

Treatment NN N
with IN N
ramipril NN 1_i
significantly RB N
reduced VBD N
the DT N
rates NNS 1_o
of IN 1_o
death NN 1_o
, , 1_o
myocardial JJ 1_o
infarction NN 1_o
, , 1_o
stroke NN 1_o
, , 1_o
coronary JJ 1_o
revascularization NN 1_o
, , 1_o
cardiac JJ 1_o
arrest NN 1_o
and CC 1_o
heart NN 1_o
failure NN 1_o
, , N
as RB N
well RB N
as IN N
the DT N
risk NN 1_o
of IN 1_o
diabetes-related JJ 1_o
complications NNS 1_o
and CC 1_o
of IN 1_o
diabetes NNS 1_o
itself PRP 1_o
. . 1_o

The DT N
effects NNS N
of IN N
therapy NN N
with IN N
vitamin JJ 1_i
E NN 1_i
were VBD N
also RB N
evaluated VBN N
, , N
but CC N
no DT N
statistical JJ N
benefits NNS N
were VBD N
shown VBN N
. . N

The DT N
benefits NNS N
of IN N
ACE NNP 1_i
inhibitor NN 1_i
therapy NN N
that WDT N
were VBD N
observed VBN N
were VBD N
likely JJ N
due JJ N
to TO N
a DT N
variety NN N
of IN N
mechanisms NNS N
, , N
not RB N
just RB N
a DT N
reduction NN N
in IN N
blood NN N
pressure NN N
. . N

Randomized VBN N
trial NN N
of IN N
intensive JJ 1_i
early JJ 1_i
intervention NN 1_i
for IN N
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
. . 1_p

Young NNP 1_p
children NNS 1_p
with IN 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
intensive VB 1_i
treatment NN 1_i
or CC N
parent NN 1_i
training NN 1_i
. . 1_i

The DT N
intensive JJ 1_i
treatment NN 1_i
group NN N
( ( 1_p
7 CD 1_p
with IN 1_p
autism NN 1_p
, , 1_p
8 CD 1_p
with IN 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
not RB 1_p
otherwise RB 1_p
specified VBN 1_p
-- : 1_p
NOS NNP 1_p
) ) 1_p
averaged VBD N
24.52 CD N
hours NNS N
per IN N
week NN N
of IN N
individual JJ N
treatment NN N
for IN N
one CD N
year NN N
, , N
gradually RB N
reducing VBG N
hours NNS N
over IN N
the DT N
next JJ N
1 CD N
to TO N
2 CD N
years NNS N
. . N

The DT N
parent NN 1_i
training NN 1_i
group NN N
( ( 1_p
7 CD 1_p
with IN 1_p
autism NN 1_p
, , 1_p
6 CD 1_p
with IN 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
NOS NNP 1_p
) ) 1_p
received VBD N
3 CD N
to TO N
9 CD N
months NNS N
of IN N
parent NN 1_i
training NN 1_i
. . 1_i

The DT N
groups NNS N
appeared VBD N
similar JJ N
at IN N
intake NN N
on IN N
all DT N
measures NNS N
; : N
however RB N
, , N
at IN N
follow-up JJ N
the DT N
intensive JJ 1_i
treatment NN 1_i
group NN N
outperformed VBD N
the DT N
parent NN 1_i
training VBG 1_i
group NN N
on IN N
measures NNS N
of IN N
intelligence NN 1_o
, , 1_o
visual-spatial JJ 1_o
skills NNS 1_o
, , 1_o
language NN 1_o
, , 1_o
and CC 1_o
academics NNS 1_o
, , N
though IN N
not RB N
adaptive JJ 1_o
functioning NN 1_o
or CC N
behavior NN 1_o
problems NNS 1_o
. . 1_o

Children NNP 1_p
with IN 1_p
pervasive JJ 1_p
developmental JJ 1_p
disorder NN 1_p
NOS NNP 1_p
may MD N
have VB N
gained VBN N
more JJR N
than IN N
those DT N
with IN N
autism NN 1_p
. . 1_p

Combined VBN 1_i
descriptive JJ 1_i
and CC 1_i
explanatory JJ 1_i
information NN 1_i
improves VBZ N
peers NNS 1_o
' POS 1_o
perceptions NNS 1_o
of IN N
autism NN N
. . N

Authors NNS N
examined VBD N
the DT N
combined JJ N
effects NNS N
of IN N
descriptive JJ 1_i
and CC 1_i
explanatory JJ 1_i
information NN 1_i
on IN N
peers NNS 1_o
' POS 1_o
perceptions NNS 1_o
and CC 1_o
behavioral JJ 1_o
intentions NNS 1_o
toward IN N
an DT N
unfamiliar JJ N
child NN 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Children NNP 1_p
( ( 1_p
N NNP 1_p
= NNP 1_p
576 CD 1_p
; : 1_p
M NNP 1_p
age NN 1_p
= VBD 1_p
10.06 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
two CD N
videotapes NNS N
of IN N
a DT N
boy NN N
engaging VBG N
in IN N
typical JJ N
and CC N
autistic JJ N
behaviors NNS N
receiving VBG N
either RB N
descriptive JJ 1_i
( ( 1_i
AUT-D NNP 1_i
) ) 1_i
or CC N
descriptive JJ 1_i
and CC 1_i
explanatory JJ 1_i
information NN 1_i
( ( 1_i
AUT-D NNP 1_i
+ NNP 1_i
E NNP 1_i
) ) 1_i
. . 1_i

Children NNP N
responded VBD N
to TO N
measures NNS 1_o
of IN 1_o
attitudes NNS 1_o
( ( 1_o
Adjective NNP 1_o
Checklist NNP 1_o
) ) 1_o
and CC 1_o
behavioral JJ 1_o
intentions NNS 1_o
( ( 1_o
Shared NNP 1_o
Activities NNP 1_o
Questionnaire NNP 1_o
) ) 1_o
. . 1_o

Children NNP N
rated VBD N
the DT N
typical JJ N
boy NN N
more RBR N
favorably RB N
than IN N
the DT N
boy NN N
showing VBG N
autistic JJ N
symptoms NNS N
. . N

When WRB N
compared VBN N
to TO N
descriptive VB 1_i
information NN 1_i
alone RB N
, , N
the DT N
combination NN 1_i
of IN 1_i
descriptive JJ 1_i
and CC 1_i
explanatory JJ 1_i
information NN 1_i
resulted VBD N
in IN N
improved JJ N
third- JJ N
and CC N
fourth-graders NNS N
' '' N
but CC N
not RB N
fifth-graders NNS N
' POS N
attitudes NNS N
toward IN N
the DT N
child NN N
with IN N
autism NN N
. . N

Combined VBN N
information NN N
improved VBN N
behavioral JJ 1_o
intentions NNS 1_o
across IN N
grades NNS N
; : N
however RB N
, , N
girls NNS N
( ( N
vs. FW N
boys NNS N
) ) N
were VBD N
more RBR N
responsive JJ N
to TO N
information NN N
as IN N
evidenced VBN N
by IN N
differences NNS N
in IN N
academic JJ 1_o
intentions NNS 1_o
. . 1_o

The DT N
combination NN 1_i
of IN 1_i
descriptive JJ 1_i
and CC 1_i
explanatory JJ 1_i
information NN 1_i
about IN N
autism NN N
appears VBZ N
to TO N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
children NNS 1_o
's POS 1_o
attitudes NNS 1_o
and CC 1_o
behavioral JJ 1_o
intentions NNS 1_o
. . 1_o

Implications NNS N
of IN N
the DT N
findings NNS N
are VBP N
briefly RB N
discussed VBN N
as RB N
well RB N
as IN N
study NN N
limitations NNS N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
. . N

Distinct NNP N
fast RB N
and CC N
slow VB N
processes NNS N
contribute VBP N
to TO N
the DT N
selection NN N
of IN N
preferred JJ N
step NN N
frequency NN N
during IN N
human JJ 1_p
walking VBG N
. . N

Humans NNPS N
spontaneously RB N
select VB N
a DT N
step NN 1_o
frequency NN 1_o
that WDT N
minimizes VBZ N
the DT N
energy NN N
expenditure NN N
of IN N
walking VBG N
. . N

This DT N
selection NN N
might MD N
be VB N
embedded VBN N
within IN N
the DT N
neural JJ N
circuits NNS N
that WDT N
generate VBP N
gait NNS N
so RB N
that IN N
the DT N
optimum NN N
is VBZ N
pre-programmed JJ N
for IN N
a DT N
given VBN N
walking VBG N
speed NN N
. . N

Or CC N
perhaps RB N
step JJ N
frequency NN N
is VBZ N
directly RB N
optimized VBN N
, , N
based VBN N
on IN N
sensed JJ N
feedback NN N
of IN N
energy NN N
expenditure NN N
. . N

Direct JJ N
optimization NN N
is VBZ N
expected VBN N
to TO N
be VB N
slow JJ N
due JJ N
to TO N
the DT N
compounded JJ N
effect NN N
of IN N
delays NNS N
and CC N
iteration NN N
, , N
whereas IN N
a DT N
pre-programmed JJ N
mechanism NN N
presumably RB N
allows VBZ N
for IN N
faster JJR N
step NN N
frequency NN N
selection NN N
, , N
albeit JJ N
dependent NN N
on IN N
prior JJ N
experience NN N
. . N

To TO N
test VB N
for IN N
both DT N
pre-programmed JJ N
selection NN N
and CC N
direct JJ N
optimization NN N
, , N
we PRP N
applied VBD N
perturbations NNS 1_i
to TO 1_i
treadmill VB 1_i
walking VBG 1_i
to TO N
elicit VB N
transient JJ N
changes NNS N
in IN N
step NN N
frequency NN N
. . N

We PRP N
found VBD N
that IN N
human JJ 1_o
step NN 1_o
frequency NN 1_o
adjustments NNS 1_o
( ( N
n JJ N
= NNP N
7 CD N
) ) N
occurred VBD N
with IN N
two CD N
components NNS N
, , N
the DT N
first JJ N
dominating VBG N
the DT N
response NN N
( ( N
66 CD N
± RB N
10 CD N
% NN N
of IN N
total JJ N
amplitude JJ N
change NN N
; : N
mean JJ N
± NNP N
SD NNP N
) ) N
and CC N
occurring VBG N
quite RB 1_o
quickly RB 1_o
( ( N
1.44 CD N
± RB N
1.14 CD N
s NNS N
to TO N
complete VB N
95 CD N
% NN N
of IN N
total JJ N
change NN N
) ) N
. . N

The DT N
other JJ N
component NN N
was VBD N
of IN N
smaller JJR 1_o
amplitude NN 1_o
( ( N
35 CD N
± RB N
10 CD N
% NN N
of IN N
total JJ N
change NN N
) ) N
and CC N
took VBD N
tens NNS 1_o
of IN 1_o
seconds NNS 1_o
( ( N
27.56 CD N
± RB N
16.18 CD N
s NN N
for IN N
95 CD N
% NN N
completion NN N
) ) N
. . N

The DT N
fast JJ N
process NN N
appeared VBD N
to TO N
be VB N
too RB N
fast JJ N
for IN N
direct JJ N
optimization NN N
and CC N
more RBR N
indicative JJ N
of IN N
a DT N
pre-programmed JJ N
response NN N
. . N

It PRP N
also RB N
persisted VBD N
even RB N
with IN N
unusual JJ N
closed-loop JJ N
perturbations NNS N
that WDT N
conflicted VBD N
with IN N
prior JJ N
experience NN N
and CC N
rendered VBD N
the DT N
response NN N
energetically RB N
suboptimal JJ N
. . N

The DT N
slow JJ N
process NN N
was VBD N
more RBR N
consistent JJ N
with IN N
the DT N
timing NN N
expected VBN N
for IN N
direct JJ N
optimization NN N
. . N

Our PRP$ N
interpretation NN N
of IN N
these DT N
results NNS N
is VBZ N
that IN N
humans NNS N
may MD N
rely VB N
heavily RB N
on IN N
pre-programmed JJ N
gaits NNS N
to TO N
rapidly RB N
select VB N
their PRP$ N
preferred JJ 1_o
step NN 1_o
frequency NN 1_o
and CC N
then RB N
gradually RB N
fine-tune JJ N
that IN N
selection NN N
with IN N
direct JJ N
optimization NN N
. . N

Effect NN N
of IN N
the DT N
essential JJ 1_i
oils NNS 1_i
of IN 1_i
garlic NN 1_i
and CC 1_i
onion NN 1_i
on IN N
alimentary JJ N
hyperlipemia NN N
. . N

SUMMARY VB N
The DT N
effect NN N
of IN N
garlic NN 1_i
and CC 1_i
onion NN 1_i
on IN N
alimentary JJ N
hyperlipemia NN N
, , N
induced VBN N
by IN N
feeding VBG N
100 CD N
g JJ N
butter NN N
, , N
has VBZ N
been VBN N
studied VBN N
in IN N
10 CD 1_p
healthy JJ 1_p
subjects NNS 1_p
. . 1_p

The DT N
freshly RB N
extracted JJ N
juice NN N
of IN N
50 CD N
g NN N
of IN N
garlic NN 1_i
or CC 1_i
onion NN 1_i
, , N
as RB N
well RB N
as IN N
an DT N
equivalent JJ N
amount NN N
of IN N
their PRP$ N
ether-extracted JJ N
essential JJ 1_i
oils NNS 1_i
, , N
was VBD N
administered VBN N
randomly RB N
on IN N
four CD N
different JJ N
days NNS N
during IN N
a DT N
one-week JJ N
period NN N
. . N

Garlic NNP 1_i
and CC 1_i
onion NN 1_i
have VBP N
a DT N
significant JJ N
protective JJ N
action NN N
against IN N
fat-induced JJ N
increases NNS N
in IN N
serum NN 1_o
cholesterol NN 1_o
and CC 1_o
plasma NN 1_o
fibrinogen NN 1_o
and CC N
decreases NNS N
in IN N
coagulation NN 1_o
time NN 1_o
and CC N
fibrinolytic JJ 1_o
activity NN 1_o
. . 1_o

The DT N
essential JJ 1_i
oil NN 1_i
fraction NN N
, , N
which WDT N
contains VBZ N
all PDT N
the DT N
taste NN N
and CC N
odour NN N
, , N
exactly RB N
duplicated VBD N
the DT N
beneficial JJ N
effects NNS 1_o
of IN N
whole JJ N
garlic NN 1_i
and CC N
onion NN 1_i
. . 1_i

It PRP N
is VBZ N
, , N
therefore RB N
, , N
concluded VBD N
that IN N
the DT N
active JJ N
principle NN N
of IN N
garlic JJ 1_i
and CC 1_i
onion NN 1_i
is VBZ N
the DT N
essential JJ 1_i
oil NN 1_i
, , N
which WDT N
chemically RB N
is VBZ N
a DT N
combination NN N
of IN N
sulphur-containing JJ N
compounds NNS N
, , N
mainly RB N
allyl VBZ N
propyl JJ N
disulphide NN N
and CC N
diallyl JJ N
disulphide NN N
. . N

Intermediate-term JJ 1_o
mortality NN 1_o
and CC 1_o
cardiac JJ 1_o
transplantation NN 1_o
in IN N
infants NNS 1_p
with IN 1_p
single-ventricle JJ 1_p
lesions NNS 1_p
: : 1_p
risk NN 1_o
factors NNS 1_o
and CC N
their PRP$ N
interaction NN N
with IN N
shunt NN N
type NN N
. . N

OBJECTIVE CC N
The DT N
study NN N
objective NN N
was VBD N
to TO N
identify VB N
factors NNS 1_o
associated VBN 1_o
with IN 1_o
death NN 1_o
and CC 1_o
cardiac JJ 1_o
transplantation NN 1_o
in IN N
infants NNS 1_p
undergoing VBG 1_p
the DT 1_p
Norwood NNP 1_p
procedure NN 1_p
and CC N
to TO N
determine VB N
differences NNS N
in IN N
associations NNS N
that WDT N
might MD N
favor VB N
the DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
or CC N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
. . N

METHODS NNP N
We PRP N
used VBD N
competing VBG N
risks NNS N
methodology NN N
to TO N
analyze VB N
death NN 1_o
without IN 1_o
transplantation NN 1_o
, , 1_o
cardiac JJ 1_o
transplantation NN 1_o
, , 1_o
and CC 1_o
survival NN 1_o
without IN 1_o
transplantation NN 1_o
. . 1_o

Parametric NNP 1_o
time-to-event JJ 1_o
modeling NN 1_o
and CC 1_o
bootstrapping NN 1_o
were VBD 1_o
used VBN 1_o
to TO 1_o
identify VB 1_o
independent JJ 1_o
predictors NNS 1_o
. . 1_o

RESULTS NNP N
Data NNP N
from IN N
549 CD 1_p
subjects NNS 1_p
( ( 1_p
follow-up JJ 1_p
, , 1_p
2.7 CD 1_p
± JJ 1_p
0.9 CD 1_p
years NNS 1_p
) ) 1_p
were VBD N
analyzed VBN N
. . 1_o

Mortality NNP 1_o
risk NN 1_o
was VBD N
characterized VBN N
by IN N
early JJ N
and CC N
constant JJ N
phases NNS N
; : N
transplant NN N
was VBD N
characterized VBN N
by IN N
only RB N
a DT N
constant JJ N
phase NN N
. . N

Early JJ N
phase NN N
factors NNS N
associated VBN N
with IN 1_o
death NN 1_o
included VBD N
lower JJR 1_o
socioeconomic JJ 1_o
status NN 1_o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
obstructed VBD 1_o
pulmonary JJ 1_o
venous JJ 1_o
return NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
smaller JJR 1_o
ascending VBG 1_o
aorta NN 1_o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
and CC 1_o
anatomic JJ 1_o
subtype NN 1_o
. . N

Constant JJ N
phase NN N
factors NNS N
associated VBN N
with IN 1_o
death NN 1_o
included VBD 1_o
genetic JJ 1_o
syndrome NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
lower JJR 1_o
gestational JJ 1_o
age NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
demonstrated VBD N
better JJR 1_o
survival NN 1_o
in IN N
the DT N
51 CD N
% NN N
of IN N
subjects NNS N
who WP N
were VBD N
full JJ N
term NN N
with IN N
aortic JJ N
atresia NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
was VBD N
better RBR N
among IN N
the DT N
4 CD N
% NN N
of IN N
subjects NNS N
who WP N
were VBD N
preterm VBN N
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Lower JJR 1_o
pre-Norwood NN 1_o
right JJ 1_o
ventricular JJ 1_o
fractional JJ 1_o
area NN 1_o
change NN 1_o
, , 1_o
pre-Norwood NN 1_o
surgery NN 1_o
, , 1_o
and CC 1_o
anatomy VBZ 1_o
other JJ 1_o
than IN 1_o
hypoplastic JJ 1_o
left JJ 1_o
heart NN 1_o
syndrome NN 1_o
were VBD N
independently RB N
associated VBN N
with IN N
transplantation NN N
( ( N
all DT N
P NNP N
< NNP N
.03 NNP N
) ) N
, , N
but CC N
shunt NN N
type NN N
was VBD N
not RB N
( ( N
P NNP N
= NNP N
.43 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Independent NNP 1_o
risk NN 1_o
factors NNS 1_o
for IN 1_o
intermediate-term JJ 1_o
mortality NN 1_o
include VBP N
lower JJR N
socioeconomic JJ N
status NN N
, , N
anatomy RB N
, , N
genetic JJ N
syndrome NN N
, , N
and CC N
lower JJR N
gestational JJ N
age NN N
. . N

Term JJ N
infants NNS N
with IN N
aortic JJ N
atresia NN N
benefited VBD N
from IN N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
, , N
and CC N
preterm JJ N
infants NNS N
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
benefited VBD N
from IN N
a DT N
modified VBN N
Blalock-Taussig NNP N
shunt NN N
. . 1_o

Right NNP 1_o
ventricular JJ 1_o
function NN 1_o
and CC 1_o
anatomy NN 1_o
, , N
but CC N
not RB 1_o
shunt VB 1_o
type NN 1_o
, , N
were VBD N
associated VBN N
with IN N
transplantation NN N
. . N

Analysis NN N
of IN N
prevention NN 1_i
program NN 1_i
effectiveness NN 1_o
with IN N
clustered VBN N
data NNS N
using VBG N
generalized JJ N
estimating NN N
equations NNS N
. . N

Experimental JJ N
studies NNS N
of IN N
prevention NN 1_i
programs NNS 1_i
often RB N
randomize VBP N
clusters NNS N
of IN N
individuals NNS N
rather RB N
than IN N
individuals NNS N
to TO N
treatment NN N
conditions NNS N
. . N

When WRB N
the DT N
correlation NN N
among IN N
individuals NNS N
within IN N
clusters NNS N
is VBZ N
not RB N
accounted VBN N
for IN N
in IN N
statistical JJ N
analysis NN N
, , N
the DT N
standard JJ N
errors NNS N
are VBP N
biased VBN N
, , N
potentially RB N
resulting VBG N
in IN N
misleading VBG N
conclusions NNS N
about IN N
the DT N
significance NN N
of IN N
treatment NN N
effects NNS N
. . N

This DT N
study NN N
demonstrates VBZ N
the DT N
generalized JJ 1_i
estimating NN 1_i
equations NNS 1_i
( ( 1_i
GEE NNP 1_i
) ) 1_i
method NN N
, , N
focusing VBG N
specifically RB N
on IN N
the DT N
GEE-independent NNP 1_i
method NN N
, , N
to TO N
control VB N
for IN N
within-cluster JJ N
correlation NN N
in IN N
regression NN N
models NNS N
with IN N
either DT N
continuous JJ N
or CC N
binary JJ N
outcomes NNS N
. . N

The DT N
GEE-independent JJ 1_i
method NN N
yields NNS N
consistent JJ N
and CC N
robust JJ N
variance NN N
estimates NNS N
. . N

Data NNS N
from IN N
project NN N
DARE NNP N
, , N
a DT N
youth NN N
substance NN N
abuse NN N
prevention NN N
program NN N
, , N
are VBP N
used VBN N
for IN N
illustration NN N
. . N

Randomized VBN N
controlled JJ N
trial NN N
of IN N
acupuncture NN 1_i
versus NN N
sham JJ 1_i
acupuncture NN 1_i
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
aim VBP N
to TO N
study VB N
the DT N
efficacy NN 1_o
of IN N
acupuncture NN 1_i
versus NN N
sham JJ 1_i
acupuncture NN 1_i
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

METHODS VB N
A DT N
single-blind JJ N
randomized VBN N
control NN N
trial NN N
was VBD N
conducted VBN N
in IN N
50 CD 1_p
children NNS 1_p
. . 1_p

These DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
group NN N
with IN N
tongue JJ 1_i
acupuncture NN 1_i
( ( N
40 CD N
sessions NNS N
over IN N
8 CD N
weeks NNS N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( 1_i
sham JJ 1_i
tongue NN 1_i
acupuncture NN 1_i
to TO N
nonacupoints NNS N
in IN N
the DT N
tongue NN N
) ) N
. . N

RESULTS NNP N
There EX N
was VBD N
improvement NN N
in IN N
both CC N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
in IN N
all DT N
assessed JJ N
measures NNS N
but CC N
more JJR N
so RB N
in IN N
the DT N
treatment NN N
than IN N
in IN N
the DT N
control NN N
group NN N
: : N
( ( N
1 CD N
) ) N
eye-hand NN 1_o
coordination NN 1_o
, , 1_o
performance NN 1_o
, , 1_o
and CC 1_o
practical JJ 1_o
reasoning NN 1_o
of IN 1_o
Griffiths NNP 1_o
Mental NNP 1_o
Developmental NNP 1_o
Scale NNP 1_o
; : 1_o
( ( 1_o
2 CD 1_o
) ) 1_o
sensory-motor NN 1_o
, , 1_o
social JJ 1_o
, , 1_o
affectual JJ 1_o
, , 1_o
language NN 1_o
, , 1_o
and CC 1_o
total JJ 1_o
score NN 1_o
of IN 1_o
Ritvo-Freeman NNP 1_o
Real NNP 1_o
Life NNP 1_o
Scale NNP 1_o
; : 1_o
( ( 1_o
3 CD 1_o
) ) 1_o
Comprehension NN 1_o
Language NNP 1_o
age NN 1_o
in IN 1_o
the DT 1_o
Reynell NNP 1_o
Language NNP 1_o
Developmental NNP 1_o
Scale NNP 1_o
; : 1_o
and CC 1_o
( ( 1_o
4 CD 1_o
) ) 1_o
Total NN 1_o
Score NNP 1_o
and CC 1_o
Mental NNP 1_o
Age NNP 1_o
in IN 1_o
Symbolic NNP 1_o
Play NNP 1_o
Test NNP 1_o
. . 1_o

The DT N
only JJ N
statistically RB N
significant JJ N
improvement NN N
in IN N
the DT N
treatment NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
was VBD N
seen VBN N
in IN N
self-care JJ 1_o
and CC 1_o
cognition NN 1_o
domains NNS 1_o
of IN 1_o
the DT 1_o
Functional NNP 1_o
Independence NNP 1_o
Measure NN 1_o
for IN 1_o
children NNS 1_o
. . 1_o

CONCLUSIONS NNP N
We PRP N
had VBD N
demonstrated VBN N
that IN N
a DT N
short JJ N
course NN N
of IN N
acupuncture NN 1_i
had VBD N
efficacy NN 1_o
in IN N
improving VBG N
various JJ N
developmental JJ N
and CC N
behavioral JJ N
aspects NNS N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

The DT N
long-term JJ N
efficacy NN 1_o
in IN N
functional JJ N
gain NN N
needs NNS N
to TO N
be VB N
further RB N
explored VBN N
. . N

The DT N
effect NN N
of IN N
cognitive-behavioral JJ 1_i
therapy NN 1_i
versus NN N
treatment NN 1_i
as IN 1_i
usual JJ 1_i
for IN N
anxiety NN N
in IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
efficacy NN 1_o
of IN N
a DT N
modular JJ N
cognitive-behavioral JJ 1_i
therapy NN 1_i
( ( 1_i
CBT NNP 1_i
) ) 1_i
protocol VBP N
relative JJ N
to TO N
treatment NN 1_i
as IN 1_i
usual JJ 1_i
( ( 1_i
TAU NNP 1_i
) ) 1_i
among IN N
children NNS 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
and CC 1_p
clinically RB 1_p
significant JJ 1_p
anxiety NN 1_p
. . 1_p

METHOD NNP N
A NNP N
total NN N
of IN N
45 CD 1_p
children NNS 1_p
( ( 1_p
7-11 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
with IN 1_p
high-functioning JJ 1_p
ASD NNP 1_p
and CC 1_p
clinically RB 1_p
significant JJ 1_p
anxiety NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
sessions NNS N
of IN N
weekly JJ N
CBT NNP 1_i
or CC N
TAU NNP 1_i
for IN N
an DT N
equivalent JJ N
duration NN N
. . N

After IN N
screening VBG N
, , N
assessments NNS N
were VBD N
conducted VBN N
at IN N
baseline NN N
, , N
post-treatment JJ N
, , N
and CC N
3-month JJ N
follow-up NN N
. . N

Raters NNPS N
were VBD N
blind RB N
to TO N
treatment NN N
condition NN N
. . N

RESULTS NNP N
Youth NNP N
receiving VBG N
CBT NNP 1_i
showed VBD N
substantial JJ N
improvement NN N
relative NN N
to TO N
TAU VB 1_i
on IN N
primary JJ 1_o
anxiety NN 1_o
outcomes NNS 1_o
. . 1_o

Of IN N
24 CD N
children NNS N
randomized VBN N
to TO N
the DT N
CBT NNP 1_i
arm NN N
, , N
18 CD N
( ( N
75 CD N
% NN N
) ) N
were VBD N
treatment NN 1_o
responders NNS 1_o
, , N
versus IN N
only RB N
3 CD N
of IN N
21 CD N
children NNS N
( ( N
14 CD N
% NN N
) ) N
in IN N
the DT N
TAU NNP 1_i
arm NN N
. . N

Gains NNS N
were VBD N
generally RB N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
for IN N
CBT NNP 1_i
responders NNS N
. . N

CONCLUSIONS NNP N
Relative NNP N
to TO N
usual JJ N
care NN N
, , N
CBT NNP 1_i
adapted VBD N
for IN N
anxious JJ N
youth NN N
with IN N
high-functioning JJ N
ASD NNP N
demonstrates VBZ N
large JJ N
effects NNS N
in IN N
reducing VBG N
anxiety NN 1_o
symptoms NNS 1_o
. . 1_o

This DT N
study NN N
contributes VBZ N
to TO N
the DT N
growing VBG N
literature NN N
supporting VBG N
adapted VBN N
CBT NNP 1_i
approaches NNS N
for IN N
treating VBG N
anxiety NN N
in IN N
youth NN 1_p
with IN 1_p
ASD NNP 1_p
. . 1_p

Spotty JJ N
calcification NN N
as IN N
a DT N
marker NN N
of IN N
accelerated JJ N
progression NN 1_o
of IN 1_o
coronary JJ 1_o
atherosclerosis NN 1_o
: : 1_o
insights NNS N
from IN N
serial JJ N
intravascular JJ N
ultrasound NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
atheroma JJ 1_o
progression NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
spotty JJ 1_p
calcification NN 1_p
. . 1_p

BACKGROUND NNP N
Although IN N
extensively RB N
calcified VBN N
atherosclerotic JJ N
lesions NNS N
have VBP N
been VBN N
proposed VBN N
to TO N
be VB N
clinically RB N
quiescent JJ N
, , N
the DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
within IN N
plaque NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
ischemic JJ N
cardiovascular JJ N
events NNS N
. . N

The DT N
relationship NN N
between IN N
spotty JJ 1_o
calcification NN 1_o
and CC N
disease NN 1_o
progression NN 1_o
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
1,347 CD 1_p
stable JJ 1_p
patients NNS 1_p
with IN 1_p
angiographic JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
underwent JJ N
serial JJ 1_i
evaluation NN 1_i
of IN 1_i
atheroma JJ 1_o
burden NN 1_o
with IN 1_o
intravascular JJ 1_o
ultrasound NN 1_o
imaging NN 1_o
. . 1_o

Patients NNS 1_p
with IN 1_p
spotty JJ 1_p
calcification NN 1_p
were VBD 1_p
identified VBN 1_p
based VBN 1_p
on IN 1_p
the DT 1_p
presence NN 1_p
of IN 1_p
lesions NNS 1_p
( ( 1_p
1 CD 1_p
to TO 1_p
4 CD 1_p
mm NNS 1_p
in IN 1_p
length NN 1_p
) ) 1_p
containing VBG 1_p
an DT 1_p
arc NN 1_p
of IN 1_p
calcification NN 1_p
of IN 1_p
< $ 1_p
90° CD 1_p
. . 1_o

Clinical JJ 1_o
characteristics NNS 1_o
and CC 1_o
disease NN 1_o
progression NN 1_o
were VBD N
compared VBN N
between IN N
patients NNS N
with IN N
spotty JJ N
calcification NN N
( ( N
n JJ N
= NNP N
922 CD N
) ) N
and CC N
those DT N
with IN N
no DT N
calcification NN N
( ( N
n JJ N
= NNP N
425 CD N
) ) N
. . N

RESULTS JJ 1_p
Patients NNS 1_p
with IN 1_p
spotty JJ 1_p
calcification NN 1_p
were VBD 1_p
older JJR 1_p
( ( 1_p
age NN 1_p
56 CD 1_p
years NNS 1_p
vs. IN 1_p
54 CD 1_p
years NNS 1_p
; : 1_p
p VBZ 1_p
= $ 1_p
0.001 CD 1_p
) ) 1_p
, , 1_p
more RBR 1_p
likely JJ 1_p
to TO 1_p
be VB 1_p
male JJ 1_p
( ( 1_p
68 CD 1_p
% NN 1_p
vs. FW 1_p
54 CD 1_p
% NN 1_p
; : 1_p
p CC N
= VB N
0.01 CD N
) ) N
, , N
and CC N
have VBP N
a DT N
history NN N
of IN N
diabetes NNS N
mellitus NNS N
( ( N
30 CD N
% NN N
vs. FW N
24 CD N
% NN N
; : N
p CC N
= VB N
0.01 CD N
) ) N
and CC N
myocardial JJ N
infarction NN N
( ( N
28 CD N
% NN N
vs. FW N
20 CD N
% NN N
; : N
p CC N
= VB N
0.004 CD N
) ) N
, , N
and CC N
have VBP N
lower JJR N
on-treatment JJ 1_o
high-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
levels NNS 1_o
( ( N
48 CD N
± RB N
16 CD N
mg/dl NNS N
vs. FW N
51 CD N
± $ N
17 CD N
mg/dl NN N
; : N
p CC N
= VB N
0.001 CD 1_p
) ) 1_p
. . N

Patients NNS N
with IN N
spotty JJ N
calcification NN N
demonstrated VBD N
a DT N
greater JJR 1_o
percent JJ 1_o
atheroma NN 1_o
volume NN 1_o
( ( 1_o
PAV NNP 1_o
) ) 1_o
( ( N
36.0 CD N
± RB N
7.6 CD N
% NN N
vs. FW N
29.0 CD N
± $ N
8.5 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD 1_o
) ) 1_o
and CC 1_o
total JJ 1_o
atheroma NN 1_o
volume NN 1_o
( ( N
174.6 CD N
± RB N
71.9 CD N
mm NN N
( ( N
3 CD N
) ) N
vs. FW N
133.9 CD N
± $ N
64.9 CD N
mm NN N
( ( N
3 CD N
) ) N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

On IN N
serial JJ N
evaluation NN N
, , N
spotty JJ N
calcification NN N
was VBD N
associated VBN N
with IN N
greater JJR 1_o
progression NN 1_o
of IN N
PAV NNP N
( ( N
+0.43 NNP N
± RB N
0.07 CD N
% NN N
vs. FW N
+0.02 NNP N
± VBD N
0.11 CD N
% NN N
; : N
p CC N
= VB N
0.002 CD N
) ) N
. . N

Although IN N
intensive JJ N
low-density NN N
lipoprotein NN N
cholesterol NN N
and CC N
blood NN N
pressure NN N
lowering VBG N
therapy NN N
slowed VBD N
disease JJ N
progression NN N
, , N
these DT N
efficacies NNS N
were VBD N
attenuated VBN 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
spotty JJ 1_p
calcification NN 1_p
. . N

CONCLUSIONS VB N
The DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
is VBZ N
associated VBN N
with IN N
more RBR N
extensive JJ N
and CC 1_o
diffuse NN 1_o
coronary JJ 1_o
atherosclerosis NN 1_o
and CC N
accelerated JJ 1_o
disease NN 1_o
progression NN 1_o
despite IN N
use NN N
of IN N
medical JJ N
therapies NNS N
. . N

Changes NNS 1_o
in IN 1_o
the DT 1_o
fatty JJ 1_o
acid JJ 1_o
composition NN 1_o
of IN 1_o
the DT 1_o
plasma NN 1_o
lipid JJ 1_o
esters NNS 1_o
during IN N
lipid-lowering JJ N
treatment NN N
with IN N
diet JJ 1_i
, , 1_i
clofibrate NN 1_i
and CC N
niceritrol NN 1_i
. . 1_i

Reduction NN N
of IN N
the DT N
proportion NN 1_o
of IN 1_o
linoleate NN 1_o
by IN N
clofibrate NN 1_i
but CC N
not RB N
by IN N
niceritrol NN 1_i
. . 1_i

The DT N
fatty JJ 1_o
acid JJ 1_o
composition NN 1_o
of IN 1_o
the DT 1_o
plasma NN 1_o
lipid JJ 1_o
esters NNS 1_o
has VBZ N
been VBN N
studied VBN N
during IN N
lipid-lowering JJ N
treatment NN N
of IN N
95 CD 1_p
patients NNS 1_p
with IN 1_p
atherosclerotic JJ 1_p
disease NN 1_p
. . 1_p

During IN N
the DT N
first JJ N
two CD N
months NNS N
of IN N
the DT N
trial NN N
only RB N
a DT N
diet NN N
was VBD N
prescribed VBN N
. . N

During IN N
the DT N
ensuing VBG N
two CD N
months NNS N
either CC N
clofibrate NN 1_i
or CC N
niceritrol NN 1_i
, , N
a DT N
nicotinic JJ N
acid NN N
ester NN N
, , N
was VBD N
added VBN N
in IN N
a DT N
randomized JJ N
order NN N
. . N

During IN N
the DT N
last JJ N
two CD N
months NNS N
the DT N
second JJ N
drug NN N
was VBD N
added VBN N
. . N

The DT N
combined JJ N
treatment NN N
with IN N
diet JJ 1_i
, , 1_i
clofibrate NN 1_i
and CC N
niceritrol NN 1_i
caused VBN N
highly RB N
significant JJ N
serum NN 1_o
lipid JJ 1_o
reductions NNS 1_o
. . 1_o

The DT N
fatty JJ 1_o
acid JJ 1_o
composition NN 1_o
in IN 1_o
the DT 1_o
plasma NN 1_o
lipid JJ 1_o
esters NNS 1_o
was VBD N
determined VBN N
in IN N
samples NNS N
from IN N
each DT N
trial NN N
period NN N
to TO N
measure VB N
the DT N
degree NN 1_o
of IN 1_o
dietary JJ 1_o
adherence NN 1_o
. . 1_o

During IN N
dietary JJ 1_i
treatment NN 1_i
the DT N
relative JJ N
content NN 1_o
of IN 1_o
saturated JJ 1_o
and CC 1_o
monounsaturated VBD 1_o
fatty JJ 1_o
acids NNS 1_o
secreased VBD N
and CC N
the DT N
polyunsaturated JJ 1_o
fatty JJ 1_o
acids NNS 1_o
increased VBD N
with IN N
an DT N
increasing VBG N
ratio NN 1_o
between IN 1_o
pulyunsaturated VBN 1_o
and CC 1_o
saturated VBN 1_o
fatty JJ 1_o
acids NNS 1_o
( ( 1_o
P/S NNP 1_o
ratio NN 1_o
) ) 1_o
in IN 1_o
the DT 1_o
cholesterol NN 1_o
esters NNS 1_o
and CC 1_o
triglycerides NNS 1_o
. . 1_o

Only RB N
minor JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
the DT N
phospholipids NNS 1_o
. . 1_o

The DT N
changes NNS N
caused VBN N
by IN N
the DT N
diet NN 1_i
were VBD N
partly RB N
reversed VBN N
by IN N
clofibrate NN 1_i
while IN N
niceritrol NN 1_i
did VBD N
not RB N
cause VB N
any DT N
major JJ N
changes NNS 1_o
of IN 1_o
the DT 1_o
fatty JJ 1_o
acid JJ 1_o
composition NN 1_o
. . 1_o

Clofibrate NNP 1_i
treatment NN N
coincided VBD N
with IN N
increasing VBG N
amounts NNS 1_o
of IN 1_o
monounsaturated JJ 1_o
fatty JJ 1_o
acids NNS 1_o
, , 1_o
especially RB 1_o
oleate JJ 1_o
( ( 1_o
18 CD 1_o
: : 1_o
1 CD 1_o
) ) 1_o
, , 1_o
in IN 1_o
the DT 1_o
cholesterol NN 1_o
esters NNS 1_o
, , 1_o
triglycerides NNS 1_o
and CC 1_o
phospholipids NNS 1_o
while IN N
there EX N
were VBD N
significant JJ N
reductions NNS N
of IN N
the DT N
content NN 1_o
of IN 1_o
linoleic NN 1_o
( ( 1_o
18 CD 1_o
: : 1_o
2 CD 1_o
) ) 1_o
acid NN 1_o
in IN 1_o
both CC 1_o
the DT 1_o
cholesterol NN 1_o
esters NNS 1_o
and CC 1_o
triglycerides NNS 1_o
. . 1_o

The DT N
18 CD N
: : N
2/18 CD N
: : N
1 CD N
ratio NN N
decreased VBN N
significantly RB N
in IN N
all PDT N
the DT N
lipid JJ N
esters NNS N
analyzed VBD N
. . N

However RB N
, , N
the DT N
P/S NNP 1_o
ratio NN 1_o
was VBD N
not RB N
significantly RB N
affected VBN N
, , N
partly RB N
because IN N
the DT N
relative JJ 1_o
content NN 1_o
of IN 1_o
saturated JJ 1_o
fatty JJ 1_o
acids NNS 1_o
also RB N
tended VBD N
to TO N
decrease VB N
during IN N
clofibrate JJ 1_i
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
addition NN N
of IN N
clofibrate NN 1_i
treatment NN N
to TO N
patients NNS N
who WP N
are VBP N
on IN N
a DT N
diet JJ 1_i
enriched VBN N
with IN N
polyunsaturated JJ N
fats NNS N
is VBZ N
associated VBN N
with IN N
a DT N
change NN 1_o
from IN 1_o
polyunsaturated VBN 1_o
to TO 1_o
monounsaturated VBN 1_o
fatty JJ 1_o
acids NNS 1_o
in IN 1_o
the DT 1_o
plasma NN 1_o
lipid JJ 1_o
esters NNS 1_o
but CC N
does VBZ N
not RB N
significantly RB N
effect NN N
the DT N
ratio NN 1_o
between IN 1_o
polyunsaturated VBN 1_o
and CC 1_o
saturated VBN 1_o
fatty JJ 1_o
acids NNS 1_o
. . 1_o

The DT 1_o
fatty JJ 1_o
acid NN 1_o
changes NNS 1_o
caused VBN N
by IN N
clofibrate NN 1_i
treatment NN N
and CC N
counteracted VBN N
by IN N
an DT N
increased JJ N
amount NN N
of IN N
polyunsaturated JJ N
fat NN N
in IN N
the DT N
diet NN 1_i
. . 1_i

Language NNP 1_o
outcome NN 1_o
in IN N
autism NN 1_p
: : 1_p
randomized JJ N
comparison NN N
of IN N
joint JJ 1_i
attention NN 1_i
and CC N
play NN 1_i
interventions NNS 1_i
. . 1_i

This DT N
study NN N
reports VBZ N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
aimed VBN N
at IN N
joint JJ 1_i
attention NN 1_i
( ( 1_i
JA NNP 1_i
) ) 1_i
and CC N
symbolic JJ 1_i
play NN 1_i
( ( 1_i
SP NNP 1_i
) ) 1_i
in IN N
preschool NN 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
, , N
with IN N
prediction NN N
to TO N
language NN 1_o
outcome RB 1_o
12 CD N
months NNS N
later RB N
. . N

Participants NNS 1_p
were VBD 1_p
58 CD 1_p
children NNS 1_p
( ( 1_p
46 CD 1_p
boys NNS 1_p
) ) 1_p
with IN 1_p
autism NN 1_p
between IN 1_p
3 CD 1_p
and CC 1_p
4 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

Children NNP N
were VBD N
randomized VBN N
to TO N
a DT N
JA NNP 1_i
intervention NN N
, , N
an DT N
SP NNP 1_i
intervention NN N
, , N
or CC N
control NN N
group NN N
. . N

Interventions NNS N
were VBD N
conducted VBN N
30 CD N
min JJ N
daily JJ N
for IN N
5-6 JJ N
weeks NNS N
. . N

Assessments NNS N
of IN N
JA NNP 1_o
skills NNS 1_o
, , 1_o
SP NNP 1_o
skills NNS 1_o
, , 1_o
mother-child JJ 1_o
interactions NNS 1_o
, , 1_o
and CC 1_o
language NN 1_o
development NN 1_o
were VBD N
collected VBN N
at IN N
4 CD N
time NN N
points NNS N
: : N
pre- NN N
and CC N
postintervention NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
postintervention NN N
by IN N
independent JJ N
testers NNS N
. . N

Results NNS N
indicate VBP N
that IN N
expressive JJ 1_o
language NN 1_o
gains NNS 1_o
were VBD N
greater JJR N
for IN N
both DT N
treatment NN N
groups NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
and CC N
results NNS N
could MD N
not RB N
be VB N
explained VBN N
by IN N
differences NNS N
in IN N
other JJ N
interventions NNS N
in IN N
which WDT N
children NNS N
participated VBD N
. . N

For IN N
children NNS N
beginning VBG N
treatment NN N
with IN N
the DT N
lowest JJS N
language NN N
levels NNS N
, , N
the DT N
JA NNP 1_i
intervention NN N
improved VBD N
language NN 1_o
outcome NN 1_o
significantly RB N
more RBR N
than IN N
did VBD N
the DT N
SP NNP 1_i
or CC N
control VB N
interventions NNS N
. . N

These DT N
findings NNS N
suggest VBP N
clinically RB N
significant JJ N
benefits NNS N
of IN N
actively RB N
treating VBG N
JA NNP 1_i
and CC N
SP NNP 1_i
skills NNS N
in IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Role NNP N
of IN N
posterior JJ 1_i
tibial JJ 1_i
nerve NN 1_i
stimulation NN 1_i
in IN N
the DT N
treatment NN N
of IN N
refractory JJ 1_p
monosymptomatic JJ 1_p
nocturnal JJ 1_p
enuresis NN 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
early JJ 1_o
clinical JJ 1_o
and CC 1_o
urodynamic JJ 1_o
results NNS 1_o
of IN N
posterior JJ 1_i
tibial JJ 1_i
nerve NN 1_i
stimulation NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
refractory JJ 1_p
monosymptomatic JJ 1_p
nocturnal JJ 1_p
enuresis NN 1_p
. . 1_p

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
28 CD 1_p
patients NNS 1_p
with IN 1_p
refractory JJ 1_p
monosymptomatic JJ 1_p
nocturnal JJ 1_p
enuresis NN 1_p
to TO N
2 CD N
equal JJ N
groups NNS N
. . N

Group NNP N
1 CD N
received VBD N
a DT N
weekly JJ N
session NN N
of IN N
posterior JJ 1_i
tibial JJ 1_i
nerve NN 1_i
stimulation NN 1_i
for IN N
12 CD N
weeks NNS N
and CC N
group NN N
2 CD N
was VBD N
the DT N
placebo NN 1_i
group NN N
. . N

Evaluation NN N
was VBD N
performed VBN N
in IN N
each DT N
group NN N
at IN N
baseline NN N
and CC N
after IN N
posterior JJ 1_i
tibial JJ 1_i
nerve NN 1_i
stimulation NN 1_i
to TO N
compare VB N
clinical JJ 1_o
and CC 1_o
urodynamic JJ 1_o
findings NNS 1_o
. . 1_o

Another DT N
clinical JJ N
assessment NN N
was VBD N
done VBN N
3 CD N
months NNS N
after IN N
the DT N
first JJ N
followup NN N
. . N

RESULTS VB N
The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
baseline JJ 1_o
clinical JJ 1_o
and CC 1_o
urodynamic JJ 1_o
data NNS 1_o
. . 1_o

Overall NNP N
, , N
13 CD N
patients NNS N
( ( N
46.4 CD N
% NN N
) ) N
had VBD N
detrusor VBN 1_o
overactivity NN 1_o
and CC N
14 CD N
( ( N
50 CD N
% NN N
) ) N
had VBD N
decreased VBN N
bladder NN 1_o
capacity NN 1_o
. . 1_o

After IN N
treatment NN N
11 CD N
group NN N
1 CD N
patients NNS N
( ( N
78.6 CD N
% NN N
) ) N
had VBD N
a DT N
partial JJ N
or CC N
full JJ N
response NN 1_o
to TO 1_o
posterior VB 1_o
tibial JJ 1_o
nerve NN 1_o
stimulation NN 1_o
but CC N
only RB N
2 CD N
( ( N
14.3 CD N
% NN N
) ) N
in IN N
group NN N
2 CD N
had VBD N
a DT N
partial JJ N
response NN 1_o
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Also RB N
, , N
the DT N
average JJ N
number NN 1_o
of IN 1_o
wet JJ 1_o
nights NNS 1_o
in IN N
group NN N
1 CD N
was VBD N
significantly RB N
lower JJR N
than IN N
at IN N
baseline NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

All DT N
urodynamic JJ 1_o
parameters NNS 1_o
significantly RB N
improved VBN N
in IN N
group NN N
1 CD N
. . N

In IN N
contrast NN N
, , N
the DT N
number NN 1_o
of IN 1_o
wet JJ 1_o
nights NNS 1_o
and CC 1_o
urodynamic JJ 1_o
parameters NNS 1_o
did VBD N
not RB N
change VB N
significantly RB N
in IN N
group NN N
2 CD N
. . N

At IN N
3-month JJ N
followup NN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
a DT N
partial JJ N
or CC N
full JJ N
response NN 1_o
in IN N
group NN N
1 CD N
had VBD N
decreased VBN N
from IN N
11 CD N
( ( N
78.6 CD N
% NN N
) ) N
to TO N
6 CD N
( ( N
42.9 CD N
% NN N
) ) N
. . N

No DT N
change NN N
was VBD N
evident JJ N
in IN N
group NN N
2 CD N
. . N

CONCLUSIONS NNP N
Posterior NNP 1_i
tibial JJ 1_i
nerve NN 1_i
stimulation NN 1_i
can MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
in IN N
some DT N
patients NNS 1_p
with IN 1_p
refractory JJ 1_p
monosymptomatic JJ 1_p
nocturnal JJ 1_p
enuresis NN 1_p
. . 1_p

However RB N
, , N
deterioration NN N
in IN N
some DT N
responders NNS N
with IN N
time NN N
suggests VBZ N
the DT N
need NN N
for IN N
maintenance NN N
protocols NNS N
. . N

The DT N
effect NN N
of IN N
four CD N
different JJ N
irrigation NN N
systems NNS N
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ N
canal JJ N
sealer NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficiency NN 1_o
of IN N
sonic JJ 1_i
, , 1_i
ultrasonic JJ 1_i
, , 1_i
and CC 1_i
hydrodynamic JJ 1_i
devices NNS 1_i
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ 1_p
canal JJ 1_p
sealer NN N
from IN N
the DT N
surface NN N
and CC N
from IN N
simulated JJ N
irregularities NNS N
of IN N
root NN N
canals NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty-three NNP 1_p
root NN 1_p
canals NNS 1_p
with IN 1_p
two CD 1_p
standardized JJ 1_p
grooves NNS 1_p
in IN 1_p
the DT 1_p
apical JJ 1_p
and CC 1_p
coronal JJ 1_p
parts NNS 1_p
of IN 1_p
longitudinally RB 1_p
split VBN 1_p
roots NNS 1_p
were VBD N
covered VBN N
with IN N
AH NNP N
Plus NNP N
root VBP N
canal JJ N
sealer NN N
. . N

Compared VBN N
were VBD N
the DT N
effects NNS N
of IN N
( ( N
control NN N
) ) N
syringe NN 1_i
irrigation NN 1_i
, , N
( ( N
1 CD N
) ) N
CanalBrush NN 1_i
, , N
( ( N
2 CD N
) ) N
passive NN 1_i
ultrasonic JJ 1_i
irrigation NN 1_i
, , N
( ( N
3 CD N
) ) N
EndoActivator NN 1_i
, , N
and CC N
( ( N
4 CD N
) ) N
RinsEndo NN 1_i
on IN N
the DT N
removal NN N
of IN N
the DT N
sealer NN N
. . N

The DT N
specimens NNS N
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
( ( N
N NNP N
= NNP N
12 CD N
) ) N
and CC N
one CD N
control NN N
group NN N
( ( N
N NNP N
= NNP N
5 CD N
) ) N
via IN N
randomization NN 1_o
. . 1_o

The DT 1_o
amount NN 1_o
of IN 1_o
remaining VBG 1_o
sealer NN 1_o
in IN 1_o
the DT 1_o
root NN 1_o
canal JJ 1_o
irregularities NNS 1_o
was VBD 1_o
evaluated VBN 1_o
under IN 1_o
a DT 1_o
microscope NN 1_o
using VBG 1_o
a DT 1_o
4-grade JJ 1_o
scoring NN 1_o
system NN N
, , N
whereas IN 1_o
the DT 1_o
remaining VBG 1_o
sealer NN 1_o
on IN 1_o
the DT 1_o
root NN 1_o
canal JJ 1_o
surface NN 1_o
was VBD 1_o
evaluated VBN 1_o
with IN 1_o
a DT 1_o
7-grade JJ 1_o
scoring NN 1_o
system NN N
. . N

RESULTS NNP 1_i
Passive NNP 1_i
ultrasonic JJ 1_i
irrigation NN 1_i
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
other JJ 1_i
tested JJ 1_i
irrigation NN 1_i
systems NNS 1_i
or CC 1_i
syringe JJ 1_i
irrigation NN 1_o
in IN 1_o
removing VBG 1_o
sealer NN 1_o
from IN 1_o
root JJ 1_o
canal JJ 1_o
walls NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

None NN N
of IN N
the DT N
techniques NNS N
had VBD N
a DT N
significant JJ 1_o
effect NN 1_o
on IN 1_o
cleaning VBG 1_o
the DT 1_o
lateral JJ 1_o
grooves NNS N
. . N

CONCLUSIONS NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN 1_i
protocol VBZ 1_i
ultrasonic JJ 1_i
irrigation NN N
shows VBZ N
a DT N
superior JJ 1_o
effect NN 1_o
on IN 1_o
sealer NN 1_o
removal NN 1_o
from IN 1_o
the DT 1_o
root NN 1_o
canal JJ 1_o
surface NN N
during IN N
endodontic JJ N
retreatment NN N
. . N

Cleaning NN N
of IN N
lateral JJ N
grooves NNS N
seems VBZ N
not RB N
to TO N
be VB N
possible JJ N
with IN N
one CD N
of IN N
the DT N
techniques NNS N
investigated VBN N
. . N

CLINICAL JJ N
RELEVANCE NNP 1_o
Incomplete NNP 1_o
removal NN 1_o
of IN 1_o
root JJ 1_o
canal JJ 1_o
sealer NN N
during IN N
re-treatment NN N
may MD N
cause VB N
treatment NN 1_i
failure NN 1_i
. . 1_i

Passive NNP 1_i
Ultrasonic NNP 1_i
irrigation NN N
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
effective JJ 1_o
system NN 1_o
to TO 1_o
remove VB 1_o
sealer NN 1_o
from IN 1_o
a DT 1_o
root NN N
canal NN N
. . N

Teaching VBG N
emotion NN 1_i
recognition NN 1_i
skills NNS N
to TO N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
: : 1_p
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
an DT N
emotion NN 1_i
training NN 1_i
programme NN 1_i
. . 1_i

BACKGROUND NNP N
Children NNP N
with IN N
autism NN N
have VBP N
difficulties NNS N
in IN N
emotion NN N
recognition NN N
and CC N
a DT N
number NN N
of IN N
interventions NNS N
have VBP N
been VBN N
designed VBN N
to TO N
target VB N
these DT N
problems NNS N
. . N

However RB N
, , N
few JJ N
emotion NN 1_i
training NN 1_i
interventions NNS N
have VBP N
been VBN N
trialled VBN N
with IN N
young JJ N
children NNS N
with IN N
autism NN N
and CC N
co-morbid JJ N
ID NNP N
. . N

This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN 1_o
of IN N
an DT N
emotion NN 1_i
training NN 1_i
programme NN 1_i
for IN N
a DT N
group NN N
of IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
with IN 1_p
a DT 1_p
range NN 1_p
of IN 1_p
intellectual JJ 1_p
ability NN 1_p
. . 1_p

METHODS NNP N
Participants NNPS 1_p
were VBD 1_p
55 CD 1_p
children NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
, , 1_p
aged VBN 1_p
4-7 CD 1_p
years NNS 1_p
( ( 1_p
FSIQ NNP 1_p
42-107 CD 1_p
) ) 1_p
. . 1_p

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
control VB N
group NN N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
watched VBD N
a DT N
DVD NNP N
designed VBN N
to TO N
teach VB N
emotion NN 1_i
recognition NN 1_i
skills NNS 1_i
to TO N
children NNS N
with IN N
autism NN N
( ( 1_i
the DT 1_i
Transporters NNPS 1_i
) ) 1_i
, , N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
DVD NNP N
of IN N
Thomas NNP 1_i
the DT 1_i
Tank NNP 1_i
Engine NNP 1_i
. . 1_i

Participants NNS N
were VBD N
assessed VBN N
on IN N
their PRP$ N
ability NN 1_o
to TO 1_o
complete VB 1_o
basic JJ 1_o
emotion NN 1_o
recognition NN 1_o
tasks NNS 1_o
, , 1_o
mindreading VBG 1_o
and CC 1_o
theory NN 1_o
of IN 1_o
mind NN 1_o
( ( 1_o
TOM NNP 1_o
) ) 1_o
tasks NNS 1_o
before IN N
and CC N
after IN N
the DT N
4-week JJ N
intervention NN N
period NN N
, , N
and CC N
at IN N
3-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Analyses NNP N
controlled VBD N
for IN N
the DT N
effect NN N
of IN N
chronological JJ N
age NN N
, , N
verbal JJ N
intelligence NN N
, , N
gender NN N
and CC N
DVD NNP N
viewing VBG N
time NN N
on IN N
outcomes NNS N
. . N

Children NNP N
in IN N
the DT N
intervention NN N
group NN N
showed VBD N
improved JJ N
performance NN N
in IN N
the DT N
recognition NN 1_o
of IN 1_o
anger NN 1_o
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
with IN N
few JJ N
improvements NNS N
maintained VBD N
at IN N
3-month JJ N
follow-up NN N
. . N

There EX N
was VBD N
no DT N
generalisation NN N
of IN N
skills NNS N
to TO N
TOM NNP 1_o
or CC 1_o
social JJ 1_o
skills NNS 1_o
. . 1_o

CONCLUSIONS VB N
The DT 1_i
Transporters NNP 1_i
programme NN N
showed VBD N
limited JJ N
efficacy NN 1_o
in IN N
teaching VBG N
basic JJ N
emotion NN 1_o
recognition NN 1_o
skills NNS 1_o
to TO N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
with IN N
a DT N
lower JJR N
range NN N
of IN N
cognitive JJ N
ability NN N
. . N

Improvements NNS N
were VBD N
limited VBN N
to TO N
the DT N
recognition NN 1_o
of IN 1_o
expressions NNS 1_o
of IN 1_o
anger NN 1_o
, , N
with IN N
poor JJ N
maintenance NN N
of IN N
these DT N
skills NNS N
at IN N
follow-up NN N
. . N

These DT N
findings NNS N
provide VBP N
limited JJ N
support NN N
for IN N
the DT N
efficacy NN 1_o
of IN N
the DT 1_i
Transporters NNP 1_i
programme NN N
for IN N
young JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
of IN N
a DT N
lower JJR N
cognitive JJ N
range NN N
. . N

Efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
selamectin NN 1_i
against IN N
fleas NNS N
and CC N
heartworms NNS N
in IN N
dogs NNS 1_p
and CC 1_p
cats NNS 1_p
presented VBD 1_p
as IN 1_p
veterinary JJ 1_p
patients NNS 1_p
in IN 1_p
North NNP 1_p
America NNP 1_p
. . 1_p

A NNP N
series NN N
of IN N
randomized VBN N
, , N
controlled VBN N
, , N
masked VBD N
field NN N
studies NNS N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
selamectin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
flea NN N
infestations NNS N
on IN 1_p
dogs NNS 1_p
and CC 1_p
cats NNS 1_p
, , N
and CC N
in IN N
the DT N
prevention NN N
of IN N
heartworm NN N
infection NN N
in IN N
dogs NNS N
. . N

In IN N
addition NN N
, , N
observations NNS N
were VBD N
made VBN N
on IN N
the DT N
beneficial JJ N
effect NN N
of IN N
selamectin NN 1_i
treatment NN N
on IN N
dogs NNS 1_p
and CC 1_p
cats NNS 1_p
showing VBG 1_p
signs NNS 1_p
of IN 1_p
flea NN 1_p
allergy NN 1_p
dermatitis NN 1_p
( ( 1_p
FAD NNP 1_p
) ) 1_p
. . 1_p

In IN N
all DT N
studies NNS N
selamectin VBP 1_i
was VBD N
applied VBN N
topically RB N
, , N
once RB N
per IN N
month NN N
, , N
in IN N
unit NN N
doses NNS N
providing VBG N
a DT N
minimum JJ N
dosage NN N
of IN N
6mgkg CD N
( ( N
-1 NN N
) ) N
. . N

Dogs NNS 1_p
and CC 1_p
cats NNS 1_p
with IN 1_p
naturally RB 1_p
occurring VBG 1_p
flea NN 1_p
infestations NNS 1_p
, , 1_p
some DT 1_p
of IN 1_p
which WDT 1_p
also RB 1_p
had VBD 1_p
signs NNS 1_p
associated VBN 1_p
with IN 1_p
FAD NNP 1_p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
three CD N
months NNS N
of IN N
topical JJ N
treatment NN N
with IN N
selamectin NN 1_i
( ( 1_p
220 CD 1_p
dogs NNS 1_p
, , 1_p
189 CD 1_p
cats NNS 1_p
) ) 1_p
or CC N
a DT N
positive-control JJ N
product NN N
( ( N
dogs NNS N
: : N
fenthion NN 1_i
, , N
n=81 RB N
; : N
cats NNS N
: : N
pyrethrins NNS 1_i
, , N
n=66 NN N
) ) N
. . N

Selamectin NNP 1_i
was VBD N
administered VBN N
on IN N
days NNS N
0 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
. . N

Day NNP N
0 CD N
was VBD N
defined VBN N
as IN N
the DT N
day NN N
that IN N
the DT N
animal NN N
first RB N
received VBD N
treatment NN N
. . N

Flea NN N
burdens NNS N
were VBD N
assessed VBN N
by IN N
flea NN 1_o
comb NN 1_o
counts NNS 1_o
and CC 1_o
clinical JJ 1_o
evaluations NNS 1_o
of IN 1_o
FAD NNP 1_o
were VBD N
performed VBN N
before IN N
treatment NN N
, , N
and CC N
on IN N
days NNS N
14 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
. . N

On IN N
days NNS N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
, , N
mean JJ 1_o
flea NN 1_o
counts NNS 1_o
in IN N
selamectin-treated JJ 1_i
dogs NNS N
were VBD N
reduced VBN N
by IN N
92.1 CD N
, , N
99.0 CD N
, , N
and CC N
99.8 CD N
% NN N
, , N
and CC N
mean JJ 1_o
flea NN 1_o
counts NNS 1_o
in IN N
fenthion-treated JJ 1_i
dogs NNS N
were VBD N
reduced VBN N
by IN N
81.5 CD N
, , N
86.8 CD N
, , N
and CC N
86.1 CD N
% NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
. . N

Also RB N
, , N
on IN N
days NNS N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
, , N
mean JJ 1_o
flea NN 1_o
counts NNS 1_o
in IN N
selamectin-treated JJ 1_i
cats NNS N
were VBD N
reduced VBN N
by IN N
92.5 CD N
, , N
98.3 CD N
, , N
and CC N
99.3 CD N
% NN N
, , N
and CC N
mean JJ 1_o
flea NN 1_o
counts NNS 1_o
in IN N
pyrethrin-treated JJ 1_i
cats NNS N
were VBD N
reduced VBN N
by IN N
66.4 CD N
, , N
73.9 CD N
, , N
and CC N
81.3 CD N
% NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
. . N

Selamectin NNP 1_i
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS 1_o
in IN N
dogs NNS 1_p
and CC 1_p
cats NNS 1_p
diagnosed VBD 1_p
clinically RB 1_p
with IN 1_p
FAD NNP 1_p
. . 1_p

A NNP N
total NN N
of IN N
397 CD 1_p
dogs NNS 1_p
free JJ 1_p
of IN 1_p
adult NN 1_p
heartworm NN 1_p
infection NN 1_p
from IN 1_p
four CD 1_p
heartworm-endemic JJ 1_p
areas NNS 1_p
of IN 1_p
the DT 1_p
USA NNP 1_p
were VBD N
allocated VBN N
randomly RB N
to TO N
six CD N
months NNS N
of IN N
treatment NN N
with IN N
selamectin NN 1_i
( ( N
n=298 JJ N
) ) N
or CC N
ivermectin NN 1_i
( ( N
n=99 JJ N
) ) N
. . N

Selamectin NNP 1_i
achieved VBD N
a DT N
heartworm JJ 1_o
prevention NN 1_o
rate NN 1_o
of IN N
100 CD N
% NN N
, , N
with IN N
all DT N
dogs NNS N
testing VBG N
negative JJ N
for IN N
microfilariae NN 1_o
and CC 1_o
adult NN 1_o
heartworm NN 1_o
antigen NN 1_o
on IN N
days NNS N
180 CD N
and CC N
300 CD N
. . N

Selamectin NNP 1_i
was VBD N
administered VBN N
to TO N
a DT N
total NN N
of IN N
673 CD 1_p
dogs NNS 1_p
and CC 1_p
347 CD 1_p
cats NNS 1_p
having VBG 1_p
an DT 1_p
age NN 1_p
range NN 1_p
of IN 1_p
6 CD 1_p
weeks NNS 1_p
to TO 1_p
19 CD 1_p
years NNS 1_p
( ( N
3954 CD N
doses NNS N
) ) N
. . N

The DT N
animals NNS N
included VBD N
19 CD 1_p
purebred VBD 1_p
or CC 1_p
crossbred JJ 1_p
Collies NNS 1_p
( ( 1_p
Bearded NNP 1_p
, , 1_p
Border NNP 1_p
, , 1_p
and CC 1_p
unspecified JJ 1_p
) ) 1_p
. . 1_p

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ 1_o
events NNS 1_o
. . 1_o

Results NNS N
of IN N
these DT N
studies NNS N
indicated VBD N
that IN N
selamectin NN 1_i
was VBD N
highly RB N
effective JJ 1_o
in IN N
the DT N
control NN N
of IN N
flea NN N
infestations NNS N
in IN 1_p
dogs NNS 1_p
and CC 1_p
cats NNS 1_p
without IN N
the DT N
need NN N
for IN N
simultaneous JJ N
treatment NN N
of IN N
the DT N
environment NN N
or CC N
of IN N
in-contact JJ N
animals NNS N
and CC N
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS 1_o
associated VBN 1_o
with IN 1_o
FAD NNP 1_o
. . 1_o

Selamectin NNP 1_i
also RB N
was VBD N
100 CD N
% NN N
effective JJ 1_o
in IN N
preventing VBG N
the DT N
development NN N
of IN N
canine NN N
heartworms NNS 1_o
and CC N
was VBD N
safe JJ 1_o
for IN N
topical JJ N
use NN N
in IN N
dogs NNS 1_p
and CC 1_p
cats NNS 1_p
. . 1_p

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
of IN N
the DT N
impact NN N
on IN N
quality NN 1_o
of IN 1_o
life NN 1_o
of IN N
continuing VBG N
dexamethasone JJ 1_i
beyond IN N
24 CD N
h NN N
following VBG N
adjuvant JJ N
chemotherapy NN N
for IN 1_p
breast NN 1_p
cancer NN 1_p
. . N

Uncertainty NN N
remains VBZ N
about IN N
the DT N
optimal JJ N
anti-emetic JJ N
regimen NNS N
for IN N
control NN N
of IN N
delayed JJ N
nausea NN N
and CC N
vomiting NN N
after IN N
adjuvant JJ N
chemotherapy NN N
for IN N
breast NN N
cancer NN N
. . N

Many JJ N
patients NNS N
receive VBP 1_i
dexamethasone NN 1_i
but CC N
complain NN N
of IN N
insomnia NN N
, , N
anxiety/agitation NN N
, , N
and CC N
indigestion NN N
. . N

The DT N
aim NN N
was VBD N
to TO N
determine VB N
if IN 1_p
patients NNS 1_p
receiving VBG 1_p
chemotherapy NN 1_p
for IN 1_p
breast NN 1_p
cancer NN 1_o
prefer VBP 1_o
treatment NN N
with IN 1_i
dexamethasone NN 1_i
or CC 1_i
placebo NN 1_i
for IN N
prophylaxis NN N
against IN N
delayed VBN N
nausea NN N
and CC N
vomiting NN N
, , N
and CC N
to TO N
compare VB 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QOL NNP 1_o
) ) 1_o
between IN N
the DT N
two CD N
treatments NNS N
. . N

In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
trial NN N
, , N
we PRP N
compared VBN N
oral JJ 1_i
dexamethasone NN 1_i
( ( N
4 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
days NNS N
) ) N
versus VBP 1_i
placebo NN 1_i
for IN 1_p
chemotherapy-naïve JJ 1_p
patients NNS 1_p
with IN 1_p
breast JJ 1_p
cancer NN 1_p
. . N

All DT N
patients NNS N
received VBD N
intravenous JJ 1_i
granisetron NN 1_i
and CC 1_i
dexamethasone NN 1_i
pre-chemotherapy NN N
and CC N
oral JJ 1_i
granisetron NN 1_i
on IN N
day NN N
2 CD N
. . N

Primary JJ N
endpoints NNS N
were VBD N
: : N
( ( 1_o
i NN 1_o
) ) 1_o
patient NN 1_o
preference NN 1_o
; : 1_o
( ( N
ii NN N
) ) N
difference NN N
between IN N
cycles NNS 1_o
in IN 1_o
change NN 1_o
of IN 1_o
QOL NNP N
from IN N
days NNS N
1 CD N
to TO 1_p
8 CD 1_p
. . 1_p

Median JJ 1_p
age NN 1_p
of IN 1_p
the DT 1_p
94 CD 1_p
women NNS 1_p
was VBD 1_p
51 CD 1_p
years NNS 1_p
( ( 1_p
range VB 1_p
27-76 JJ 1_p
) ) 1_p
: : 1_p
79 CD N
received VBD 1_i
fluorouracil/epirubicin/cyclophosphamide NN 1_i
and CC N
15 CD N
received VBD 1_i
doxorubicin/cyclophosphamide NN 1_i
. . N

Thirteen JJ N
withdrew VBD N
pre-cycle JJ N
2 CD N
with IN N
no DT N
differences NNS N
between IN N
arms NNS N
. . N

Of IN N
80 CD N
patients NNS N
stating VBG 1_o
a DT 1_o
preference NN 1_o
, , 1_o
31 CD 1_o
preferred JJ 1_o
placebo NN 1_i
( ( N
39 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
28-50 CD N
% NN N
) ) N
and CC N
37 CD N
( ( N
46 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP 1_o
: : 1_o
35-58 CD 1_o
% NN 1_o
) ) 1_o
preferred VBD 1_i
dexamethasone NN 1_o
; : 1_o
12 CD 1_o
had VBD 1_o
no DT 1_o
preference NN N
. . N

There EX N
were VBD N
no DT N
differences NNS 1_o
in IN 1_o
intensity NN 1_o
of IN 1_o
vomiting VBG 1_o
, , 1_o
nausea NN 1_o
, , 1_o
or CC 1_o
time NN 1_o
to TO 1_o
onset VB 1_o
of IN 1_o
vomiting VBG N
. . N

There EX N
was VBD N
greater JJR N
decrease NN 1_o
in IN 1_o
global JJ N
QOL NNP N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
when WRB N
patients NNS 1_i
received VBD 1_i
dexamethasone NN 1_o
. . 1_o

No DT 1_o
other JJ 1_o
symptom/QOL NN N
domains NNS N
differed VBD N
significantly RB N
. . N

In IN N
conclusion NN N
, , N
no DT N
significant JJ N
difference NN N
was VBD 1_o
found VBN 1_o
in IN 1_o
patient JJ 1_o
preference NN 1_o
, , 1_o
QOL NNP 1_o
, , N
or CC N
symptoms NNS N
regardless RB 1_i
of IN 1_i
whether IN 1_i
dexamethasone NN 1_i
or CC N
placebo NN N
was VBD N
used VBN N
after IN N
adjuvant JJ N
chemotherapy NN N
. . N

A DT N
New NNP N
Interactive NNP 1_i
Screening NNP 1_i
Test NNP 1_i
for IN N
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNP 1_p
in IN 1_p
Toddlers NNP 1_p
. . 1_p

OBJECTIVE NNP N
To TO N
develop VB N
a DT N
clinically RB N
valid JJ N
interactive JJ N
level NN N
2 CD N
screening NN N
assessment NN N
for IN N
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
in IN 1_p
toddlers NNS 1_p
that WDT N
is VBZ N
brief JJ N
, , N
easily RB N
administered VBN N
, , N
and CC N
scored VBN N
by IN N
clinicians NNS N
. . N

STUDY NNP N
DESIGN NNP N
We PRP N
describe VBP N
the DT N
development NN N
, , N
training NN N
, , N
standardization NN N
, , N
and CC N
validation NN N
of IN N
the DT N
Rapid NNP 1_o
Interactive NNP 1_o
Screening NNP 1_o
Test NNP 1_o
for IN 1_o
Autism NNP 1_o
in IN 1_o
Toddlers NNP 1_o
( ( 1_o
RITA-T NNP 1_o
) ) 1_o
with IN N
ASD-specific NNP N
diagnostic JJ N
instruments NNS N
. . N

The DT N
RITA-T JJ 1_o
can MD N
be VB N
administered VBN N
and CC N
scored VBN N
in IN N
10 CD N
minutes NNS N
. . N

We PRP N
studied VBD N
the DT N
validity NN N
of IN N
the DT N
RITA-T NNP 1_o
to TO N
distinguish VB N
between IN N
toddlers NNS 1_p
with IN 1_p
ASD NNP 1_p
from IN 1_p
toddlers NNS 1_p
with IN 1_p
developmental JJ 1_p
delay NN 1_p
( ( 1_p
DD NNP 1_p
) ) 1_p
/non-ASD NN 1_p
in IN 1_p
an DT 1_p
early JJ 1_p
childhood NN 1_p
clinic NN 1_p
. . 1_p

We PRP N
also RB N
evaluated VBD N
the DT N
test NN 1_o
's POS 1_o
performance NN 1_o
in IN N
toddlers NNS 1_p
with IN 1_p
no DT 1_p
developmental JJ 1_p
concerns NNS 1_p
. . 1_p

We PRP N
identified VBD N
a DT N
cutoff NN 1_o
score NN 1_o
based VBN N
on IN N
sensitivity NN 1_o
, , 1_o
specificity NN 1_o
, , 1_o
and CC 1_o
positive JJ 1_o
predictive JJ 1_o
value NN 1_o
of IN 1_o
the DT 1_o
RITA-T NNP 1_o
that WDT N
best JJS N
differentiates NNS N
between IN N
ASD NNP N
and CC N
DD/non-ASD NNP N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
61 CD 1_p
toddlers NNS 1_p
were VBD 1_p
enrolled VBN 1_p
. . 1_p

RITA-T JJ 1_o
scores NNS 1_o
were VBD N
correlated VBN N
with IN N
ASD-specific NNP N
diagnostic JJ N
tools NNS N
( ( N
r VB N
= RB N
0.79 CD N
; : N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
ASD NNP N
clinical JJ N
diagnoses NNS N
( ( N
r VB N
= RB N
0.77 CD N
; : N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Mean JJ N
scores NNS 1_o
were VBD N
significantly RB N
different JJ N
in IN N
subjects NNS N
with IN N
ASD NNP N
, , N
those DT N
with IN N
DD/non-ASD NNP N
, , N
and CC N
those DT N
with IN N
no DT N
developmental JJ N
concerns NNS N
( ( N
20.8 CD N
vs RB N
13 CD N
vs NN N
10.6 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

At IN N
a DT N
cutoff NN N
score NN N
of IN N
> $ N
14 CD N
, , N
the DT N
RITA-T NNP 1_o
had VBD N
a DT N
sensitivity NN 1_o
of IN N
1.00 CD N
, , N
specificity NN 1_o
of IN N
0.84 CD N
, , N
and CC N
positive JJ 1_o
predictive JJ 1_o
value NN 1_o
of IN N
0.88 CD N
for IN N
identifying VBG N
ASD NNP N
risk NN N
in IN N
a DT N
high-risk JJ N
group NN N
. . N

CONCLUSION VB N
The DT N
RITA-T NNP 1_o
is VBZ N
a DT N
promising JJ N
new JJ N
level NN N
2 CD N
interactive JJ N
screening VBG N
tool NN N
for IN N
improving VBG N
the DT N
early JJ N
identification NN N
of IN N
ASD NNP 1_p
in IN 1_p
toddlers NNS 1_p
in IN N
general JJ N
pediatric NN N
and CC N
early JJ N
intervention NN N
settings NNS N
and CC N
allowing VBG N
access NN N
to TO N
treatment NN N
. . N

Phase NNP N
III NNP N
study NN N
of IN N
two CD N
different JJ N
dosing VBG N
schedules NNS N
of IN N
erythropoietin NN 1_i
in IN N
anemic JJ 1_p
patients NNS 1_p
with IN 1_p
cancer NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
compare VB N
maintenance NN N
epoetin NN 1_i
alfa NN 1_i
administered VBD N
once RB N
every DT N
3 CD N
weeks NNS N
with IN N
continued JJ N
weekly JJ N
epoetin NN 1_i
alfa NN 1_i
for IN N
patients NNS 1_p
with IN 1_p
cancer-associated JJ 1_p
anemia NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
at IN N
enrollment NN N
to TO N
receive VB N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN 1_i
alfa NN 1_i
40,000 CD N
U NNP N
subcutaneously RB N
( ( N
SC NNP N
) ) N
, , N
followed VBN N
by IN N
either DT N
standard JJ N
weekly JJ N
epoetin NN 1_i
alfa NN 1_i
( ( N
40K CD N
arm NN N
) ) N
or CC N
120,000 CD N
U NNP N
of IN N
epoetin NN 1_i
alfa NN 1_i
( ( N
120K CD N
arm NN N
) ) N
SC NNP N
every DT N
3 CD N
weeks NNS N
for IN N
18 CD N
additional JJ N
weeks NNS N
. . N

RESULTS NNP N
Three CD 1_p
hundred VBD 1_p
sixty-five JJ 1_p
patients NNS 1_p
were VBD N
enrolled VBN N
. . N

One CD N
hundred VBD N
eighty-three JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
, , N
and CC N
182 CD N
were VBD N
assigned VBN N
to TO N
the DT N
120K CD N
arm NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
patients NNS N
requiring VBG 1_o
transfusions NNS 1_o
during IN N
the DT N
study NN N
( ( N
23 CD N
% NN N
in IN N
40K CD N
arm NN N
and CC N
18 CD N
% NN N
in IN N
120K CD N
arm NN N
, , N
P NNP N
= NNP N
.22 NNP N
) ) N
or CC N
specifically RB N
during IN N
the DT N
maintenance NN N
phase NN N
( ( N
13 CD N
% NN N
in IN N
40K CD N
arm NN N
v NN N
15 CD N
% NN N
in IN N
120K CD N
arm NN N
, , N
P NNP N
= NNP N
.58 NNP N
) ) N
. . N

Patients NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
> NN N
or CC N
= VB N
2 CD N
or CC N
> CD N
or CC N
= VB N
3 CD N
g/dL NN N
hemoglobin NN 1_o
( ( 1_o
Hb NNP 1_o
) ) 1_o
increment NN 1_o
, , N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
drug NN 1_o
dose RB 1_o
held VBD N
because IN N
of IN N
high JJ N
Hb NNP 1_o
, , N
and CC N
had VBD N
higher JJR N
mean JJ N
end-of-study JJ N
Hb NNP 1_o
levels NNS N
. . N

Toxicities NNS 1_o
, , 1_o
including VBG 1_o
thromboembolism NN 1_o
, , N
and CC N
overall JJ 1_o
survival NN 1_o
were VBD N
similar JJ N
. . N

Patients NNS N
in IN N
the DT N
40K CD N
arm NN N
had VBD N
a DT N
higher JJR N
global JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QOL NNP 1_o
) ) 1_o
at IN N
baseline NN N
for IN N
unclear JJ N
reasons NNS N
, , N
whereas JJ N
patients NNS N
in IN N
the DT N
120K CD N
arm NN N
had VBD N
a DT N
greater JJR N
global JJ 1_o
QOL NNP 1_o
improvement NN N
during IN N
the DT N
study NN N
, , N
so IN N
end-of-study JJ N
QOL NNP 1_o
was VBD N
equivalent JJ N
. . N

CONCLUSION NN N
After IN N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN 1_i
alfa NN 1_i
40,000 CD N
U NNP N
, , N
a DT N
dose NN N
of IN N
120,000 CD N
U NNS N
can MD N
be VB N
administered VBN N
safely RB 1_o
once RB N
every DT N
3 CD N
weeks NNS N
without IN N
increasing VBG N
transfusion NN 1_o
needs NNS 1_o
or CC N
sacrificing VBG N
QOL NNP 1_o
. . 1_o

The DT N
Hb NNP 1_o
increment NN 1_o
is VBZ N
somewhat RB N
greater JJR N
with IN N
continued JJ N
weekly JJ N
epoetin NN 1_i
alfa NN 1_i
. . 1_i

Lack NNP N
of IN N
blinding VBG N
as IN N
a DT N
result NN N
of IN N
different JJ N
treatment NN N
schedules NNS N
may MD N
have VB N
confounded VBN N
results NNS N
. . N

Social NNP 1_o
skills NNS 1_o
improvement NN N
in IN N
children NNS 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
: : 1_p
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

High-functioning JJ N
autism NN N
( ( N
HFA NNP N
) ) N
is VBZ N
characterized VBN N
by IN N
persistent JJ N
impairment NN N
in IN N
social JJ N
interaction NN N
despite IN N
the DT N
absence NN N
of IN N
mental JJ N
retardation NN N
. . N

Although IN N
an DT N
increasing VBG N
number NN N
of IN N
group-based JJ N
programs NNS N
for IN N
the DT N
improvement NN N
of IN N
social JJ 1_o
skills NNS 1_o
have VBP N
been VBN N
described VBN N
, , N
randomized VBN N
controlled VBN N
trials NNS N
are VBP N
needed VBN N
to TO N
evaluate VB N
their PRP$ N
efficacy NN 1_o
. . 1_o

To TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
Social NNP 1_i
Skills NNP 1_i
Training NNP 1_i
Group-based JJ 1_i
Program NNP 1_i
( ( 1_i
SST-GP NNP 1_i
) ) 1_i
and CC N
a DT N
Leisure NN 1_i
Activities VBZ 1_i
Group-based JJ 1_i
Program NNP 1_i
( ( 1_i
LA-GP NNP 1_i
) ) 1_i
on IN N
the DT N
perception NN 1_o
of IN 1_o
facial JJ 1_o
emotions NNS 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
in IN N
young JJ 1_p
people NNS 1_p
with IN 1_p
HFA NNP 1_p
. . 1_p

Eligible JJ 1_p
patients NNS 1_p
were VBD 1_p
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
HFA NNP 1_p
. . 1_p

Participants NNS N
were VBD N
randomized VBN N
to TO N
the DT N
SST NNP 1_i
or CC N
LA NNP 1_i
group NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
an DT N
improvement NN 1_o
of IN 1_o
2 CD 1_o
points NNS 1_o
in IN 1_o
error NN 1_o
rates NNS 1_o
for IN 1_o
facial JJ 1_o
emotion NN 1_o
labeling NN 1_o
( ( 1_o
DANVA2 NNP 1_o
) ) 1_o
from IN 1_o
baseline NN 1_o
. . 1_o

After IN N
the DT N
6-month JJ N
training NN N
period NN N
, , N
the DT N
SST NNP 1_i
Group NNP N
made VBD N
fewer JJR N
errors NNS N
in IN N
labeling VBG 1_o
anger NN 1_o
on IN N
adult NN N
faces VBZ N
, , N
whereas JJ N
error NN N
rates NNS N
in IN N
the DT N
LA NNP 1_i
Group NNP N
remained VBD N
stable JJ N
. . N

Progress NN N
in IN N
the DT N
ability NN 1_o
to TO 1_o
recognize VB 1_o
anger NN 1_o
in IN N
the DT N
SST NNP 1_i
Group NNP N
was VBD N
due JJ N
to TO N
better JJR N
recognition NN N
of IN N
low JJ N
intensity NN N
stimuli NN N
on IN N
adult NN N
faces VBZ N
. . N

QoL NNP 1_o
increased VBD N
in IN N
the DT N
SST NNP 1_i
Group NNP N
in IN N
the DT N
dimension NN N
of IN N
school NN N
environment NN N
, , N
as IN N
a DT N
marker NN N
of IN N
the DT N
transfer NN N
of IN N
skills NNS N
acquired VBN N
in IN N
the DT N
treatment NN N
setting VBG N
to TO N
their PRP$ N
use NN N
in IN N
the DT N
community NN N
. . N

The DT N
SST-GP NNP 1_i
had VBD N
higher JJR N
efficacy NN 1_o
than IN N
the DT N
LA-GP NNP 1_i
. . 1_i

Data NNP N
justify NN N
replication NN N
using VBG N
larger JJR N
samples NNS N
. . N

Sleep-anticipating JJ N
effects NNS 1_o
of IN N
melatonin NN 1_i
in IN N
the DT N
human JJ 1_p
brain NN N
. . N

Melatonin NNP N
, , N
the DT N
hormone NN N
produced VBN N
nocturnally RB N
by IN N
the DT N
pineal NN N
gland NN N
, , N
is VBZ N
an DT N
endogenous JJ N
regulator NN N
of IN N
the DT N
sleep-wake JJ N
cycle NN N
. . N

The DT N
effects NNS N
of IN N
melatonin NN 1_i
on IN N
brain NN 1_o
activities NNS 1_o
and CC N
their PRP$ N
relation NN N
to TO N
induction NN 1_o
of IN 1_o
sleepiness NN 1_o
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo NN N
controlled VBD N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
study NN N
. . N

Melatonin NNP 1_i
, , N
but CC N
not RB N
placebo VB 1_i
, , N
reduced VBN N
task-related JJ 1_o
activity NN 1_o
in IN N
the DT N
rostro-medial JJ N
aspect NN N
of IN N
the DT N
occipital JJ N
cortex NN N
during IN N
a DT N
visual-search JJ N
task NN N
and CC N
in IN N
the DT N
auditory JJ N
cortex NN N
during IN N
a DT N
music NN N
task NN N
. . N

These DT N
effects NNS N
correlated VBD N
with IN N
subjective JJ 1_o
measurements NNS 1_o
of IN 1_o
fatigue NN 1_o
. . 1_o

In IN N
addition NN N
, , N
melatonin NN 1_i
enhanced VBD N
the DT N
activation NN 1_o
in IN 1_o
the DT 1_o
left NN 1_o
parahippocampus NN 1_o
in IN N
an DT N
autobiographic JJ N
memory NN N
task NN N
. . N

Results VB N
demonstrate NN N
that IN N
melatonin NN 1_i
modulates NNS N
brain NN 1_o
activity NN 1_o
in IN N
a DT N
manner NN N
resembling VBG N
actual JJ N
sleep NN N
although IN N
subjects NNS N
are VBP N
fully RB N
awake RB N
. . N

Furthermore RB N
, , N
the DT N
fatigue NN 1_o
inducing VBG N
effect NN 1_o
of IN N
melatonin NN 1_i
on IN N
brain NN 1_o
activity NN 1_o
is VBZ N
essentially RB N
different JJ N
from IN N
that DT N
of IN N
sleep JJ N
deprivation NN N
thus RB N
revealing VBG N
differences NNS N
between IN N
fatigues NNS N
related VBN N
to TO N
the DT N
circadian JJ N
sleep NN N
regulation NN N
as IN N
opposed VBN N
to TO N
increased VBN N
homeostatic JJ N
sleep NN N
need NN N
. . N

Our PRP$ N
findings NNS N
highlight VBD N
the DT N
role NN N
of IN N
melatonin NN 1_i
in IN N
priming VBG N
sleep-associated JJ 1_o
brain NN 1_o
activation NN 1_o
patterns NNS N
in IN N
anticipation NN N
of IN N
sleep NN N
. . N

The DT N
role NN N
of IN N
somatostatin NN 1_i
( ( 1_i
octreotide JJ 1_i
) ) 1_i
in IN N
the DT N
regulation NN 1_o
of IN 1_o
melatonin JJ 1_o
secretion NN 1_o
in IN N
healthy JJ 1_p
volunteers NNS 1_p
and CC 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
hypothyroidism NN 1_p
. . 1_p

Somatostatin NNP 1_i
has VBZ N
been VBN N
found VBN N
in IN N
the DT N
pineal JJ N
gland NN N
of IN N
several JJ N
animal JJ N
species NNS N
, , N
which WDT N
suggests VBZ N
that IN N
it PRP N
may MD N
be VB N
involved VBN N
in IN N
the DT N
regulation NN 1_o
of IN 1_o
melatonin JJ 1_o
secretion NN 1_o
. . 1_o

Whether NNP N
somatostatin NN 1_i
has VBZ N
regulatory JJ 1_o
influence NN 1_o
on IN 1_o
melatonin NN 1_o
secretion NN 1_o
in IN N
man NN N
has VBZ N
never RB N
been VBN N
unequivocally RB N
shown VBN N
. . N

We PRP N
studied VBD N
the DT N
nocturnal JJ 1_o
melatonin NN 1_o
secretion NN 1_o
in IN N
8 CD 1_p
healthy JJ 1_p
volunteers NNS 1_p
, , 1_p
and CC 1_p
6 CD 1_p
women NNS 1_p
with IN 1_p
untreated JJ 1_p
primary JJ 1_p
hypothyroidism NN 1_p
, , N
a DT N
disease NN N
state NN N
that WDT N
is VBZ N
associated VBN N
with IN N
increased JJ N
nocturnal JJ N
secretion NN N
of IN N
melatonin NN N
. . N

The DT N
participants NNS N
were VBD N
given VBN N
subcutaneous JJ N
injections NNS N
at IN N
18:00 CD N
h NN N
and CC N
23:00 CD N
h NN N
of IN N
either DT N
saline NN 1_i
or CC N
octreotide NN 1_i
( ( 1_i
Sandostatin NNP 1_i
; : 1_i
each DT N
injection NN N
50 CD N
microg NN N
) ) N
. . N

During IN N
the DT N
nights NNS N
when WRB N
the DT N
healthy JJ 1_p
volunteers NNS 1_p
were VBD N
given VBN N
octreotide RB 1_i
, , N
melatonin JJ 1_o
secretion NN 1_o
was VBD N
similar JJ N
to TO N
that DT N
recorded VBN N
during IN N
administration NN N
of IN N
saline NN 1_i
. . 1_i

Also RB N
the DT N
urinary JJ 1_o
excretion NN 1_o
of IN 1_o
melatonin NN 1_o
was VBD N
of IN N
similar JJ N
magnitude NN N
at IN N
these DT N
two CD N
occasions NNS N
. . N

By IN N
contrast NN N
, , N
the DT N
GH NNP 1_o
secretion NN 1_o
was VBD N
significantly RB N
lower JJR N
the DT N
nights NNS N
the DT N
healthy JJ 1_p
controls NNS 1_p
were VBD N
given VBN N
octreotide RB 1_i
( ( N
GH NNP N
AUC NNP N
22.6+/-5.4 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ 1_i
and CC N
126.6+/-21.9 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline NN 1_i
; : 1_i
p CC N
< VB N
0.01 CD N
) ) N
. . N

The DT 1_p
patients NNS 1_p
with IN 1_p
hypothyroidism NN 1_p
also RB N
showed VBD N
similar JJ N
nocturnal JJ 1_o
melatonin NN 1_o
secretion NN 1_o
during IN N
octreotide NN 1_i
and CC N
saline NN 1_i
. . 1_i

Urinary JJ 1_o
excretion NN 1_o
of IN 1_o
melatonin NN 1_o
also RB N
remained VBD N
unchanged JJ N
, , N
as IN N
did VBD N
GH NNP N
secretion NN N
. . N

The DT N
total JJ 1_o
nocturnal JJ 1_o
secretion NN 1_o
of IN 1_o
TSH NNP 1_o
was VBD N
, , N
however RB N
, , N
significantly RB N
reduced VBN N
by IN N
octreotide NN 1_i
( ( N
TSH NNP N
AUC NNP N
562+/-136 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ 1_i
and CC N
851+/-185 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline NN 1_i
; : 1_i
p CC N
< VB N
0.05 CD N
) ) N
, , N
thus RB N
suggesting VBG N
that IN N
100 CD N
microg NN N
of IN N
octreotide NN 1_i
should MD N
be VB N
sufficient JJ N
to TO N
inhibit VB N
also RB N
the DT N
pinealocytes NNS N
if IN N
their PRP$ N
function NN N
were VBD N
regulated VBN N
by IN N
somatostatin NN 1_i
. . 1_i

Since IN N
exogenous JJ N
somatostatin NN 1_i
-- : 1_i
in IN 1_i
the DT N
form NN N
of IN N
octreotide NN 1_i
-- : 1_i
fails VBZ 1_i
to TO N
influence VB N
nocturnal JJ 1_o
secretion NN 1_o
and CC 1_o
urinary JJ 1_o
excretion NN 1_o
of IN 1_o
melatonin NN 1_o
in IN N
normal JJ 1_p
subjects NNS 1_p
and CC 1_p
in IN 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
hypothyroidism NN 1_p
, , N
it PRP N
is VBZ N
reasonable JJ N
to TO N
assume VB N
that DT N
endogenous JJ N
somatostatin NN 1_i
may MD N
not RB N
be VB N
an DT N
important JJ N
regulator NN 1_o
of IN 1_o
melatonin JJ 1_o
secretion NN 1_o
in IN N
man NN N
. . N

The DT N
efficacy NN 1_o
of IN N
prophylactic JJ N
ondansetron NN 1_i
, , 1_i
droperidol NN 1_i
, , 1_i
perphenazine NN 1_i
, , N
and CC N
metoclopramide RB 1_i
in IN N
the DT N
prevention NN N
of IN N
nausea NN N
and CC N
vomiting NN N
after IN N
major JJ 1_p
gynecologic NN 1_p
surgery NN 1_p
. . 1_p

The DT N
prophylactic JJ N
antiemetic JJ N
efficacy NN 1_o
of IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
ondansetron NN 1_i
, , 1_i
droperidol NN 1_i
, , 1_i
perphenazine NN 1_i
, , N
and CC N
metoclopramide NN 1_i
was VBD N
evaluated VBN N
in IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
of IN N
360 CD 1_p
ASA NNP 1_p
physical JJ 1_p
status NN 1_p
I-III NNP 1_p
patients NNS 1_p
undergoing VBG 1_p
total JJ 1_p
abdominal JJ 1_p
hysterectomy NN 1_p
( ( 1_p
TAH NNP 1_p
) ) 1_p
. . 1_p

Subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
i.v. NN N
, , N
one CD N
of IN N
ondansetron NN 1_i
4 CD N
mg NN N
, , N
droperidol VBZ 1_i
1.25 CD N
mg NN N
, , N
perphenazine VBP 1_i
5 CD N
mg NN N
, , N
metoclopramide RB 1_i
10 CD N
mg NN N
, , N
or CC N
placebo RB 1_i
prior JJ N
to TO N
induction NN N
of IN N
anesthesia NN N
. . N

Hypotension NNP 1_o
immediately RB N
after IN N
administration NN N
of IN N
metoclopramide NN 1_i
was VBD N
observed VBN N
in IN N
two CD N
patients NNS N
and CC N
four CD N
patients NNS N
given VBN N
ondansetron RP 1_i
developed JJ N
profound NN N
systolic JJ 1_o
hypotension NN 1_o
at IN N
induction NN N
of IN N
anesthesia NN N
. . N

Twenty-two JJ N
percent NN N
of IN N
patients NNS N
receiving VBG N
droperidol NN 1_i
became VBD N
sedated JJ N
. . N

Postoperatively RB N
, , N
patients NNS N
developing VBG N
severe JJ 1_o
nausea NN 1_o
, , 1_o
retching NN 1_o
, , 1_o
or CC 1_o
vomiting NN 1_o
, , 1_o
defined VBD 1_o
as IN 1_o
severe JJ 1_o
emetic JJ 1_o
sequelae NN 1_o
( ( 1_o
SES NNP 1_o
) ) 1_o
, , N
were VBD N
deemed VBN N
to TO N
have VB N
failed VBN N
antiemetic JJ N
prophylaxis NN N
and CC N
received VBN N
antiemetic JJ N
rescue NN N
. . N

A DT N
significantly RB N
larger JJR N
number NN N
of IN N
patients NNS N
who WP N
received VBD N
i.v NN N
. . N

ondansetron NN 1_i
( ( N
63 CD N
% NN N
) ) N
, , N
droperidol NN 1_i
( ( N
76 CD N
% NN N
) ) N
, , N
and CC N
perphenazine NN 1_i
( ( N
70 CD N
% NN N
) ) N
were VBD N
free JJ N
of IN N
SES NNP 1_o
when WRB N
compared VBN N
to TO N
placebo VB 1_i
( ( N
43 CD N
% NN N
) ) N
; : N
P NNP N
< VBD N
0.05 CD N
. . N

Metoclopramide NNP 1_i
was VBD N
ineffective JJ N
. . N

Although IN N
ondansetron NN 1_i
, , 1_i
droperidol NN 1_i
, , N
and CC N
perphenazine NN 1_i
were VBD N
effective JJ 1_o
in IN N
providing VBG N
antiemetic JJ N
prophylaxis NN N
, , N
only RB N
i.v NN N
. . N

perphenazine NN 1_i
was VBD N
free JJ N
of IN N
side JJ 1_o
effects NNS 1_o
. . 1_o

Hence NNP N
, , N
we PRP N
conclude VBP N
that DT N
perphenazine NN 1_i
is VBZ N
the DT N
best JJS N
choice NN N
for IN N
antiemetic JJ N
prophylaxis NN N
after IN N
TAH NNP N
. . N

Atomoxetine NNP 1_i
in IN N
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
no DT N
effects NNS N
on IN N
social JJ 1_o
functioning NN 1_o
; : 1_o
some DT N
beneficial JJ N
effects NNS N
on IN N
stereotyped JJ 1_o
behaviors NNS 1_o
, , 1_o
inappropriate JJ 1_o
speech NN 1_o
, , 1_o
and CC 1_o
fear NN 1_o
of IN 1_o
change NN 1_o
. . 1_o

UNLABELLED NNP N
Abstract NNP N
Objective NNP N
: : N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
treatment NN N
effects NNS 1_o
of IN N
atomoxetine NN 1_i
on IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
symptoms NNS N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
both DT 1_p
ASD NNP 1_p
and CC 1_p
attention-deficit/hyperactivity JJ 1_p
disorder NN 1_p
( ( 1_p
ADHD NNP 1_p
) ) 1_p
. . 1_p

METHODS CC N
A DT N
total NN N
of IN N
97 CD 1_p
patients NNS 1_p
6-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
ADHD NNP 1_p
, , N
were VBD N
treated VBN N
with IN N
1.2 CD N
mg/kg/day NN N
of IN 1_i
atomoxetine NN 1_i
during IN N
an DT N
8 CD N
week NN N
double-blind JJ 1_i
placebo-controlled JJ 1_i
period NN N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
effects NNS N
on IN N
two CD N
parent-based JJ N
secondary JJ N
outcome NN N
measures NNS 1_o
, , 1_o
the DT 1_o
Aberrant NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
( ( 1_o
ABC NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
Children NNP 1_o
's POS 1_o
Social NNP 1_o
Behavior NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
CSBQ NNP 1_o
) ) 1_o
. . N

RESULTS NNP N
After IN N
8 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN 1_i
, , 1_i
atomoxetine JJ 1_i
administration NN N
was VBD N
associated VBN N
with IN N
significant JJ N
treatment NN N
effects NNS N
on IN N
the DT 1_o
ABC NNP 1_o
subscales VBZ 1_o
Hyperactivity NNP 1_o
, , 1_o
Inappropriate NNP 1_o
Speech NNP 1_o
, , 1_o
and CC 1_o
Stereotypic NNP 1_o
Behavior NNP 1_o
, , N
and CC N
on IN N
the DT 1_o
CSBQ NNP 1_o
subscale NN 1_o
Fear NNP 1_o
for IN 1_o
Changes NNP 1_o
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
results NNS N
indicate VBP N
no DT N
beneficial JJ N
effects NNS N
of IN 1_i
atomoxetine NN 1_i
on IN N
social JJ N
functioning NN N
. . N

However RB 1_i
, , 1_i
atomoxetine NN 1_i
may MD N
ameliorate VB 1_o
restricted VBN 1_o
and CC 1_o
stereotyped VBN 1_o
behaviors NNS 1_o
and CC 1_o
communication NN 1_o
. . N

This DT N
study NN N
has VBZ N
been VBN N
registered VBN N
in IN N
ClinicalTrials.gov NNP N
( ( N
www.clinicaltrials.gov NN N
) ) N
under IN N
registration NN N
number NN N
NCT00380692 NNP N
. . N

[ JJ 1_i
Antazoline/tetryzoline NNP 1_i
eyedrops NNS N
in IN N
comparison NN N
with IN N
levocabastine JJ 1_i
eyedrops NNS N
in IN N
acute JJ 1_p
allergic JJ 1_p
conjunctivitis NN 1_p
] NNP 1_p
. . N

BACKGROUND NNP N
Allergic NNP N
conjunctivitis NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
allergic JJ N
diseases NNS N
of IN N
the DT N
anterior JJ N
eye NN N
segment NN N
. . N

METHODS NNP N
This DT N
multicentre NN N
, , N
clinical JJ N
trial NN N
was VBD N
an DT N
investigation NN N
to TO N
compare VB N
the DT N
antiallergic JJ N
efficacy NN 1_o
, , 1_o
local JJ 1_o
tolerance NN 1_o
and CC 1_o
safety NN 1_o
of IN N
Antazolin/Tetryzolin NNP 1_i
eye NN N
drops NNS N
and CC N
Levocabastine NNP 1_i
eye NN N
drops NNS N
. . N

69 CD 1_p
patients NNS 1_p
were VBD N
treated VBN N
over IN N
a DT N
2 CD N
weeks NNS N
course NN N
of IN N
therapy NN N
. . N

The DT N
subjective JJ 1_o
and CC 1_o
objective JJ 1_o
ocular NN 1_o
symptoms NNS 1_o
were VBD N
documented VBN N
over IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS NNP N
Both NNP N
eye NN N
drops NNS N
reduced VBD N
subjective JJ 1_o
and CC 1_o
objective JJ 1_o
ocular NN 1_o
symptoms NNS 1_o
effective JJ N
. . N

The DT N
difference NN N
between IN N
the DT N
treatments NNS N
( ( N
p JJ N
= NNP N
0.0395 CD N
) ) N
was VBD N
the DT N
faster JJ N
onset NN 1_o
of IN 1_o
action NN 1_o
of IN N
Antazolin/Tetryzolin NNP 1_i
30 CD N
minutes NNS N
after IN N
administration NN N
of IN N
the DT N
first JJ N
drop NN N
of IN N
trial NN N
medication NN N
. . N

CONCLUSION VB N
A DT N
fast JJ N
and CC N
effective JJ 1_o
onset NN 1_o
of IN 1_o
action NN 1_o
is VBZ N
of IN N
high JJ N
clinical JJ N
relevance NN N
. . N

Therefore IN N
the DT N
benefits NNS N
of IN N
using VBG N
Antazolin/Tetryzolin NNP 1_i
eye NN N
drops NN N
was VBD N
clearly RB N
outweigh JJ N
. . N

Lowering VBG N
the DT N
triglyceride/high-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
ratio NN 1_o
is VBZ N
associated VBN N
with IN N
the DT N
beneficial JJ N
impact NN N
of IN N
pioglitazone NN 1_i
on IN N
progression NN 1_o
of IN 1_o
coronary JJ 1_o
atherosclerosis NN 1_o
in IN N
diabetic JJ 1_p
patients NNS 1_p
: : 1_p
insights NNS N
from IN N
the DT N
PERISCOPE NNP N
( ( 1_i
Pioglitazone NNP 1_i
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation NNP N
) ) N
study NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
factors NNS N
associated VBN N
with IN N
the DT N
favorable JJ N
effect NN 1_o
of IN N
pioglitazone NN 1_i
on IN N
atheroma JJ 1_o
progression NN 1_o
. . 1_o

BACKGROUND NNP N
Diabetes NNP N
mellitus NN N
is VBZ N
associated VBN N
with IN N
accelerated JJ N
coronary JJ 1_o
atheroma NN 1_o
progression NN 1_o
. . 1_o

Pioglitazone NN 1_i
slowed VBD N
progression NN 1_o
compared VBN N
with IN N
glimepiride NN 1_i
in IN N
this DT N
population NN N
. . N

METHODS NNP N
In IN N
all DT N
, , N
360 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
were VBD N
treated VBN N
with IN N
pioglitazone NN 1_i
or CC N
glimepiride NN 1_i
for IN N
18 CD N
months NNS N
in IN N
the DT N
PERISCOPE NNP N
( ( 1_i
Pioglitazone NNP 1_i
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation NNP N
) ) N
study NN N
. . N

Coronary NNP 1_o
atheroma NN 1_o
progression NN 1_o
was VBD 1_o
evaluated VBN 1_o
by IN 1_o
serial JJ 1_o
intravascular JJ 1_o
ultrasound NN 1_o
. . 1_o

The DT N
relationship NN N
between IN N
changes NNS 1_o
in IN 1_o
biochemical JJ 1_o
parameters NNS 1_o
, , 1_o
percent JJ 1_o
atheroma NN 1_o
volume NN 1_o
, , 1_o
and CC 1_o
total JJ 1_o
atheroma NN 1_o
volume NN 1_o
was VBD N
investigated VBN N
. . N

RESULTS JJ N
Pioglitazone-treated JJ 1_i
patients NNS N
demonstrated VBD N
greater JJR N
increases NNS N
in IN N
high-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
( ( 1_o
HDL-C NNP 1_o
) ) 1_o
and CC N
reductions NNS N
in IN N
glycated JJ 1_o
hemoglobin NN 1_o
, , 1_o
triglycerides NNS 1_o
, , 1_o
and CC 1_o
C-reactive JJ 1_o
protein NN 1_o
. . 1_o

Significant JJ N
correlations NNS N
were VBD N
observed VBN N
between IN N
changes NNS N
in IN N
percent NN 1_o
atheroma NN 1_o
volume NN 1_o
and CC 1_o
triglycerides NNS 1_o
( ( N
r VB N
= RB N
0.15 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
, , N
triglyceride/HDL-C JJ 1_o
ratio NN 1_o
( ( N
r JJ N
= NN N
0.16 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
glycated VBD 1_o
hemoglobin NN 1_o
( ( N
r JJ N
= NN N
0.16 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
with IN N
pioglitazone NN 1_i
, , N
and CC N
changes NNS N
in IN N
low-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
( ( N
r JJ N
= NNP N
-0.15 NNP N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
apolipoprotein RB 1_o
B NNP 1_o
( ( N
r NN N
= NNP N
-0.16 NNP N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
apolipoprotein RB 1_o
A-I NNP 1_o
( ( N
r NN N
= NNP N
-0.20 NNP N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
with IN N
glimepiride NN 1_i
. . 1_i

Substantial JJ 1_o
atheroma JJ 1_o
regression NN 1_o
, , N
compared VBN N
to TO N
progression NN 1_o
, , N
was VBD N
associated VBN N
with IN N
greater JJR N
relative JJ N
increases NNS N
in IN N
HDL-C NNP 1_o
( ( N
14.2 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
, , N
relative JJ N
decreases NNS N
in IN N
triglycerides NNS 1_o
( ( N
-13.3 CD N
% NN N
vs. FW N
-1.9 CD N
% NN N
, , N
p NN N
= NNP N
0.045 CD N
) ) N
, , N
triglyceride/HDL-C JJ 1_o
ratio NN 1_o
( ( N
-22.5 NNP N
vs. FW N
-9.9 NNP N
% NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
and CC N
decrease NN N
in IN N
glycated JJ 1_o
hemoglobin NN 1_o
( ( N
-0.6 CD N
% NN N
vs. FW N
-0.3 CD N
% NN N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

Multivariable JJ N
analysis NN N
revealed VBD N
that IN N
pioglitazone-induced JJ 1_i
effects NNS N
on IN N
triglyceride/HDL-C NN 1_o
were VBD N
associated VBN N
with IN N
changes NNS N
in IN N
percent NN 1_o
atheroma NN 1_o
volume NN 1_o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
total JJ 1_o
atheroma NN 1_o
volume NN 1_o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP N
Favorable JJ N
effects NNS N
of IN N
pioglitazone NN 1_i
on IN N
the DT N
triglyceride/HDL-C JJ 1_o
ratio NN 1_o
correlated VBN N
with IN N
delayed JJ N
atheroma NN 1_o
progression NN 1_o
in IN N
diabetic JJ 1_p
patients NNS 1_p
. . 1_p

This DT N
finding NN N
highlights VBZ N
the DT N
potential JJ N
importance NN N
of IN N
targeting VBG N
atherogenic JJ N
dyslipidemia NN N
in IN N
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
. . 1_p

A DT N
randomized JJ N
comparison NN N
of IN N
alternative JJ N
techniques NNS N
to TO N
achieve VB N
coronary JJ N
sinus NN N
cannulation NN N
during IN N
biventricular JJ 1_p
implantation NN 1_p
procedures NNS 1_p
. . 1_p

INTRODUCTION NNP N
Biventricular NNP N
pacing VBG N
system NN N
implantation NN N
is VBZ N
a DT N
time-consuming JJ N
and CC N
challenging JJ N
procedure NN N
. . N

A DT N
critical JJ N
step NN N
in IN N
biventricular JJ N
pacemaker NN N
implantation NN N
is VBZ N
coronary JJ N
sinus NN N
( ( N
CS NNP N
) ) N
cannulation NN N
. . N

CS NNP N
cannulation NN N
can MD N
be VB N
achieved VBN N
either DT N
using VBG N
dedicated JJ N
guiding NN N
catheters NNS 1_i
( ( 1_i
guiding VBG 1_i
catheter NN 1_i
alone RB 1_i
positioning VBG N
strategy NN N
, , N
GCA NNP N
) ) N
or CC N
with IN N
the DT N
aid NN N
of IN N
an DT N
electrophysiology NN 1_i
catheter NN 1_i
advanced VBD 1_i
inside IN N
the DT N
guiding NN N
catheter NN N
( ( 1_i
electrophysiology JJ 1_i
catheter NN 1_i
aided VBD 1_i
positioning VBG N
strategy NN N
, , N
EPA NNP N
) ) N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
evaluate VB N
whether IN N
the DT N
EPA NNP 1_i
technique NN N
is VBZ N
useful JJ N
for IN N
reducing VBG N
CS NNP 1_o
cannulation NN 1_o
time NN 1_o
compared VBN N
to TO N
a DT N
conventional JJ N
GCA NNP 1_i
technique NN N
. . N

METHODS NNP N
Thirty-four JJ 1_p
consecutive JJ 1_p
patients NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
GCA NNP 1_i
( ( N
18 CD N
patients NNS N
) ) N
or CC N
EPA NNP 1_i
( ( N
16 CD N
patients NNS N
) ) N
CS NNP N
cannulation NN N
strategy NN N
. . N

RESULTS JJ N
Time NNP 1_o
to TO 1_o
successful JJ 1_o
catheterization NN 1_o
of IN 1_o
CS NNP 1_o
was VBD N
5.0 CD N
+/- JJ N
2.4 CD N
min NN N
in IN N
the DT N
EPA NNP 1_i
group NN N
versus VBD N
10.1 CD N
+/- JJ N
5.4 CD N
min NN N
in IN N
the DT N
GCA NNP 1_i
group NN N
p VBD N
= RB N
0.004 CD N
. . N

Fluoroscopy NN 1_o
time NN 1_o
was VBD N
4.6 CD N
+/- JJ N
2.3 CD N
min NN N
in IN N
the DT N
EPA NNP 1_i
group NN N
versus VBD N
9.2 CD N
+/- JJ N
4.9 CD N
min NN N
in IN N
the DT N
GCA NNP 1_i
group NN N
p VBD N
= RB N
0.004 CD N
. . N

Total JJ N
contrast NN 1_o
dye NN 1_o
volume NN 1_o
to TO N
search NN N
and CC N
engage VB N
the DT N
CS NNP N
ostium NN N
was VBD N
0.0 CD N
ml NN N
in IN N
the DT N
EPA NNP 1_i
group NN N
versus VBD N
14.3 CD N
+/- JJ N
3.4 CD N
ml NN N
in IN N
the DT N
GCA NNP 1_i
group NN N
p VBD N
< RB N
0.001 CD N
. . N

CONCLUSIONS NNP N
Cannulation NNP N
of IN N
CS NNP N
with IN N
the DT N
adjunct NN N
of IN N
an DT N
electrophysiology NN N
catheter NN N
to TO N
dedicated VBN N
delivery NN N
systems NNS N
significantly RB N
reduces VBZ N
procedural JJ 1_o
time NN 1_o
, , 1_o
fluoroscopy JJ 1_o
time NN 1_o
and CC 1_o
contrast NN 1_o
dye NN 1_o
volume NN 1_o
compared VBN N
to TO N
a DT N
conventional JJ N
strategy NN N
. . N

Role NNP N
of IN N
angiotensin-converting JJ 1_i
enzyme NN 1_i
inhibitors NNS 1_i
in IN N
early JJ N
antihypertensive JJ N
treatment NN N
in IN N
non-insulin JJ 1_p
dependent NN 1_p
diabetes VBZ 1_p
mellitus NN 1_p
. . 1_p

The DT N
effect NN N
of IN N
captopril NN 1_i
monotherapy NN N
on IN N
blood NN 1_o
pressure NN 1_o
and CC 1_o
metabolism NN 1_o
was VBD N
investigated VBN N
in IN N
a DT N
placebo-controlled JJ 1_i
study NN N
in IN N
30 CD 1_p
non-insulin JJ 1_p
dependent NN 1_p
( ( 1_p
Type NNP 1_p
II NNP 1_p
) ) 1_p
diabetic JJ 1_p
subjects NNS 1_p
during IN N
a DT N
3-week JJ N
observation NN N
period NN N
( ( N
run-in/drug JJ N
; : N
placebo/wash-out NN 1_i
) ) 1_i
on IN N
a DT N
metabolic JJ N
ward NN N
. . N

Captopril NNP 1_i
significantly RB N
reduced VBD N
both DT N
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( N
154/90 CD N
+/- JJ N
5/2 CD N
vs. FW N
144/86 CD N
+/- JJ N
4/3 CD N
mmHg NN N
) ) N
without IN N
major JJ N
side NN N
effects NNS N
. . N

Mean JJ N
run-in JJ N
postprandial JJ 1_o
blood NN 1_o
glucose JJ 1_o
concentrations NNS 1_o
were VBD N
also RB N
reduced VBN N
upon IN N
ACE-inhibition NNP N
( ( N
9 CD N
a.m. RB N
: : N
12.7 CD N
+/- JJ N
0.4 CD N
vs. FW N
11.1 CD N
+/- JJ N
0.4 CD N
mmol/l NN N
; : N
1 CD N
p.m. NN N
: : N
11.0 CD N
+/- JJ N
0.3 CD N
vs. FW N
8.9 CD N
+/- JJ N
0.3 CD N
mmol/l NN N
; : N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
while IN N
blood NN 1_o
kinin NN 1_o
concentrations NNS 1_o
( ( N
40.0 CD N
+/- JJ N
2.5 CD N
pmol/l NN N
) ) N
were VBD N
approximately RB N
doubled VBN N
( ( N
108.8 CD N
+/- JJ N
23.5 CD N
pmol/l NN N
; : N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Body NNP 1_o
mass NN 1_o
index NN 1_o
, , 1_o
fasting VBG 1_o
plasma JJ 1_o
insulin NN 1_o
, , 1_o
serum JJ 1_o
electrolyte NN 1_o
pattern NN 1_o
, , 1_o
uric JJ 1_o
acid NN 1_o
, , 1_o
white JJ 1_o
blood NN 1_o
count NN 1_o
, , 1_o
lipid JJ 1_o
profile NN 1_o
as RB 1_o
well RB 1_o
as IN 1_o
hepatic JJ 1_o
and CC 1_o
renal JJ 1_o
function NN 1_o
parameters NNS N
remained VBD N
unaltered JJ N
throughout IN N
the DT N
observation NN N
period NN N
. . N

The DT N
data NNS N
are VBP N
in IN N
line NN N
with IN N
recent JJ N
experimental JJ N
studies NNS N
showing VBG N
a DT N
beneficial JJ N
metabolic JJ 1_o
effect NN 1_o
of IN N
captopril NN 1_i
in IN N
Type NNP 1_p
II NNP 1_p
diabetes VBZ 1_p
. . 1_p

ACE NNP 1_i
inhibitors NNS 1_i
might MD N
therefore VB N
become JJ N
first-line JJ N
drugs NNS N
in IN N
early JJ N
antihypertensive JJ N
intervention NN N
in IN N
Type NNP 1_p
II NNP 1_p
diabetic JJ 1_p
patients NNS 1_p
. . 1_p

Necessary NNP N
but CC N
not RB N
sufficient JJ N
: : N
the DT N
effect NN N
of IN N
screening NN N
and CC N
feedback NN N
on IN N
outcomes NNS 1_o
of IN N
primary JJ 1_p
care NN 1_p
patients NNS 1_p
with IN 1_p
untreated JJ 1_p
anxiety NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
consider VB N
the DT N
impact NN N
on IN N
primary JJ N
care NN N
patient JJ N
outcomes NNS N
of IN N
using VBG N
both DT N
a DT N
screener NN 1_i
to TO N
determine VB N
elevated VBN 1_o
anxiety NN 1_o
levels NNS 1_o
among IN N
patients NNS 1_p
with IN 1_p
previously RB 1_p
undetected VBN 1_p
anxiety NN 1_p
and CC N
a DT N
physician JJ 1_i
intervention NN 1_i
to TO N
inform VB N
physicians NNS N
of IN N
their PRP$ N
patients NNS N
' POS N
conditions NNS N
. . N

DESIGN NNP N
Participating VBG N
physicians NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
demonstration NN 1_i
or CC N
the DT N
control NN N
arm NN N
, , N
and CC N
patients NNS N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
arm NN N
based VBN N
on IN N
the DT N
randomization NN N
of IN N
their PRP$ N
physicians NNS N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
for IN N
change NN N
in IN N
outcome JJ N
measures NNS N
during IN N
the DT N
five-month JJ N
study NN N
period NN N
. . N

SETTING VB N
A DT N
mixed-model JJ N
health NN N
maintenance NN N
organization NN N
serving VBG N
approximately RB N
110,000 CD N
enrollees NNS N
in IN N
central JJ N
Colorado NNP N
. . N

PATIENTS/PARTICIPANTS NNP N
573 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
unrecognized VBN 1_p
and CC 1_p
untreated JJ 1_p
anxiety NN 1_p
identified VBN 1_p
from IN 1_p
the DT 1_p
approximately RB 1_p
8,000 CD 1_p
patients NNS 1_p
who WP 1_p
completed VBD 1_p
the DT 1_p
waiting VBG 1_p
room NN 1_p
screening NN 1_p
questionnaire NN 1_p
. . 1_p

INTERVENTIONS VBZ N
A DT N
physician JJ 1_i
intervention NN 1_i
served VBD N
the DT N
dual JJ N
function NN N
of IN N
1 CD N
) ) N
providing VBG N
an DT N
educational JJ N
demonstration NN N
of IN N
anxiety NN N
in IN N
the DT N
primary JJ N
care NN N
setting VBG N
and CC N
2 CD N
) ) N
providing VBG N
a DT N
reporting NN N
system NN N
for IN N
summarizing VBG N
the DT N
anxiety NN 1_o
symptom NN 1_o
levels NNS 1_o
and CC N
functioning VBG 1_o
status NN 1_o
of IN N
the DT N
patients NNS N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Patient NNP 1_o
outcomes NNS 1_o
were VBD N
measured VBN N
as IN N
changes NNS N
in IN N
global JJ 1_o
anxiety NN 1_o
scores NNS 1_o
, , 1_o
functioning VBG 1_o
and CC 1_o
well-being JJ 1_o
, , N
and CC N
patients NNS 1_o
' POS 1_o
reports NNS 1_o
of IN 1_o
global JJ 1_o
improvements NNS 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
this DT N
method NN N
of IN N
reporting VBG N
symptoms NNS N
and CC N
functioning VBG N
status NN N
to TO N
primary VB N
care NN N
physicians NNS N
did VBD N
not RB N
significantly RB N
change VBP N
patient JJ N
outcomes NNS N
. . N

Improvement NN N
in IN N
outcomes NNS N
appeared VBD N
to TO N
be VB N
more RBR N
closely RB N
associated VBN N
with IN N
the DT N
patient NN N
's POS N
severity NN N
of IN N
psychological JJ N
distress NN N
. . N

Adherence NN 1_o
to TO N
lifestyle VB 1_i
recommendations NNS 1_i
by IN N
patients NNS 1_p
with IN 1_p
depression NN 1_p
. . 1_p

INTRODUCTION NNP N
There EX N
is VBZ N
an DT N
increasing VBG N
amount NN N
of IN N
evidence NN N
showing VBG N
that DT N
physical JJ N
activity NN N
and CC N
sun NN N
exposure NN N
are VBP N
effective JJ N
coadjuvant JJ N
treatments NNS N
for IN N
patients NNS 1_p
with IN 1_p
mild JJ 1_p
to TO 1_p
moderate VB 1_p
depression NN 1_p
. . 1_p

However RB N
, , N
there EX N
is VBZ N
a DT N
lack NN N
of IN N
information NN N
regarding VBG N
patient NN 1_o
's POS 1_o
adherence NN 1_o
to TO N
these DT N
recommendations NNS N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
study NN N
including VBG N
15 CD 1_p
depressive JJ 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
been VBN 1_p
under IN 1_p
antidepressant JJ 1_p
treatment NN 1_p
for IN 1_p
at IN 1_p
least JJS 1_p
one CD 1_p
month NN 1_p
. . 1_p

They PRP N
wore VBD N
a DT N
wrist-watch-like JJ N
actimetry NN N
sensor NN N
to TO N
measure VB N
physical JJ 1_o
activity NN 1_o
and CC 1_o
sun NN 1_o
exposure NN 1_o
24 CD N
hours NNS N
a DT N
day NN N
. . N

After IN N
one CD N
week NN N
of IN N
baseline NN N
assessment NN N
, , N
patients NNS N
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
the DT N
two CD N
arms NNS N
of IN N
the DT N
study NN N
. . N

Patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
received VBD N
a DT N
brief JJ N
note NN N
in IN N
which WDT N
they PRP N
were VBD N
explicitly RB N
asked VBN N
to TO N
increase VB N
both DT N
their PRP$ N
physical JJ 1_o
activity NN 1_o
level NN 1_o
and CC N
time NN 1_o
of IN 1_o
sun NN 1_o
exposure NN 1_o
, , N
while IN N
control NN 1_i
group NN N
patients NNS N
did VBD 1_i
not RB 1_i
receive VB 1_i
these DT 1_i
explicit JJ 1_i
recommendations NNS 1_i
. . 1_i

RESULTS NNP N
One CD N
week NN N
after IN N
recommendations NNS N
were VBD N
delivered VBN N
, , N
only RB N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
had VBD N
increased VBN N
time NN 1_o
of IN 1_o
sun NN 1_o
exposure NN 1_o
and CC 1_o
physical JJ 1_o
activity NN 1_o
( ( N
25.8 CD N
% NN N
and CC N
14.3 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Depressive JJ 1_p
patients NNS 1_p
are VBP N
able JJ N
to TO N
follow VB N
prescribed JJ N
lifestyle JJ 1_i
recommendations NNS 1_i
in IN N
the DT N
short-term JJ N
. . N

Oral JJ N
ciprofloxacin NN 1_i
vs. FW N
intramuscular JJ N
ceftriaxone NN 1_i
as IN N
empiric JJ N
treatment NN N
of IN N
acute JJ 1_p
invasive JJ 1_p
diarrhea NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

BACKGROUND NNP N
Acute NNP 1_p
invasive JJ 1_p
diarrhea NN 1_p
is VBZ N
a DT N
potentially RB N
serious JJ N
condition NN N
in IN 1_p
children NNS 1_p
. . 1_p

Because IN N
of IN N
the DT N
increasing VBG N
resistance NN N
of IN N
enteric JJ N
pathogens NNS N
to TO N
commonly RB N
used JJ N
oral JJ N
antibiotics NNS N
, , N
intramuscular JJ N
ceftriaxone NN 1_i
has VBZ N
become VBN N
the DT N
routine JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ 1_p
invasive JJ 1_p
diarrhea NN 1_p
requiring VBG 1_p
an DT 1_p
emergency NN 1_p
visit NN 1_p
in IN 1_p
southern JJ 1_p
Israel NNP 1_p
. . 1_p

The DT N
inconvenience NN N
of IN N
this DT N
parenteral JJ N
regimen NNS N
created VBD N
an DT N
increased VBN N
need NN N
for IN N
oral JJ N
pediatric JJ N
formulations NNS N
for IN N
the DT N
treatment NN N
of IN N
invasive JJ 1_p
diarrhea NN 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
a DT N
suspension NN N
formulation NN N
of IN N
ciprofloxacin NN 1_i
in IN N
the DT N
treatment NN N
of IN N
acute JJ 1_p
invasive JJ 1_p
diarrhea NN 1_p
in IN 1_p
infants NNS 1_p
and CC 1_p
children NNS 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP N
July NNP N
1996 CD N
through IN N
December NNP N
1997 CD N
, , N
201 CD 1_p
evaluable JJ 1_p
children NNS 1_p
ages VBZ 1_p
6 CD 1_p
months NNS 1_p
to TO 1_p
10 CD 1_p
years NNS 1_p
( ( 1_p
35 CD 1_p
% NN 1_p
< CC 1_p
1 CD 1_p
year NN 1_p
; : 1_p
70 CD 1_p
% NN 1_p
< JJ 1_p
3 CD 1_p
years NNS 1_p
) ) 1_p
presenting VBG 1_p
with IN 1_p
acute JJ 1_p
invasive JJ 1_p
diarrhea NN 1_p
at IN 1_p
the DT 1_p
Pediatric NNP 1_p
Emergency NNP 1_p
Room NNP 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ciprofloxacin NN 1_i
suspension NN N
( ( N
10 CD N
mg/kg NN N
twice RB N
a DT N
day NN N
+ NNP N
im NN N
placebo NN N
; : N
n CC N
= VB N
95 CD N
) ) N
or CC N
im VB N
ceftriaxone NN 1_i
( ( N
50 CD N
mg/kg/day NN N
+ NNP N
placebo NN N
suspension NN N
; : N
n CC N
= VB N
106 CD N
) ) N
for IN N
3 CD N
days NNS N
in IN N
a DT N
double JJ N
blind NN N
manner NN N
. . N

Stool NNP 1_o
cultures NNS 1_o
for IN 1_o
Shigella NNP 1_o
, , 1_o
Salmonella NNP 1_o
, , 1_o
Campylobacter NNP 1_o
spp NN 1_o
. . 1_o

and CC 1_o
diarrheagenic JJ 1_o
Escherichia NNP 1_o
coli NNS 1_o
were VBD N
obtained VBN N
on IN N
Days NNP N
1 CD N
, , N
3 CD N
, , N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
. . N

Clinical JJ 1_o
response NN 1_o
and CC 1_o
safety NN 1_o
were VBD N
assessed VBN N
on IN N
Days NNP N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
. . N

RESULTS NNP N
We PRP N
isolated VBD N
127 CD N
pathogens NNS N
from IN N
121 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
: : N
73 CD N
( ( N
57 CD N
% NN N
) ) N
Shigella NNP N
; : N
23 CD N
( ( N
18 CD N
% NN N
) ) N
Salmonella NNP N
; : N
18 CD N
( ( N
14 CD N
% NN N
) ) N
E. NNP N
coli NNS N
; : N
and CC N
13 CD N
( ( N
10 CD N
% NN N
) ) N
Campylobacter NNP N
. . N

Overall NNP N
bacteriologic JJ N
eradication NN N
on IN N
Day NNP N
4 CD N
to TO N
5 CD N
was VBD N
99 CD N
% NN N
for IN N
Shigella NNP N
, , N
77 CD N
% NN N
for IN N
Salmonella NNP N
and CC N
77 CD N
% NN N
for IN N
Campylobacter NNP N
, , N
with IN N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Clinical JJ 1_o
cure NN 1_o
or CC 1_o
improvement NN 1_o
was VBD N
observed VBN N
in IN N
100 CD N
and CC N
99 CD N
% NN N
of IN N
the DT N
ciprofloxacin NN 1_i
and CC N
ceftriaxone NN 1_i
groups NNS N
, , N
respectively RB N
. . N

Serum NNP N
ciprofloxacin NN 1_i
values NNS N
determined VBN N
on IN N
Day NNP N
3 CD N
of IN N
the DT N
treatment NN N
were VBD N
higher JJR N
in IN N
the DT N
majority NN N
of IN N
patients NNS N
than IN N
were VBD N
the DT N
MIC50 NNP N
and CC N
MIC90 NNP N
values NNS N
for IN N
the DT N
Shigella NNP N
and CC N
Salmonella NNP N
spp NN N
. . N

isolated VBN N
. . N

Possible JJ N
drug-related JJ N
adverse JJ 1_o
events NNS 1_o
occurred VBD N
in IN N
13 CD N
patients NNS N
[ JJ 1_i
ciprofloxacin NN 1_i
, , N
8 CD N
( ( N
8 CD N
% NN N
) ) N
; : N
ceftriaxone NN 1_i
, , N
5 CD N
( ( N
4.7 CD N
% NN N
) ) N
] NN N
and CC N
were VBD N
mild NNS N
and CC N
transient NN N
. . N

Joint JJ 1_o
examination NN 1_o
was VBD N
normal JJ N
during IN N
and CC N
after IN N
completion NN N
of IN N
therapy NN N
in IN N
all DT N
patients NNS N
. . N

CONCLUSION NNP N
Oral NNP N
ciprofloxacin NN 1_i
was VBD N
as IN N
safe JJ 1_o
and CC 1_o
effective JJ 1_o
as IN N
intramuscular JJ N
ceftriaxone NN 1_i
for IN N
the DT N
empiric JJ N
treatment NN N
of IN N
acute JJ 1_p
invasive JJ 1_p
diarrhea NN 1_p
in IN 1_p
ambulatory JJ 1_p
pediatric JJ 1_p
patients NNS 1_p
requiring VBG 1_p
an DT 1_p
emergency NN 1_p
room NN 1_p
visit NN 1_p
. . 1_p

Systemic NNP 1_o
hemodynamic NN 1_o
, , 1_o
neurohormonal JJ 1_o
, , 1_o
and CC 1_o
renal JJ 1_o
effects NNS 1_o
of IN N
a DT N
steady-state JJ N
infusion NN N
of IN N
human JJ 1_i
brain NN 1_i
natriuretic JJ 1_i
peptide NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
hemodynamically RB 1_p
decompensated VBN 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

BACKGROUND NNP N
Human NNP 1_i
brain NN 1_i
natriuretic JJ 1_i
peptide NN 1_i
( ( 1_i
hBNP NN 1_i
) ) 1_i
is VBZ N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
decompensated JJ N
cardiac JJ N
failure NN N
. . N

However RB N
, , N
the DT N
systemic JJ 1_o
hemodynamic NN 1_o
, , 1_o
neurohormonal JJ 1_o
, , 1_o
and CC 1_o
renal JJ 1_o
effects NNS 1_o
of IN N
hBNP NNS 1_i
have VBP N
been VBN N
incompletely RB N
studied VBN N
in IN N
human JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
effects NNS N
of IN N
a DT N
continuous JJ N
4-hour JJ N
infusion NN N
of IN N
hBNP NN 1_i
were VBD N
determined VBN N
in IN N
16 CD 1_p
decompensated JJ 1_p
heart NN 1_p
failure NN 1_p
patients NNS 1_p
in IN N
an DT N
invasive JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
during IN N
three CD N
4-hour JJ N
study NN N
periods NNS N
: : N
baseline NN N
, , N
treatment NN N
( ( 1_i
placebo JJ 1_i
[ NNP N
n NN N
= VBD N
4 CD N
] NNP N
versus NN N
hBNP NN 1_i
0.025 CD N
or CC N
0.05 CD N
microgram/kg/min NNS N
[ JJ N
n JJ N
= NN N
12 CD N
] NN N
) ) N
, , N
and CC N
post-treatment NN N
. . N

Urinary JJ 1_o
volume NN 1_o
losses NNS 1_o
were VBD N
replaced VBN N
hourly RB N
to TO N
separate VB N
the DT N
vasodilatory NN N
and CC N
diuretic JJ N
effects NNS N
of IN N
hBNP NN 1_i
. . 1_i

Two CD N
patients NNS N
in IN N
the DT N
hBNP NN 1_i
group NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
because IN N
of IN N
adverse JJ 1_o
events NNS 1_o
. . 1_o

hBNP NN 1_i
significantly RB N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
reduced VBD N
right JJ 1_o
atrial JJ 1_o
pressure NN 1_o
and CC 1_o
pulmonary JJ 1_o
capillary JJ 1_o
wedge NN 1_o
pressure NN 1_o
by IN N
approximately RB N
30 CD N
% NN N
and CC N
40 CD N
% NN N
, , N
respectively RB N
. . N

hBNP NN 1_i
also RB N
significantly RB N
lowered VBN N
systemic JJ 1_o
vascular JJ 1_o
resistance NN 1_o
from IN N
1722 CD N
+/- JJ N
139 CD N
to TO N
1101 CD N
+/- JJ N
83 CD N
dynes.s.cm-5 NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

These DT N
unloading JJ N
effects NNS N
of IN N
hBNP NN 1_i
produced VBD N
a DT N
28 CD N
% NN N
increase NN N
in IN N
cardiac JJ 1_o
index NN 1_o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
with IN N
no DT N
change NN N
in IN N
heart NN 1_o
rate NN 1_o
. . 1_o

Compared VBN N
to TO N
placebo VB 1_i
, , 1_i
hBNP VB 1_i
decreased VBN N
plasma JJ 1_o
norepinephrine NN 1_o
and CC 1_o
aldosterone NN 1_o
. . 1_o

Renal JJ 1_o
hemodynamics NNS 1_o
were VBD N
unaffected VBN N
by IN N
hBNP NN 1_i
; : 1_i
however RB N
, , N
most JJS N
patients NNS N
were VBD N
resistant JJ N
to TO N
its PRP$ N
natriuretic JJ 1_o
effect NN 1_o
. . 1_o

CONCLUSIONS NNP N
1 CD N
) ) N
The DT N
predominant JJ N
hemodynamic JJ 1_o
effects NNS 1_o
of IN N
hBNP NN 1_i
were VBD N
a DT N
decrease NN N
in IN N
cardiac JJ 1_o
preload NN 1_o
and CC 1_o
systemic JJ 1_o
vascular JJ 1_o
resistance NN 1_o
. . 1_o

2 CD N
) ) N
hBNP NN 1_i
also RB N
improved VBD N
cardiac JJ 1_o
output NN 1_o
without IN N
increasing VBG N
heart NN 1_o
rate NN 1_o
. . 1_o

3 CD N
) ) N
Plasma NNP 1_o
norepinephrine NN 1_o
and CC 1_o
aldosterone NN 1_o
levels NNS 1_o
decreased VBN N
during IN N
hBNP JJ 1_i
infusion NN N
. . N

4 CD N
) ) N
hBNP NN 1_i
is VBZ N
pharmacologically RB N
active JJ N
and CC N
has VBZ N
potential VBN N
in IN N
the DT N
therapy NN N
for IN N
decompensated JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

Low JJ N
doses NNS N
of IN N
ketazolam NN 1_i
in IN N
anxiety NN 1_p
: : 1_p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

A DT N
multicenter NN N
, , N
double-blind JJ N
, , N
between-patient JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
ketazolam NN 1_i
( ( N
15 CD N
and CC N
30 CD N
mg NN N
) ) N
with IN N
placebo NN 1_i
, , N
each DT N
given VBN N
once RB N
daily JJ N
, , N
in IN N
the DT N
evening NN N
, , N
to TO N
92 CD 1_p
outpatients NNS 1_p
affected VBN 1_p
by IN 1_p
generalized JJ 1_p
anxiety NN 1_p
disorders NNS 1_p
for IN N
at IN N
least JJS N
1 CD N
month NN N
, , N
was VBD N
carried VBN N
out RP N
. . N

After IN N
1-week JJ N
washout NN N
period NN N
47 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
ketazolam VB 1_i
15 CD N
mg NN N
, , N
and CC N
45 CD N
to TO N
placebo VB 1_i
for IN N
15 CD N
days NNS N
( ( N
first JJ N
period NN N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
this DT N
period NN N
, , N
if IN N
the DT N
patient NN N
experienced VBD N
a DT N
decrease NN N
on IN N
the DT N
total JJ 1_o
Hamilton NNP 1_o
Anxiety NNP 1_o
Rating NNP 1_o
Scale NNP 1_o
( ( 1_o
HAM-A NNP 1_o
) ) 1_o
of IN N
at IN N
least JJS N
25 CD N
% NN N
of IN N
basal NN N
value NN N
, , N
the DT N
treatment NN N
was VBD N
kept VBN N
unchanged JJ N
for IN N
a DT N
further JJ N
15 CD N
days NNS N
, , N
otherwise RB N
15 CD N
mg NN N
of IN N
ketazolam NNS 1_i
were VBD N
added VBN N
to TO N
the DT N
previous JJ N
treatment NN N
( ( N
second JJ N
period NN N
) ) N
. . N

Anxiety NN 1_o
was VBD N
rated VBN N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
with IN N
the DT N
Italian JJ 1_o
HAM-A NNP 1_o
scale NN 1_o
and CC 1_o
with IN 1_o
a DT 1_o
4-point JJ 1_o
scale NN 1_o
( ( 1_o
patient NN 1_o
's POS 1_o
assessment NN 1_o
) ) 1_o
. . 1_o

Seventy-eight JJ 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
first JJ 1_p
period NN 1_p
and CC 1_p
75 CD 1_p
the DT 1_p
whole NN 1_p
study NN 1_p
. . 1_p

During IN N
the DT N
first JJ N
period NN N
the DT N
percentage NN N
of IN N
responders NNS N
was VBD N
almost RB N
identical JJ N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
but CC N
during IN N
the DT N
second JJ N
period NN N
a DT N
further JJ N
slight NN N
improvement NN N
was VBD N
observed VBN N
in IN N
the DT N
early JJ N
placebo NN 1_i
responders NNS N
, , N
while IN N
the DT N
HAM-A NNP 1_o
score NN 1_o
of IN N
patients NNS N
on IN N
ketazolam NNS 1_i
continued VBN N
to TO N
improve VB N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
throughout IN N
the DT N
study NN N
. . N

Likewise VB N
a DT N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
difference NN N
between IN N
treatments NNS N
was VBD N
observed VBN N
, , N
on IN N
the DT N
4-point JJ 1_o
scale NN 1_o
, , N
in IN N
the DT N
population NN N
as IN N
a DT N
whole NN N
( ( N
end NN N
of IN N
first JJ N
period NN N
) ) N
as RB N
well RB N
as IN N
in IN N
responder NN N
patients NNS N
( ( N
end JJ N
second JJ N
period NN N
) ) N
. . N

Tolerability NN N
was VBD N
good JJ N
, , N
except IN N
in IN N
1 CD N
patient NN N
on IN N
placebo NN 1_i
, , N
who WP N
was VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
severe JJ 1_o
headache NN 1_o
. . 1_o

Randomized VBN N
phase NN N
II NNP N
study NN N
of IN N
two CD N
different JJ N
schedules NNS N
of IN N
gemcitabine NN 1_i
and CC N
oral JJ N
S-1 NNP 1_i
in IN N
chemo-naïve JJ 1_p
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
non-small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
. . N

INTRODUCTION NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT 1_o
efficacy NN 1_o
and CC 1_o
safety NN 1_o
and CC N
to TO 1_o
compare VB 1_o
dosing VBG 1_o
schedules NNS 1_o
of IN 1_i
gemcitabine NN 1_i
combined VBN N
with IN 1_i
S-1 NNP 1_i
in IN 1_p
chemo-naïve JJ 1_p
non-small JJ 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
patients NNS 1_p
. . N

METHODS NNP 1_p
Patients NNPS 1_p
with IN 1_p
chemo-naïve JJ 1_p
stage NN 1_p
IIIB/IV NNP 1_p
non-small NN 1_p
cell NN 1_p
lung NN 1_p
cancer NN 1_p
were VBD N
randomized VBN N
into IN N
two CD N
treatment NN N
arms NNS N
. . N

Patients NNS N
were VBD N
given VBN N
oral JJ 1_i
S-1 NNP 1_i
( ( N
60 CD N
mg/m/d NN N
, , N
twice RB N
a DT N
day NN N
) ) N
from IN N
days NNS N
1 CD N
to TO N
14 CD N
with IN 1_i
gemcitabine NN 1_i
( ( N
1000 CD N
mg/m/d NN N
) ) N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
( ( N
arm VB N
A NNP N
) ) N
or CC N
on IN N
days NNS N
8 CD N
and CC N
15 CD N
( ( N
arm NN N
B NNP N
) ) N
. . N

This DT N
cycle NN N
was VBD N
repeated VBN N
every DT N
21 CD N
days NNS N
. . N

RESULTS VB 1_p
A DT 1_p
total NN 1_p
of IN 1_p
80 CD 1_p
patients NNS 1_p
were VBD 1_p
entered VBN 1_p
in IN 1_p
this DT 1_p
trial NN 1_p
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
this DT N
study NN N
was VBD 1_o
response NN 1_o
rate NN 1_o
. . N

The DT 1_o
response NN 1_o
rates NNS 1_o
of IN N
arm NN N
A NNP N
and CC N
arm NN N
B NNP N
were VBD N
22.0 CD N
and CC N
28.9 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.606 CD 1_o
) ) 1_o
. . 1_o

Median JJ 1_o
time NN 1_o
to TO 1_o
treatment NN 1_o
failure NN 1_o
in IN N
arm NN N
A NN N
was VBD N
3.6 CD N
months NNS N
and CC N
4.8 CD N
months NNS N
in IN N
arm NN N
B NNP 1_o
. . 1_o

Median JJ 1_o
time NN 1_o
to TO 1_o
progression NN 1_o
in IN N
arm NN N
A NN N
was VBD N
4.1 CD N
months NNS N
and CC N
5.5 CD N
months NNS N
in IN N
arm NN N
B NNP 1_o
. . 1_o

Median JJ 1_o
survival JJ 1_o
time NN 1_o
in IN N
arm NN N
A NN N
and CC N
arm NN N
B NNP N
was VBD N
15.5 CD N
months NNS N
and CC N
18.8 CD N
months NNS N
, , N
respectively RB N
. . N

The DT 1_o
toxicity NN 1_o
profile NN 1_o
was VBD N
relatively RB N
mild JJ N
and CC N
did VBD N
not RB N
differ VB N
very RB N
much RB N
between IN N
two CD N
arms NNS N
. . N

CONCLUSION VB N
The DT N
combination NN N
of IN 1_i
gemcitabine NN 1_i
and CC 1_i
S-1 NNP 1_i
was VBD N
determined VBN N
to TO N
be VB 1_o
feasible JJ 1_o
and CC 1_o
effective JJ 1_o
for IN N
advanced JJ N
non-small JJ N
cell NN N
lung NN N
cancer NN N
. . N

We PRP N
selected VBD N
arm NN N
B NNP N
for IN N
further JJ N
studies NNS N
because IN N
of IN N
its PRP$ N
higher JJR 1_o
response NN 1_o
rate NN 1_o
and CC 1_o
survival NN 1_o
data NNS 1_o
. . N

Comparison NNP N
of IN N
budesonide JJ 1_i
Turbuhaler NNP 1_i
with IN N
budesonide JJ 1_i
aqua NN 1_i
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ 1_p
allergic JJ 1_p
rhinitis NN 1_p
. . 1_p

Rhinocort NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effect NN N
of IN N
budesonide NN 1_i
Turbuhaler NNP 1_i
400 CD N
microg/day NN N
with IN N
budesonide JJ 1_i
aqua NN 1_i
256 CD N
microg/day NN N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ 1_p
allergic JJ 1_p
rhinitis NN 1_p
( ( 1_p
SAR NNP 1_p
) ) 1_p
. . 1_p

Secondarily RB N
to TO N
ascertain VB N
patients NNS 1_o
' POS 1_o
preferences NNS 1_o
for IN 1_o
the DT 1_o
two CD 1_o
nasal JJ 1_o
devices NNS 1_o
and CC N
to TO N
assess VB N
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

DESIGN NNP N
Randomized NNP N
, , N
multicentre NN N
, , N
double-blind JJ N
, , N
double- JJ N
dummy NN N
, , N
parallel JJ N
groups NNS N
study NN N
. . N

SETTING NNP N
Private NNP N
practices NNS N
and CC N
hospital NN N
clinics NNS N
in IN N
Ontario NNP 1_p
, , 1_p
Quebec NNP 1_p
and CC 1_p
Manitoba NNP 1_p
. . 1_p

POPULATION NNP N
Two CD 1_p
hundred VBD 1_p
and CC 1_p
eighty-four JJ 1_p
out-patients NNS 1_p
with IN 1_p
SAR NNP 1_p
, , 1_p
who WP 1_p
were VBD 1_p
symptomatic JJ 1_p
during IN 1_p
the DT 1_p
ragweed NN 1_p
season NN 1_p
, , 1_p
volunteered VBD 1_p
for IN 1_p
enrolment NN 1_p
( ( 1_p
243 CD 1_p
randomized VBN 1_p
) ) 1_p
. . 1_p

RESULTS JJ N
Mean JJ 1_o
daily JJ 1_o
nasal NN 1_o
symptom NN 1_o
scores NNS 1_o
were VBD N
significantly RB N
reduced VBN N
with IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
from IN N
baseline NN N
for IN N
eye NN 1_o
symptoms NNS 1_o
. . 1_o

Most JJS N
patients NNS N
( ( N
more JJR N
than IN N
80 CD N
% NN N
) ) N
achieved VBN N
substantial JJ N
control NN N
of IN N
their PRP$ N
symptoms NNS N
with IN N
budesonide NN 1_i
. . 1_i

The DT N
most RBS N
common JJ N
nasal NN 1_o
and CC 1_o
non-nasal JJ 1_o
adverse JJ 1_o
events NNS 1_o
for IN N
both DT N
groups NNS N
were VBD N
epistaxis JJ 1_o
and CC N
headache NN 1_o
. . 1_o

Turbuhaler NNP 1_i
was VBD N
easier JJR N
to TO N
use VB N
and CC N
more RBR N
convenient JJ N
to TO N
carry VB N
, , N
had VBD N
less JJR N
of IN N
an DT N
unpleasant JJ 1_o
taste NN 1_o
, , N
and CC N
caused VBD N
less JJR N
nasal JJ 1_o
irritation NN 1_o
than IN N
the DT N
aqua JJ N
spray NN N
. . N

More JJR N
than IN N
twice RB N
as IN N
many JJ N
patients NNS N
preferred JJ N
Turbuhaler NNP 1_i
to TO N
the DT N
aqua NN 1_i
spray NN 1_i
( ( N
69 CD N
% NN N
versus IN N
31 CD N
% NN N
) ) N
. . N

Improvement NN N
in IN N
quality NN 1_o
of IN 1_o
life NN 1_o
from IN N
baseline NN N
to TO N
clinic VB N
visits NNS N
was VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Once RB N
daily JJ N
use NN N
of IN N
256 CD N
mg NN N
of IN N
budesonide NN 1_i
aqua NN 1_i
and CC N
400 CD N
mg NN N
of IN N
budesonide NN 1_i
Turbuhaler NNP 1_i
are VBP N
equally RB N
safe JJ 1_o
and CC N
efficacious JJ 1_o
in IN N
the DT N
treatment NN N
of IN N
SAR NNP 1_p
. . 1_p

Patients NNS N
preferred VBD N
the DT N
budesonide NN 1_i
powder NN 1_i
formulation NN N
delivered VBD N
via IN N
Turbuhaler NNP 1_i
two CD N
to TO N
one CD N
over IN N
the DT N
aqua JJ 1_i
formulation NN N
. . N

Recurrent JJ 1_p
epithelial JJ 1_p
ovarian JJ 1_p
carcinoma NN 1_p
: : 1_p
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
of IN N
pegylated VBN 1_i
liposomal JJ 1_i
doxorubicin NN 1_i
versus NN N
topotecan JJ 1_i
. . 1_i

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
pegylated JJ 1_i
liposomal JJ 1_i
doxorubicin NN 1_i
( ( 1_i
PLD NNP 1_i
) ) 1_i
and CC N
topotecan JJ 1_i
in IN N
patients NNS 1_p
with IN 1_p
epithelial JJ 1_p
ovarian JJ 1_p
carcinoma NN 1_p
that WDT 1_p
recurred VBD 1_p
after IN 1_p
or CC 1_p
did VBD 1_p
n't RB 1_p
respond VB 1_p
to TO 1_p
first-line JJ 1_p
, , 1_p
platinum-based JJ 1_p
chemotherapy NN 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 1_p
with IN 1_p
measurable JJ 1_p
and CC 1_p
assessable JJ 1_p
disease NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
PLD NNP 1_i
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
as IN N
a DT N
1-hour JJ N
infusion NN N
every DT N
4 CD N
weeks NNS N
or CC N
topotecan JJ 1_i
1.5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
stratified VBN N
prospectively RB N
for IN N
platinum NN N
sensitivity NN N
and CC N
for IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
bulky JJ N
disease NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
474 CD 1_p
patients NNS 1_p
were VBD 1_p
treated VBN 1_p
( ( N
239 CD N
PLD NNP 1_i
and CC N
235 CD N
topotecan JJ 1_i
) ) 1_i
. . N

They PRP N
comprised VBD N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
overall JJ 1_o
progression-free JJ 1_o
survival NN 1_o
rates NNS 1_o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
arms NNS N
( ( N
P NNP N
=.095 NNP N
) ) N
. . N

The DT N
overall JJ 1_o
response NN 1_o
rates NNS 1_o
for IN N
PLD NNP 1_i
and CC N
topotecan JJ 1_i
were VBD N
19.7 CD N
% NN N
and CC N
17.0 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
=.390 NNP N
) ) N
. . N

Median JJ 1_o
overall JJ 1_o
survival NN 1_o
times NNS 1_o
were VBD N
60 CD N
weeks NNS N
for IN N
PLD NNP 1_i
and CC N
56.7 CD N
weeks NNS N
for IN N
topotecan JJ 1_i
. . 1_i

Data NNP N
analyzed VBD N
in IN N
platinum-sensitive JJ N
patients NNS N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
PLD NNP 1_i
for IN N
progression-free JJ N
survival NN N
( ( N
P NNP N
=.037 NNP N
) ) N
, , N
with IN N
medians NNS N
of IN N
28.9 CD N
for IN N
PLD NNP 1_i
versus FW N
23.3 CD N
weeks NNS N
for IN N
topotecan JJ 1_i
. . 1_i

For IN N
overall JJ 1_o
survival NN 1_o
, , N
PLD NNP 1_i
was VBD N
significantly RB N
superior JJ N
to TO N
topotecan VB 1_i
( ( N
P NNP N
=.008 NNP N
) ) N
, , N
with IN N
a DT N
median NN N
of IN N
108 CD N
weeks NNS N
versus RB N
71.1 CD N
weeks NNS N
. . N

The DT N
platinum-refractory JJ N
subgroup NN N
demonstrated VBD N
a DT N
nonstatistically RB N
significant JJ N
survival JJ 1_o
trend NN N
in IN N
favor NN N
of IN N
topotecan JJ 1_i
( ( N
P NNP N
=.455 NNP N
) ) N
. . N

Severe JJ 1_o
hematologic JJ 1_o
toxicity NN 1_o
was VBD N
more RBR N
common JJ N
with IN N
topotecan JJ 1_i
and CC N
was VBD N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
dosage NN N
modification NN N
, , N
or CC N
growth NN N
factor NN N
or CC N
blood NN N
product NN N
utilization NN N
. . N

CONCLUSION VB N
The DT N
comparable JJ N
efficacy NN 1_o
, , 1_o
favorable JJ 1_o
safety NN 1_o
profile NN 1_o
, , N
and CC N
convenient NN 1_o
dosing VBG 1_o
support NN N
the DT N
role NN N
of IN N
PLD NNP 1_i
as IN N
a DT N
valuable JJ N
treatment NN N
option NN N
in IN N
this DT N
patient JJ N
population NN N
. . N

Reduced VBN N
platelet NN 1_o
thromboxane NN 1_o
formation NN 1_o
after IN N
long-term JJ N
administration NN N
of IN N
a DT N
dihydropyridine JJ 1_i
calcium NN 1_i
channel NN 1_i
blocker NN 1_i
: : 1_i
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
with IN N
nitrendipine NN 1_i
in IN N
borderline JJ 1_p
hypertensive JJ 1_p
patients NNS 1_p
with IN 1_p
IDDM-type NNP 1_p
diabetes NNS 1_p
mellitus NN 1_p
. . 1_p

Twenty-nine JJ 1_p
IDDM NNP 1_p
patients NNS 1_p
with IN 1_p
borderline JJ 1_p
hypertension NN 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
placebo VB 1_i
or CC N
nitrendipine VB 1_i
treatment NN N
. . N

Nitrendipine NNP 1_i
was VBD N
given VBN N
orally RB N
at IN N
a DT N
dosage NN N
of IN N
20 CD N
mg NNS N
once RB N
daily RB N
over IN N
4 CD N
weeks NNS N
. . N

Stimulated VBN 1_o
platelet NN 1_o
thromboxane NN 1_o
formation NN 1_o
at IN N
rest NN N
and CC N
after IN N
standardized VBN N
, , N
non JJ 1_o
exhausting VBG 1_o
exercise NN 1_o
was VBD N
measured VBN N
by IN N
standard JJ N
methods NNS N
. . N

In IN N
addition NN N
, , N
plasma NN 1_o
levels NNS 1_o
of IN 1_o
platelet NN 1_o
factor NN 1_o
4 CD 1_o
and CC 1_o
aggregation NN 1_o
responses NNS 1_o
to TO 1_o
collagen VB 1_o
and CC 1_o
ADP NNP 1_o
were VBD N
determined VBN N
. . N

In IN N
the DT N
treatment NN N
group NN N
thromboxane NN 1_o
formation NN 1_o
after IN N
stimulation NN N
with IN N
collagen NN N
( ( N
0.3 CD N
and CC N
1.0 CD N
micrograms/ml NN N
) ) N
and CC N
1 CD N
mM NN N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
was VBD N
reduced VBN N
in IN N
the DT N
resting NN N
state NN N
. . N

Exercise NN 1_o
induced JJ 1_o
change NN 1_o
of IN 1_o
thromboxane NN 1_o
synthesis NN 1_o
in IN N
response NN N
to TO N
1.0 CD N
micrograms/ml NNS N
collagen NN N
was VBD N
significantly RB N
lower JJR N
as IN N
compared VBN N
to TO N
placebo VB 1_i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
parallel JJ N
, , N
PF4 NNP 1_o
plasma NN 1_o
levels NNS 1_o
were VBD N
significantly RB N
lowered VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Whole JJ 1_o
blood NN 1_o
aggregation NN 1_o
after IN 1_o
collagen NN 1_o
stimulation NN 1_o
( ( N
1.0 CD N
micrograms/ml NN N
) ) N
was VBD N
reduced VBN N
after IN N
4 CD N
weeks NNS N
of IN N
nitrendipine JJ 1_i
treatment NN N
, , N
but CC N
ADP NNP N
( ( N
5 CD N
microM NN N
) ) N
induced VBD N
aggregation NN 1_o
was VBD N
not RB N
. . N

These DT N
effects NNS N
of IN N
nitrendipine NN 1_i
were VBD N
not RB N
seen VBN N
in IN N
platelet NN N
rich JJ N
plasma NN N
. . N

In IN N
conclusion NN N
long-term JJ N
nitrendipine JJ 1_i
treatment NN N
may MD N
inhibit VB N
collagen NN 1_o
dependent JJ 1_o
platelet NN 1_o
activation NN 1_o
in IN N
the DT N
blood NN N
of IN N
diabetic JJ 1_p
patients NNS 1_p
with IN 1_p
borderline JJ 1_p
hypertension NN 1_p
. . 1_p

[ JJ N
Postural NNP N
biofeedback NN N
and CC N
locomotion NN N
reeducation NN N
in IN N
stroke NN 1_p
patients NNS 1_p
] VBP 1_p
. . N

AIMS NNP N
To TO N
compare VB N
, , N
in IN N
post-acute JJ 1_p
hemiparetic JJ 1_p
patients NNS 1_p
, , N
gait NN 1_o
improvement NN 1_o
after IN N
conventional JJ 1_i
physical JJ 1_i
therapy NN 1_i
alone RB 1_i
or CC N
with IN 1_i
a DT 1_i
specialised JJ 1_i
balance NN 1_i
retraining VBG 1_i
program NN 1_i
. . 1_i

PATIENTS VB N
Twenty-six JJ 1_p
patients NNS 1_p
within IN 1_p
3 CD 1_p
months NNS 1_p
of IN 1_p
onset NN 1_p
of IN 1_p
stroke NN 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
physical JJ 1_i
therapy NN 1_i
( ( N
control VB N
group NN N
) ) N
or CC N
therapy NN 1_i
and CC 1_i
retraining NN 1_i
( ( N
experimental JJ N
group NN N
) ) N
, , N
most JJS N
of IN N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
with IN N
left JJ N
hemiplegia NN N
. . N

The DT N
experimental JJ N
group NN N
was VBD N
significantly RB N
older JJR N
than IN N
the DT N
control NN N
group NN N
. . N

METHOD NNP N
Thirteen NNP N
patients NNS N
received VBD N
early JJ N
conventional JJ 1_i
therapy NN 1_i
, , N
and CC N
13 CD N
received VBD N
therapy NN 1_i
combined VBN 1_i
with IN 1_i
standing VBG 1_i
balance NN 1_i
training NN 1_i
by IN 1_i
biofeedback NN 1_i
( ( 1_i
BPM NNP 1_i
Monitor NNP 1_i
) ) 1_i
. . 1_i

Clinical JJ 1_o
measures NNS 1_o
were VBD N
collected VBN N
at IN N
entry NN N
( ( N
J0 NNP N
) ) N
, , N
once RB N
when WRB N
subjects NNS N
began VBD N
to TO N
walk VB N
( ( N
JM NNP N
) ) N
and CC N
30 CD N
days NNS N
later RB N
( ( N
JM NNP N
+ NNP N
30 CD N
) ) N
. . N

Gait NNP 1_o
spatiotemporal JJ 1_o
parameters NNS 1_o
were VBD N
collected VBN N
by IN N
use NN N
of IN N
the DT N
Vicon NNP N
system NN N
at IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
. . N

RESULTS VB N
Whatever IN N
the DT N
method NN N
of IN N
rehabilitation NN N
, , N
the DT N
clinical JJ 1_o
scores NNS 1_o
improved VBN N
significantly RB N
between IN N
J0 NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
, , N
except IN N
for IN N
spasticity NN N
. . N

The DT N
time NN 1_o
between IN 1_o
stroke NN 1_o
and CC 1_o
the DT 1_o
beginning NN 1_o
of IN 1_o
walking NN 1_o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
both DT N
groups NNS N
. . N

Gait NNP 1_o
velocity NN 1_o
increased VBD N
significantly RB N
between IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
in IN N
both DT N
groups NNS N
, , N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
. . N

The DT N
walking NN 1_o
pattern NN 1_o
was VBD N
improved VBN N
for IN N
both DT N
groups NNS N
, , N
with IN N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
duration NN 1_o
of IN 1_o
the DT 1_o
paretic JJ 1_o
limb NN 1_o
single JJ 1_o
stance NN 1_o
. . 1_o

The DT N
experimental JJ N
group NN N
significantly RB N
improved VBD N
the DT N
duration NN 1_o
of IN 1_o
the DT 1_o
reception NN 1_o
double JJ 1_o
stance NN 1_o
on IN 1_o
the DT 1_o
paretic JJ 1_o
limb NN 1_o
between IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Both NNP N
groups NNS N
demonstrated VBD N
improvement NN N
in IN N
the DT N
rehabilitation NN N
unit NN N
. . N

The DT N
benefits NNS N
of IN N
visual JJ N
biofeedback NN N
by IN N
forceplate NN N
system NN N
training VBG N
suggest JJ N
particular JJ N
improvement NN N
of IN N
anticipation NN 1_o
equilibrium NN 1_o
with IN N
conventional JJ 1_i
therapy NN 1_i
. . 1_i

Effects NNS N
of IN N
tryptophan JJ 1_i
depletion NN 1_i
in IN N
drug-free JJ 1_p
adults NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
behavioral JJ 1_o
and CC 1_o
biochemical JJ 1_o
responses NNS 1_o
to TO N
acute VB N
tryptophan JJ 1_i
depletion NN 1_i
in IN N
drug-free JJ 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

METHODS NNP N
Twenty NNP 1_p
drug-free JJ 1_p
adults NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
( ( 1_p
16 CD 1_p
men NNS 1_p
and CC 1_p
4 CD 1_p
women NNS 1_p
) ) 1_p
( ( 1_p
mean JJ 1_p
[ NNP 1_p
+/- NN 1_p
SD NNP 1_p
] NNP 1_p
age NN 1_p
, , 1_p
30.5 CD 1_p
+/- JJ 1_p
8.5 CD 1_p
years NNS 1_p
) ) 1_p
underwent JJ N
short-term JJ N
tryptophan NN 1_i
depletion NN 1_i
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
crossover NN N
design NN N
. . N

Patients NNS N
received VBD N
a DT N
24-hour JJ N
, , N
low-tryptophan JJ 1_i
diet NN 1_i
followed VBD N
the DT N
next JJ N
morning NN N
by IN N
an DT N
amino NN 1_i
acid NN 1_i
drink NN 1_i
. . 1_i

Behavioral JJ 1_o
ratings NNS 1_o
were VBD N
obtained VBN N
on IN N
the DT N
morning NN N
of IN N
the DT N
amino NN 1_i
acid NN 1_i
drink NN 1_i
( ( N
baseline NN N
) ) N
and CC N
180 CD N
, , N
300 CD N
, , N
and CC N
420 CD N
minutes NNS N
after IN N
the DT N
drink NN N
. . N

Plasma NNP 1_o
free JJ 1_o
and CC 1_o
total JJ 1_o
tryptophan NN 1_o
levels NNS 1_o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
5 CD N
hours NNS N
after IN N
the DT N
drink NN N
. . N

The DT N
active JJ N
and CC N
sham JJ N
testing NN N
sessions NNS N
were VBD N
separated VBN N
by IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
Eleven NNP N
( ( N
65 CD N
% NN N
) ) N
of IN N
the DT N
17 CD N
patients NNS N
who WP N
completed VBD N
both DT N
test NN N
days NNS N
showed VBD N
a DT N
significant JJ N
global JJ N
worsening NN N
of IN N
behavioral JJ 1_o
symptoms NNS 1_o
with IN N
short-term JJ N
tryptophan NN 1_i
depletion NN 1_i
, , N
but CC N
none NN N
of IN N
the DT N
17 CD N
patients NNS N
showed VBD N
any DT N
significant JJ N
change NN N
in IN N
clinical JJ N
status NN N
from IN N
baseline NN N
after IN N
sham JJ 1_i
depletion NN 1_i
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Tryptophan NNP 1_i
depletion NN 1_i
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
in IN N
behaviors NNS 1_o
such JJ 1_o
as IN 1_o
whirling NN 1_o
, , 1_o
flapping NN 1_o
, , 1_o
pacing NN 1_o
, , 1_o
banging NN 1_o
and CC 1_o
hitting VBG 1_o
self NN 1_o
, , 1_o
rocking NN 1_o
, , 1_o
and CC 1_o
toe NN 1_o
walking NN 1_o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
patients NNS N
were VBD N
significantly RB N
less JJR N
calm JJ 1_o
and CC 1_o
happy JJ 1_o
and CC N
more RBR N
anxious JJ 1_o
. . 1_o

No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
social JJ 1_o
relatedness NN 1_o
or CC 1_o
repetitive JJ 1_o
thoughts NNS 1_o
and CC 1_o
behavior NN 1_o
. . 1_o

Plasma NNP 1_o
total JJ 1_o
and CC 1_o
free JJ 1_o
tryptophan NN 1_o
levels NNS 1_o
were VBD N
reduced VBN N
86 CD N
% NN N
and CC N
69 CD N
% NN N
, , N
respectively RB N
, , N
5 CD N
hours NNS N
after IN N
the DT N
tryptophan-deficient JJ 1_i
amino NN 1_i
acid NN 1_i
drink NN 1_i
. . 1_i

Patients NNS N
who WP N
had VBD N
a DT N
significant JJ N
global JJ N
exacerbation NN N
of IN N
symptoms NNS 1_o
had VBD N
significantly RB N
higher JJR N
baseline NN N
plasma IN 1_o
total JJ 1_o
tryptophan NN 1_o
levels NNS 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
Autism NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
scores NNS 1_o
( ( N
P NNP N
= NNP N
.005 NNP N
) ) N
than IN N
did VBD N
patients NNS N
who WP N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
symptoms NNS 1_o
after IN N
tryptophan JJ 1_i
depletion NN 1_i
. . 1_i

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
that WDT N
has VBZ N
implicated VBN N
a DT N
dysregulation NN N
in IN N
serotonin JJ N
function NN N
in IN N
some DT N
patients NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
short-term JJ N
reduction NN N
of IN N
serotonin NN N
precursor NN N
availability NN N
may MD N
exacerbate VB N
some DT N
symptoms NNS 1_o
characteristic JJ N
of IN N
autism NN N
in IN N
some DT N
patients NNS N
. . N

Continued JJ N
investigation NN N
into IN N
the DT N
role NN N
of IN N
serotonin NN N
in IN N
the DT N
pathogenesis NN N
and CC N
treatment NN N
of IN N
autistic JJ N
disorder NN N
is VBZ N
warranted VBN N
. . N

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
multicenter NN N
study NN N
to TO N
assess VB N
the DT N
safety NN 1_o
and CC N
cardiovascular JJ 1_o
effects NNS 1_o
of IN N
skeletal JJ 1_i
myoblast NN 1_i
implantation NN 1_i
by IN N
catheter NN N
delivery NN N
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
heart NN 1_p
failure NN 1_p
after IN 1_p
myocardial JJ 1_p
infarction NN 1_p
. . 1_p

BACKGROUND NNP N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN 1_o
and CC N
preliminary JJ 1_o
efficacy NN 1_o
of IN N
transcatheter NN N
intramyocardial JJ N
administration NN N
of IN N
myoblasts NNS 1_i
in IN N
patients NNS 1_p
with IN 1_p
heart NN 1_p
failure NN 1_p
( ( 1_p
HF NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
MARVEL NNP N
is VBZ N
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
of IN N
image-guided JJ N
, , N
catheter-based JJ N
intramyocardial JJ N
injection NN N
of IN N
placebo NN 1_i
or CC N
myoblasts NNS 1_i
( ( N
400 CD N
or CC N
800 CD N
million CD N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
class NN 1_p
II NNP 1_p
to TO 1_p
IV NNP 1_p
HF NNP 1_p
and CC 1_p
ejection NN 1_p
fraction NN 1_p
< VBD 1_p
35 CD 1_p
% NN 1_p
. . 1_p

Primary JJ N
end NN N
points NNS N
were VBD N
frequency NN 1_o
of IN 1_o
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
safety NN 1_o
) ) 1_o
and CC 1_o
changes NNS 1_o
in IN 1_o
6-minute JJ 1_o
walk NN 1_o
test NN 1_o
and CC 1_o
Minnesota NNP 1_o
Living NNP 1_o
With IN 1_o
HF NNP 1_o
score NN 1_o
( ( 1_o
efficacy NN 1_o
) ) 1_o
. . 1_o

Of IN 1_p
330 CD 1_p
patients NNS 1_p
intended VBN 1_p
for IN 1_p
enrollment NN 1_p
, , 1_p
23 CD 1_p
were VBD 1_p
randomized VBN 1_p
( ( 1_p
MARVEL-1 NNP 1_p
) ) 1_p
before IN 1_p
stopping VBG 1_p
the DT 1_p
study NN 1_p
for IN 1_p
financial JJ 1_p
reasons NNS 1_p
. . 1_p

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
similar JJ N
numbers NNS N
of IN N
events NNS N
occurred VBN N
in IN N
each DT N
group NN N
: : N
8 CD N
( ( 1_i
placebo NN 1_i
) ) 1_i
, , N
7 CD N
( ( N
low JJ N
dose NN N
) ) N
, , N
and CC N
8 CD N
( ( N
high JJ N
dose NN N
) ) N
, , N
without IN N
deaths NNS N
. . N

Ventricular JJ 1_o
tachycardia NN 1_o
responsive NN 1_o
to TO N
amiodarone VB N
was VBD N
more RBR N
frequent JJ N
in IN N
myoblast-treated JJ 1_i
patients NNS N
: : N
1 CD N
( ( 1_i
placebo NN 1_i
) ) 1_i
, , N
3 CD N
( ( N
low JJ N
dose NN N
) ) N
, , N
and CC N
4 CD N
( ( N
high JJ N
dose NN N
) ) N
. . N

A DT N
trend NN N
toward IN N
improvement NN N
in IN N
functional JJ 1_o
capacity NN 1_o
was VBD N
noted VBN N
in IN N
myoblast-treated JJ 1_i
groups NNS N
( ( N
Δ6-minute JJ N
walk NN N
test NN N
of IN N
-3.6 NNP N
vs FW N
+95.6 NNP N
vs FW N
+85.5 NNP N
m FW N
[ NNP N
placebo NN N
vs NN N
low JJ N
dose NN N
vs NN N
high JJ N
dose NN N
; : N
P NNP N
= NNP N
.50 NNP N
] NNP N
) ) N
without IN N
significant JJ N
changes NNS N
in IN 1_o
Minnesota NNP 1_o
Living NNP 1_o
With IN 1_o
HF NNP 1_o
scores NNS 1_o
. . N

CONCLUSIONS NNP N
In IN 1_p
HF NNP 1_p
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
postinfarction NN 1_p
cardiomyopathy NN 1_p
, , N
transcatheter JJ N
administration NN N
of IN 1_i
myoblasts NNS 1_i
in IN N
doses NNS N
of IN N
400 CD N
to TO N
800 CD N
million CD N
cells NNS N
is VBZ N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
important JJ N
clinical JJ N
benefits NNS N
. . N

Ventricular JJ N
tachycardia NN N
may MD N
be VB N
provoked VBN N
by IN 1_i
myoblast JJ 1_i
injection NN N
but CC N
appears VBZ N
to TO N
be VB N
a DT N
transient NN N
and CC N
treatable JJ N
problem NN N
. . N

A DT N
large-scale JJ N
outcome JJ N
trial NN N
of IN 1_i
myoblast JJ 1_i
administration NN N
in IN 1_p
HF NNP 1_p
patients NNS 1_p
with IN 1_p
postinfarction NN 1_p
cardiomyopathy NN 1_p
is VBZ N
feasible JJ N
and CC N
warranted VBD N
. . N

Use NNP N
of IN N
hormonal JJ 1_i
contraceptives NNS 1_i
and CC N
risk NN 1_o
of IN 1_o
HIV-1 NNP 1_o
transmission NN 1_o
: : 1_o
a DT N
prospective JJ N
cohort NN N
study NN N
. . N

BACKGROUND NNP N
Hormonal NNP 1_i
contraceptives NNS 1_i
are VBP N
used VBN N
widely RB N
but CC N
their PRP$ N
effects NNS N
on IN N
HIV-1 NNP N
risk NN N
are VBP N
unclear JJ N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
association NN N
between IN N
hormonal JJ 1_i
contraceptive NN 1_i
use NN N
and CC N
risk NN 1_o
of IN 1_o
HIV-1 NNP 1_o
acquisition NN 1_o
by IN N
women NNS N
and CC N
HIV-1 JJ 1_o
transmission NN 1_o
from IN N
HIV-1-infected JJ N
women NNS N
to TO N
their PRP$ N
male JJ N
partners NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
study NN N
, , N
we PRP N
followed VBD N
up RP N
3790 CD 1_p
heterosexual JJ 1_p
HIV-1-serodiscordant JJ 1_p
couples NNS 1_p
participating VBG 1_p
in IN 1_p
two CD 1_p
longitudinal JJ 1_p
studies NNS 1_p
of IN 1_p
HIV-1 NNP 1_p
incidence NN 1_p
in IN 1_p
seven CD 1_p
African JJ 1_p
countries NNS 1_p
. . 1_p

Among IN N
injectable JJ N
and CC N
oral JJ N
hormonal JJ 1_i
contraceptive NN 1_i
users NNS N
and CC N
non-users NNS N
, , N
we PRP N
compared VBN N
rates NNS 1_o
of IN 1_o
HIV-1 NNP 1_o
acquisition NN 1_o
by IN N
women NNS N
and CC N
HIV-1 JJ 1_o
transmission NN 1_o
from IN N
women NNS N
to TO N
men NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
HIV-1 JJ 1_o
seroconversion NN 1_o
. . 1_o

We PRP N
used VBD N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
and CC N
marginal JJ N
structural JJ N
modelling NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
contraceptive NN N
use NN N
on IN N
HIV-1 NNP 1_o
risk NN 1_o
. . 1_o

FINDINGS NNP N
Among IN 1_p
1314 CD 1_p
couples NNS 1_p
in IN 1_p
which WDT 1_p
the DT 1_p
HIV-1-seronegative JJ 1_p
partner NN 1_p
was VBD 1_p
female JJ 1_p
( ( N
median JJ N
follow-up NN N
18·0 CD N
[ JJ N
IQR NNP N
12·6-24·2 JJ N
] NNP N
months NNS N
) ) N
, , N
rates NNS N
of IN 1_o
HIV-1 NNP 1_o
acquisition NN 1_o
were VBD N
6·61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
women NNS N
who WP N
used VBD 1_i
hormonal JJ 1_i
contraception NN 1_i
and CC N
3·78 CD N
per IN N
100 CD N
person-years NNS N
in IN N
those DT N
who WP N
did VBD N
not RB N
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
1·98 CD N
, , N
95 CD N
% NN N
CI NNP N
1·06-3·68 CD N
, , N
p=0·03 NN 1_p
) ) 1_p
. . 1_p

Among IN 1_p
2476 CD 1_p
couples NNS 1_p
in IN 1_p
which WDT 1_p
the DT 1_p
HIV-1-seronegative JJ 1_p
partner NN 1_p
was VBD N
male JJ N
( ( N
median JJ N
follow-up NN N
18·7 CD N
[ JJ N
IQR NNP N
12·8-24·2 JJ N
] NNP N
months NNS 1_o
) ) 1_o
, , 1_o
rates NNS 1_o
of IN 1_o
HIV-1 NNP 1_o
transmission NN 1_o
from IN N
women NNS N
to TO N
men NNS N
were VBD N
2·61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT 1_i
women NNS 1_i
used VBD 1_i
hormonal JJ 1_i
contraception NN 1_i
and CC N
1·51 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS 1_i
did VBD 1_i
not RB 1_i
use VB 1_i
hormonal JJ 1_i
contraception NN N
( ( N
adjusted VBN N
hazard RB N
ratio JJ N
1·97 CD N
, , N
95 CD N
% NN N
CI NNP N
1·12-3·45 CD N
, , N
p=0·02 NN N
) ) N
. . N

Marginal JJ N
structural JJ N
model NN N
analyses NNS N
generated VBD N
much RB N
the DT N
same JJ N
results NNS N
to TO N
the DT N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
. . N

INTERPRETATION NNP N
Women NNP N
should MD N
be VB N
counselled VBN N
about IN N
potentially RB 1_o
increased VBN 1_o
risk NN 1_o
of IN 1_o
HIV-1 NNP 1_o
acquisition NN 1_o
and CC N
transmission NN 1_i
with IN 1_i
hormonal JJ 1_i
contraception NN N
, , N
especially RB N
injectable JJ N
methods NNS N
, , N
and CC N
about IN N
the DT N
importance NN N
of IN N
dual JJ N
protection NN N
with IN N
condoms NNS N
to TO N
decrease VB N
HIV-1 NNP N
risk NN N
. . N

Non-hormonal JJ 1_i
or CC 1_i
low-dose JJ 1_i
hormonal JJ 1_i
contraceptive NN N
methods NNS N
should MD N
be VB N
considered VBN N
for IN N
women NNS N
with IN N
or CC N
at-risk JJ N
for IN N
HIV-1 NNP N
. . N

FUNDING NNP N
US NNP N
National NNP N
Institutes NNP N
of IN N
Health NNP N
and CC N
the DT N
Bill NNP N
& CC N
Melinda NNP N
Gates NNP N
Foundation NNP N
. . N

Effect NN N
of IN N
treatment NN N
with IN N
paromomycin NN 1_i
on IN N
endotoxemia NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
alcoholic JJ 1_p
liver NN 1_p
disease NN 1_p
-- : 1_p
a DT 1_p
double-blind JJ N
, , N
placebo-controlled JJ 1_i
trial NN N
. . N

The DT N
results NNS N
of IN N
experimental JJ N
and CC N
clinical JJ N
studies NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
gut-derived JJ N
endotoxins NNS N
might MD N
be VB N
of IN N
relevance NN N
for IN N
the DT N
development NN N
and CC N
course NN N
of IN N
alcoholic JJ N
liver NN N
disease NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
nonabsorbable JJ N
, , N
broad-spectrum JJ N
antibiotic NN 1_i
on IN N
endotoxemia NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
alcoholic JJ 1_p
liver NN 1_p
disease NN 1_p
. . 1_p

Fifty JJ 1_p
patients NNS 1_p
with IN 1_p
alcoholic JJ 1_p
liver NN 1_p
disease NN 1_p
( ( 1_p
27 CD 1_p
with IN 1_p
cirrhosis NN 1_p
, , 1_p
23 CD 1_p
without IN 1_p
cirrhosis NN 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
paromomycin NN 1_i
sulfate NN 1_i
( ( N
3 CD N
x RB N
1 CD N
g/day NN N
) ) N
or CC N
placebo NN 1_i
in IN N
a DT N
double-blind JJ N
fashion NN N
for IN N
at IN N
least JJS N
3 CD N
weeks NNS N
, , N
and CC N
if IN N
possible JJ N
4 CD N
weeks NNS N
. . N

Endotoxin NNP 1_o
concentration NN 1_o
, , 1_o
liver JJ 1_o
function NN 1_o
tests NNS 1_o
, , 1_o
and CC 1_o
other JJ 1_o
laboratory NN 1_o
parameters NNS 1_o
were VBD N
determined VBN N
in IN N
weekly JJ N
intervals NNS N
. . N

Endotoxin NNP 1_o
concentration NN 1_o
was VBD N
also RB N
determined VBN N
in IN N
15 CD 1_p
healthy JJ 1_p
controls NNS 1_p
. . 1_p

Groups NNP N
receiving VBG N
paromomycin NN 1_i
or CC N
placebo NN 1_i
were VBD N
similar JJ N
for IN N
clinical JJ N
and CC N
biological JJ N
items NNS N
collected VBN N
initially RB N
. . N

Mean JJ N
initial JJ N
endotoxin NN 1_o
concentrations NNS 1_o
were VBD N
significantly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
; : N
paromomycin NN 1_i
, , N
16.7 CD N
+/- JJ N
5.3 CD N
pg/ml NN N
; : N
placebo NN 1_i
, , N
17.5 CD N
+/- JJ N
6.9 CD N
pg/ml NN N
; : N
healthy JJ N
controls NNS N
, , N
2.3 CD N
+/- JJ N
0.4 CD N
pg/ml NN N
) ) N
. . N

Although IN N
the DT N
mean JJ N
endotoxin NN 1_o
concentration NN 1_o
was VBD N
lower JJR N
in IN N
the DT N
verum NN N
group NN N
after IN N
1 CD N
week NN N
( ( 1_i
paromomycin NN 1_i
, , N
8.0 CD N
+/- JJ N
1.9 CD N
pg/ml NN N
; : N
placebo NN 1_i
, , N
14.6 CD N
+/- JJ N
3.5 CD N
pg/ml NN N
; : N
p CC N
> VB N
0.05 CD N
) ) N
, , N
paromomycin JJ 1_i
treatment NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
endotoxin NN 1_o
concentration NN 1_o
or CC 1_o
liver JJ 1_o
function NN 1_o
tests NNS 1_o
during IN N
the DT N
4-week JJ N
period NN N
. . N

The DT N
beneficial JJ N
effect NN N
of IN N
paromomycin NN 1_i
treatment NN N
on IN N
endotoxemia NN N
in IN N
cirrhotics NNS N
reported VBN N
in IN N
earlier JJR N
studies NNS N
could MD N
not RB N
be VB N
reproduced VBN N
under IN N
the DT N
conditions NNS N
of IN N
this DT N
trial NN N
in IN N
patients NNS 1_p
with IN 1_p
alcoholic JJ 1_p
liver NN 1_p
disease NN 1_p
. . 1_p

Rationale NNP N
and CC N
design NN N
of IN N
RE-LY NNP N
: : N
randomized JJ N
evaluation NN N
of IN N
long-term JJ N
anticoagulant JJ N
therapy NN N
, , N
warfarin NN 1_i
, , N
compared VBN N
with IN N
dabigatran NN 1_i
. . 1_i

Vitamin NNP 1_i
K NNP 1_i
antagonists NNS 1_i
( ( N
VKAs NNP N
) ) N
are VBP N
effective JJ N
for IN N
stroke NN 1_o
prevention NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
atrial JJ 1_p
fibrillation NN 1_p
( ( 1_p
AF NNP 1_p
) ) 1_p
but CC N
are VBP N
difficult JJ N
to TO N
use VB N
. . N

Dabigatran NNP 1_i
etexilate NN 1_i
is VBZ N
a DT N
prodrug NN N
that WDT N
is VBZ N
rapidly RB N
converted VBN N
to TO N
the DT N
active JJ N
direct JJ N
thrombin NN N
inhibitor NN N
dabigatran NN 1_i
. . 1_i

It PRP N
is VBZ N
administered VBN N
in IN N
a DT N
fixed JJ N
dose NN N
without IN N
laboratory JJ N
monitoring NN N
and CC N
is VBZ N
being VBG N
compared VBN N
with IN N
warfarin NN 1_i
( ( N
international JJ N
normalized VBN N
ratio JJ N
2-3 JJ N
) ) N
in IN N
the DT N
RE-LY JJ N
trial NN N
. . N

Two CD N
doses NNS N
of IN N
dabigatran NN 1_i
( ( N
110 CD N
and CC N
150 CD N
mg NNS N
BID NNP N
) ) N
are VBP N
being VBG N
evaluated VBN N
. . N

RE-LY NNP N
is VBZ N
a DT N
phase NN N
3 CD N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
multinational NN N
( ( N
44 CD N
countries NNS N
) ) N
trial NN N
of IN N
patients NNS 1_p
with IN 1_p
nonvalvular JJ 1_p
AF NNP 1_p
and CC 1_p
at IN 1_p
least JJS 1_p
1 CD 1_p
risk NN 1_p
factor NN 1_p
for IN 1_p
stroke NN 1_p
. . 1_p

Recruitment NNP 1_p
concluded VBD 1_p
with IN 1_p
a DT 1_p
total NN 1_p
of IN 1_p
18,113 CD 1_p
patients NNS 1_p
. . 1_p

Patients NNS 1_p
who WP 1_p
were VBD 1_p
VKA-naive NNP 1_p
and CC 1_p
experienced VBN 1_p
are VBP 1_p
included VBN 1_p
in IN 1_p
balanced JJ 1_p
proportions NNS 1_p
. . 1_p

The DT N
primary JJ N
outcome NN N
is VBZ N
stroke VBN 1_o
( ( 1_o
including VBG 1_o
hemorrhagic NN 1_o
) ) 1_o
or CC 1_o
systemic JJ 1_o
embolism NN 1_o
. . 1_o

Safety NNP 1_o
outcomes NNS N
are VBP N
bleeding VBG 1_o
, , 1_o
liver JJ 1_o
function NN 1_o
abnormalities NNS 1_o
, , 1_o
and CC 1_o
other JJ 1_o
adverse JJ 1_o
events NNS 1_o
. . 1_o

Adjudication NN N
of IN N
end NN N
points NNS N
is VBZ N
blinded VBN N
to TO N
drug NN N
assignment NN N
. . N

The DT N
trial NN N
is VBZ N
expected VBN N
to TO N
accrue VB N
a DT N
minimum NN N
of IN N
450 CD N
events NNS N
with IN N
a DT N
minimum JJ N
1-year JJ N
of IN N
follow-up JJ N
. . N

RE-LY NN N
is VBZ N
the DT N
largest JJS N
AF NNP N
stroke VBD 1_o
prevention NN N
trial NN N
yet RB N
undertaken VBN N
. . N

It PRP N
is VBZ N
unique JJ N
because IN N
it PRP N
includes VBZ N
equal JJ N
numbers NNS N
of IN N
VKA-experienced NNP N
and CC N
naive JJ N
patients NNS N
and CC N
evaluates VBZ N
2 CD N
different JJ N
dosages NNS N
of IN N
dabigatran NN 1_i
, , N
which WDT N
may MD N
allow VB N
tailoring NN N
of IN N
dosing VBG N
to TO N
individual JJ N
patient NN N
needs NNS N
. . N

The DT N
worldwide JJ N
site NN N
distribution NN N
and CC N
broad JJ N
range NN N
of IN N
stroke NN N
risk NN N
further RBR N
increase VB N
the DT N
general JJ N
applicability NN N
of IN N
the DT N
trial NN N
. . N

Results NNS N
are VBP N
expected VBN N
in IN N
2009 CD N
. . N

Superior JJ N
visual JJ 1_i
search NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
children NNS N
with IN N
autism NN N
perform NN N
better RBR N
than IN N
matched VBN N
controls NNS N
on IN N
visual JJ 1_o
search NN 1_o
tasks NNS 1_o
and CC N
that IN N
this DT N
stems VBZ N
from IN N
a DT N
superior JJ N
visual JJ N
discrimination NN N
ability NN N
. . N

This DT N
study NN N
assessed VBD N
whether IN N
these DT N
findings NNS N
generalize VBP N
from IN N
children NNS N
to TO N
adults NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

Experiments NNS N
1 CD N
and CC N
2 CD N
showed VBD N
that IN N
, , N
like IN N
children NNS N
, , N
adults NNS 1_p
with IN 1_p
autism NN 1_p
were VBD N
superior JJ N
to TO N
controls NNS N
at IN N
searching VBG 1_o
for IN 1_o
targets NNS 1_o
. . 1_o

Experiment NN N
3 CD N
showed VBD N
that IN N
increases NNS N
in IN N
target-distractor JJ N
similarity NN N
slowed VBD N
the DT N
visual JJ 1_o
search NN 1_o
performance NN 1_o
of IN N
the DT N
control NN N
group NN N
significantly RB N
more RBR N
than IN N
that DT N
of IN N
the DT N
autism NN N
group NN N
, , N
suggesting VBG N
that IN N
the DT N
adults NNS 1_p
with IN 1_p
autism NN 1_p
have VBP N
a DT N
superior JJ N
visual JJ 1_o
discrimination NN 1_o
ability NN 1_o
. . 1_o

Thus RB N
, , N
these DT N
experiments NNS N
replicate VBP N
in IN N
adults NNS N
previous JJ N
findings NNS N
in IN N
children NNS N
with IN N
autism NN N
. . N

Superior NNP N
unique JJ 1_o
item NN 1_o
detection NN 1_o
in IN N
adults NNS 1_p
with IN 1_p
autism NN 1_p
, , N
stemming VBG N
from IN N
enhanced VBN N
discrimination NN 1_o
, , N
is VBZ N
discussed VBN N
in IN N
the DT N
light NN N
of IN N
the DT N
possible JJ N
role NN N
of IN N
stimulus JJ N
processing NN N
disturbances NNS N
in IN N
the DT N
disorder NN N
in IN N
general JJ N
. . N

Development NNP 1_o
of IN 1_o
renal JJ 1_o
disease NN 1_o
in IN 1_p
people NNS 1_p
at IN 1_p
high JJ 1_p
cardiovascular JJ 1_p
risk NN 1_p
: : 1_p
results NNS N
of IN N
the DT N
HOPE NNP N
randomized VBD N
study NN N
. . N

In IN N
people NNS 1_p
with IN 1_p
diabetes NNS 1_p
, , N
renal JJ N
disease NN N
tends VBZ N
to TO N
progress VB 1_o
from IN 1_o
microalbuminuria NN 1_o
to TO N
clinical JJ 1_o
proteinuria NN 1_o
to TO N
renal JJ 1_o
insufficiency NN 1_o
. . 1_o

Little JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
for IN N
the DT N
nondiabetic JJ N
population NN N
. . N

This DT N
study NN N
retrospectively RB N
analyzed VBD N
changes NNS 1_o
of IN 1_o
proteinuria NN 1_o
over IN N
4.5 CD N
yr NNS N
in IN N
the DT N
HOPE NNP N
( ( N
Heart NNP N
Outcomes NNP N
and CC N
Prevention NNP N
Evaluation NNP N
) ) N
study NN N
, , N
which WDT N
compared VBN N
ramipril NN 1_i
's POS 1_i
effects NNS N
to TO N
placebo VB 1_i
in IN N
9297 CD N
participants NNS N
, , N
including VBG N
3577 CD N
with IN N
diabetes NNS N
and CC N
1956 CD N
with IN N
microalbuminuria NN N
. . N

This DT N
report NN N
is VBZ N
restricted VBN N
to TO N
7674 CD 1_p
participants NNS 1_p
with IN 1_p
albuminuria NNS 1_p
data NNS 1_p
at IN 1_p
baseline NN 1_p
and CC 1_p
at IN 1_p
follow-up JJ 1_p
. . 1_p

Inclusion NN 1_p
criteria NNS 1_p
were VBD 1_p
known VBN 1_p
vascular JJ 1_p
disease NN 1_p
or CC 1_p
diabetes VBZ 1_p
plus CC 1_p
one CD 1_p
other JJ 1_p
cardiovascular JJ 1_p
risk NN 1_p
factor NN 1_p
, , 1_p
exclusion NN 1_p
criteria NNS 1_p
included VBD 1_p
heart NN 1_p
failure NN 1_p
or CC 1_p
known VBN 1_p
impaired JJ 1_p
left VBD 1_p
ventricular JJ 1_p
function NN 1_p
, , 1_p
dipstick-positive JJ 1_p
proteinuria NN 1_p
( ( 1_p
> JJ 1_p
1+ CD 1_p
) ) 1_p
, , 1_p
and CC 1_p
serum JJ 1_p
creatinine NN 1_p
> $ 1_p
2.3 CD 1_p
mg/dl NN 1_p
( ( 1_p
200 CD 1_p
microM NN 1_p
) ) 1_p
. . 1_p

Baseline NNP N
microalbuminuria NN N
predicted VBD N
subsequent JJ N
clinical JJ 1_o
proteinuria NN 1_o
for IN N
the DT N
study NN N
participants NNS N
overall JJ N
( ( N
adjusted VBN N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
17.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
12.6 CD N
to TO N
24.4 CD N
) ) N
, , N
in IN N
participants NNS N
without IN N
diabetes NNS N
( ( N
OR NNP N
, , N
16.7 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
8.6 CD N
to TO N
32.4 CD N
) ) N
, , N
and CC N
in IN N
participants NNS N
with IN N
diabetes NNS N
( ( N
OR NNP N
, , N
18.2 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
12.4 CD N
to TO N
26.7 CD N
) ) N
. . N

Any DT N
progression NN 1_o
of IN 1_o
albuminuria NNS 1_o
( ( N
defined VBN N
as IN N
new JJ 1_o
microalbuminuria NNS 1_o
or CC 1_o
new JJ 1_o
clinical JJ 1_o
proteinuria NN 1_o
) ) 1_o
occurred VBD N
in IN N
1859 CD N
participants NNS N
; : N
1542 CD N
developed VBD N
new JJ 1_o
microalbuminuria NNS 1_o
, , N
and CC N
317 CD N
participants NNS N
developed VBD N
clinical JJ 1_o
proteinuria NN 1_o
. . 1_o

Ramipril NNP 1_i
reduced VBD N
the DT N
risk NN N
for IN N
any DT N
progression NN 1_o
( ( N
OR NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.78 CD N
to TO N
0.97 CD N
; : N
P NNP N
= NNP N
0.0146 CD N
) ) N
. . N

People NNS 1_p
without IN 1_p
and CC 1_p
with IN 1_p
diabetes NNS 1_p
who WP 1_p
are VBP 1_p
at IN 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
cardiovascular JJ 1_p
disease NN 1_p
are VBP N
also RB N
at IN N
risk NN N
for IN N
a DT N
progressive JJ N
rise NN N
in IN N
albuminuria NN 1_o
. . 1_o

Microalbuminuria NNP N
itself PRP N
predicts VBZ N
clinical JJ 1_o
proteinuria NNS 1_o
in IN N
nondiabetic JJ 1_p
and CC 1_p
in IN 1_p
diabetic JJ 1_p
people NNS 1_p
. . 1_p

Ramipril JJ 1_i
prevents NNS N
or CC N
delays VBZ N
the DT N
progression NN 1_o
of IN 1_o
albuminuria NN 1_o
. . 1_o

Comparison NNP N
of IN N
weakness NN 1_o
progression NN 1_o
in IN N
inclusion NN 1_p
body NN 1_p
myositis NN 1_p
during IN N
treatment NN N
with IN N
methotrexate NN 1_i
or CC N
placebo NN 1_i
. . 1_i

We PRP N
investigated VBD N
whether IN N
5 CD N
to TO N
20mg CD N
per IN N
week NN N
oral JJ N
methotrexate NN 1_i
could MD N
slow VB N
down RP N
disease NN 1_o
progression NN 1_o
in IN N
44 CD 1_p
patients NNS 1_p
with IN 1_p
inclusion NN 1_p
body NN 1_p
myositis NN 1_p
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
over IN N
48 CD N
weeks NNS N
. . N

Mean NNP 1_o
change NN 1_o
of IN 1_o
quantitative JJ 1_o
muscle NN 1_o
strength NN 1_o
testing VBG 1_o
sum NN 1_o
scores NNS 1_o
was VBD N
the DT N
primary JJ N
study NN N
outcome JJ N
measure NN N
. . N

Quantitative JJ 1_o
muscle NN 1_o
strength NN 1_o
testing VBG 1_o
sum NN 1_o
scores NNS 1_o
declined VBD N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
-0.2 CD N
% NN N
for IN N
methotrexate NN 1_i
and CC N
-3.4 CD N
% NN N
for IN N
placebo NN 1_i
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
= NNP N
-2.5 NNP N
% NN N
to TO N
+9.1 CD N
% NN N
for IN N
difference NN N
) ) N
. . N

There EX N
were VBD N
also RB N
no DT N
differences NNS N
in IN N
manual JJ 1_o
muscle NN 1_o
testing VBG 1_o
sum JJ 1_o
scores NNS 1_o
, , 1_o
activity NN 1_o
scale NN 1_o
scores NNS 1_o
and CC 1_o
patients NNS 1_o
' POS 1_o
own JJ 1_o
assessments NNS 1_o
after IN N
48 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Serum NNP 1_o
creatine JJ 1_o
kinase NN 1_o
activity NN 1_o
decreased VBN N
significantly RB N
in IN N
the DT N
methotrexate NN 1_i
group NN N
. . N

We PRP N
conclude VBP N
that IN N
oral JJ N
methotrexate NN 1_i
did VBD N
not RB N
slow VB N
down RP N
progression NN 1_o
of IN 1_o
muscle NN 1_o
weakness NN 1_o
but CC N
decreased VBD N
serum JJ 1_o
creatine JJ 1_o
kinase NN 1_o
activity NN 1_o
. . 1_o

Bolus NNP N
injection NN N
of IN N
contrast NN N
agents NNS N
with IN N
various JJ N
iodine JJ N
concentrations NNS N
and CC N
delivery NN N
rates NNS N
for IN N
intracranial JJ N
three-dimensional JJ N
CT NNP N
angiography NN N
: : N
evaluation NN N
of IN N
intracranial JJ 1_o
arteriovenous JJ 1_o
contrast NN 1_o
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
scanner NN N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
difference NN 1_o
in IN N
computed JJ N
tomography NN N
( ( N
CT NNP N
) ) N
attenuation NN N
values NNS N
of IN N
the DT N
intracranial JJ N
arterial NN N
and CC N
venous JJ N
systems NNS N
among IN N
the DT N
various JJ N
contrast NN N
injection NN N
protocols NNS N
( ( N
higher JJR N
iodine NN N
delivery NN N
rate NN N
or CC N
higher JJR N
concentration NN N
of IN N
the DT N
agent NN N
) ) N
on IN N
the DT N
source NN N
images NNS N
of IN N
intracranial JJ N
three-dimensional JJ N
CT NNP N
angiography NN N
( ( N
3D-CTA JJ N
) ) N
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
( ( N
MDCT NNP N
) ) N
scanner NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
used VBD N
100 CD N
ml NN N
of IN N
iopamidol JJ 1_i
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NNS N
, , N
100 CD N
ml NN N
of IN N
iopamidol JJ 1_i
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.7 CD N
ml/s NN N
, , N
and CC N
80 CD N
ml NN N
of IN N
iopamidol JJ 1_i
370 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NN N
. . N

There EX N
were VBD N
10 CD 1_p
patients NNS 1_p
in IN 1_p
each DT 1_p
group NN 1_p
. . 1_p

Attenuation NNP 1_o
values NNS 1_o
of IN 1_o
the DT 1_o
bilateral JJ 1_o
internal JJ 1_o
carotid NN 1_o
arteries NNS 1_o
( ( 1_o
ICAs NNP 1_o
) ) 1_o
, , 1_o
basilar JJ 1_o
artery NN 1_o
trunk NN 1_o
, , 1_o
bilateral JJ 1_o
cavernous JJ 1_o
sinuses NNS 1_o
( ( 1_o
CSs NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
Galenic NNP 1_o
vein NNS 1_o
were VBD N
measured VBN N
quantitatively RB N
on IN N
the DT N
axial JJ N
CT NNP N
angiographic JJ N
source NN N
images NNS N
obtained VBN N
by IN N
four-channel JJ 1_o
MDCT NNP 1_o
. . 1_o

RESULTS NNP N
Injection NNP N
of IN N
the DT N
high-concentration NN N
contrast NN N
with IN N
a DT N
higher JJR N
iodine-delivery JJ N
rate NN N
achieved VBN N
good JJ N
arteriovenous JJ 1_o
contrast NN 1_o
at IN 1_o
the DT 1_o
cavernous JJ 1_o
portion NN 1_o
. . 1_o

With IN N
the DT N
same JJ N
rate NN N
of IN N
iodine NN N
delivery NN N
, , N
injection NN N
of IN N
the DT N
intermediate JJ N
concentrate NN N
agent NN N
increased VBD N
the DT N
CT NNP 1_o
value NN 1_o
of IN N
not RB N
only RB N
the DT N
ICAs NNP N
but CC N
also RB N
the DT N
CSs NNP N
. . N

CONCLUSION NNP N
High-concentration NNP N
contrast NN N
could MD N
increase VB N
ICA NNP 1_o
attenuation NN 1_o
without IN N
intracavernous JJ 1_o
attenuation NN 1_o
gain NN N
during IN N
the DT N
" JJ N
first-pass NN N
" NNP N
phase NN N
. . N

RESPECT-PTSD JJ N
: : N
re-engineering JJ N
systems NNS N
for IN N
the DT N
primary JJ N
care NN N
treatment NN N
of IN N
PTSD NNP 1_p
, , N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
collaborative JJ 1_i
care NN 1_i
is VBZ N
effective JJ N
for IN N
treating VBG N
depression NN N
and CC N
other JJ N
mental JJ N
disorders NNS N
in IN N
primary JJ N
care NN N
, , N
there EX N
have VBP N
been VBN N
no DT N
randomized JJ N
trials NNS N
of IN N
collaborative JJ N
care NN N
specifically RB N
for IN N
patients NNS 1_p
with IN 1_p
Posttraumatic NNP 1_p
stress NN 1_p
disorder NN 1_p
( ( 1_p
PTSD NNP 1_p
) ) 1_p
. . 1_p

OBJECTIVE UH N
To TO N
compare VB N
a DT N
collaborative JJ N
approach NN N
, , N
the DT N
Three NNP 1_i
Component NNP 1_i
Model NNP 1_i
( ( 1_i
3CM CD 1_i
) ) 1_i
, , N
with IN N
usual JJ 1_i
care NN 1_i
for IN N
treating VBG N
PTSD NNP 1_p
in IN N
primary JJ N
care NN N
. . N

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
two-arm JJ N
, , N
parallel JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

PTSD JJ 1_p
patients NNS 1_p
were VBD 1_p
recruited VBN 1_p
from IN 1_p
five CD 1_p
primary JJ 1_p
care NN 1_p
clinics NNS 1_p
at IN 1_p
four CD 1_p
Veterans NNS 1_p
Affairs NNP 1_p
healthcare NN 1_p
facilities NNS 1_p
and CC N
randomized VBN N
to TO N
receive VB N
usual JJ 1_i
care NN 1_i
or CC N
usual JJ 1_i
care NN 1_i
plus CC 1_i
3CM CD 1_i
. . 1_i

Blinded VBN N
assessors NNS N
collected VBD N
data NNS N
at IN N
baseline NN N
and CC N
3-month JJ N
and CC N
6-month JJ N
follow-up NN N
. . N

PARTICIPANTS JJ N
Participants NNS 1_p
were VBD 1_p
195 CD 1_p
Veterans NNPS 1_p
. . 1_p

Their PRP$ 1_p
average JJ 1_p
age NN 1_p
was VBD 1_p
45 CD 1_p
years NNS 1_p
, , 1_p
91 CD 1_p
% NN 1_p
were VBD 1_p
male JJ 1_p
, , 1_p
58 CD 1_p
% NN 1_p
were VBD 1_p
white JJ 1_p
, , 1_p
40 CD 1_p
% NN 1_p
served VBN 1_p
in IN 1_p
Iraq NNP 1_p
or CC 1_p
Afghanistan NNP 1_p
, , 1_p
and CC 1_p
42 CD 1_p
% NN 1_p
served VBD 1_p
in IN 1_p
Vietnam NNP 1_p
. . 1_p

INTERVENTION NNP N
All NNP N
participants NNS N
received VBD N
usual JJ N
care NN N
. . N

Participants NNS N
assigned VBD N
to TO N
3CM CD 1_i
also RB N
received VBD N
telephone NN 1_i
care NN 1_i
management NN 1_i
. . 1_i

Care NN N
managers NNS N
received VBD N
supervision NN N
from IN N
a DT N
psychiatrist NN N
. . N

MAIN NNP N
MEASURES NNP N
PTSD NNP 1_o
symptom NN 1_o
severity NN 1_o
was VBD N
the DT N
primary JJ N
outcome NN N
. . N

Depression NNP 1_o
, , 1_o
functioning NN 1_o
, , 1_o
perceived VBD 1_o
quality NN 1_o
of IN 1_o
care NN 1_o
, , 1_o
utilization NN 1_o
, , 1_o
and CC 1_o
costs NNS 1_o
were VBD N
secondary JJ N
outcomes NNS N
. . N

KEY JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
3CM CD 1_i
and CC N
usual JJ 1_i
care NN 1_i
in IN N
symptoms NNS 1_o
or CC 1_o
functioning VBG 1_o
. . 1_o

Participants NNS N
assigned VBD N
to TO N
3CM CD 1_i
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
mental JJ 1_o
health NN 1_o
visit NN 1_o
, , 1_o
fill VB 1_o
an DT 1_o
antidepressant JJ 1_o
prescription NN 1_o
, , N
and CC N
have VBP N
adequate VBN 1_o
antidepressant JJ 1_o
refills NNS 1_o
. . 1_o

3CM CD 1_i
participants NNS N
also RB N
had VBD N
more RBR N
mental JJ 1_o
health NN 1_o
visits NNS 1_o
and CC N
higher JJR N
outpatient NN 1_o
pharmacy NN 1_o
costs NNS 1_o
. . 1_o

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
the DT N
need NN N
for IN N
careful JJ N
examination NN N
of IN N
the DT N
way NN N
that IN N
collaborative JJ 1_i
care NN 1_i
models NNS N
are VBP N
implemented VBN N
for IN N
treating VBG N
PTSD NNP N
, , N
and CC N
for IN N
additional JJ N
supports NNS N
to TO N
encourage VB N
primary JJ N
care NN N
providers NNS N
to TO N
manage VB N
PTSD NNP N
. . N

[ VB N
The DT N
effect NN N
of IN N
ionic JJ 1_i
and CC N
nonionic JJ 1_i
x-ray JJ 1_i
contrast NN 1_i
media NNS N
on IN N
myocardial JJ 1_o
perfusion NN 1_o
and CC 1_o
myocardial JJ 1_o
function NN 1_o
] NN 1_o
. . N

The DT N
influence NN N
of IN N
injections NNS N
of IN N
Amidotrizoate NNP 1_i
and CC N
Iopromide NNP 1_i
into IN N
the DT N
left JJ N
coronary JJ N
artery NN N
on IN N
global JJ 1_o
myocardial JJ 1_o
perfusion NN 1_o
and CC 1_o
function NN 1_o
( ( 1_o
pressures NNS 1_o
in IN 1_o
the DT 1_o
left JJ 1_o
ventricle NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
) ) 1_o
as RB N
well RB N
as IN N
excitation NN 1_o
formation NN 1_o
and CC 1_o
transmission NN 1_o
was VBD N
studied VBN N
in IN N
16 CD 1_p
patients NNS 1_p
with IN 1_p
ischaemic JJ 1_p
heart NN 1_p
disease NN 1_p
. . 1_p

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
myocardial JJ 1_o
perfusion NN 1_o
measured VBN N
were VBD N
found VBN N
with IN N
xenon-133 JJ N
in IN N
this DT N
small JJ N
group NN N
between IN N
rest NN N
and CC N
dipyridamole JJ 1_i
load NN N
for IN N
ionic JJ N
and CC N
non-ionic JJ N
contrast NN N
media NNS N
. . N

Subjective JJ N
and CC N
objective JJ N
levels NNS N
of IN N
physical JJ 1_o
activity NN 1_o
and CC N
their PRP$ N
association NN N
with IN N
cardiorespiratory NN N
fitness NN N
in IN N
rheumatoid JJ 1_p
arthritis NN 1_p
patients NNS 1_p
. . 1_p

INTRODUCTION NNP N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
: : N
( ( N
a DT N
) ) N
to TO N
examine VB N
the DT N
agreement NN 1_o
between IN N
subjective JJ 1_o
( ( 1_o
assessed JJ 1_o
via IN 1_o
the DT 1_o
International NNP 1_o
Physical NNP 1_o
Activity NNP 1_o
Questionnaire NNP 1_o
; : 1_o
IPAQ NNP 1_o
) ) 1_o
and CC 1_o
objective JJ 1_o
( ( 1_o
accelerometry NN 1_o
; : 1_o
GT3X NNP 1_o
) ) 1_o
physical JJ 1_o
activity NN 1_o
( ( 1_o
PA NNP 1_o
) ) 1_o
levels NNS 1_o
in IN N
patients NNS 1_p
with IN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
, , N
and CC N
( ( N
b NN N
) ) N
to TO N
evaluate VB N
the DT N
associations NNS 1_o
of IN N
RA NNP 1_p
patients NNS 1_p
' POS 1_p
subjective JJ 1_o
and CC 1_o
objective JJ 1_o
PA NNP 1_o
to TO N
their PRP$ N
scores NNS 1_o
on IN 1_o
the DT 1_o
maximal JJ 1_o
oxygen NN 1_o
uptake JJ 1_o
test NN 1_o
( ( 1_o
VO2max NNP 1_o
) ) 1_o
. . 1_o

METHODS PDT N
The DT N
participants NNS N
wore VBD N
the DT N
GT3X NNP N
for IN N
seven CD N
days NNS N
before IN N
completing VBG N
the DT N
IPAQ NNP 1_o
and CC 1_o
VO2max NNP 1_o
test NN 1_o
. . 1_o

The DT N
Bland-Altman NNP 1_o
plot NN 1_o
was VBD N
used VBN N
to TO N
illustrate VB N
the DT N
agreement NN 1_o
between IN N
the DT N
objective NN N
and CC N
subjective JJ N
PA NNP 1_i
data NN N
, , N
and CC N
the DT N
Wilcoxon NNP 1_o
test NN 1_o
was VBD N
employed VBN N
to TO N
examine VB N
the DT N
differences NNS N
. . N

The DT N
association NN 1_o
between IN 1_o
the DT 1_o
PA NNP 1_o
measurement NN 1_o
and CC 1_o
VO2max NNP 1_o
test NN 1_o
was VBD 1_o
examined VBN 1_o
via IN 1_o
the DT 1_o
correlations NNS 1_o
and CC 1_o
the DT 1_o
magnitude NN 1_o
was VBD 1_o
presented VBN 1_o
by IN 1_o
the DT 1_o
Steiger NNP 1_o
's POS 1_o
Z NNP 1_o
value NN 1_o
. . 1_o

RESULTS NNP N
Sixty-eight JJ 1_p
RA NNP 1_p
patients NNS 1_p
( ( 1_p
age=55±13 JJ 1_p
years NNS 1_p
, , 1_p
body NN 1_p
mass NN 1_p
index NN 1_p
: : 1_p
27.8±5.4 CD 1_p
kg/m2 NN 1_p
, , 1_p
median NN 1_p
of IN 1_p
disease NN 1_p
duration=5 NN 1_p
( ( 1_p
2-8 JJ 1_p
) ) 1_p
yrs NN 1_p
) ) 1_p
were VBD N
recruited VBN N
. . N

Smaller NNP N
differences NNS N
between IN N
the DT 1_o
subjective JJ 1_o
and CC 1_o
objective JJ 1_o
measures NNS 1_o
were VBD N
found VBN N
when WRB 1_i
PA NNP 1_i
was VBD N
assessed VBN N
at IN N
the DT N
moderate JJ N
level NN 1_o
. . 1_o

Wilcoxon NNP 1_o
tests NNS 1_o
revealed VBD N
that IN N
patients NNS N
reported VBD N
less JJR N
time NN N
spent VBN N
engaged VBN N
in IN 1_o
sedentary JJ 1_o
behaviours NNS 1_o
( ( N
Z=-6.80 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC 1_o
light JJ 1_o
PA NNP 1_o
( ( N
Z=-6.89 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
more JJR 1_o
moderate JJ 1_o
PA NNP 1_o
( ( N
Z=-6.26 NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
was VBD N
objectively RB N
indicated VBN N
. . N

Significant NNP N
positive JJ N
correlations NNS N
were VBD N
revealed VBN N
between IN 1_o
VO2max NNP 1_o
with IN N
all DT 1_i
PA NNP 1_i
levels NNS N
derived VBN N
from IN 1_o
accelerometry NN 1_o
( ( N
light JJ N
PA NNP N
rho=.35 NN N
, , N
P NNP N
< NNP N
.01 NNP N
; : N
moderate JJ N
PA NNP N
rho=.34 NN N
, , N
P=.01 NNP N
; : N
moderate JJ N
and CC N
vigorous JJ N
PA NNP N
, , N
( ( N
MVPA NNP N
) ) N
rho=.33 NN N
, , N
P=.01 NNP N
) ) N
, , N
and CC N
a DT N
negative JJ N
association NN N
to TO 1_o
sedentary JJ 1_o
time NN 1_o
( ( 1_o
ST NNP 1_o
) ) 1_o
emerged VBD N
( ( N
rho=-.27 JJ N
, , N
P=.04 NNP 1_o
) ) 1_o
. . 1_o

IPAQ-reported JJ 1_o
moderate JJ 1_o
PA NNP 1_o
and CC 1_o
MVPA NNP 1_o
positively RB N
correlated VBD N
with IN 1_o
maxV02 NN 1_o
( ( N
rho=.25 NN N
, , N
P=.01 NNP N
, , N
rho=.27 NN N
, , N
P=.01 NNP N
, , N
respectively RB N
) ) N
. . N

Differences NNS N
between IN N
the DT N
magnitude NN N
of IN N
correlations NNS N
between IN N
the DT 1_o
IPAQ-VO2 NNP 1_o
max NN 1_o
and CC 1_o
GT3X-VO2 NNP 1_o
max NN 1_o
were VBD N
only RB N
significant JJ N
for IN N
ST NNP N
( ( N
Z=3.43 NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Via NNP N
responses VBZ N
to TO N
the DT 1_o
IPAQ NNP 1_o
, , N
RA NNP N
patients NNS N
reported VBD N
that IN N
they PRP N
were VBD N
less JJR 1_o
sedentary JJ 1_o
and CC N
engaged VBN N
in IN N
more RBR N
higher JJR N
intensity NN 1_o
PA NNP 1_o
than IN N
what WP N
was VBD N
objectively RB N
assessed VBN 1_o
. . 1_o

Accelerometry NNP 1_o
data NNS N
correlated VBD N
with IN 1_o
VO2max NNP 1_o
at IN N
all DT 1_i
PA NNP 1_i
levels NNS N
. . N

Only RB N
subjective JJ N
moderate NN N
and CC 1_o
MPVA NNP 1_o
correlated VBD N
with IN 1_o
VO2max NNP 1_o
. . N

Findings NNS N
suggest VBP N
that IN N
self-reported JJ 1_o
PA NNP 1_o
and CC 1_o
ST NNP 1_o
should MD N
be VB N
interpreted VBN N
with IN N
caution NN N
in IN 1_p
people NNS 1_p
with IN 1_p
RA NNP 1_p
and CC N
complemented VBN N
with IN 1_o
accelerometry NN 1_o
when WRB N
possible JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
registration NN N
: : N
ClinicalTrials.gov NNP N
ISRCTN04121489 NNP N
. . N

Registered VBD N
5 CD N
September NNP N
2012 CD N
. . N

Bacteremia NNP 1_o
due JJ N
to TO N
Bacteroides NNP N
fragilis NN N
after IN N
elective JJ N
appendectomy NN N
in IN 1_p
renal JJ 1_p
transplant NN 1_p
recipients NNS 1_p
. . 1_p

Bacteremia NNP 1_o
caused VBN N
by IN N
Bacteroides NNP N
fragilis NN N
occurred VBD N
in IN N
four CD N
of IN N
75 CD 1_p
children NNS 1_p
after IN 1_p
renal JJ 1_p
transplantation NN 1_p
, , N
and CC N
B. NNP N
fragilis NN N
was VBD N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
postoperative JJ 1_o
bacteremia NN 1_o
. . 1_o

Bacteroides NNP N
bacteremia NN 1_o
was VBD N
significantly RB N
associated VBN N
with IN N
performance NN 1_o
of IN 1_o
elective JJ 1_o
appendectomy NN 1_o
at IN N
the DT N
time NN N
of IN N
transplantation NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
with IN N
profound JJ N
lymphocytopenia NN 1_o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

No DT N
patient NN N
received VBD N
antibiotics NNS N
at IN N
the DT N
time NN N
of IN N
surgery NN N
or CC N
prior RB N
to TO N
the DT N
first JJ N
positive JJ N
blood NN N
culture NN N
, , N
yet RB N
B. NNP N
fragilis NN N
was VBD N
the DT N
single JJ N
organism NN N
isolated VBN N
from IN N
blood NN N
and CC N
abscesses NNS N
in IN N
these DT N
patients NNS N
. . N

A DT N
role NN N
for IN N
lymphocytes NNS N
in IN N
containment NN N
of IN N
B. NNP N
fragilis NN N
has VBZ N
not RB N
been VBN N
suggested VBN N
previously RB N
, , N
although IN N
unexplained JJ N
occurrence NN 1_o
of IN 1_o
bacteroides NNS 1_o
bacteremia VBP 1_o
in IN N
immunocompromised JJ N
patients NNS N
has VBZ N
occasionally RB N
been VBN N
reported VBN N
. . N

Lymphocytes VBZ N
themselves PRP N
may MD N
be VB N
important JJ N
in IN N
this DT N
host-bacterium JJ N
interaction NN N
, , N
or CC N
lymphocytopenia NN 1_o
may MD N
be VB N
the DT N
marker NN N
for IN N
a DT N
more RBR N
generalized JJ N
deficiency NN N
in IN N
host NN N
defenses NNS N
. . N

[ JJ N
Impact NNP N
of IN N
CCND1 NNP N
A870G NNP N
polymorphism NN N
on IN N
acute JJ 1_o
adverse JJ 1_o
events NNS 1_o
in IN N
postoperative JJ 1_p
rectal JJ 1_p
cancer NN 1_p
patients NNS 1_p
treated VBN 1_p
with IN 1_p
adjuvant JJ 1_p
concurrent NN 1_p
chemoradiotherapy NN 1_i
] NNP 1_i
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
association NN 1_o
between IN N
single JJ 1_o
nucleotide JJ 1_o
polymorphism NN 1_o
( ( 1_o
SNP NNP 1_o
) ) 1_o
of IN 1_o
CCND1 NNP 1_o
A870G NNP 1_o
and CC 1_o
acute JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
AEs NNP 1_o
) ) 1_o
in IN N
postoperative JJ 1_p
rectal JJ 1_p
cancer NN 1_p
patients NNS 1_p
who WP 1_p
received VBD 1_p
capecitabine-based JJ 1_i
postoperative JJ 1_p
chemoradiotherapy NN 1_i
( ( 1_i
CRT NNP 1_i
) ) 1_i
. . 1_p

METHODS NNP N
Four CD 1_p
hundred VBD 1_p
patients NNS 1_p
with IN 1_p
stage NN 1_p
II NNP 1_p
and CC 1_p
III NNP 1_p
rectal JJ 1_p
cancer NN 1_p
received VBD 1_p
postoperative JJ 1_p
CRT NNP 1_p
of IN N
capecitabine NN 1_i
with IN N
or CC N
without IN N
oxaliplatin NNS 1_i
were VBD N
accumulated VBN N
and CC N
prostectively RB N
studied VBN N
in IN N
this DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Two CD N
hundred CD N
and CC N
twenty-eight JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
concurrent JJ N
capecitabine NN 1_i
and CC 1_i
radiotherapy NN 1_i
( ( 1_i
Cap-CRT NNP 1_i
) ) 1_i
, , N
and CC N
172 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
capecitabine NN 1_i
and CC 1_i
oxaliplatin JJ 1_i
plus CC 1_i
radiotherapy JJ 1_i
( ( 1_i
Cap-Oxa-CRT NNP 1_i
) ) 1_i
. . 1_i

Adverse JJ 1_o
events NNS 1_o
were VBD 1_o
graded VBN 1_o
according VBG 1_o
to TO 1_o
the DT 1_o
Common NNP 1_o
Terminology NNP 1_o
Criteria NNP 1_o
for IN 1_o
Adverse NNP 1_o
Events NNP 1_o
, , 1_o
v. NN 1_o
3.0 CD 1_o
( ( 1_o
CTCAE NNP 1_o
v3.0 NN 1_o
) ) 1_o
. . 1_o

The DT N
genotype NN 1_o
of IN 1_o
CCND1 NNP 1_o
A870G NNP 1_o
in IN N
the DT N
patients NNS N
was VBD N
detected VBN N
by IN N
polymerase NN 1_o
chain NN 1_o
reaction-based JJ 1_o
restriction NN 1_o
fragment NN 1_o
length NN 1_o
polymorphism NN 1_o
( ( 1_o
PCR-RFLP NNP 1_o
) ) 1_o
analysis NN 1_o
. . 1_o

The DT N
associations NNS 1_o
between IN 1_o
the DT 1_o
SNP NNP 1_o
and CC 1_o
acute JJ 1_o
AEs NNP 1_o
were VBD N
indicated VBN N
by IN N
odds NNS 1_o
ratios NNS 1_o
( ( 1_o
ORs NNP 1_o
) ) 1_o
and CC N
95 CD N
% NN N
confidence NN 1_o
intervals NNS 1_o
( ( 1_o
CIs NNP 1_o
) ) 1_o
, , N
which WDT N
were VBD N
computed VBN N
with IN N
logistic JJ 1_o
regression NN 1_o
model NN 1_o
. . 1_o

RESULTS VB N
A DT N
total NN N
of IN N
136 CD N
patients NNS N
presented VBN N
severe JJ N
AEs NNP 1_o
. . 1_o

Among IN N
them PRP N
the DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS 1_o
GG NNP N
, , N
GA NNP N
and CC N
AA NNP N
were VBD N
16.9 CD N
% NN N
, , N
50.7 CD N
% NN N
and CC N
32.4 CD N
% NN N
, , N
compared VBN N
with IN N
24.6 CD N
% NN N
, , N
48.1 CD N
% NN N
and CC N
27.3 CD N
% NN N
, , N
respectively RB N
, , N
among IN N
the DT N
patients NNS N
without IN N
severe JJ N
AEs NNP 1_o
. . 1_o

Diarrhea NNP 1_o
was VBD N
the DT N
most RBS N
common JJ N
AE NNP 1_o
, , N
and CC N
severe JJ 1_o
diarrhea NN 1_o
occurred VBD N
in IN N
109 CD N
patients NNS N
. . N

The DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS 1_o
GG NNP N
, , N
GA NNP N
and CC N
AA NNP N
were VBD N
15.6 CD N
% NN N
, , N
47.7 CD N
% NN N
and CC N
36.7 CD N
% NN N
among IN N
these DT N
patients NNS N
, , N
compared VBN N
with IN N
24.4 CD N
% NN N
, , N
49.5 CD N
% NN N
and CC N
26.1 CD N
% NN N
, , N
respectively RB N
, , N
among IN N
patients NNS N
without IN N
severe JJ 1_o
diarrhea NN 1_o
. . 1_o

Multivariate NNP N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
a DT N
1.66-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ 1_o
diarrhea NN 1_o
in IN N
patients NNS N
with IN N
AA NNP N
genotype NN N
( ( N
95 CD N
% NN N
CI NNP N
1.03 CD N
- : N
2.67 CD N
, , N
P NNP N
= NNP N
0.038 CD N
) ) N
compared VBN N
with IN N
the DT N
cases NNS N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
. . N

Stratified VBN N
analysis NN N
showed VBD N
that IN N
in IN N
the DT N
Cap-Oxa-CRT NNP 1_i
group NN N
, , N
patients NNS N
with IN N
AA NNP N
genotype NN N
showed VBD N
a DT N
2.34-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ 1_o
diarrhea NN 1_o
( ( N
95 CD N
% NN N
CI NNP N
1.16 CD N
- : N
4.76 CD N
, , N
P NNP N
= NNP N
0.018 CD N
) ) N
compared VBN N
with IN N
those DT N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
, , N
but CC N
in IN N
the DT N
Cap-CRT NNP 1_i
group NN N
, , N
the DT N
SNP NNP N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
severe JJ 1_o
diarrhea NN 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
genetic JJ 1_o
polymorphism NN 1_o
of IN 1_o
CCND1 NNP 1_o
A870G NNP 1_o
might MD N
be VB N
a DT N
potential JJ N
biomarker NN N
for IN N
predicting VBG N
acute JJ 1_o
AEs NNP 1_o
in IN N
postoperative JJ 1_p
stage NN 1_p
II NNP 1_p
and CC 1_p
III NNP 1_p
rectal JJ 1_p
cancer NN 1_p
patients NNS 1_p
treated VBN N
with IN N
adjuvant JJ N
concurrent JJ N
chemoradiotherapy NN 1_i
of IN N
capecitabine NN 1_i
and CC N
oxaliplatin NN 1_i
. . 1_i

Salbutamol NNP 1_i
or CC N
mist NN 1_i
in IN N
acute JJ 1_p
bronchiolitis NN 1_p
. . 1_p

BACKGROUND IN N
The DT N
role NN N
of IN N
bronchodilators NNS N
in IN N
the DT N
treatment NN N
of IN N
bronchiolitis NN N
remains VBZ N
controversial JJ N
. . N

METHODS VB N
A DT N
double-blind NN N
, , N
placebo NN 1_i
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ 1_o
response NN 1_o
to TO N
nebulized VBN N
salbutamol NN 1_i
. . 1_i

One CD 1_p
hundred CD 1_p
and CC 1_p
fifty-six JJ 1_p
infants NNS 1_p
aged VBN 1_p
between IN 1_p
7 CD 1_p
weeks NNS 1_p
and CC 1_p
24 CD 1_p
months NNS 1_p
who WP 1_p
had VBD 1_p
had VBN 1_p
an DT 1_p
episode NN 1_p
of IN 1_p
wheezing NN 1_p
and CC 1_p
other JJ 1_p
signs NNS 1_p
and CC 1_p
symptoms NNS 1_p
of IN 1_p
bronchiolitis NN 1_p
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
as IN N
follows VBZ N
: : N
( ( N
i NN N
) ) N
nebulized VBD N
salbutamol NN 1_i
was VBD N
administered VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
I PRP N
at IN N
a DT N
dose NN N
of IN N
0.15 CD N
mg/kg NNS N
in IN N
2 CD N
mL JJ N
saline NN 1_i
; : 1_i
( ( N
ii NN N
) ) N
saline NN 1_i
was VBD N
nebulized VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
II NNP N
and CC N
( ( N
iii NN N
) ) N
in IN N
group NN N
III NNP N
52 CD N
patients NNS N
received JJ N
mist NN 1_i
in IN N
a DT N
tent NN N
. . N

All DT N
three CD N
groups NNS N
were VBD N
administered VBN N
oxygen NN 1_i
during IN N
the DT N
procedures NNS N
. . N

Treatment NNP N
was VBD N
repeated VBN N
with IN N
the DT N
same JJ N
agent NN N
after IN N
30 CD N
min NN N
if IN N
the DT N
respiratory NN 1_o
score NN 1_o
was VBD N
5 CD N
or CC N
more JJR N
. . N

Respiratory JJ 1_o
rate NN 1_o
, , 1_o
heart NN 1_o
rate NN 1_o
, , 1_o
oxygen NN 1_o
saturation NN 1_o
and CC 1_o
presence NN 1_o
of IN 1_o
cyanosis NN 1_o
, , 1_o
wheezing VBG 1_o
, , 1_o
retractions NNS 1_o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

RESULTS VB N
The DT N
decrease NN N
in IN N
the DT N
respiratory NN 1_o
score NN 1_o
was VBD N
5.2 CD N
+/- JJ N
1.8 CD N
, , N
0.82 CD N
+/- JJ N
2.4 CD N
and CC N
1.7 CD N
+/- JJ N
1.3 CD N
in IN N
group NN N
I PRP N
, , N
II NNP N
and CC N
III NNP N
, , N
respectively RB N
. . N

The DT N
decrease NN N
in IN N
group NN N
I PRP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Heart NNP 1_o
rate NN 1_o
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

Oxygen NNP 1_o
saturation NN 1_o
decreased VBD N
in IN N
group NN N
I PRP N
without IN N
reaching VBG N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Salbutamol NNP 1_i
was VBD N
shown VBN N
to TO N
be VB N
effective JJ 1_o
and CC N
safe JJ 1_o
in IN N
the DT N
treatment NN N
of IN N
acute JJ 1_p
bronchiolitis NN 1_p
. . 1_p

Double-blind NNP N
comparison NN N
of IN N
doxepin NN 1_i
versus NN N
bupropion NN 1_i
in IN N
outpatients NNS 1_p
with IN 1_p
a DT 1_p
major JJ 1_p
depressive JJ 1_p
disorder NN 1_p
. . 1_p

A DT N
double-blind NN N
controlled VBN N
study NN N
comparing VBG N
the DT N
effects NNS N
of IN N
bupropion NN 1_i
to TO N
doxepin VB 1_i
in IN N
outpatients NNS 1_p
with IN 1_p
primary JJ 1_p
depression NN 1_p
was VBD N
conducted VBN N
to TO N
evaluate VB N
efficacy NN 1_o
and CC N
safety NN 1_o
differences NNS 1_o
between IN N
the DT N
two CD N
drugs NNS N
. . N

Following VBG N
a DT N
7-day JJ N
placebo NN 1_i
washout NN N
period NN N
, , N
patients NNS N
could MD N
be VB N
treated VBN N
for IN N
up RB N
to TO N
13 CD N
weeks NNS N
on IN N
either DT N
treatment NN N
. . N

Antidepressant JJ 1_o
response NN 1_o
was VBD N
assessed VBN N
by IN N
the DT N
Hamilton NNP 1_o
Depression NNP 1_o
and CC 1_o
Anxiety NNP 1_o
Scales NNP 1_o
, , 1_o
Clinical NNP 1_o
Global NNP 1_o
Severity NNP 1_o
and CC 1_o
Improvement NNP 1_o
Ratings NNP 1_o
, , 1_o
and CC 1_o
the DT 1_o
Zung NNP 1_o
Self-Rating NNP 1_o
Depression NNP 1_o
Scale NNP 1_o
. . 1_o

Comparable JJ N
efficacy NN 1_o
between IN N
the DT N
compounds NNS N
was VBD N
found VBN N
across IN N
the DT N
13-week JJ N
study NN N
. . N

Doxepin NNP 1_i
differed VBD N
from IN N
bupropion NN 1_i
mainly RB N
on IN N
the DT N
sleep JJ 1_o
factor NN N
of IN N
the DT N
Hamilton NNP 1_o
Depression NNP 1_o
Scale NNP 1_o
, , N
with IN N
doxepin NN 1_i
improving VBG N
sleep NN 1_o
to TO N
a DT N
greater JJR N
extent NN N
than IN N
bupropion NN 1_i
. . 1_i

Doxepin NNP 1_i
produced VBD N
a DT N
greater JJR N
incidence NN N
of IN N
anticholinergic JJ 1_o
side NN 1_o
effects NNS 1_o
, , N
including VBG N
dry JJ 1_o
mouth NN 1_o
, , 1_o
constipation NN 1_o
, , 1_o
sleepiness NN 1_o
, , 1_o
and CC 1_o
tiredness NN 1_o
, , N
in IN N
comparison NN N
to TO N
bupropion NN 1_i
. . 1_i

Also RB N
, , N
increased VBD 1_o
appetite NN 1_o
and CC 1_o
weight JJ 1_o
gain NN 1_o
were VBD N
consistent JJ N
side NN 1_o
effects NNS 1_o
of IN N
doxepin NN 1_i
relative NN N
to TO N
bupropion NN 1_i
. . 1_i

Influence NN N
of IN N
lime NN 1_i
juice NN 1_i
on IN N
the DT N
severity NN N
of IN N
sickle NN 1_p
cell NN 1_p
anemia NN 1_p
. . 1_p

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
The DT N
pain NN N
in IN N
sickle NN 1_p
cell NN 1_p
anemia NN 1_p
( ( 1_p
SCA NNP 1_p
) ) 1_p
is VBZ N
often RB N
triggered VBN N
by IN N
dehydration NN N
, , N
acidosis NN N
, , N
and CC N
fever NN N
that WDT N
are VBP N
usually RB N
due JJ N
to TO N
malaria VB N
. . N

Intake NNP N
of IN N
lime JJ 1_i
juice NN 1_i
was VBD N
recently RB N
demonstrated VBN N
to TO N
facilitate VB N
clearance NN N
of IN N
the DT N
malaria NN N
parasite NN N
. . N

It PRP N
was VBD N
therefore RB N
sought VBN N
to TO N
determine VB N
whether IN N
regular JJ N
intake NN N
of IN N
lime JJ 1_i
juice NN 1_i
will MD N
ameliorate VB N
crisis NN 1_o
, , N
especially RB N
recurrent JJ 1_o
bone NN 1_o
pain NN 1_o
. . 1_o

DESIGN NN N
In IN N
this DT N
preliminary JJ N
, , N
open-labeled JJ N
, , N
randomized JJ N
study NN N
, , N
the DT N
effects NNS N
of IN N
lime JJ 1_i
juice NN 1_i
on IN N
the DT N
clinical JJ 1_o
and CC 1_o
some DT 1_o
laboratory JJ 1_o
characteristics NNS 1_o
of IN N
children NNS 1_p
with IN 1_p
SCA NNP 1_p
were VBD N
tested VBN N
. . N

RESULTS NNP N
Among IN N
the DT N
113 CD 1_p
children NNS 1_p
with IN 1_p
SCA NNP 1_p
studied VBN 1_p
in IN 1_p
two CD 1_p
hospitals NNS 1_p
, , N
the DT N
58 CD N
receiving NN N
lime NN 1_i
treatment NN N
had VBD N
lower JJR N
rates NNS 1_o
of IN 1_o
significant JJ 1_o
painful JJ 1_o
episodes NNS 1_o
than IN N
the DT N
55 CD N
without IN 1_i
lime NN 1_i
( ( N
37 CD N
versus NN N
83 CD N
crises NNS N
in IN N
6 CD N
months NNS N
, , N
and CC N
0.64±0.11 CD N
versus NN N
1.51±0.34 CD N
average JJ N
rates NNS N
per IN N
child NN N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Also RB N
, , N
fewer JJR N
subjects NNS N
than IN N
the DT N
controls NNS N
had VBD 1_o
significant JJ 1_o
painful JJ 1_o
episodes NNS 1_o
( ( N
50.0 CD N
% NN N
versus IN N
92.7 CD 1_o
% NN 1_o
) ) 1_o
; : 1_o
febrile JJ 1_o
illness NN 1_o
( ( N
46.6 CD N
% NN N
versus IN N
87.3 CD N
% NN N
) ) N
and CC 1_o
admission NN 1_o
rate NN 1_o
( ( N
3.4 CD N
% NN N
versus IN N
34.5 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT 1_o
mean JJ 1_o
hematocrit NN 1_o
of IN N
the DT N
subjects NNS N
( ( N
26.23±2.03 CD N
% NN N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
also RB N
higher JJR N
, , N
p JJ N
< NN N
0.001 CD N
. . N

However RB 1_o
, , 1_o
transfusion NN 1_o
rate NN 1_o
, , 1_o
presence NN 1_o
of IN 1_o
hepatomegaly NN 1_o
, , 1_o
splenomegaly NN 1_o
, , 1_o
and CC 1_o
jaundice NN 1_o
was VBD N
similar JJ N
. . N

Treatment NN N
with IN 1_i
lime NN 1_i
did VBD N
not RB N
cause VB N
any DT 1_o
significant JJ 1_o
side-effect JJ 1_o
. . N

CONCLUSIONS NNP N
Regular NNP N
intake NN N
of IN 1_i
lime JJ 1_i
juice NN 1_i
may MD N
be VB N
of IN N
great JJ N
therapeutic JJ N
and CC N
nutritional JJ N
relevance NN N
in IN 1_p
children NNS 1_p
with IN 1_p
SCA NNP 1_p
. . N

Quality NN N
of IN N
individual JJ N
INR NNP N
control NN N
and CC N
the DT N
risk NN 1_o
of IN 1_o
stroke NN 1_o
and CC 1_o
bleeding VBG 1_o
events NNS 1_o
in IN N
atrial JJ 1_p
fibrillation NN 1_p
patients NNS 1_p
: : 1_p
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
of IN N
the DT N
ACTIVE NNP N
W NNP N
study NN N
. . N

INTRODUCTION NNP N
Time NNP 1_o
in IN 1_o
therapeutic JJ 1_o
range NN 1_o
( ( 1_o
TTR NNP 1_o
) ) 1_o
for IN N
international JJ N
normalized JJ N
ratio NN N
( ( N
INR NNP N
) ) N
is VBZ N
an DT N
accepted JJ N
quality NN N
measure NN N
of IN N
anticoagulation NN N
control NN N
in IN N
patient JJ N
populations NNS N
, , N
but CC N
its PRP$ N
usefulness NN N
for IN N
predicting VBG N
stroke NN 1_o
and CC 1_o
bleeding NN 1_o
in IN N
individuals NNS N
is VBZ N
not RB N
well RB N
understood RB N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
among IN N
ACTIVE NNP 1_p
W NNP 1_p
study NN 1_p
patients NNS 1_p
, , 1_p
cases NNS 1_p
with IN 1_p
stroke NN 1_p
and CC 1_p
cases NNS 1_p
with IN 1_p
bleeding NN 1_p
were VBD 1_p
separately RB 1_p
matched VBN 1_p
with IN 1_p
controls NNS 1_p
. . 1_p

Several JJ N
anticoagulation NN 1_o
quality NN 1_o
measures NNS 1_o
were VBD N
compared VBN N
, , N
overall JJ N
and CC N
in IN N
a DT N
time-dependent JJ N
manner NN N
. . N

RESULTS CC N
32 CD 1_p
cases NNS 1_p
with IN 1_p
ischemic JJ 1_p
stroke NN 1_p
and CC 1_p
234 CD 1_p
cases NNS 1_p
with IN 1_p
bleeding NN 1_p
in IN 1_p
the DT 1_p
analysis NN 1_p
were VBD 1_p
matched VBN 1_p
in IN N
a DT N
4:1 CD N
ratio NN N
to TO N
122 CD 1_p
and CC 1_p
865 CD 1_p
controls NNS 1_p
, , N
respectively RB N
. . N

Follow-up JJ N
duration NN N
was VBD N
257±154days CD N
for IN N
the DT 1_o
stroke NN 1_o
analysis NN 1_o
and CC N
222±146days CD N
for IN N
the DT 1_o
bleeding NN 1_o
analysis NN 1_o
. . N

Compared VBN N
with IN N
their PRP$ N
respective NN N
controls NNS N
, , N
the DT N
study NN N
mean JJ 1_o
TTR NNP 1_o
of IN N
both DT N
stroke NN N
cases NNS N
( ( N
53.9 CD N
% NN N
±25.1 NNP N
vs VBZ N
63.4 CD N
% NN N
±24.8 NN N
; : N
p=0.055 CC N
) ) N
and CC N
bleeding VBG N
cases NNS N
( ( N
56.2 CD N
% NN N
±25.4 NNP N
vs VBZ N
63.4 CD N
% NN N
±26.8 NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
was VBD N
lower JJR 1_o
. . 1_o

Time NNP N
below IN N
range NN N
for IN N
stroke NN 1_o
and CC 1_o
time NN N
above IN N
range NN N
for IN N
bleeding VBG N
were VBD N
only RB N
greater JJR N
in IN N
the DT N
last JJ N
month NN N
leading VBG N
up RP N
to TO N
the DT N
event NN N
, , N
not RB N
over IN N
the DT N
entire JJ N
study NN N
period NN N
. . N

Rather CC N
, , N
over IN N
the DT N
entire JJ N
study NN N
period NN N
bleeding VBG N
cases NNS N
spent VBD 1_o
more JJR 1_o
time NN N
below IN N
range NN N
than IN N
controls NNS N
( ( N
26.8 CD N
% NN N
±25.9 NNP N
vs VBZ N
20.8 CD N
% NN N
±24.0 NN N
; : N
p=0.001 NN N
) ) N
. . N

CONCLUSIONS NNP 1_o
TTR NNP N
was VBD N
lower JJR 1_p
in IN 1_p
individual JJ 1_p
AF NNP 1_p
patients NNS 1_p
with IN N
stroke NN N
or CC N
bleeding NN N
compared VBN N
with IN N
matched JJ N
controls NNS N
in IN N
ACTIVE NNP N
W. NNP N
Maintaining VBG 1_o
a DT 1_o
high JJ 1_o
TTR NNP N
, , N
with IN N
equal JJ N
importance NN N
to TO N
avoid VB N
low JJ N
and CC N
high JJ N
INRs NNP N
, , N
is VBZ N
a DT N
relevant JJ N
goal NN N
of IN N
individual JJ N
patient NN N
treatment NN 1_o
to TO 1_o
prevent VB 1_o
stroke NN 1_o
and CC 1_o
bleeding NN 1_o
. . N

Intervention NN N
to TO N
lower VB N
household NN N
wood NN N
smoke NN N
exposure NN N
in IN N
Guatemala NNP 1_p
reduces NNS N
ST-segment NNP 1_o
depression NN 1_o
on IN N
electrocardiograms NNS N
. . N

BACKGROUND VB N
A DT N
large JJ N
body NN N
of IN N
evidence NN N
suggests VBZ N
that IN N
fine JJ N
particulate NN N
matter NN N
( ( N
PM NNP N
) ) N
air NN N
pollution NN N
is VBZ N
a DT N
cause NN N
of IN N
cardiovascular JJ N
disease NN N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
particular JJ N
about IN N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
indoor JJ N
air NN N
pollution NN N
from IN N
household NN N
use NN N
of IN N
solid JJ N
fuels NNS N
in IN N
developing VBG N
countries NNS N
. . N

RESPIRE NNP N
( ( N
Randomized NNP N
Exposure NNP N
Study NNP N
of IN N
Pollution NNP N
Indoors NNP N
and CC N
Respiratory NNP N
Effects NNP N
) ) N
was VBD N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
chimney NN 1_i
woodstove NN 1_i
that WDT N
reduces VBZ N
wood NN N
smoke NN N
exposure NN N
. . N

OBJECTIVES IN N
We PRP N
tested VBD N
the DT N
hypotheses NNS N
that IN N
the DT N
stove NN 1_i
intervention NN 1_i
, , N
compared VBN N
with IN N
open JJ 1_i
fire NN 1_i
use NN N
, , N
would MD N
reduce VB N
ST-segment NNP 1_o
depression NN 1_o
and CC N
increase VB N
heart NN 1_o
rate NN 1_o
variability NN 1_o
( ( 1_o
HRV NNP 1_o
) ) 1_o
. . 1_o

METHODS NNP N
We PRP N
used VBD N
two CD N
complementary JJ N
study NN N
designs NNS N
: : N
a DT N
) ) N
between-groups NN N
comparisons NNS N
based VBN N
on IN N
randomized JJ N
stove NN 1_i
assignment NN N
, , N
and CC N
b NN N
) ) N
before-and-after NN N
comparisons NNS N
within IN N
control NN N
subjects NNS N
who WP N
used VBD N
open JJ 1_i
fires NNS 1_i
during IN N
the DT N
trial NN N
and CC N
received VBD N
chimney NN 1_i
stoves NNS 1_i
after IN N
the DT N
trial NN N
. . N

Electrocardiogram NNP 1_o
sessions NNS 1_o
that WDT N
lasted VBD N
20 CD N
hr NNS N
were VBD N
repeated VBN N
up RP N
to TO N
three CD N
times NNS N
among IN N
49 CD 1_p
intervention NN 1_p
and CC 1_p
70 CD 1_p
control NN 1_p
women NNS 1_p
38-84 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , 1_p
and CC 1_p
55 CD 1_p
control NN 1_p
subjects NNS 1_p
were VBD 1_p
also RB 1_p
assessed VBN 1_p
after IN 1_p
receiving VBG 1_p
stoves NNS 1_i
. . 1_i

HRV NNP 1_o
and CC 1_o
ST-segment JJ 1_o
values NNS 1_o
were VBD N
assessed VBN N
for IN N
each DT N
30-min JJ N
period NN N
. . N

ST-segment JJ 1_o
depression NN 1_o
was VBD 1_o
defined VBN 1_o
as IN 1_o
an DT 1_o
average JJ 1_o
value NN 1_o
below IN 1_o
-1.00 NNP 1_o
mm NN 1_o
. . 1_o

Personal JJ 1_o
fine JJ 1_o
PM NNP 1_o
[ NNP 1_o
aerodynamic JJ 1_o
diameter NN 1_o
≤ VBD 1_o
2.5 CD 1_o
μm NNP 1_o
( ( 1_o
PM₂.₅ NNP 1_o
] NNP 1_o
exposures NNS 1_o
were VBD N
measured VBN N
for IN N
24 CD N
hr NN N
before IN 1_o
each DT 1_o
electrocardiogram NN 1_o
. . N

RESULTS NNP 1_o
PM₂.₅ NNP 1_o
exposure NN N
means NNS N
were VBD N
266 CD N
and CC N
102 CD N
μg/m³ NN N
during IN N
the DT N
trial NN N
period NN N
in IN N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
, , N
respectively RB N
. . N

During IN N
the DT 1_i
trial NN 1_i
, , 1_i
the DT 1_i
stove NN 1_i
intervention NN N
was VBD N
associated VBN N
with IN N
an DT N
odds NNS N
ratio NN N
of IN N
0.26 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.08-0.90 NN 1_o
) ) 1_o
for IN 1_o
ST-segment JJ 1_o
depression NN N
. . N

We PRP N
found VBD N
similar JJ N
associations NNS N
with IN N
the DT N
before-and-after JJ N
comparison NN N
. . N

The DT N
intervention NN N
was VBD N
not RB N
significantly RB N
associated VBN 1_o
with IN N
HRV NNP N
. . N

CONCLUSIONS NNP 1_i
The DT 1_i
stove NN 1_i
intervention NN N
was VBD N
associated VBN N
with IN N
reduced JJ N
occurrence NN N
of IN 1_o
nonspecific JJ 1_o
ST-segment JJ 1_o
depression NN N
, , N
suggesting VBG N
that IN N
household NN N
wood NN N
smoke NN N
exposures NNS N
affect VBP N
ventricular JJ N
repolarization NN N
and CC N
potentially RB N
cardiovascular JJ N
health NN N
. . N

Neural JJ 1_o
basis NN 1_o
of IN 1_o
self NN 1_o
and CC 1_o
other JJ 1_o
representation NN 1_o
in IN N
autism NN N
: : N
an DT N
FMRI NNP 1_o
study NN N
of IN N
self-face JJ 1_o
recognition NN 1_o
. . 1_o

BACKGROUND NNP N
Autism NNP N
is VBZ N
a DT N
developmental JJ N
disorder NN N
characterized VBN N
by IN N
decreased JJ N
interest NN N
and CC N
engagement NN N
in IN N
social JJ N
interactions NNS N
and CC N
by IN N
enhanced JJ N
self-focus NN N
. . N

While IN N
previous JJ N
theoretical JJ N
approaches NNS N
to TO N
understanding VBG N
autism NN N
have VBP N
emphasized VBN N
social JJ N
impairments NNS N
and CC N
altered VBD N
interpersonal JJ N
interactions NNS N
, , N
there EX N
is VBZ N
a DT N
recent JJ N
shift NN N
towards NNS N
understanding VBG N
the DT N
nature NN N
of IN N
the DT N
representation NN N
of IN N
the DT N
self NN N
in IN N
individuals NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Still RB N
, , N
the DT N
neural JJ 1_o
mechanisms NNS 1_o
subserving VBG N
self-representations NNS N
in IN N
ASD NNP N
are VBP N
relatively RB N
unexplored JJ N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
We PRP N
used VBD N
event-related JJ N
fMRI NN 1_o
to TO N
investigate VB N
brain NN 1_o
responsiveness NN 1_o
to TO 1_o
images NNS 1_o
of IN 1_o
the DT 1_o
subjects NNS 1_o
' POS 1_o
own JJ 1_o
face NN 1_o
and CC 1_o
to TO 1_o
faces VBZ 1_o
of IN 1_o
others NNS 1_o
. . 1_o

Children NNP 1_p
with IN 1_p
ASD NNP 1_p
and CC 1_p
typically RB 1_p
developing VBG 1_p
( ( 1_p
TD NNP 1_p
) ) 1_p
children NNS 1_p
viewed VBD N
randomly RB N
presented VBN N
digital JJ N
morphs NN N
between IN N
their PRP$ 1_i
own JJ 1_i
face NN 1_i
and CC 1_i
a DT 1_i
gender-matched JJ 1_i
other JJ 1_i
face NN 1_i
, , N
and CC N
made VBD N
" NNP N
self/other CC N
" JJ N
judgments NNS N
. . N

Both DT N
groups NNS N
of IN N
children NNS N
activated VBD N
a DT N
right JJ 1_o
premotor/prefrontal NN 1_o
system NN 1_o
when WRB N
identifying VBG N
images NNS 1_i
containing VBG N
a DT N
greater JJR N
percentage NN N
of IN N
the DT N
self JJ N
face NN N
. . N

However RB N
, , N
while IN N
TD NNP N
children NNS N
showed VBD N
activation NN N
of IN N
this DT N
system NN 1_o
during IN N
both DT N
self- JJ 1_i
and CC 1_i
other-processing JJ 1_i
, , N
children NNS N
with IN N
ASD NNP N
only RB N
recruited VBD N
this DT N
system NN N
while IN N
viewing VBG N
images NNS 1_i
containing VBG N
mostly RB N
their PRP$ N
own JJ N
face NN N
. . N

CONCLUSIONS/SIGNIFICANCE VB N
This DT N
functional JJ N
dissociation NN N
between IN N
the DT N
representation NN N
of IN N
self NN N
versus NN N
others NNS N
points NNS N
to TO N
a DT N
potential JJ N
neural JJ N
substrate NN N
for IN N
the DT N
characteristic JJ N
self-focus NN N
and CC N
decreased VBN N
social JJ N
understanding NN N
exhibited VBN N
by IN N
these DT N
individuals NNS N
, , N
and CC N
suggests VBZ N
that IN N
individuals NNS N
with IN N
ASD NNP N
lack VBP N
the DT N
shared JJ N
neural JJ 1_o
representations NNS 1_o
for IN 1_o
self NN 1_o
and CC 1_o
others NNS 1_o
that IN N
TD NNP N
children NNS N
and CC N
adults NNS N
possess NN N
and CC N
may MD N
use VB N
to TO N
understand VB N
others NNS N
. . N

Group NNP 1_i
cognitive JJ 1_i
behavior NN 1_i
therapy NN 1_i
for IN N
children NNS 1_p
with IN 1_p
high-functioning JJ 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
and CC 1_p
anxiety NN 1_p
: : 1_p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Children NNP N
with IN N
high-functioning JJ N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
developing VBG N
significant JJ N
anxiety NN N
. . N

Anxiety NN N
can MD N
adversely RB N
impact VB N
functioning VBG N
across IN N
school NN N
, , N
home NN N
and CC N
community NN N
environments NNS N
. . N

Cognitive JJ 1_i
behavioral JJ 1_i
therapies NNS 1_i
( ( 1_i
CBT NNP 1_i
) ) 1_i
are VBP N
frequently RB N
used VBN N
with IN N
success NN N
for IN N
children NNS N
with IN N
anxiety NN 1_o
symptoms NNS 1_o
. . 1_o

Modified NNP N
CBT NNP 1_i
interventions NNS N
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
ASD NNP N
have VBP N
also RB N
yielded VBN N
promising JJ N
results NNS N
. . N

METHODS NNP N
Fifty NNP 1_p
children NNS 1_p
with IN 1_p
high-functioning JJ 1_p
ASD NNP 1_p
and CC 1_p
anxiety NN 1_p
were VBD N
randomizedto JJ N
group NN N
CBT NNP 1_i
or CC N
treatment-as-usual JJ 1_i
( ( 1_i
TAU NNP 1_i
) ) 1_i
for IN N
12 CD N
weeks NNS N
. . N

Independent NNP N
clinical JJ N
evaluators NNS N
, , N
blind NN N
to TO N
condition NN N
, , N
completed VBN N
structured JJ 1_o
interviews NNS 1_o
( ( 1_o
Anxiety NNP 1_o
Disorders NNP 1_o
Interview NNP 1_o
Schedule NNP 1_o
– NNP 1_o
Parent NNP 1_o
Version NNP 1_o
; : 1_o
ADIS-P NNP 1_o
) ) 1_o
pre- NN N
and CC N
post-intervention NN N
condition NN N
. . N

RESULTS NNP 1_p
Forty-seven JJ 1_p
children NNS 1_p
completed VBN 1_p
either CC 1_p
the DT 1_i
CBT NNP 1_i
or CC 1_i
TAU NNP 1_i
condition NN 1_p
. . N

Results NNS N
indicated VBD N
markedly RB N
better RBR N
outcomes NNS N
for IN N
the DT 1_i
CBT NNP 1_i
group NN N
. . N

Significant JJ N
differences NNS N
by IN N
group NN N
were VBD N
noted VBN N
in IN 1_o
Clinician JJ 1_o
Severity NNP 1_o
Ratings NNP 1_o
, , 1_o
diagnostic JJ 1_o
status NN 1_o
, , 1_o
and CC 1_o
clinician JJ 1_o
ratings NNS 1_o
of IN 1_o
global JJ 1_o
improvement NN 1_o
. . N

In IN N
the DT N
intent-to-treat JJ N
sample NN N
, , N
10 CD N
of IN N
20 CD N
children NNS N
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT 1_i
CBT NNP 1_i
group NN N
had VBD N
a DT N
clinically RB N
meaningful JJ N
positive JJ 1_o
treatment NN 1_o
response NN 1_o
, , N
compared VBN N
to TO N
2 CD N
of IN N
23 CD N
children NNS N
( ( N
8.7 CD N
% NN N
) ) N
in IN N
the DT 1_i
TAU NNP 1_i
group NN N
. . N

CONCLUSIONS NNP N
Initial JJ N
results NNS N
from IN N
this DT N
randomized VBN N
, , N
designed VBN N
treatment NN N
study NN N
suggest VBP N
that IN N
agroup NN 1_i
CBT NNP 1_i
intervention NN N
specifically RB N
developed VBD N
for IN 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
may MD N
be VB N
effective JJ N
in IN N
decreasing VBG N
anxiety NN N
. . N

Limitations NNS N
of IN N
this DT N
study NN N
include VBP N
small JJ N
sample JJ N
size NN N
, , N
lack NN N
of IN N
an DT N
attention NN N
control NN N
group NN N
, , N
and CC N
use NN N
of IN N
outcome NN N
measures NNS N
normed VBN N
with IN N
typically RB N
developing VBG N
children NNS N
Once-daily RB N
amoxicillin JJ 1_i
versus IN N
twice-daily JJ N
penicillin NN 1_i
V NNP 1_i
in IN N
group NN 1_p
A NNP 1_p
beta-haemolytic JJ 1_p
streptococcal JJ 1_p
pharyngitis NN 1_p
. . 1_p

BACKGROUND NNP N
Rheumatic NNP N
fever NN N
is VBZ N
a DT N
preventable JJ N
chronic JJ N
disease NN N
preceded VBN N
by IN N
group NN N
A NNP N
beta-haemolytic JJ N
streptococcal NN N
( ( N
GABHS NNP N
) ) N
pharyngitis NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
non-inferiority NN 1_o
of IN N
once-daily JJ N
( ( N
QD NNP N
) ) N
oral JJ N
amoxicillin NN 1_i
to TO N
the DT N
recommended VBN N
twice-daily RB N
( ( N
BID NNP N
) ) N
oral JJ N
penicillin NN 1_i
V NNP 1_i
in IN N
GABHS NNP 1_p
pharyngitis NN 1_p
. . 1_p

METHODS NNP N
This DT N
was VBD N
a DT N
randomised JJ N
non-inferiority JJ 1_o
trial NN N
carried VBD N
out RP N
in IN N
a DT N
school-based JJ 1_p
clinic NN 1_p
in IN 1_p
New NNP 1_p
Zealand NNP 1_p
. . 1_p

Children NNP 1_p
presenting VBG 1_p
with IN 1_p
GABHS NNP 1_p
pharyngitis NN 1_p
were VBD N
randomised VBN N
to TO N
oral JJ N
amoxicillin NN 1_i
1500 CD N
mg NN N
QD NNP N
( ( N
or CC N
750 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
< JJ N
or=30 JJ N
kg NN N
) ) N
or CC N
to TO N
oral JJ N
penicillin NN 1_i
V NNP N
500 CD N
mg NN N
BID NNP N
( ( N
or CC N
250 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
< JJ N
or=20 JJ N
kg NN N
) ) N
for IN N
10 CD N
days NNS N
. . N

Observed VBN N
medication NN 1_o
and CC 1_o
weekend NN 1_o
diary JJ 1_o
cards NNS 1_o
were VBD N
used VBN N
to TO N
monitor VB N
adherence NN N
. . N

OUTCOME NNP N
Eradication NNP 1_o
of IN 1_o
GABHS NNP 1_o
, , N
determined VBD N
with IN N
follow-up JJ 1_o
throat NN 1_o
cultures NNS 1_o
on IN N
days NNS N
3-6 CD N
, , N
12-16 CD N
and CC N
26-36 JJ N
. . N

GABHS NNP 1_o
isolates NNS 1_o
were VBD 1_o
serotyped VBN 1_o
to TO N
distinguish VB N
bacteriological JJ 1_o
treatment NN 1_o
failures NNS 1_o
( ( N
and CC N
relapses NNS 1_o
) ) 1_o
from IN N
new JJ 1_o
acquisitions NNS 1_o
. . 1_o

Non-inferiority NN 1_o
was VBD N
defined VBN N
as IN N
an DT N
upper JJ 1_o
95 CD 1_o
% NN 1_o
confidence NN 1_o
limit NN 1_o
( ( 1_o
CL NNP 1_o
) ) 1_o
for IN 1_o
the DT 1_o
difference NN 1_o
in IN 1_o
success NN 1_o
of IN 1_o
eradication NN 1_o
in IN N
the DT N
amoxicillin NN 1_i
and CC N
penicillin NN 1_i
V NNP N
treatment NN N
groups NNS N
of IN N
< NNP N
or=10 FW N
% NN N
. . N

RESULTS CC N
353 CD 1_p
children NNS 1_p
with IN 1_p
positive JJ 1_p
throat NN 1_p
swabs NN 1_p
for IN 1_p
GABHS NNP 1_p
were VBD N
randomised VBN N
to TO N
amoxicillin VB 1_i
( ( N
n JJ N
= NNP N
177 CD N
) ) N
or CC N
penicillin JJ 1_i
V NNP N
( ( N
n JJ N
= NNP N
176 CD N
) ) N
. . N

The DT N
upper JJ 1_o
95 CD 1_o
% NN 1_o
CL NNP 1_o
for IN N
the DT N
differences NNS N
in IN N
positive JJ N
cultures NNS N
between IN N
the DT N
antibiotics NNS N
was VBD N
4.9 CD N
% NN N
at IN N
days NNS N
3-6 CD N
, , N
6.5 CD N
% NN N
at IN N
days NNS N
12-16 CD N
and CC N
8.5 CD N
% NN N
at IN N
days NNS N
26-36 JJ N
. . N

Treatment NN 1_o
failures NNS 1_o
( ( N
including VBG N
relapses NNS 1_o
) ) 1_o
occurred VBD N
at IN N
each DT N
visit NN N
in IN N
5.8 CD N
% NN N
, , N
12.7 CD N
% NN N
and CC N
10.7 CD N
% NN N
of IN N
amoxicillin NN 1_i
recipients NNS N
and CC N
6.2 CD N
% NN N
, , N
11.9 CD N
% NN N
and CC N
11.3 CD N
% NN N
of IN N
penicillin NN 1_i
V NNP N
recipients NNS N
, , N
respectively RB N
. . N

No UH N
significant JJ N
differences NNS N
in IN N
resolution NN 1_o
of IN 1_o
symptoms NNS 1_o
were VBD N
noted VBN N
between IN N
treatment NN N
groups NNS N
. . N

One CD N
case NN N
of IN N
unsubstantiated JJ N
acute JJ N
rheumatic JJ N
fever NN N
occurred VBD N
after IN N
7 CD N
days NNS N
of IN N
amoxicillin NN 1_i
. . 1_i

CONCLUSION NN N
In IN N
this DT N
adequately RB N
powered VBN N
study NN N
, , N
once-daily JJ N
oral JJ N
amoxicillin NN 1_i
is VBZ N
not RB 1_o
inferior JJ 1_o
to TO N
twice-daily JJ N
penicillin NN 1_i
V NNP N
for IN N
the DT N
treatment NN N
and CC N
eradication NN N
of IN N
GABHS NNP 1_p
in IN 1_p
children NNS 1_p
with IN 1_p
pharyngitis NN 1_p
. . 1_p

Effect NN N
of IN N
rosuvastatin NN 1_i
monotherapy NN N
or CC N
in IN N
combination NN N
with IN N
fenofibrate NN 1_i
or CC N
ω-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
on IN 1_o
lipoprotein JJ 1_o
subfraction NN 1_o
profile NN 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
mixed JJ 1_p
dyslipidaemia NN 1_p
and CC 1_p
metabolic JJ 1_p
syndrome NN 1_p
. . N

BACKGROUND NNP N
Raised VBD N
triglycerides NNS N
( ( N
TG NNP N
) ) N
, , N
decreased VBD N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
levels NNS N
and CC N
a DT N
predominance NN N
of IN N
small JJ N
dense NN N
low JJ N
density NN N
lipoproteins NNS N
( ( N
sdLDL NN N
) ) N
are VBP N
characteristics NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
( ( N
MetS NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
high-dose JJ 1_i
rosuvastatin NN 1_i
monotherapy NN N
with IN N
moderate JJ N
dosing NN N
combined VBN N
with IN 1_i
fenofibrate NN 1_i
or CC 1_i
ω-3 JJ 1_i
fatty JJ 1_i
acids NNS 1_i
on IN N
the DT 1_o
lipoprotein JJ 1_o
subfraction NN 1_o
profile NN 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
mixed JJ 1_p
dyslipidaemia NN 1_p
and CC 1_p
MetS NNP 1_p
. . N

METHODS NNP N
We PRP N
previously RB N
randomised VBD N
patients NNS N
with IN N
low-density JJ N
lipoprotein NNS N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
> VBZ N
160 CD N
and CC N
TG NNP N
> NNP N
200 CD 1_i
mg/dl NN 1_i
to TO 1_i
rosuvastatin VB 1_i
monotherapy NN N
40 CD N
mg/day NN N
( ( N
R NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD 1_i
) ) 1_i
or CC 1_i
rosuvastatin $ 1_i
10 CD N
mg/day NN N
combined VBN 1_i
with IN 1_i
fenofibrate JJ 1_i
200 CD N
mg/day NN N
( ( N
RF NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD 1_i
) ) 1_i
or CC 1_i
ω-3 JJ 1_i
fatty JJ 1_i
acids NNS N
2 CD N
g/day NN N
( ( N
Rω NNP N
group NN N
, , N
n RB N
= VBZ N
30 CD N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN 1_p
, , 1_p
only RB 1_p
patients NNS 1_p
with IN 1_p
MetS NNP 1_p
were VBD 1_p
included VBN 1_p
( ( N
24 CD N
, , N
23 CD N
and CC N
24 CD N
in IN 1_i
the DT 1_i
R NNP N
, , N
RF NNP 1_i
and CC N
Rω NNP N
groups NNS N
respectively RB N
) ) N
. . N

At IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN 1_o
, , 1_o
the DT 1_o
lipoprotein JJ 1_o
subfraction NN 1_o
profile NN 1_o
was VBD 1_o
determined VBN 1_o
by IN 1_o
polyacrylamide JJ 1_o
3 CD 1_o
% NN 1_o
gel JJ 1_o
electrophoresis NN 1_o
. . N

RESULTS VB 1_o
The DT 1_o
mean JJ 1_o
LDL NNP N
size NN N
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
. . N

This DT N
change NN N
was VBD N
more RBR N
prominent JJ 1_i
with IN N
RF NNP N
than IN N
with IN N
other JJ N
treatments NNS N
in IN N
parallel JJ N
with IN N
its PRP$ 1_o
greater JJR 1_o
hypotriglyceridemic JJ 1_o
capacity NN N
( ( N
p JJ N
< $ N
0.05 CD N
compared VBN 1_i
with IN 1_i
R NNP N
and CC N
Rω NNP N
) ) N
. . N

A DT N
decrease NN 1_o
in IN 1_o
insulin NN 1_o
resistance NN 1_o
by IN N
RF NNP N
was VBD N
also RB N
noted VBN 1_i
. . N

Only RB N
RF NNP N
significantly RB 1_o
raised VBD 1_o
HDL-C NNP 1_o
levels NNS N
( ( N
by IN N
7.7 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
by IN N
increasing VBG 1_o
the DT 1_o
cholesterol NN 1_o
of IN 1_o
small JJ 1_o
HDL NNP 1_o
particles NNS 1_o
. . 1_o

The DT 1_o
cholesterol NN 1_o
of IN 1_o
larger JJR 1_o
HDL NNP 1_o
subclasses NNS 1_o
was VBD N
significantly RB N
increased VBN 1_i
by IN 1_i
R NNP N
and CC N
Rω NNP N
. . N

CONCLUSIONS NNP N
All NNP N
regimens VBZ 1_o
increased VBN 1_o
mean JJ 1_o
LDL NNP 1_i
size NN N
; : N
RF NNP N
was VBD N
the DT N
most RBS N
effective JJ N
. . N

A DT N
differential JJ N
effect NN N
of IN N
treatments NNS N
was VBD N
noted VBN 1_o
on IN 1_o
the DT 1_o
HDL NNP 1_o
subfraction NN 1_o
profile NN N
. . N

Remote NNP 1_i
ischaemic JJ 1_i
conditioning NN 1_i
before IN N
hospital JJ N
admission NN N
, , N
as IN N
a DT N
complement NN N
to TO N
angioplasty VB N
, , N
and CC N
effect NN N
on IN N
myocardial JJ 1_o
salvage NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
: : 1_p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Remote NNP 1_i
ischaemic JJ 1_i
preconditioning NN 1_i
attenuates NNS N
cardiac JJ N
injury NN N
at IN N
elective JJ N
surgery NN N
and CC N
angioplasty NN N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
remote VBP 1_i
ischaemic JJ 1_i
conditioning NN 1_i
during IN N
evolving VBG N
ST-elevation NNP 1_p
myocardial JJ 1_p
infarction NN 1_p
, , N
and CC N
done VBN N
before IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
, , N
increases VBZ N
myocardial JJ 1_o
salvage NN 1_o
. . 1_o

METHODS NNP N
333 CD 1_p
consecutive JJ 1_p
adult NN 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
suspected VBN 1_p
first JJ 1_p
acute JJ 1_p
myocardial JJ 1_p
infarction NN 1_p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
by IN N
computerised JJ N
block NN N
randomisation NN N
to TO N
receive VB N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
with IN N
( ( N
n=166 JJ N
patients NNS N
) ) N
versus NN N
without IN N
( ( N
n=167 NN N
) ) N
remote VBP 1_i
conditioning VBG 1_i
( ( N
intermittent JJ N
arm NN N
ischaemia NN N
through IN N
four CD N
cycles NNS N
of IN N
5-min JJ N
inflation NN N
and CC N
5-min JJ N
deflation NN N
of IN N
a DT N
blood-pressure JJ N
cuff NN N
) ) N
. . N

Allocation NN N
was VBD N
concealed VBN N
with IN N
opaque NN N
sealed VBN N
envelopes NNS N
. . N

Patients NNS N
received VBD N
remote JJ 1_i
conditioning NN 1_i
during IN N
transport NN N
to TO N
hospital NN N
, , N
and CC N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
hospital NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
myocardial JJ 1_o
salvage NN 1_o
index NN 1_o
at IN 1_o
30 CD 1_o
days NNS 1_o
after IN 1_o
primary JJ 1_o
percutaneous JJ 1_o
coronary JJ 1_o
intervention NN 1_o
, , 1_o
measured VBN 1_o
by IN 1_o
myocardial JJ 1_o
perfusion NN 1_o
imaging NN 1_o
as IN N
the DT N
proportion NN 1_o
of IN 1_o
the DT 1_o
area NN 1_o
at IN 1_o
risk NN 1_o
salvaged VBN 1_o
by IN 1_o
treatment NN 1_o
; : 1_o
analysis NN N
was VBD N
per IN N
protocol NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00435266 NNP N
. . N

FINDINGS NNP N
82 CD 1_p
patients NNS 1_p
were VBD 1_p
excluded VBN 1_p
on IN 1_p
arrival NN 1_p
at IN 1_p
hospital NN 1_p
because IN 1_p
they PRP 1_p
did VBD 1_p
not RB 1_p
meet VB 1_p
inclusion NN 1_p
criteria NNS 1_p
, , 1_p
32 CD 1_p
were VBD 1_p
lost VBN 1_p
to TO 1_p
follow-up NN 1_p
, , 1_p
and CC 1_p
77 CD 1_p
did VBD 1_p
not RB 1_p
complete VB 1_p
the DT 1_p
follow-up JJ 1_p
with IN N
data NNS N
for IN N
salvage NN 1_o
index NN 1_o
. . 1_o

Median JJ 1_o
salvage NN 1_o
index NN 1_o
was VBD N
0.75 CD N
( ( N
IQR NNP N
0.50-0.93 CD N
, , N
n=73 NN N
) ) N
in IN N
the DT N
remote JJ 1_i
conditioning NN 1_i
group NN N
versus VBD N
0.55 CD N
( ( N
0.35-0.88 CD N
, , N
n=69 NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
with IN N
median JJ 1_o
difference NN 1_o
of IN N
0.10 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.01-0.22 CD N
; : N
p=0.0333 NN N
) ) N
; : N
mean JJ 1_o
salvage NN 1_o
index NN 1_o
was VBD N
0.69 CD N
( ( N
SD NNP N
0.27 CD N
) ) N
versus NN N
0.57 CD N
( ( N
0.26 CD N
) ) N
, , N
with IN N
mean JJ 1_o
difference NN 1_o
of IN N
0.12 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.01-0.21 CD N
; : N
p=0.0333 NN N
) ) N
. . N

Major JJ 1_o
adverse JJ 1_o
coronary JJ 1_o
events NNS 1_o
were VBD N
death NN 1_o
( ( N
n=3 JJ N
per IN N
group NN N
) ) N
, , N
reinfarction NN 1_o
( ( N
n=1 JJ N
per IN N
group NN N
) ) N
, , N
and CC N
heart NN 1_o
failure NN 1_o
( ( N
n=3 JJ N
per IN N
group NN N
) ) N
. . N

INTERPRETATION NNP N
Remote NNP 1_i
ischaemic JJ 1_i
conditioning NN 1_i
before IN N
hospital JJ N
admission NN N
increases VBZ N
myocardial JJ 1_o
salvage NN 1_o
, , N
and CC N
has VBZ N
a DT N
favourable JJ N
safety NN 1_o
profile NN 1_o
. . 1_o

Our PRP$ N
findings NNS N
merit VBP N
a DT N
larger JJR N
trial NN N
to TO N
establish VB N
the DT N
effect NN N
of IN N
remote JJ 1_i
conditioning NN 1_i
on IN N
clinical JJ N
outcomes NNS N
. . N

FUNDING NN N
Fondation NNP N
Leducq NNP N
. . N

Ascaris NNP N
and CC N
growth NN 1_o
rates NNS 1_o
: : 1_o
a DT N
randomized JJ N
trial NN N
of IN N
treatment NN N
. . N

Three CD 1_p
hundred VBD 1_p
forty-one NN 1_p
Tanzanian JJ 1_p
preschool NN 1_p
children NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
levamisole VB 1_i
or CC N
placebo VB 1_i
treatment NN N
given VBN N
at IN N
three-month JJ N
intervals NNS N
. . N

Weights NNS 1_o
and CC 1_o
heights NNS 1_o
were VBD N
measured VBN N
at IN N
the DT N
tri-monthly JJ N
treatment NN N
visits NNS N
for IN N
a DT N
period NN N
of IN N
one CD N
year NN N
. . N

Among IN N
the DT N
273 CD N
children NNS N
who WP N
were VBD N
seen VBN N
and CC N
weighed VBN N
at IN N
the DT N
one-year JJ N
follow-up JJ N
visit NN N
, , N
the DT N
rate NN 1_o
of IN 1_o
weight NN 1_o
gain NN 1_o
was VBD N
8 CD N
per IN N
cent NN N
greater JJR N
for IN N
those DT N
receiving VBG N
levamisole JJR 1_i
than IN N
for IN N
placebo-treated JJ 1_i
controls NNS N
( ( N
p JJ N
= NNP N
.06 NNP N
) ) N
. . N

In IN N
78 CD N
children NNS N
known VBN N
to TO N
be VB N
infected VBN N
with IN N
Ascaris NNP N
at IN N
baseline NN N
, , N
the DT N
rate NN 1_o
of IN 1_o
weight NN 1_o
gain NN 1_o
was VBD N
21 CD N
per IN N
cent NN N
greater JJR N
in IN N
children NNS N
treated VBN N
with IN N
levamisole NN 1_i
than IN N
in IN N
those DT N
receiving VBG N
placebo NN 1_i
( ( N
p JJ N
= NNP N
.03 NNP N
) ) N
. . N

The DT N
rate NN 1_o
of IN 1_o
height NN 1_o
gain NN 1_o
was VBD N
no DT N
different JJ N
for IN N
treatment NN N
and CC N
placebo NN 1_i
groups NNS N
. . N

The DT N
effects NNS N
of IN N
sevoflurane NN 1_i
and CC N
isoflurane NN 1_i
on IN N
recovery NN N
from IN N
outpatient JJ 1_p
surgery NN 1_p
. . 1_p

This DT N
randomized JJ N
, , N
open-label JJ N
study NN N
compared VBN N
the DT N
investigational JJ N
inhalational JJ N
anesthetic JJ N
sevoflurane NN 1_i
with IN N
isoflurane NN 1_i
in IN N
47 CD 1_p
healthy JJ 1_p
women NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
ambulatory NN 1_p
surgery NN 1_p
. . 1_p

The DT N
women NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
sevoflurane NN 1_i
or CC N
isoflurane NN 1_i
in IN N
60 CD N
% NN N
nitrous JJ N
oxide-oxygen NN N
. . N

Induction NN N
with IN N
thiopental JJ 1_i
3-6 JJ N
mg/kg NN N
was VBD N
followed VBN N
by IN N
vecuronium NN 1_i
0.1 CD N
mg/kg NN N
and CC N
fentanyl JJ 1_i
0-200 JJ N
micrograms NNS N
. . N

Duration NN 1_o
of IN 1_o
anesthesia NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
emergence VB 1_o
, , 1_o
orientation NN 1_o
, , 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
in IN 1_o
the DT 1_o
surgical JJ 1_o
unit NN 1_o
, , 1_o
and CC 1_o
hospital JJ 1_o
discharge NN 1_o
were VBD N
recorded VBN N
. . N

The DT 1_o
emergence NN 1_o
, , 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
, , 1_o
and CC 1_o
discharge NN 1_o
times NNS 1_o
after IN 1_o
discontinuation NN 1_o
of IN N
sevoflurane NN 1_i
were VBD N
9.7 CD N
+/- JJ N
0.7 CD N
, , N
120.6 CD N
+/- JJ N
8.0 CD N
, , N
and CC N
244 CD N
+/- JJ N
15 CD N
minutes NNS N
, , N
respectively RB N
, , N
and CC N
for IN N
isoflurane NN 1_i
were VBD N
11.9 CD N
+/- JJ N
1.4 CD N
, , N
106.8 CD N
+/- JJ N
7.1 CD N
, , N
and CC N
282 CD N
+/- JJ N
24 CD N
minutes NNS N
, , N
respectively RB N
( ( N
NS NNP N
) ) N
. . N

The DT N
isoflurane NN 1_i
group NN N
had VBD N
a DT N
higher JJR N
frequency NN N
of IN N
postoperative JJ 1_o
cough NN 1_o
. . 1_o

At IN N
the DT N
end NN N
of IN N
surgery NN N
, , N
the DT N
sevoflurane NN 1_i
group NN N
received VBD N
a DT N
deeper JJR N
level NN 1_o
of IN 1_o
anesthesia NN 1_o
( ( N
minimum JJ N
alveolar JJ N
concentration NN N
1.5 CD N
vs NN N
1.3 CD N
) ) N
, , N
however RB N
, , N
these DT N
patients NNS N
were VBD N
oriented VBN N
earlier RB N
( ( N
13.6 CD N
+/- JJ N
1.1 CD N
min NN N
vs NN N
17.0 CD N
+/- JJ N
1.5 CD N
min NN N
isoflurane NN 1_i
; : 1_i
p CC N
= VB N
0.02 CD N
) ) N
after IN N
discontinuation NN N
of IN N
anesthesia NN N
, , N
although IN N
this DT N
difference NN N
is VBZ N
of IN N
little JJ N
clinical JJ N
significance NN N
. . N

Methodology NNP N
of IN N
serial JJ N
ECG NNP N
classification NN N
using VBG N
an DT N
adaptation NN N
of IN N
the DT N
NOVACODE NNP N
for IN N
Q NNP N
wave VBP N
myocardial JJ N
infarction NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
( ( N
BARI NNP N
) ) N
. . N

Serial JJ N
electrocardiographic JJ N
( ( N
ECG NNP N
) ) N
changes NNS N
are VBP N
a DT N
critical JJ N
component NN N
of IN N
the DT N
diagnostic JJ N
algorithm NN N
for IN N
classification NN N
of IN N
myocardial JJ N
ischemic JJ N
events NNS N
in IN N
large-scale JJ N
clinical JJ N
trials NNS N
. . N

This DT N
study NN N
describes VBZ N
a DT N
computerized JJ N
serial JJ N
ECG NNP N
classification NN N
program NN N
developed VBN N
at IN N
the DT N
St. NNP N
Louis NNP N
University NNP N
Core NNP N
ECG NNP N
Laboratory NNP N
for IN N
use NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
( ( N
BARI NNP N
) ) N
trial NN N
, , N
in IN N
which WDT N
patients NNS 1_p
with IN 1_p
multivessel JJ 1_p
coronary JJ 1_p
artery NN 1_p
disease NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
coronary JJ 1_i
artery NN 1_i
bypass NN 1_i
grafting NN 1_i
or CC N
percutaneous JJ 1_i
transluminal JJ 1_i
coronary JJ 1_i
angioplasty NN 1_i
. . 1_i

The DT N
St. NNP N
Louis NNP N
University NNP N
program NN N
detects NNS N
and CC N
codes VBZ N
serial JJ 1_o
changes NNS 1_o
in IN 1_o
Q NNP 1_o
, , 1_o
ST NNP 1_o
, , 1_o
and CC 1_o
T NNP 1_o
wave VBP 1_o
items NNS 1_o
according VBG 1_o
to TO 1_o
Minnesota NNP 1_o
code NN 1_o
( ( 1_o
MC NNP 1_o
) ) 1_o
criteria VBP 1_o
using VBG N
a DT N
modified JJ N
NOVACODE NNP N
hierarchical JJ N
classification NN N
system NN N
. . N

Measurements NNS N
using VBG N
a DT N
seven-power NN N
calibrated VBN N
coding NN N
loupe NN N
are VBP N
used VBN N
to TO N
generate VB N
the DT N
MC NNP N
from IN N
a DT N
customized JJ N
software NN N
program NN N
. . N

Significant NNP N
minor VBD N
or CC N
major JJ N
changes NNS 1_o
are VBP N
detected VBN N
by IN N
the DT N
serial JJ N
comparison NN N
program NN N
and CC N
referred VBD N
to TO N
a DT N
physician JJ N
coder NN N
for IN N
verification NN N
. . N

Serial JJ N
comparison NN N
coding NN N
rules NNS N
are VBP N
used VBN N
to TO N
adjust VB N
for IN N
weaknesses NNS N
in IN N
the DT N
standard JJ N
MC NNP N
classification NN N
system NN N
resulting VBG N
from IN N
instability NN N
at IN N
decision NN N
boundaries NNS N
. . N

Of IN N
4,244 CD 1_p
BARI NNP 1_p
randomized VBN 1_p
and CC 1_p
registry NN 1_p
study NN 1_p
participants NNS 1_p
with IN 1_p
follow-up JJ 1_p
ECGs NNP 1_p
received VBD 1_p
at IN 1_p
the DT 1_p
Core NNP 1_p
ECG NNP 1_p
Laboratory NNP 1_p
as IN 1_p
of IN 1_p
March NNP 1_p
1995 CD 1_p
, , N
a DT N
grade NN N
2 CD N
MC NNP 1_o
Q NNP 1_o
wave VBP 1_o
progression NN 1_o
was VBD N
noted VBN N
in IN N
568 CD N
participants NNS N
( ( N
13.4 CD N
% NN N
) ) N
using VBG N
MC NNP N
criteria NNS N
alone RB N
, , N
as IN N
compared VBN N
with IN N
367 CD N
( ( N
8.6 CD N
% NN N
) ) N
after IN N
the DT N
St. NNP N
Louis NNP N
University NNP N
coding NN N
rules NNS N
were VBD N
applied VBN N
. . N

The DT N
incidence NN N
of IN N
grade NN N
1 CD N
MC NNP 1_o
Q NNP 1_o
wave VBP 1_o
progressions NNS 1_o
was VBD N
16.4 CD N
% NN N
( ( N
697/4,244 CD N
) ) N
versus NN N
6.1 CD N
% NN N
( ( N
259/4,244 CD N
) ) N
when WRB N
the DT N
St. NNP N
Louis NNP N
University NNP N
program NN N
was VBD N
applied VBN N
. . N

Intraobserver NNP N
variability NN N
for IN N
grade NN N
2 CD N
Q NNP 1_o
wave VBP 1_o
progression NN 1_o
codes NNS 1_o
determined VBD N
from IN N
a DT N
sample NN N
of IN N
812 CD N
serial NN N
. . N

Insulin NNP 1_i
pump NN 1_i
therapy NN N
started VBD N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
: : N
effects NNS N
on IN N
glycemic JJ 1_o
control NN 1_o
and CC 1_o
pancreatic JJ 1_o
β-cell NN 1_o
function NN 1_o
in IN 1_p
type NN 1_p
1 CD 1_p
diabetes NNS 1_p
. . N

BACKGROUND NNP N
In IN N
the DT N
interest NN N
of IN N
preserving VBG N
residual JJ N
insulin NN N
secretory NN N
capacity NN N
present NN N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
with IN 1_p
type JJ 1_p
1 CD 1_p
diabetes NNS 1_p
( ( 1_p
T1D NNP 1_p
) ) 1_p
, , N
we PRP N
compared VBN N
the DT 1_o
efficacy NN 1_o
of IN N
starting VBG 1_i
insulin JJ 1_i
pump NN 1_i
therapy NN N
at IN N
diagnosis NN N
with IN N
standard JJ N
multiple JJ N
daily JJ 1_i
insulin NN 1_i
injections NNS N
( ( N
MDIs NNP N
) ) N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
pilot JJ N
trial NN N
comparing VBG 1_i
MDI NNP 1_i
therapy NN N
with IN N
continuous JJ N
subcutaneous JJ 1_i
insulin NN 1_i
therapy NN 1_i
( ( 1_i
pump JJ 1_i
therapy NN 1_i
) ) 1_i
in IN 1_p
24 CD 1_p
patients NNS 1_p
, , 1_p
8-18 CD 1_p
years NNS 1_p
old JJ 1_p
, , 1_p
with IN 1_p
newly RB 1_p
diagnosed VBN 1_p
T1D NNP 1_p
. . N

Subjects NNS N
were VBD N
evaluated VBN N
at IN N
enrollment NN N
and CC N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
diagnosis NN N
of IN N
T1D NNP N
. . 1_o

Preservation NN 1_o
of IN 1_o
insulin NN 1_o
secretion NN 1_o
, , 1_o
measured VBN 1_o
by IN 1_o
mixed-meal-stimulated JJ 1_o
C-peptide JJ 1_o
secretion NN 1_o
, , N
was VBD N
compared VBN N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

Between-group JJ N
differences NNS N
in IN 1_o
glycosylated JJ 1_o
hemoglobin NN 1_o
( ( 1_o
HbA1c NNP 1_o
) ) 1_o
, , 1_o
continuous JJ 1_o
glucose NN 1_o
sensor NN 1_o
data NNS 1_o
, , 1_o
insulin NN 1_o
utilization NN 1_o
, , 1_o
anthropometric JJ 1_o
measures NNS 1_o
, , 1_o
and CC 1_o
patient JJ 1_o
satisfaction NN 1_o
with IN 1_o
therapy NN 1_o
were VBD N
also RB N
compared VBN N
at IN N
multiple JJ N
time NN N
points NNS N
. . N

RESULTS NNP N
Initiation NNP N
of IN 1_i
pump NN 1_i
therapy NN 1_i
within IN N
1 CD N
month NN N
of IN N
diagnosis NN N
resulted VBD N
in IN N
consistently RB N
higher JJR 1_o
mixed-meal JJ 1_o
tolerance NN 1_o
test-stimulated JJ 1_o
C-peptide JJ 1_o
values NNS 1_o
at IN N
all DT N
time NN N
points NNS N
, , N
although IN N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Nonetheless NNP N
, , N
improved JJ 1_o
glycemic JJ 1_o
control NN 1_o
was VBD N
observed VBN N
in IN 1_i
insulin JJ 1_i
pump-treated JJ N
subjects NNS N
( ( N
more JJR N
time NN N
spent VBN N
with IN N
normoglycemia NN N
, , N
better JJR N
mean JJ 1_o
HbA1c NNP 1_o
) ) 1_o
, , N
and CC N
pump-treated JJ N
subjects NNS N
reported VBN N
comparatively RB N
greater JJR 1_o
satisfaction NN 1_o
with IN N
route NN N
of IN N
treatment NN N
administration NN N
. . N

CONCLUSIONS NNP N
Initiation NNP N
of IN 1_i
insulin NN 1_i
pump NN 1_i
therapy NN 1_i
at IN N
diagnosis NN N
improved JJ 1_o
glycemic JJ 1_o
control NN 1_o
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
contributed VBD N
to TO N
improved VBN 1_o
patient JJ 1_o
satisfaction NN 1_o
with IN N
treatment NN N
. . N

This DT N
study NN N
also RB N
suggests VBZ N
that IN N
earlier JJR N
use NN N
of IN N
pump NN N
therapy NN N
might MD N
help VB N
to TO N
preserve VB 1_o
residual JJ 1_o
β-cell NNP 1_o
function NN 1_o
, , N
although IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
would MD N
be VB N
required VBN N
to TO N
confirm VB N
this DT N
. . N

Effect NN N
of IN N
antipyretic JJ 1_i
drugs NNS 1_i
in IN N
children NNS 1_p
with IN 1_p
malaria NN 1_p
. . 1_p

A DT N
comparison NN N
of IN N
different JJ N
antipyretics NNS 1_i
in IN N
children NNS 1_p
with IN 1_p
malaria NN 1_p
showed VBD N
a DT N
small JJ N
effect NN N
of IN N
naproxen NN 1_i
, , N
but CC N
not RB N
of IN N
metamizol NN 1_i
, , N
on IN N
the DT N
reduction NN 1_o
of IN 1_o
fever NN 1_o
peaks NNS 1_o
. . 1_o

Antipyretic JJ 1_i
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
fever NN 1_o
clearance NN 1_o
and CC N
therefore NN N
should MD N
be VB N
used VBN N
cautiously RB N
in IN N
the DT N
treatment NN N
of IN N
malaria NN 1_p
. . 1_p

Eltrombopag NNP 1_i
for IN N
management NN N
of IN N
chronic JJ 1_p
immune NN 1_p
thrombocytopenia NN 1_p
( ( N
RAISE NNP N
) ) N
: : N
a DT N
6-month JJ N
, , N
randomised VBN N
, , N
phase VB N
3 CD N
study NN N
. . N

BACKGROUND NNP N
Eltrombopag NNP 1_i
is VBZ N
an DT N
oral JJ N
thrombopoietin NN N
receptor NN N
agonist NN N
for IN N
the DT N
treatment NN N
of IN N
thrombocytopenia NN N
. . N

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
response NN 1_o
to TO N
once RB N
daily JJ N
eltrombopag NNS 1_i
versus VBP N
placebo NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
immune JJ 1_p
thrombocytopenia NN 1_p
during IN N
a DT N
6-month JJ N
period NN N
. . N

METHODS NNP N
We PRP N
undertook VBD N
a DT N
phase NN N
3 CD N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
in IN N
adults NNS 1_p
with IN 1_p
previously RB 1_p
treated VBN 1_p
immune JJ 1_p
thrombocytopenia NN 1_p
of IN 1_p
more JJR 1_p
than IN 1_p
6 CD 1_p
months NNS 1_p
' POS 1_p
duration NN 1_p
who WP 1_p
had VBD 1_p
baseline NN 1_p
platelet NN 1_p
counts VBZ 1_p
lower JJR 1_p
than IN 1_p
30,000 CD 1_p
per IN 1_p
μL NN 1_p
. . N

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
( ( N
in IN N
a DT N
2:1 CD N
ratio NN N
) ) N
treatment NN N
with IN N
local JJ N
standard NN N
of IN N
care NN N
plus CC N
50 CD N
mg NN 1_i
eltrombopag NN 1_i
or CC N
matching VBG 1_i
placebo JJ 1_i
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Randomisation NN N
was VBD N
done VBN N
centrally RB N
with IN N
a DT N
computer-generated JJ N
randomisation NN N
schedule NN N
and CC N
was VBD N
stratified VBN N
by IN N
baseline JJ N
platelet NN N
count NN N
( ( N
≤ JJ N
15,000 CD N
per IN N
μL NN N
) ) N
, , N
use NN N
of IN N
treatment NN N
for IN N
immune JJ N
thrombocytopenia NN N
, , N
and CC N
splenectomy JJ N
status NN N
. . N

Patients NNS N
, , N
investigators NNS N
, , N
and CC N
those DT N
assessing VBG N
data NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
. . N

Dose JJ N
modifications NNS N
were VBD N
made VBN N
on IN N
the DT N
basis NN N
of IN N
platelet NN N
response NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
for IN 1_o
response NN 1_o
to TO 1_o
treatment NN 1_o
( ( 1_o
defined VBN 1_o
as IN 1_o
a DT 1_o
platelet NN 1_o
count NN 1_o
of IN 1_o
50,000-400,000 CD 1_o
per IN 1_o
μL NN N
) ) N
weekly NN N
during IN N
the DT N
first JJ N
6 CD N
weeks NNS N
and CC N
at IN N
least JJS N
once RB N
every DT N
4 CD N
weeks NNS N
thereafter RB N
; : N
the DT N
primary JJ N
endpoint NN N
was VBD 1_o
the DT 1_o
odds NNS 1_o
of IN 1_o
response NN 1_o
to TO 1_i
eltrombopag VB 1_i
versus NN 1_i
placebo NN 1_i
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00370331 NNP N
. . N

FINDINGS NNP 1_p
Between NNP 1_p
Nov NNP 1_p
22 CD 1_p
, , 1_p
2006 CD 1_p
, , 1_p
and CC 1_p
July NNP 1_p
31 CD 1_p
, , 1_p
2007 CD 1_p
, , 1_p
197 CD 1_p
patients NNS 1_p
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
groups NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
analysis NN N
( ( 1_i
135 CD 1_i
eltrombopag NN 1_i
, , 1_i
62 CD 1_i
placebo NN 1_i
) ) 1_i
. . N

106 CD N
( ( N
79 CD N
% NN N
) ) N
patients NNS N
in IN 1_i
the DT 1_i
eltrombopag NN 1_i
group NN 1_o
responded VBD 1_o
to TO N
treatment NN N
at IN N
least JJS N
once RB N
during IN N
the DT N
study NN N
, , N
compared VBN N
with IN N
17 CD N
( ( N
28 CD N
% NN N
) ) N
patients NNS N
in IN 1_i
the DT 1_i
placebo NN 1_i
group NN N
. . 1_o

The DT 1_o
odds NNS 1_o
of IN 1_o
responding VBG 1_o
were VBD N
greater JJR N
in IN N
patients NNS N
in IN 1_i
the DT 1_i
eltrombopag NN 1_i
group NN N
compared VBN N
with IN N
those DT N
in IN 1_i
the DT 1_i
placebo NN 1_i
group NN N
throughout IN N
the DT N
6-month JJ N
treatment NN N
period NN N
( ( N
odds NNS N
ratio VBP N
8·2 CD N
, , N
99 CD N
% NN N
CI NNP N
3·59-18·73 CD N
; : N
p CC N
< VB N
0·0001 CD N
) ) N
. . N

37 CD N
( ( N
59 CD N
% NN N
) ) N
patients NNS N
receiving VBG 1_i
eltrombopag NN 1_o
reduced VBD 1_o
concomitant JJ 1_o
treatment NN 1_o
versus NN N
ten NN N
( ( N
32 CD N
% NN N
) ) N
patients NNS N
receiving VBG 1_i
placebo NN N
( ( N
p=0·016 NN N
) ) N
. . N

24 CD N
( ( N
18 CD N
% NN N
) ) N
patients NNS N
receiving VBG 1_i
eltrombopag NN 1_o
needed VBN 1_o
rescue NN 1_o
treatment NN N
compared VBN N
with IN N
25 CD N
( ( N
40 CD N
% NN N
) ) N
patients NNS N
receiving VBG 1_i
placebo NN N
( ( N
p=0·001 NN N
) ) N
. . N

Three NNP N
( ( N
2 CD N
% NN N
) ) N
patients NNS 1_i
receiving VBG 1_i
eltrombopag NN 1_o
had VBD 1_o
thromboembolic JJ 1_o
events NNS N
compared VBN N
with IN N
none NN N
in IN N
patients NNS 1_i
on IN N
placebo NN N
. . 1_i

Nine NNP 1_i
( ( 1_i
7 CD 1_i
% NN 1_i
) ) 1_i
eltrombopag-treated JJ 1_i
patients NNS N
and CC N
two CD N
( ( 1_i
3 CD 1_i
% NN 1_i
) ) 1_i
in IN 1_i
the DT 1_i
placebo NN N
group NN N
had VBD N
mild VBN N
increases NNS 1_o
in IN 1_o
alanine JJ 1_o
aminotransferase NN 1_o
concentration NN 1_o
, , N
and CC 1_i
five CD 1_i
( ( 1_i
4 CD 1_i
% NN 1_i
) ) 1_i
eltrombopag-treated JJ 1_i
patients NNS N
( ( N
vs IN N
none NN N
allocated VBN 1_i
to TO N
placebo VB N
) ) N
had VBD N
increases NNS 1_o
in IN 1_o
total JJ 1_o
bilirubin NN N
. . N

Four CD N
( ( N
7 CD N
% NN N
) ) N
patients NNS 1_i
taking VBG 1_i
placebo NN 1_o
had VBD 1_o
serious JJ 1_o
bleeding VBG 1_o
events NNS N
, , N
compared VBN N
with IN N
one CD N
( ( N
< VB N
1 CD N
% NN N
) ) N
patient NN N
treated VBN 1_i
with IN 1_i
eltrombopag NN 1_i
. . N

INTERPRETATION NNP 1_i
Eltrombopag NNP 1_o
is VBZ 1_o
effective JJ N
for IN N
management NN N
of IN N
chronic JJ N
immune NN N
thrombocytopenia NN N
, , N
and CC N
could MD N
be VB N
particularly RB N
beneficial JJ N
for IN N
patients NNS N
who WP N
have VBP N
not RB N
responded VBN N
to TO N
splenectomy VB N
or CC N
previous JJ N
treatment NN N
. . N

These DT N
benefits NNS N
should MD N
be VB N
balanced VBN N
with IN N
the DT N
potential JJ N
risks NNS N
associated VBN 1_i
with IN 1_i
eltrombopag JJ 1_i
treatment NN N
. . N

FUNDING NN N
GlaxoSmithKline NNP N
. . N

A DT N
physiotherapy NN 1_i
service NN 1_i
to TO N
an DT N
emergency NN N
extended VBD N
care NN N
unit NN N
does VBZ N
not RB N
decrease VB N
admission NN 1_o
rates NNS 1_o
to TO 1_o
hospital VB 1_o
: : 1_o
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
One CD N
of IN N
the DT N
reasons NNS N
physiotherapy NN 1_i
services NNS N
are VBP N
provided VBN N
to TO N
emergency NN N
departments NNS N
( ( N
EDs NNP N
) ) N
and CC N
emergency NN N
extended VBN N
care NN N
units NNS N
( ( N
EECUs NNP N
) ) N
is VBZ N
to TO N
review VB N
patients NNS N
' POS N
mobility NN N
to TO N
ensure VB N
they PRP N
are VBP N
safe JJ N
to TO N
be VB N
discharged VBN N
home NN N
. . N

AIM NNP N
To TO N
investigate VB N
whether IN N
a DT N
physiotherapy NN 1_i
service NN 1_i
to TO N
an DT N
EECU NNP N
altered VBD N
the DT N
rate NN 1_o
of IN 1_o
hospital NN 1_o
admission NN 1_o
, , 1_o
rate NN 1_o
of IN 1_o
re-presentation NN 1_o
to TO 1_o
the DT 1_o
ED NNP 1_o
, , 1_o
visits VBZ 1_o
to TO 1_o
community NN 1_o
healthcare NN 1_o
practitioners NNS 1_o
, , 1_o
return NN 1_o
to TO 1_o
usual JJ 1_o
work/home/leisure NN 1_o
activities NNS 1_o
and CC 1_o
patient JJ 1_o
satisfaction NN 1_o
. . 1_o

METHODS NNP N
A DT N
randomised JJ N
trial NN N
with IN N
concealed JJ N
allocation NN N
, , N
assessor NN N
blinding NN N
and CC N
intention-to-treat JJ N
analysis NN N
was VBD N
undertaken VBN N
in IN N
an DT N
EECU NNP N
. . N

The DT 1_p
sample NN 1_p
comprised VBD 1_p
186 CD 1_p
patients NNS 1_p
( ( 1_p
mean JJ 1_p
age NN 1_p
70 CD 1_p
years NNS 1_p
, , 1_p
123 CD 1_p
( ( 1_p
66 CD 1_p
% NN 1_p
) ) 1_p
female NN 1_p
patients NNS 1_p
, , 1_p
130 CD 1_p
( ( 1_p
70 CD 1_p
% NN 1_p
) ) 1_p
trauma NN 1_p
) ) 1_p
who WP 1_p
were VBD 1_p
referred VBN 1_p
for IN 1_p
physiotherapy NN 1_i
assessment/intervention NN 1_i
. . 1_i

Referral JJ N
occurred VBD N
at IN N
any DT N
stage NN N
of IN N
the DT N
patients NNS N
' POS N
EECU NNP N
admission NN N
. . N

All DT N
participants NNS N
received VBD N
medical/nursing VBG N
care NN N
as IN N
required VBN N
. . N

The DT N
physiotherapy NN 1_i
group NN N
also RB N
received VBD N
physiotherapy JJ 1_i
assessment/intervention NN 1_i
. . 1_i

RESULTS VB N
The DT N
physiotherapy NN 1_i
group NN N
had VBD N
a DT N
4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-18 CD N
% NN N
to TO N
9 CD N
% NN N
) ) N
lower JJR N
rate NN 1_o
of IN 1_o
admission NN 1_o
to TO 1_o
hospital NN 1_o
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-6 NNP N
% NN N
to TO N
13 CD N
% NN N
) ) N
higher JJR N
rate NN 1_o
of IN 1_o
re-presentation NN 1_o
to TO 1_o
the DT 1_o
ED NNP 1_o
, , N
which WDT N
were VBD N
statistically RB N
non-significant JJ N
( ( N
p≥0.45 NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
for IN 1_o
use NN 1_o
of IN 1_o
community NN 1_o
healthcare NN 1_o
resources NNS 1_o
, , 1_o
return NN 1_o
to TO 1_o
usual JJ 1_o
work/home/leisure NN 1_o
activities NNS 1_o
and CC 1_o
satisfaction NN 1_o
with IN 1_o
their PRP$ 1_o
EECU NNP 1_o
care NN 1_o
were VBD N
small JJ N
and CC N
not RB N
significant JJ N
. . N

CONCLUSION VB N
A NNP 1_i
physiotherapy NN 1_i
service NN 1_i
for IN N
EECU NNP N
patients NNS N
, , N
as IN N
provided VBN N
in IN N
this DT N
study NN N
, , N
did VBD N
not RB N
reduce VB N
the DT 1_o
rate NN 1_o
of IN 1_o
hospital NN 1_o
admission NN 1_o
, , 1_o
rate NN 1_o
of IN 1_o
re-presentation NN 1_o
to TO 1_o
the DT 1_o
ED NNP 1_o
, , 1_o
use NN 1_o
of IN 1_o
community NN 1_o
healthcare NN 1_o
resources NNS 1_o
, , N
or CC N
improve VB N
the DT 1_o
rate NN 1_o
of IN 1_o
return NN 1_o
to TO 1_o
usual JJ 1_o
work/home/leisure NN 1_o
activities NNS 1_o
or CC 1_o
patient JJ 1_o
satisfaction NN 1_o
. . N

Trial JJ N
registration NN N
number NN N
ANZCTRN12609000106235 NNP N
. . N

Economic JJ 1_o
evaluation NN 1_o
of IN N
aquatic JJ 1_i
exercise NN 1_i
for IN N
persons NNS 1_p
with IN 1_p
osteoarthritis NN 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
estimate VB N
cost NN 1_o
and CC 1_o
outcomes NNS 1_o
of IN N
the DT N
Arthritis NNP N
Foundation NNP N
aquatic JJ 1_i
exercise NN 1_i
classes NNS 1_i
from IN N
the DT N
societal JJ N
perspective NN N
. . N

DESIGN NNP N
Randomized NNP N
trial NN N
of IN N
20-week JJ N
aquatic JJ 1_i
classes NNS 1_i
. . 1_i

Cost NN 1_o
per IN 1_o
quality-adjusted JJ 1_o
life NN 1_o
year NN 1_o
( ( 1_o
QALY NNP 1_o
) ) 1_o
gained VBD 1_o
was VBD N
estimated VBN N
using VBG N
trial NN N
data NNS N
. . N

Sample NNP N
size NN N
was VBD N
based VBN N
on IN N
80 CD N
% NN N
power NN N
to TO N
reject VB N
the DT N
null JJ N
hypothesis NN N
that IN N
the DT N
cost/QALY NN 1_o
gained VBD 1_o
would MD N
not RB N
exceed VB N
$ $ N
50,000 CD N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Recruited VBD N
249 CD 1_p
adults NNS 1_p
from IN 1_p
Washington NNP 1_p
State NNP 1_p
aged VBD 1_p
55 CD 1_p
to TO 1_p
75 CD 1_p
with IN 1_p
a DT 1_p
doctor-confirmed JJ 1_p
diagnosis NN 1_p
of IN 1_p
osteoarthritis NN 1_p
to TO 1_p
participate VB 1_p
in IN 1_p
aquatic JJ 1_i
classes NNS 1_i
. . 1_i

The DT N
Quality NN 1_o
of IN 1_o
Well-Being NNP 1_o
Scale NNP 1_o
( ( 1_o
QWB NNP 1_o
) ) 1_o
and CC N
Current NNP 1_o
Health NNP 1_o
Desirability NNP 1_o
Rating NNP 1_o
( ( 1_o
CHDR NNP 1_o
) ) 1_o
were VBD N
used VBN N
for IN N
economic JJ 1_o
evaluation NN 1_o
, , N
supplemented VBN N
by IN N
the DT N
arthritis-specific JJ 1_o
Health NNP 1_o
Assessment NNP 1_o
Questionnaire NNP 1_o
( ( 1_o
HAQ NNP 1_o
) ) 1_o
, , 1_o
Center NNP 1_o
for IN 1_o
Epidemiologic NNP 1_o
Studies-Depression NNP 1_o
Scale NNP 1_o
( ( 1_o
CES-D NNP 1_o
) ) 1_o
, , N
and CC N
Perceived NNP 1_o
Quality NNP 1_o
of IN 1_o
Life NNP 1_o
Scale NNP 1_o
( ( 1_o
PQOL NNP 1_o
) ) 1_o
collected VBD N
at IN N
baseline NN N
and CC N
postclass NN N
. . N

Outcome NNP N
results NNS N
applied VBD N
to TO N
life NN 1_o
expectancy NN 1_o
tables NNS 1_o
were VBD N
used VBN N
to TO N
estimate VB N
QALYs NNP 1_o
. . 1_o

Use NNP 1_o
of IN 1_o
health NN 1_o
care NN 1_o
facilities NNS 1_o
was VBD N
assessed VBN N
from IN N
diaries/questionnaires NNS 1_o
and CC N
Medicare NNP 1_o
reimbursement NN 1_o
rates NNS 1_o
used VBD N
to TO N
estimate VB N
costs NNS 1_o
. . 1_o

Nonparametric NNP 1_o
bootstrap NN 1_o
sampling NN 1_o
of IN 1_o
costs/QALY NN 1_o
ratios NNS 1_o
established VBD N
the DT N
95 CD N
% NN N
CI NNP N
around IN N
the DT N
estimates NNS N
. . N

RESULTS NNP N
Aquatic JJ 1_i
exercisers NNS 1_i
reported VBD N
equal JJ N
( ( 1_o
QWB NNP 1_o
) ) 1_o
or CC N
better JJR N
( ( 1_o
CHDR NNP 1_o
, , 1_o
HAQ NNP 1_o
, , 1_o
PQOL NNP 1_o
) ) 1_o
health-related JJ N
quality NN N
of IN N
life NN N
compared VBN N
with IN N
controls NNS N
. . N

Outcomes NNS N
improved VBN N
with IN N
regular JJ N
class NN N
attendance NN N
. . N

Costs/QALY NNP 1_o
gained VBD N
discounted VBN N
at IN N
3 CD N
% NN N
were VBD N
$ $ N
205,186 CD N
using VBG N
the DT N
QWB NNP 1_o
and CC N
$ $ N
32,643 CD N
using VBG N
the DT N
CHRD NNP 1_o
. . 1_o

CONCLUSION NNP N
Aquatic NNP 1_i
exercise NN 1_i
exceeded VBD N
$ $ N
50,000 CD N
per IN N
QALY NN 1_o
gained VBN 1_o
using VBG N
the DT N
community-weighted JJ N
outcome NN N
but CC N
fell VBD N
below IN N
this DT N
arbitrary JJ N
budget NN N
constraint NN N
when WRB N
using VBG N
the DT N
participant-weighted JJ N
measure NN N
. . N

Confidence NN N
intervals NNS N
around IN N
these DT N
ratios NNS N
suggested VBD N
wide JJ N
variability NN N
of IN N
cost NN N
effectiveness NN N
of IN N
aquatic JJ 1_i
exercise NN 1_i
. . 1_i

[ JJ 1_i
Neoton NNP 1_i
and CC N
thrombolytic JJ 1_i
therapy NN 1_i
of IN N
myocardial JJ N
infarction NN N
] NNP N
. . N

AIM NNP N
To TO N
evaluate VB N
neoton JJ 1_i
therapy NN N
effects NNS N
in IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
on IN N
systolic JJ 1_o
function NN 1_o
of IN 1_o
the DT 1_o
left JJ 1_o
ventricle NN 1_o
, , 1_o
arrhythmia NN 1_o
and CC 1_o
clinical JJ 1_o
symptoms NNS 1_o
in IN N
patients NNS 1_p
on IN 1_p
thrombolytic JJ 1_i
therapy NN 1_i
( ( 1_i
TLT NNP 1_i
) ) 1_i
. . 1_p

MATERIAL NNP N
AND NNP N
METHODS NNP N
106 CD 1_p
males NNS 1_p
with IN 1_p
Q-MI NNP 1_p
entered VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

47 CD N
received VBD N
treatment NN N
without IN N
TLT NNP 1_i
and CC N
neoton NN 1_i
, , N
30 CD N
patients NNS N
received VBD N
TLT NNP 1_i
with IN N
streptokinase JJ 1_i
preparations NNS N
, , N
29 CD N
patients NNS N
were VBD N
given VBN N
streptokinase JJ 1_i
preparations NNS 1_i
and CC N
neoton NN 1_i
. . 1_i

Left NNP 1_o
ventricular JJ 1_o
systolic JJ 1_o
function NN 1_o
was VBD 1_o
measured VBN 1_o
by IN 1_o
echocardiography NN 1_o
on IN N
day NN N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
and CC N
28 CD N
; : N
arrhythmia NN 1_o
was VBD 1_o
analysed VBN 1_o
at IN 1_o
Holter NNP 1_o
monitoring VBG 1_o
in IN N
day NN N
1 CD N
and CC N
2 CD N
of IN N
MI NNP N
. . N

RESULTS NNP N
TLT NNP 1_i
failed VBD N
to TO N
arrest VB N
progression NN N
of IN N
left JJ N
ventricular JJ N
dilation NN N
by IN N
the DT N
end NN N
of IN N
the DT N
hospital NN N
stay NN N
. . N

Patients NNS N
given VBN N
neoton NNS 1_i
in IN N
acute JJ N
period NN N
of IN N
MI NNP N
had VBD N
no DT N
increase NN N
in IN N
the DT N
end NN N
systolic NN 1_o
and CC 1_o
diastolic JJ 1_o
volumes NNS 1_o
of IN N
the DT N
left JJ N
ventricle NN N
in IN N
the DT N
course NN N
of IN N
the DT N
first JJ N
months NNS N
after IN N
MI NNP N
onset NN N
. . N

Antiarrhythmic NNP N
action NN N
of IN N
neoton NN 1_i
manifested VBN N
on IN N
MI NNP N
day NN N
2 CD N
. . N

CONCLUSION NNP N
Neoton NNP 1_i
given VBN N
to TO N
MI NNP 1_p
patients NNS 1_p
receiving VBG 1_p
TLT NNP 1_i
prevents NNS N
progression NN N
of IN N
left JJ 1_o
ventricular JJ 1_o
systolic JJ 1_o
dysfunction NN 1_o
and CC N
establishment NN N
of IN N
predictors NNS N
of IN N
unfavourable JJ N
outcome NN N
. . N

Inverse JJ N
Effect NNP N
of IN N
Fluoxetine NNP 1_i
on IN N
Medial NNP 1_o
Prefrontal NNP 1_o
Cortex NNP 1_o
Activation NNP 1_o
During IN N
Reward NNP N
Reversal NNP N
in IN N
ADHD NNP 1_p
and CC 1_p
Autism NNP 1_p
. . 1_p

Attention NNP 1_p
deficit NN 1_p
hyperactivity NN 1_p
disorder NN 1_p
( ( 1_p
ADHD NNP 1_p
) ) 1_p
and CC 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
share NN N
brain NN N
function NN N
abnormalities NNS N
during IN N
cognitive JJ N
flexibility NN N
. . N

Serotonin NNP N
is VBZ N
involved VBN N
in IN N
both DT N
disorders NNS N
, , N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitors NNS N
( ( N
SSRIs NNP N
) ) N
can MD N
modulate VB N
cognitive JJ N
flexibility NN N
and CC N
improve VB N
behavior NN N
in IN N
both DT N
disorders NNS N
. . N

Thus RB N
, , N
this DT N
study NN N
investigates VBZ N
shared VBN 1_o
and CC 1_o
disorder-specific JJ 1_o
brain NN 1_o
dysfunctions NNS 1_o
in IN N
these DT N
2 CD N
disorders NNS N
during IN N
reward NN N
reversal NN N
, , N
and CC N
the DT N
acute JJ N
effects NNS N
of IN N
an DT N
SSRI NNP N
on IN N
these DT N
. . N

Age-matched JJ 1_p
boys NNS 1_p
with IN 1_p
ADHD NNP 1_p
( ( 1_p
15 CD 1_p
) ) 1_p
, , 1_p
ASD NNP 1_p
( ( 1_p
18 CD 1_p
) ) 1_p
, , 1_p
and CC 1_p
controls NNS 1_p
( ( 1_p
21 CD 1_p
) ) 1_p
were VBD N
compared VBN N
with IN N
functional JJ 1_o
magnetic JJ 1_o
resonance NN 1_o
imaging NN 1_o
( ( 1_o
fMRI JJ 1_o
) ) 1_o
during IN N
a DT N
reversal NN N
task NN N
. . N

Patients NNS N
were VBD N
scanned VBN N
twice RB N
, , N
under IN N
either DT N
an DT N
acute NN N
dose NN N
of IN N
Fluoxetine NNP 1_i
or CC N
placebo NN 1_i
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
design NN N
. . N

Repeated-measures JJ N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN N
effects NNS N
. . N

Patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
with IN N
controls NNS N
to TO N
assess VB N
normalization NN N
effects NNS N
. . N

fMRI NN 1_o
data NNS N
showed VBD N
that IN N
, , N
under IN N
placebo NN 1_i
, , N
ASD NNP N
boys VBZ N
underactivated JJ N
medial JJ 1_o
prefrontal NN 1_o
cortex NN 1_o
( ( 1_o
mPFC NN 1_o
) ) 1_o
, , N
compared VBN N
with IN N
control NN N
and CC N
ADHD NNP N
boys NNS N
. . N

Both DT N
patient JJ N
groups NNS N
shared VBD N
decreased JJ N
precuneus NN 1_o
activation NN 1_o
. . 1_o

Under IN N
Fluoxetine NNP 1_i
, , N
mPFC JJ 1_o
activation NN 1_o
was VBD N
up-regulated JJ N
and CC N
normalized VBN N
in IN N
ASD NNP N
boys NNS N
relative VBP N
to TO N
controls NNS N
, , N
but CC N
down-regulated JJ N
in IN N
ADHD NNP N
boys NNS N
relative VBP N
to TO N
placebo VB 1_i
, , N
which WDT N
was VBD N
concomitant NN N
with IN N
worse JJR N
task NN 1_o
performance NN 1_o
in IN N
ADHD NNP N
. . N

Fluoxetine NNP 1_i
therefore NN N
has VBZ N
inverse JJ N
effects NNS 1_o
on IN N
mPFC JJ 1_o
activation NN 1_o
in IN N
ASD NNP N
and CC N
ADHD NNP N
during IN N
reversal NN N
learning NN N
, , N
suggesting VBG N
dissociated VBN N
underlying JJ N
serotonin NN N
abnormalities NNS N
. . N

Training VBG N
referential JJ 1_i
communicative JJ 1_i
skills NNS 1_i
to TO N
individuals NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
: : 1_p
a DT N
pilot NN N
study NN N
. . N

The DT N
present JJ N
study NN N
reports VBZ N
the DT N
effects NNS N
of IN N
referential JJ 1_i
communication NN 1_i
training NN 1_i
in IN N
individuals NNS 1_p
formally RB 1_p
diagnosed VBN 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Participants NNS N
were VBD N
20 CD 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
( ( 1_p
M NNP 1_p
age NN 1_p
= VBD 1_p
14.3 CD 1_p
yr. NN 1_p
, , N
SD NNP 1_p
= NNP 1_p
4.2 CD 1_p
; : 1_p
6 CD 1_p
girls NNS 1_p
, , 1_p
14 CD 1_p
boys NNS 1_p
) ) 1_p
in IN 1_p
the DT 1_p
role NN 1_p
of IN 1_p
speakers NNS 1_p
and CC 1_p
20 CD 1_p
control NN 1_p
children NNS 1_p
, , 1_p
who WP 1_p
acted VBD 1_p
as IN 1_p
listeners NNS 1_p
. . 1_p

They PRP N
were VBD N
all DT N
enrolled VBN N
in IN N
mainstream JJ N
compulsory NN N
education NN N
. . N

Inclusion/exclusion NNP 1_p
criteria NNS 1_p
were VBD 1_p
defined VBN 1_p
according VBG 1_p
to TO 1_p
the DT 1_p
clinical JJ 1_p
diagnosis NN 1_p
of IN 1_p
ASD NNP 1_p
, , 1_p
the DT 1_p
presence NN 1_p
or CC 1_p
absence NN 1_p
of IN 1_p
additional JJ 1_p
or CC 1_p
associated JJ 1_p
disability NN 1_p
, , 1_p
previous JJ 1_p
training NN 1_p
in IN 1_p
referential JJ 1_i
communication NN 1_i
, , 1_p
and CC 1_p
any DT 1_p
drug NN 1_p
treatment NN 1_p
. . 1_p

Speakers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
( ( N
trained JJ N
vs NN N
untrained VBD N
) ) N
. . N

Linguistic JJ 1_o
age NN 1_o
, , 1_o
cognitive JJ 1_o
level NN 1_o
and CC 1_o
autistic JJ 1_o
symptoms NNS 1_o
were VBD N
analyzed VBN N
, , N
respectively RB N
, , N
with IN N
the DT N
Peabody NNP 1_o
Picture NNP 1_o
Vocabulary NNP 1_o
Test NNP 1_o
( ( 1_o
PPVT NNP 1_o
) ) 1_o
, , 1_o
the DT 1_o
Wechsler NNP 1_o
Intelligence NNP 1_o
Scale NNP 1_o
( ( 1_o
WISC-R NNP 1_o
or CC 1_o
WAIS-III NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
the DT 1_o
Autistic NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
( ( 1_o
ABC NNP 1_o
) ) 1_o
. . 1_o

Communicative JJ 1_o
abilities NNS 1_o
were VBD N
analyzed VBN N
through IN N
two CD N
indexes NNS 1_o
related VBN 1_o
to TO 1_o
message VB 1_o
complexity NN 1_o
and CC 1_o
self-regulation NN 1_o
. . 1_o

The DT N
trained JJ N
group NN N
was VBD N
trained VBN N
in IN N
referential JJ 1_i
communication NN 1_i
tasks NNS 1_i
( ( 1_i
task NN 1_i
analysis NN 1_i
, , 1_i
role NN 1_i
taking NN 1_i
, , N
and CC N
task JJ 1_i
evaluation NN 1_i
) ) 1_i
, , N
while IN N
the DT N
untrained JJ N
group NN N
took VBD N
part NN N
in IN N
a DT N
communicative JJ 1_i
game NN 1_i
but CC N
without IN N
any DT N
specific JJ N
communicative JJ N
training NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
the DT N
complexity NN 1_o
of IN 1_o
emitted JJ 1_o
messages NNS 1_o
had VBD N
improved VBN N
statistically RB N
significantly RB N
in IN N
the DT N
trained JJ N
group NN N
as IN N
an DT N
effect NN N
of IN N
training NN N
. . N

Ecological JJ N
referential JJ 1_i
communication NN 1_i
is VBZ N
shown VBN N
to TO N
be VB N
an DT N
appropriate JJ N
paradigm NN N
for IN N
studying VBG N
the DT N
communicative JJ N
process NN N
and CC N
its PRP$ N
products NNS N
and CC N
could MD N
be VB N
used VBN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
training NN N
program NN N
focused VBN N
on IN N
those DT N
skills NNS N
in IN N
which WDT N
individuals NNS 1_p
with IN 1_p
ASD NNP 1_p
are VBP N
most RBS N
deficient JJ N
. . N

Interventions NNS N
in IN N
the DT N
initial JJ 1_p
prodromal JJ 1_p
states NNS 1_p
of IN 1_p
psychosis NN 1_p
in IN 1_p
Germany NNP 1_p
: : 1_p
concept NN N
and CC N
recruitment NN N
. . N

BACKGROUND VB N
The DT N
Early JJ N
Detection NN N
and CC N
Intervention NNP N
Programme NNP N
of IN N
the DT N
German JJ 1_p
Research NNP N
Network NNP N
on IN N
Schizophrenia NNP 1_p
( ( N
GRNS NNP N
) ) N
investigates VBZ N
the DT N
initial JJ N
prodromal JJ N
phase NN N
of IN N
psychosis NN N
in IN N
a DT N
multidimensional JJ N
approach NN N
. . N

Two CD N
intervention NN N
strategies NNS N
are VBP N
being VBG N
studied VBN N
by IN N
two CD N
large-scale JJ N
multicentre JJ N
projects NNS N
. . N

AIMS NNP N
To TO N
present VB N
the DT N
concept NN N
of IN N
the DT N
intervention NN N
studies NNS N
, , N
and CC N
to TO N
provide VB N
an DT N
interim JJ N
report NN N
of IN N
the DT N
recruitment JJ N
procedure NN N
. . N

METHOD NNP N
Comprehensive NNP 1_i
cognitive-behavioural JJ 1_i
therapy NN 1_i
has VBZ N
been VBN N
developed VBN N
for IN N
patients NNS 1_p
in IN 1_p
the DT 1_p
" NNP 1_p
early JJ 1_p
initial JJ 1_p
prodromal JJ 1_p
state NN 1_p
" NN 1_p
. . 1_p

For IN N
patients NNS 1_p
in IN 1_p
the DT 1_p
" NN 1_p
late JJ 1_p
initial JJ 1_p
prodromal JJ 1_p
state NN 1_p
" VBD 1_p
the DT N
atypical JJ 1_i
neuroleptic JJ 1_i
amisulpride NN 1_i
is VBZ N
explored VBN N
. . N

Both DT N
interventions NNS N
are VBP N
evaluated VBN N
in IN N
randomised JJ N
controlled VBN N
trials NNS N
using VBG N
clinical JJ N
management NN N
as IN N
the DT N
control NN N
condition NN N
. . N

RESULTS NNP N
Between NNP N
January NNP N
2001 CD N
and CC N
March NNP N
2003 CD N
, , N
1212 CD 1_p
individuals NNS 1_p
seeking VBG 1_p
help NN 1_p
for IN 1_p
mental JJ 1_p
health NN 1_p
problems NNS 1_p
were VBD N
screened VBN N
for IN N
putative JJ N
prodromal NN N
symptoms NNS N
at IN N
four CD 1_p
university NN 1_p
centres NNS 1_p
. . 1_p

More JJR 1_p
than IN 1_p
388 CD 1_p
individuals NNS 1_p
fulfilled VBD 1_p
criteria NNS 1_p
for IN 1_p
both DT 1_p
interventions NNS 1_p
and CC 1_p
188 CD 1_p
( ( 1_p
48.5 CD 1_p
% NN 1_p
) ) 1_p
gave VBD 1_p
informed VBN 1_p
consent NN 1_p
to TO 1_p
participate VB 1_p
in IN 1_p
the DT 1_p
trials NNS 1_p
. . 1_p

CONCLUSIONS VB N
The DT N
screening NN N
procedure NN N
appears VBZ N
to TO N
be VB N
feasible JJ N
and CC N
trial NN N
participation NN N
seems VBZ N
to TO N
be VB N
acceptable JJ N
to TO N
a DT N
relevant JJ N
proportion NN N
of IN N
people NNS 1_p
at IN 1_p
increased VBN 1_p
risk NN 1_p
of IN 1_p
developing VBG 1_p
psychosis NN 1_p
. . 1_p

Randomized VBN N
controlled VBD N
study NN N
of IN N
chemoimmunotherapy NN N
with IN N
bestatin NN 1_i
of IN N
acute JJ 1_p
nonlymphocytic JJ 1_p
leukemia NN 1_p
in IN 1_p
adults NNS 1_p
. . 1_p

A DT N
new JJ N
immunomodulating NN N
agent NN N
, , N
bestatin NN 1_i
( ( N
INN NNP N
: : N
Ubenimex NNP N
has VBZ N
low JJ N
toxicity NN N
even RB N
after IN N
long-term JJ N
oral JJ N
administration NN N
and CC N
has VBZ N
significant JJ N
modifications NNS N
in IN N
immunological JJ N
response NN N
. . N

A DT N
cooperative JJ N
randomized NN N
controlled VBD N
study NN N
of IN N
bestatin NN 1_i
immunotherapy NN N
in IN N
combination NN N
with IN N
remission NN N
maintenance NN N
chemotherapy NN N
for IN N
adult NN 1_p
acute JJ 1_p
nonlymphocytic JJ 1_p
leukemia NN 1_p
( ( 1_p
ANLL NNP 1_p
) ) 1_p
was VBD N
performed VBN N
. . N

After IN N
induction NN N
of IN N
complete JJ N
remission NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
bestatin NN 1_i
group NN N
( ( N
30 CD N
mg/bw NN N
per IN N
os NN N
( ( N
po NN N
) ) N
daily RB N
) ) N
and CC N
the DT N
control NN N
group NN N
. . N

The DT 1_p
101 CD 1_p
eligible JJ 1_p
cases NNS 1_p
( ( 1_i
bestatin NN 1_i
: : 1_i
48 CD 1_p
, , 1_p
control NN 1_p
: : 1_p
53 CD 1_p
) ) 1_p
were VBD N
analyzed VBN N
; : N
the DT N
bestatin NN 1_i
group NN N
achieved VBD N
longer JJR 1_o
remission NN 1_o
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
statistically RB N
significant JJ N
longer JJR 1_o
survival NN 1_o
. . 1_o

Though IN N
this DT N
prolongation NN 1_o
of IN 1_o
remission NN 1_o
was VBD N
not RB N
significant JJ N
in IN N
the DT N
bestatin NN 1_i
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
in IN N
the DT N
15-49 JJ N
yr NN N
age NN N
group NN N
, , N
in IN N
the DT N
50-65 JJ N
yr NN N
age NN N
group NN N
it PRP N
was VBD N
significantly RB N
longer JJR N
. . N

Bestatin NNP 1_i
is VBZ N
shown VBN N
to TO N
be VB N
a DT N
clinically RB N
useful JJ N
drug NN N
for IN N
immunotherapy NN N
of IN N
adult NN N
ANLL NNP N
, , N
since IN N
it PRP N
has VBZ N
prolonged VBN 1_o
survival NN 1_o
and CC 1_o
remission NN 1_o
especially RB N
in IN N
elderly JJ N
patients NNS N
, , N
with IN N
few JJ N
side-effects NNS 1_o
. . 1_o

Custom-fit NNP N
minimally RB N
invasive JJ N
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
: : 1_i
effect NN N
on IN N
blood NN 1_o
loss NN 1_o
and CC 1_o
early JJ 1_o
clinical JJ 1_o
outcomes NNS 1_o
. . 1_o

PURPOSE NNP N
Recently NNP N
, , N
new JJ N
custom-fit JJ N
pin NN N
guides NNS N
in IN N
total JJ 1_i
knee NN 1_i
arthroplasty NN 1_i
( ( 1_i
TKA NNP 1_i
) ) 1_i
have VBP N
been VBN N
introduced VBN N
. . N

Use NN N
of IN N
these DT N
guides NNS N
may MD N
reduce VB N
operating NN N
time NN N
. . N

Use NN N
of IN N
the DT N
guides NNS N
combined VBN N
with IN N
the DT N
absence NN N
of IN N
intramedullary JJ N
alignment NN N
jigs NNS N
may MD N
lead VB N
to TO N
reduced VB N
blood NN 1_o
loss NN 1_o
and CC N
improved VBN N
early JJ 1_o
outcomes NNS 1_o
. . 1_o

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
blood NN 1_o
loss NN 1_o
and CC 1_o
early JJ 1_o
clinical JJ 1_o
outcomes NNS 1_o
in IN N
patients NNS 1_p
undergoing VBG 1_p
minimally RB 1_p
invasive JJ 1_p
TKA NNP 1_p
using VBG N
custom-fit JJ 1_i
magnetic JJ 1_i
resonance NN 1_i
imaging NN 1_i
( ( 1_i
MRI NNP 1_i
) ) 1_i
-based VBD 1_i
pin NN 1_i
guides NNS 1_i
. . 1_i

METHODS NNP N
A NNP N
prospective JJ N
study NN N
in IN N
80 CD 1_p
patients NNS 1_p
was VBD N
carried VBN N
out RP N
. . N

Patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
equal JJ N
groups NNS N
. . N

In IN N
one CD N
group NN N
, , N
intramedullary JJ 1_i
alignment NN 1_i
jigs NNS 1_i
were VBD N
used VBN N
. . N

In IN N
the DT N
second JJ N
group NN N
, , N
custom-fit JJ 1_i
MRI-based JJ 1_i
pin NN 1_i
guides NNS 1_i
were VBD N
used VBN N
. . N

All DT N
patients NNS N
received VBD N
the DT N
same JJ N
cemented VBD 1_i
posterior-stabilized JJ 1_i
implant NN 1_i
through IN N
a DT N
mini-midvastus JJ N
approach NN N
. . N

The DT N
volume NN 1_o
in IN 1_o
the DT 1_o
drain NN 1_o
bottles NNS 1_o
was VBD N
recorded VBN N
after IN N
48 CD N
h. JJ N
Hb NNP 1_o
loss NN 1_o
was VBD N
estimated VBN N
by IN N
subtracting VBG N
the DT N
postoperative NN N
from IN N
the DT N
preoperative JJ N
Hb NNP 1_o
level NN 1_o
. . 1_o

Transfusion NN 1_o
requirements NNS 1_o
and CC 1_o
surgical JJ 1_o
time NN 1_o
were VBD N
recorded VBN N
. . N

Outcome JJ N
measures NNS N
were VBD N
Knee NNP 1_o
Society NNP 1_o
Scores NNP 1_o
( ( 1_o
KSS NNP 1_o
) ) 1_o
, , 1_o
knee JJ 1_o
flexion NN 1_o
, , 1_o
knee VB 1_o
swelling VBG 1_o
and CC 1_o
pain NN 1_o
. . 1_o

RESULTS NNP N
There EX N
was VBD N
lower JJR N
mean JJ N
drainage NN 1_o
of IN 1_o
blood NN 1_o
in IN N
the DT N
custom-fit JJ 1_i
group NN N
( ( N
391 CD N
ml NN N
vs. FW N
603 CD N
ml NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
estimated VBN N
loss NN 1_o
of IN 1_o
Hb NNP 1_o
( ( N
3.6 CD N
g/dl NN N
vs. FW N
4.1 CD N
g/dl NN N
; : N
n.s CC N
. . N

) ) N
and CC N
in IN N
transfusion NN N
requirements NNS N
( ( N
7.5 CD N
% NN N
vs. FW N
10 CD N
% NN N
; : N
n.s. CC N
) ) N
. . N

Surgical JJ 1_o
time NN 1_o
was VBD N
reduced VBN N
in IN N
the DT N
custom-fit JJ 1_i
group NN N
( ( N
12 CD N
min NN N
less JJR N
; : N
p NN N
= VBZ N
0.001 CD N
) ) N
. . N

KSS NNP 1_o
measured VBD N
at IN N
week NN N
2 CD N
, , N
6 CD N
and CC N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

Knee NNP 1_o
flexion NN 1_o
measured VBN N
on IN N
days NNS N
7 CD N
, , N
10 CD N
and CC N
at IN N
week NN N
6 CD N
, , N
12 CD N
and CC N
knee VB 1_o
swelling VBG 1_o
and CC N
pain NN 1_o
measured VBN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
10 CD N
and CC N
at IN N
week NN N
6 CD N
, , N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Using VBG N
custom-fit JJ 1_i
pin NN 1_i
guides NNS 1_i
reduces NNS N
blood NN 1_o
drainage NN 1_o
, , N
but CC N
not RB N
the DT N
estimated VBN N
Hb NNP 1_o
loss NN 1_o
in IN N
minimally RB N
invasive JJ N
TKA NNP N
and CC N
does VBZ N
not RB N
affect VB N
transfusion NN 1_o
rate NN 1_o
. . 1_o

Surgical JJ 1_o
time NN 1_o
is VBZ N
reduced VBN N
. . N

There EX N
is VBZ N
no DT N
effect NN N
on IN N
the DT N
early JJ 1_o
clinical JJ 1_o
outcomes NNS 1_o
. . 1_o

LEVEL NN N
OF IN N
EVIDENCE NNP N
Therapeutic NNP N
study NN N
, , N
Level NNP N
I PRP N
. . N

EORTC NNP N
protocols NNS N
in IN N
prostatic JJ 1_p
cancer NN 1_p
. . 1_p

An DT N
interim JJ N
report NN N
. . N

Two CD N
parallel JJ N
prospective JJ N
randomized VBN N
studies NNS N
have VBP N
been VBN N
undertaken VBN N
by IN N
the DT N
EORTC NNP N
Urological NNP N
Group NNP N
in IN N
previously RB 1_p
untreated JJ 1_p
patients NNS 1_p
with IN 1_p
prostatic JJ 1_p
cancer NN 1_p
in IN N
order NN N
to TO N
compare VB N
low JJ N
dose JJ N
Stilboestrol NNP 1_i
versus NN N
Cyproterone NNP 1_i
acetate NN 1_i
versus NN N
Medroxyprogesterone NNP 1_i
acetate NN 1_i
in IN N
the DT N
first JJ N
trial NN N
, , N
and CC N
Stilboestrol NNP 1_i
versus VBP N
Estracyt NNP 1_i
in IN N
the DT N
second JJ N
trial NN N
. . N

Although IN N
the DT N
follow JJ N
up NN N
is VBZ N
still RB N
short JJ N
, , N
no DT N
superiority NN N
of IN N
the DT N
other JJ N
drugs NNS N
over IN N
Stilboestrol NNP 1_i
had VBD N
appeared VBN N
so RB N
far RB N
with IN N
regard NN N
to TO N
either DT N
objective JJ N
response NN N
or CC N
significant JJ N
side NN 1_o
effects NNS 1_o
apart RB N
from IN N
gynaecomastia NN 1_o
. . 1_o

In IN N
the DT N
third JJ N
trial NN N
, , N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
disease NN 1_p
no RB 1_p
longer RBR 1_p
responsive VB 1_p
to TO 1_p
hormonal JJ 1_p
treatment NN 1_p
were VBD N
randomized VBN N
to TO N
either DT N
Adriamycin NNP 1_i
or CC N
Procarbazine NNP 1_i
. . 1_i

Toxicity NN 1_o
and CC 1_o
early JJ 1_o
death NN 1_o
were VBD N
particularly RB N
frequent JJ N
in IN N
Procarbazine NNP 1_i
treated VBD N
patients NNS N
, , N
whereas NNS N
most JJS N
patients NNS N
progressed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Clinical JJ 1_o
effects NNS 1_o
of IN N
root NN N
instrumentation NN N
using VBG N
conventional JJ 1_i
steel NN 1_i
or CC N
non-tooth JJ 1_i
substance NN 1_i
removing VBG 1_i
plastic NN 1_i
curettes NNS 1_i
during IN N
supportive JJ 1_p
periodontal JJ 1_p
therapy NN 1_p
( ( 1_p
SPT NNP 1_p
) ) 1_p
. . 1_p

Although IN N
root NN N
instrumentation NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
most RBS N
important JJ N
cause-related JJ N
treatment NN N
of IN N
periodontal JJ N
diseases NNS N
, , N
repeated VBD N
scaling NN N
and CC N
root NN N
planing NN N
may MD N
over VB N
time NN N
result NN N
in IN N
substantive JJ N
loss NN N
of IN N
tooth JJ N
substance NN N
and CC N
increased JJ N
sensitivity NN N
of IN N
the DT N
teeth NN N
. . N

In IN N
an DT N
effort NN N
to TO N
minimize VB N
these DT N
side JJ N
effects NNS N
of IN N
therapy NN N
, , N
non-root JJ 1_i
substance NN 1_i
removing VBG 1_i
curettes NNS 1_i
have VBP N
been VBN N
developed VBN N
. . N

However RB N
, , N
the DT N
clinical JJ 1_o
effects NNS 1_o
of IN N
such JJ N
plastic NN 1_i
curettes NNS 1_i
with IN N
regard NN N
to TO N
the DT N
control NN N
of IN N
the DT N
periodontal JJ N
infection NN N
has VBZ N
not RB N
yet RB N
been VBN N
established VBN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
, , N
therefore RB N
, , N
to TO N
compare VB N
the DT N
effects NNS 1_o
of IN N
root NN N
instrumentation NN N
using VBG N
plastic NN 1_i
curettes NNS 1_i
( ( N
Universal NNP N
Perio NNP N
Soft NNP N
Scaler NNP N
, , N
Hawe-Neos NNP N
Dental NNP N
, , N
Bioggio NNP N
, , N
TI NNP N
, , N
Switzerland NNP N
) ) N
versus VBP N
conventional JJ 1_i
steel NN 1_i
curettes NNS 1_i
on IN N
the DT N
periodontal JJ N
conditions NNS N
during IN 1_p
supportive JJ 1_p
periodontal JJ 1_p
therapy NN 1_p
. . 1_p

40 CD 1_p
subjects NNS 1_p
participated VBN N
in IN N
this DT N
parallel NN N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
prospective JJ N
longitudinal JJ N
clinical JJ N
study NN N
following VBG N
active JJ N
peridontal JJ N
therapy NN N
. . N

20 CD N
subjects NNS N
served VBD N
as IN N
a DT N
control NN N
group NN N
and CC N
were VBD N
treated VBN N
with IN N
conventional JJ 1_i
steel NN 1_i
curettes NNS 1_i
during IN N
a DT N
supportive JJ N
periodontal NN N
care NN N
visit NN N
( ( N
SPT NNP N
) ) N
. . N

The DT N
other JJ N
20 CD N
subjects NNS N
, , N
the DT N
experimental JJ N
group NN N
, , N
were VBD N
treated VBN N
using VBG N
plastic NN 1_i
curettes NNS 1_i
during IN N
a DT N
similar JJ N
SPT NNP N
visit NN N
. . N

Clinical JJ N
parameters NNS N
, , N
such JJ N
as IN N
bleeding VBG 1_o
on IN 1_o
probing VBG 1_o
( ( 1_o
BOP NNP 1_o
) ) 1_o
and CC 1_o
probing VBG 1_o
pocket NN 1_o
depth NN 1_o
( ( 1_o
PPD NNP 1_o
) ) 1_o
, , N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
3-6 JJ N
months NNS N
later RB N
at IN N
the DT N
next JJ N
regular JJ N
SPT NNP N
visit NN N
. . N

In IN N
addition NN N
, , N
the DT N
BOP NNP 1_o
percentage NN 1_o
was VBD N
determined VBN N
10 CD N
days NNS N
following VBG N
baseline NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
treatment NN N
modalities NNS N
regarding VBG N
BOP NNP 1_o
and CC 1_o
PPD NNP 1_o
at IN N
any DT N
observation NN N
time NN N
. . N

Both DT N
treatments NNS N
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
BOP NNP 1_o
percentage NN 1_o
which WDT N
ranged VBD N
from IN N
17-42 CD N
% NN N
at IN N
baseline NN N
by IN N
about IN N
40 CD N
% NN N
after IN N
10 CD N
days NNS N
( ( N
mean JJ N
BOP NNP 1_o
baseline NN N
: : N
26 CD N
% NN N
, , N
mean JJ N
BOP NNP 1_o
after IN N
10 CD N
days NNS N
: : N
16 CD N
% NN N
) ) N
. . N

This DT N
clinical JJ N
study NN N
suggests VBZ N
that IN N
non-root JJ 1_i
substance NN 1_i
removing VBG 1_i
curettes NNS 1_i
may MD N
be VB N
valuable JJ N
instruments NNS N
for IN N
periodontally RB N
treated JJ N
patients NNS N
during IN N
maintenance NN N
care NN N
, , N
thus RB N
minimizing VBG N
trauma NN N
on IN N
the DT N
hard JJ N
structures NNS N
of IN N
the DT N
teeth NN N
. . N

Additive JJ N
IOP-reducing JJ 1_o
effect NN N
of IN N
latanoprost NN 1_i
in IN N
patients NNS 1_p
insufficiently RB 1_p
controlled VBN 1_p
on IN 1_p
timolol NN 1_p
. . 1_p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
on IN N
intraocular JJ 1_o
pressure NN 1_o
( ( 1_o
IOP NNP 1_o
) ) 1_o
of IN N
switching VBG N
from IN N
timolol NN 1_i
to TO N
latanoprost VB 1_i
or CC N
adding VBG N
latanoprost NN 1_i
to TO N
timolol VB 1_i
in IN 1_p
patients NNS 1_p
with IN 1_p
open JJ 1_p
angle NN 1_p
glaucoma NN 1_p
or CC 1_p
ocular JJ 1_p
hypertension NN 1_p
where WRB 1_p
IOP NNP 1_p
is VBZ 1_p
not RB 1_p
adequately RB 1_p
controlled VBN 1_p
with IN 1_p
timolol NN 1_p
. . 1_p

METHODS NNP N
This DT N
was VBD N
a DT N
6-week JJ N
, , N
double-masked JJ N
, , N
randomised VBD N
multi-centre NN N
study NN N
. . N

53 CD 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
open JJ 1_p
angle NN 1_p
glaucoma NN 1_p
, , 1_p
capsular JJ 1_p
glaucoma NN 1_p
, , 1_p
or CC 1_p
ocular JJ 1_p
hypertension NN 1_p
with IN 1_p
an DT 1_p
IOP NNP 1_p
of IN 1_p
at IN 1_p
least JJS 1_p
21 CD 1_p
mmHg NN 1_p
on IN 1_p
current JJ 1_p
therapy NN 1_p
were VBD N
recruited VBN N
. . N

After IN N
a DT N
run-in JJ N
period NN N
of IN N
at IN N
least JJS N
2 CD N
weeks NNS N
on IN N
timolol NN 1_i
, , N
5 CD N
mg/ml NN N
twice RB N
daily RB N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
. . N

One CD N
group NN N
continued VBD N
on IN N
timolol NN 1_i
, , N
one CD N
switched VBN N
from IN N
timolol NN 1_i
to TO N
latanoprost VB 1_i
, , N
50 CD N
microg/ml NN N
once RB N
daily JJ N
, , N
and CC N
a DT N
third JJ N
group NN N
received VBD N
latanoprost RB 1_i
in IN N
addition NN N
to TO N
timolol VB 1_i
. . 1_i

The DT N
efficacy NN 1_o
was VBD N
evaluated VBN N
by IN N
comparing VBG N
IOP NNP 1_o
at IN N
9 CD N
AM NNP N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
IOP NNP 1_o
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
mean JJ N
+/- NNP N
SEM NNP N
) ) N
were VBD N
24.2 CD N
+/- JJ N
0.9 CD N
and CC N
23.8 CD N
+/- JJ N
1.0 CD N
mmHg NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
for IN N
patients NNS N
continuing VBG N
on IN N
timolol NN 1_i
, , N
26.3 CD N
+/- JJ N
1.2 CD N
and CC N
19.6 CD N
+/- JJ N
1.1 CD N
mmHg NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
for IN N
patients NNS N
switching VBG N
to TO N
latanoprost VB 1_i
, , N
and CC N
23.2 CD N
+/- JJ N
1.0 CD N
and CC N
17.5 CD N
+/- JJ N
0.8 CD N
mmHg NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
for IN N
patients NNS N
with IN N
combined JJ N
treatment NN N
. . N

Adding VBG N
latanoprost NN 1_i
to TO N
timolol VB 1_i
reduced VBN N
IOP NNP 1_o
with IN N
5.9 CD N
+/- JJ N
0.9 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
switching VBG N
from IN N
timolol NN 1_i
to TO N
latanoprost VB 1_i
reduced VBN N
IOP NNP 1_o
with IN N
5.0 CD N
+/- JJ N
0.9 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
which WDT N
caused VBD N
in IN N
each DT N
group NN N
a DT N
significant JJ N
IOP NNP 1_o
reduction NN N
of IN N
about RB N
25 CD N
% NN N
. . N

CONCLUSIONS VB N
The DT N
effect NN N
of IN N
latanoprost NN 1_i
was VBD N
additive JJ N
to TO N
that DT N
of IN N
timolol NN 1_i
, , N
and CC N
a DT N
good JJ N
effect NN N
on IN N
IOP NNP 1_o
reduction NN N
was VBD N
also RB N
achieved VBN N
by IN N
switching VBG N
from IN N
timolol NN 1_i
to TO N
latanoprost VB 1_i
, , N
suggesting VBG N
that IN N
a DT N
switch NN N
in IN N
many JJ N
patients NNS N
is VBZ N
an DT N
effective JJ N
alternative NN N
to TO N
combination NN N
treatment NN N
. . N

Cophenylcaine NNP 1_i
spray NN 1_i
vs. FW N
placebo NN 1_i
in IN N
flexible JJ 1_p
nasendoscopy NN 1_p
: : 1_p
a DT N
prospective JJ N
double-blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

Practices NNS N
vary VBP N
across IN N
the DT N
UK NNP N
on IN N
the DT N
use NN N
of IN N
topical JJ N
preparation NN N
prior RB N
to TO N
flexible JJ N
fibreoptic JJ N
nasendoscopy NN N
. . N

In IN N
this DT N
double-blind NN N
study NN N
, , N
we PRP N
randomised VBD N
98 CD 1_p
patients NNS 1_p
to TO N
receive VB N
cophenylcaine NN 1_i
or CC N
placebo NN 1_i
nasal JJ N
spray NN N
before IN N
flexible JJ 1_p
nasendoscopy NN 1_p
. . 1_p

A DT N
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
1-100 JJ 1_o
) ) 1_o
was VBD 1_o
used VBN 1_o
to TO 1_o
record VB 1_o
pain NN 1_o
, , 1_o
unpleasantness NN 1_o
of IN 1_o
taste NN 1_o
and CC 1_o
overall JJ 1_o
discomfort NN 1_o
experienced VBD 1_o
. . 1_o

Overall JJ N
, , N
the DT N
procedure NN N
was VBD N
associated VBN N
with IN N
minimal JJ N
pain NN 1_o
and CC 1_o
discomfort NN 1_o
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN 1_o
or CC 1_o
overall JJ 1_o
discomfort NN 1_o
experienced VBD N
between IN N
the DT N
two CD N
groups NNS N
; : N
however RB N
, , N
the DT N
sensation NN 1_o
of IN 1_o
bad JJ 1_o
taste NN 1_o
was VBD N
significantly RB N
worse JJR N
in IN N
the DT N
cophenylcaine NN 1_i
group NN N
. . N

In IN N
linear JJ N
regression NN N
, , N
factors NNS N
that WDT N
predicted VBD N
the DT N
overall JJ N
unpleasantness NN 1_o
of IN N
the DT N
experience NN N
were VBD N
primarily RB N
pain VBN 1_o
experienced JJ N
and CC N
secondarily JJ N
unpleasantness NN 1_o
of IN 1_o
taste NN 1_o
. . 1_o

We PRP N
conclude VBP N
that IN N
the DT N
routine JJ N
use NN N
of IN N
cophenylcaine NN 1_i
for IN N
nasal JJ N
preparation NN N
is VBZ N
not RB N
justified VBN N
before IN N
flexible JJ 1_p
nasendoscopy NN 1_p
. . 1_p

[ NN 1_i
Limbal NNP 1_i
epithelial NN 1_i
autograft NN 1_i
transplantation NN 1_i
in IN N
treatment NN N
of IN N
pterygium NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
therapeutic JJ 1_o
effects NNS 1_o
of IN N
limbal JJ 1_i
epithelial JJ 1_i
autograft NN 1_i
transplantation NN 1_i
and CC N
pterygium NN 1_i
excision NN 1_i
in IN N
the DT N
treatment NN N
of IN N
pterygium NN 1_p
. . 1_p

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
paired-eye JJ N
trial NN N
was VBD N
studied VBN N
. . N

There EX N
were VBD N
208 CD 1_p
patients NNS 1_p
( ( 1_p
229 CD 1_p
eyes NNS 1_p
) ) 1_p
with IN 1_p
initial JJ 1_p
pterygium NN 1_p
, , N
and CC N
they PRP N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
excision NN 1_i
of IN 1_i
pterygium NN 1_i
with IN N
limbal JJ 1_i
epithelial JJ 1_i
autograft NN 1_i
transplantation NN 1_i
surgery NN 1_i
( ( N
A NNP N
group NN N
, , N
106 CD N
cases NNS N
and CC N
124 CD N
eyes NNS N
) ) N
and CC N
simple JJ 1_i
pterygium NN 1_i
excision NN 1_i
( ( N
B NNP N
group NN N
, , N
102 CD N
cases NNS N
and CC N
105 CD N
eyes NNS N
) ) N
. . N

The DT N
criteria NN N
for IN N
recovery NN N
were VBD N
corneal JJ 1_o
transparency NN 1_o
with IN 1_o
stable JJ 1_o
epithelial JJ 1_o
healing NN 1_o
and CC 1_o
no DT 1_o
abnormal JJ 1_o
proliferation NN 1_o
of IN 1_o
pterygium-like JJ 1_o
tissue NN 1_o
. . 1_o

The DT N
post-operative JJ N
follow-up JJ N
periods NNS N
ranged VBD N
from IN N
18 CD N
approximately RB N
28 CD N
( ( N
22.4 CD N
+/- JJ N
4.9 CD N
) ) N
months NNS N
. . N

RESULTS NNP N
Some DT N
of IN N
the DT N
patients NNS N
lost VBD N
follow-up JJ N
. . N

In IN N
the DT N
eyes NNS N
followed VBD N
up RB N
, , N
5 CD N
of IN N
11 CD N
2 CD N
eyes NNS N
( ( N
4.5 CD N
% NN N
) ) N
in IN N
A NNP N
group NN N
and CC N
41 CD N
of IN N
96 CD N
eyes NNS N
( ( N
42.7 CD N
% NN N
) ) N
in IN N
B NNP N
group NN N
were VBD N
recurred VBN N
, , N
the DT N
difference NN N
being VBG N
very RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
To TO N
provide VB N
a DT N
new JJ N
stem NN N
cell NN N
source NN N
, , N
limbal JJ 1_i
epithelial JJ 1_i
autograft NN 1_i
transplantation NN 1_i
, , N
for IN N
an DT N
injured JJ N
limb NN N
us PRP N
is VBZ N
a DT N
reasonable JJ N
therapeutic JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
pterygium NN 1_p
. . 1_p

Youth NN 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
comprehend NN N
lexicalized VBN 1_i
and CC N
novel JJ N
primary JJ 1_i
conceptual JJ 1_i
metaphors NNS 1_i
. . 1_i

Individuals NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
have VBP N
difficulty NN N
comprehending VBG 1_o
metaphors NNS 1_o
. . 1_o

However RB N
, , N
no DT N
study NN N
to TO N
date NN N
has VBZ N
examined VBN N
whether IN N
or CC N
not RB N
they PRP N
understand VBP N
conceptual JJ 1_o
metaphors NNS 1_o
( ( N
i.e NN N
. . N

mappings NNS N
between IN N
conceptual JJ N
structures NNS N
) ) N
, , N
which WDT N
could MD N
be VB N
the DT N
building NN N
blocks NNS N
of IN N
metaphoric JJ N
thinking NN N
and CC N
understanding NN N
. . N

We PRP N
investigated VBD N
whether IN N
13 CD 1_p
participants NNS 1_p
with IN 1_p
ASD NNP 1_p
( ( 1_p
age NN 1_p
7 CD 1_p
; : 1_p
03-22 CD 1_p
; : 1_p
03 CD 1_p
) ) 1_p
and CC 1_p
13 CD 1_p
age-matched JJ 1_p
typically RB 1_p
developing VBG 1_p
( ( 1_p
TD NNP 1_p
) ) 1_p
controls NNS 1_p
could MD N
comprehend VB N
lexicalized JJ 1_o
conceptual JJ 1_o
metaphors NNS 1_o
( ( N
e.g. NN N
, , N
Susan NNP N
is VBZ N
a DT N
warm JJ N
person NN N
) ) N
and CC N
novel JJ 1_o
ones NNS 1_o
( ( N
e.g. NN N
, , N
Susan NNP N
is VBZ N
a DT N
toasty JJ N
person NN N
) ) N
. . N

Individuals NNS 1_p
with IN 1_p
ASD NNP 1_p
performed VBD N
at IN N
greater JJR N
than IN N
chance NN N
levels NNS N
on IN N
both DT N
metaphor NN 1_o
types NNS N
, , N
although IN N
their PRP$ N
performance NN N
was VBD N
lower JJR N
than IN N
TD CD N
participants NNS N
. . N

We PRP N
discuss VBP N
the DT N
theoretical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
and CC N
educational JJ N
implications NNS N
. . N

Measurement NN N
of IN N
transfer NN N
factor NN N
during IN N
constant JJ N
exhalation NN N
. . N

BACKGROUND NNP N
Transfer NNP 1_o
factor NN 1_o
of IN 1_o
the DT 1_o
lung NN 1_o
for IN 1_o
carbon NN 1_o
monoxide NN 1_o
( ( 1_o
TLCO NNP 1_o
) ) 1_o
was VBD N
measured VBN N
by IN N
a DT N
new JJ N
method NN N
based VBN N
on IN N
analysis NN N
of IN N
the DT N
ratio NN 1_o
of IN 1_o
the DT 1_o
concentrations NNS 1_o
of IN 1_o
carbon NN 1_o
monoxide NN 1_o
to TO N
an DT N
inert NN N
gas NN N
( ( N
methane NN N
) ) N
relative NN N
to TO N
lung NN N
volume NN N
during IN N
a DT N
constant JJ N
exhalation NN N
. . N

Since IN N
this DT N
new JJ N
technique NN N
is VBZ N
based VBN N
solely RB N
upon JJ N
exhalation NN N
, , N
anomalies NNS N
associated VBN N
with IN N
inspiration NN N
and CC N
breath NN N
holding VBG N
do VBP N
not RB N
affect VB N
results NNS N
. . N

Additionally RB N
, , N
because IN N
prolonged JJ N
breath NN N
holding NN N
is VBZ N
not RB N
required VBN N
, , N
measurements NNS N
can MD N
readily RB N
be VB N
made VBN N
in IN N
dyspnoeic JJ 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
Exhalation NNP 1_o
TLCO NNP 1_o
( ( 1_o
TLCO NNP 1_o
, , 1_o
ex NN 1_o
) ) 1_o
was VBD N
compared VBN N
with IN N
the DT N
standard NN 1_o
( ( 1_o
Jones NNP 1_o
and CC 1_o
Meade NNP 1_o
) ) 1_o
10 CD 1_o
second JJ 1_o
breath NN 1_o
holding VBG 1_o
TLCO NNP 1_o
( ( 1_o
TLCO NNP 1_o
, , 1_o
bh NN 1_o
) ) 1_o
in IN N
100 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
. . 1_p

Patients NNS N
did VBD N
not RB N
practise VB N
the DT N
exhalation NN N
manoeuvre NN N
prior RB N
to TO N
testing VBG N
. . N

RESULTS VB N
The DT N
comparative JJ N
results NNS N
were VBD N
very RB N
close RB N
; : N
mean JJ N
difference NN N
( ( N
bias JJ N
) ) N
+/- JJ N
standard JJ N
deviation NN N
( ( N
precision NN N
) ) N
was VBD N
0.05 CD N
( ( N
0.84 CD N
) ) N
mmol/min/kPa NN N
. . N

The DT N
relation NN 1_o
was VBD N
equally RB N
strong JJ N
in IN N
patients NNS 1_p
with IN 1_p
severe JJ 1_p
pulmonary JJ 1_p
disease NN 1_p
; : 1_p
for IN N
patients NNS N
with IN N
FEV1 NNP 1_o
< $ N
1.51 CD N
the DT N
mean NN N
difference NN N
was VBD N
0.21 CD N
( ( N
0.80 CD N
) ) N
mmol/min/kPa NN N
. . N

CONCLUSIONS NNP N
Since IN N
the DT N
results NNS N
were VBD N
essentially RB N
identical JJ N
between IN N
the DT N
techniques NNS N
, , N
it PRP N
seems VBZ N
that IN N
comparable JJ N
pathophysiological JJ N
factors NNS N
affect VBP N
TLCO NNP 1_i
during IN N
breath NN N
holding NN N
and CC N
constant JJ N
exhalation NN N
. . N

Constant JJ N
exhalation NN N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
breath NN N
holding NN N
technique NN N
for IN N
clinical JJ 1_o
measurement NN 1_o
of IN 1_o
TLCO NNP 1_o
. . 1_o

A DT N
selective JJ N
angiotensin NN N
receptor NN N
antagonist NN N
, , N
Valsartan NNP 1_i
, , N
produced VBD N
regression NN 1_o
of IN 1_o
left JJ 1_o
ventricular JJ 1_o
hypertrophy NN 1_o
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
arterial JJ 1_o
stiffness NN 1_o
. . 1_o

We PRP N
investigated VBD N
whether IN N
a DT N
selective JJ 1_i
angiotensin NN 1_i
II NNP 1_i
receptor NN 1_i
blocker NN 1_i
( ( 1_i
ARB NNP 1_i
) ) 1_i
would MD N
have VB N
a DT N
regressive JJ 1_o
effect NN 1_o
on IN 1_o
left NN 1_o
ventricular JJ 1_o
hypertrophy NN 1_o
( ( 1_o
LVH NNP 1_o
) ) 1_o
in IN N
patients NNS 1_p
on IN 1_p
continuous JJ 1_p
ambulatory JJ 1_p
peritoneal JJ 1_p
dialysis NN 1_p
( ( 1_p
CAPD NNP 1_p
) ) 1_p
. . 1_p

In IN N
a DT N
double-blind NN N
study NN N
, , N
24 CD 1_p
CAPD NNP 1_p
patients NNS 1_p
with IN 1_p
LVH NNP 1_p
[ NNP 1_o
left VBD 1_o
ventricular JJ 1_o
mass NN 1_o
index NN 1_o
( ( 1_o
LVMi NNP 1_o
) ) 1_o
> VBD 1_p
110 CD 1_p
g/m2 NN 1_p
for IN 1_p
women NNS 1_p
and CC 1_p
LVMi NNP 1_o
> NNP 1_p
137 CD 1_p
g/m2 NN 1_p
for IN 1_p
men NNS 1_p
] NNS 1_p
were VBD N
randomized VBN N
to TO N
12 CD N
months NNS N
' POS N
administration NN N
of IN N
either CC N
the DT N
ARB NNP 1_i
valsartan NN 1_i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
or CC N
a DT N
placebo NN 1_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

The DT N
target NN 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
was VBD N
140/90 CD N
mmHg NN N
or CC N
lower JJR N
in IN N
both DT N
groups NNS N
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
measured VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
: : N
aortic JJ 1_o
and CC 1_o
large-artery JJ 1_o
compliance NN 1_o
and CC 1_o
arterial JJ 1_o
wave NN 1_o
reflections NNS 1_o
[ VBP 1_o
pulse JJ 1_o
wave VBP 1_o
velocity NN 1_o
( ( 1_o
PWV NNP 1_o
) ) 1_o
and CC 1_o
augmentation NN 1_o
index NN 1_o
( ( 1_o
AI NNP 1_o
) ) 1_o
application NN 1_o
tonometry NN 1_o
] NNP 1_o
and CC 1_o
cardiac JJ 1_o
echocardiography NN 1_o
. . 1_o

Periodically RB N
recorded VBN N
were VBD N
body JJ 1_o
weight NN 1_o
, , 1_o
BP NNP 1_o
( ( 1_o
mercury NN 1_o
sphygmomanometer NN 1_o
) ) 1_o
, , 1_o
serum JJ 1_o
creatinine NN 1_o
, , 1_o
electrolytes VBZ 1_o
, , 1_o
complete JJ 1_o
blood NN 1_o
cell NN 1_o
counts NNS 1_o
, , 1_o
urine JJ 1_o
volume NN 1_o
, , 1_o
drainage NN 1_o
volume NN 1_o
, , 1_o
and CC 1_o
weekly JJ 1_o
creatinine NN 1_o
clearance NN 1_o
. . 1_o

Two-way JJ N
analysis NN N
of IN N
variance NN N
for IN N
repeated JJ N
measurements NNS N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

Systolic NNP 1_o
and CC 1_o
diastolic JJ 1_o
BP NNP 1_o
were VBD N
both DT N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP 1_i
. . 1_i

The DT N
LVMi NNP 1_o
was VBD N
significantly RB N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP 1_i
( ( N
to TO N
121 CD N
+/- JJ N
4 CD N
from IN N
145 CD N
+/- JJ N
5 CD N
) ) N
but CC N
not RB N
in IN N
those DT N
receiving VBG N
placebo NN 1_i
( ( N
to TO N
137 CD N
+/- JJ N
3 CD N
from IN N
152 CD N
+/- JJ N
3 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
decrease NN N
in IN N
LVMi NNP 1_o
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
PWV NNP 1_o
and CC N
AI NNP 1_o
. . 1_o

In IN N
CAPD NNP 1_p
patients NNS 1_p
with IN 1_p
LVH NNP 1_p
, , N
ARB NNP 1_i
reduced VBD N
LVMi NNP 1_o
in IN N
association NN N
with IN N
alterations NNS N
in IN N
arterial JJ 1_o
hemodynamics NNS 1_o
. . 1_o

Visual JJ 1_i
and CC 1_i
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
integrated VBN 1_i
with IN 1_i
auditory JJ 1_i
step NN 1_i
rhythm NN 1_i
for IN N
walking VBG 1_o
performance NN 1_o
of IN N
patients NNS 1_p
with IN 1_p
chronic JJ 1_p
stroke NN 1_p
. . 1_p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
visual JJ 1_i
and CC 1_i
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
on IN N
walking VBG 1_o
performance NN 1_o
and CC N
to TO N
determine VB N
the DT N
clinical JJ N
feasibility NN N
of IN N
incorporating VBG N
auditory JJ 1_i
step NN 1_i
rhythm NN 1_i
into IN N
the DT N
training NN N
. . N

DESIGN NNP N
Randomized NNP N
crossover NN N
trial NN N
. . N

SETTING NNP N
Laboratory NNP N
of IN N
a DT N
Department NNP N
of IN N
Physical NNP N
Therapy NNP N
. . N

SUBJECTS NNP N
Fifteen NNP 1_p
subjects VBZ 1_p
with IN 1_p
post-stroke JJ 1_p
hemiparesis NN 1_p
. . 1_p

INTERVENTION NNP N
Four NNP N
locomotor NN 1_i
imagery NN 1_i
trainings NNS 1_i
on IN N
walking VBG N
performance NN N
: : N
visual JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
, , 1_i
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
, , 1_i
visual JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
with IN 1_i
auditory JJ 1_i
step NN 1_i
rhythm NN 1_i
and CC N
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
with IN 1_i
auditory JJ 1_i
step NN 1_i
rhythm NN 1_i
. . 1_i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT 1_o
timed JJ 1_o
up-and-go JJ 1_o
test NN 1_o
and CC 1_o
electromyographic JJ 1_o
and CC 1_o
kinematic JJ 1_o
analyses NNS 1_o
of IN 1_o
the DT 1_o
affected JJ 1_o
lower JJR 1_o
limb NN 1_o
during IN N
one CD N
gait NN N
cycle NN N
. . N

RESULTS NNP N
After IN N
the DT N
interventions NNS N
, , N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
timed JJ 1_o
up-and-go JJ 1_o
test NN 1_o
results NNS N
between IN N
the DT N
visual JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
( ( N
25.69 CD N
± RB N
16.16 CD N
to TO N
23.97 CD N
± NNS N
14.30 CD N
) ) N
and CC N
the DT 1_i
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
with IN 1_i
auditory JJ 1_i
step NN 1_i
rhythm NN 1_i
( ( N
22.68 CD N
± RB N
12.35 CD N
to TO N
15.77 CD N
± NNS N
8.58 CD N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

During IN N
the DT N
swing NN N
and CC N
stance NN N
phases NNS N
, , N
the DT 1_i
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
exhibited VBN N
significantly RB N
increased VBN N
activation NN N
in IN N
a DT N
greater JJR 1_o
number NN 1_o
of IN 1_o
muscles NNS 1_o
and CC N
increased VBD 1_o
angular JJ 1_o
displacement NN 1_o
of IN 1_o
the DT 1_o
knee NN 1_o
and CC 1_o
ankle NN 1_o
joints NNS 1_o
compared VBN N
with IN N
the DT 1_i
visual JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
, , N
and CC N
these DT N
effects NNS N
were VBD N
more RBR N
prominent JJ N
when WRB 1_i
auditory JJ 1_i
step NN 1_i
rhythm NN 1_i
was VBD N
integrated VBN N
into IN N
each DT N
form NN 1_i
of IN 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
. . N

The DT N
activation NN N
of IN N
the DT N
hamstring NN N
during IN N
the DT N
swing JJ N
phase NN N
and CC N
the DT N
gastrocnemius NN N
during IN N
the DT N
stance NN N
phase NN N
, , N
as RB N
well RB 1_o
as IN 1_o
kinematic JJ 1_o
data NNS 1_o
of IN 1_o
the DT 1_o
knee NN 1_o
joint NN 1_o
, , N
were VBD N
significantly RB N
different JJ N
for IN N
posttest JJS N
values NNS N
between IN N
the DT 1_i
visual JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
and CC N
the DT 1_i
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
with IN 1_i
auditory JJ 1_i
step NN 1_i
rhythm NN 1_i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT 1_o
therapeutic JJ 1_o
effect NN 1_o
may MD N
be VB N
further RB N
enhanced VBN N
in IN N
the DT 1_i
kinesthetic JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
than IN N
in IN N
the DT 1_i
visual JJ 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
. . N

The DT 1_i
auditory JJ 1_i
step NN 1_i
rhythm VBZ 1_i
together RB N
with IN N
the DT 1_i
locomotor NN 1_i
imagery NN 1_i
training NN 1_i
produces VBZ N
a DT N
greater JJR N
positive JJ N
effect NN N
in IN N
improving VBG N
the DT 1_o
walking VBG 1_o
performance NN 1_o
of IN 1_p
patients NNS 1_p
with IN 1_p
post-stroke JJ 1_p
hemiparesis NN 1_p
. . N

Effect NN N
of IN N
duloxetine NN 1_i
on IN N
pain NN 1_o
, , 1_o
function NN 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
among IN N
patients NNS 1_p
with IN 1_p
chemotherapy-induced JJ 1_p
painful JJ 1_p
peripheral JJ 1_p
neuropathy NN 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
There EX N
are VBP N
no DT N
known JJ N
effective JJ N
treatments NNS N
for IN N
painful JJ N
chemotherapy-induced JJ N
peripheral JJ N
neuropathy NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
duloxetine NN 1_i
, , N
60 CD N
mg JJ N
daily RB N
, , N
on IN N
average JJ 1_o
pain NN 1_o
severity NN 1_o
. . 1_o

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
at IN N
8 CD N
National NNP N
Cancer NNP N
Institute NNP N
( ( N
NCI NNP N
) ) N
-funded VBD N
cooperative JJ N
research NN N
networks NNS N
that WDT N
enrolled VBD N
231 CD 1_p
patients NNS 1_p
who WP 1_p
were VBD 1_p
25 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
being VBG 1_p
treated VBN 1_p
at IN 1_p
community NN 1_p
and CC 1_p
academic JJ 1_p
settings NNS 1_p
between IN 1_p
April NNP 1_p
2008 CD 1_p
and CC 1_p
March NNP 1_p
2011 CD 1_p
. . 1_p

Study NNP N
follow-up NN N
was VBD N
completed VBN N
July NNP N
2012 CD N
. . N

Stratified VBN N
by IN N
chemotherapeutic JJ N
drug NN N
and CC N
comorbid NN N
pain NN N
risk NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
duloxetine NN 1_i
followed VBN N
by IN N
placebo NN 1_i
or CC N
placebo NN 1_i
followed VBN N
by IN N
duloxetine NN 1_i
. . 1_i

Eligibility NN N
required VBD N
that IN N
patients NNS N
have VBP N
grade VBN 1_p
1 CD 1_p
or CC 1_p
higher JJR 1_p
sensory NN 1_p
neuropathy JJ 1_p
according VBG 1_p
to TO 1_p
the DT 1_p
NCI NNP 1_p
Common NNP 1_p
Terminology NNP 1_p
Criteria NNP 1_p
for IN 1_p
Adverse NNP 1_p
Events NNS 1_p
and CC 1_p
at IN 1_p
least JJS 1_p
4 CD 1_p
on IN 1_p
a DT 1_p
scale NN 1_p
of IN 1_p
0 CD 1_p
to TO 1_p
10 CD 1_p
, , 1_p
representing VBG 1_p
average JJ 1_p
chemotherapy-induced JJ 1_p
pain NN 1_p
, , 1_p
after IN 1_p
paclitaxel NN 1_i
, , 1_p
other JJ 1_p
taxane NN 1_i
, , 1_p
or CC 1_p
oxaliplatin JJ 1_i
treatment NN 1_p
. . 1_p

INTERVENTIONS VBZ N
The DT N
initial JJ N
treatment NN N
consisted VBN N
of IN N
taking VBG N
1 CD N
capsule JJ N
daily RB N
of IN N
either CC N
30 CD N
mg NN N
of IN N
duloxetine NN 1_i
or CC N
placebo NN 1_i
for IN N
the DT N
first JJ N
week NN N
and CC N
2 CD N
capsules NNS N
of IN N
either DT N
30 CD N
mg NN N
of IN N
duloxetine NN 1_i
or CC N
placebo JJ 1_i
daily JJ N
for IN N
4 CD N
additional JJ N
weeks NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
hypothesis NN N
was VBD N
that IN N
duloxetine NN 1_i
would MD N
be VB N
more RBR N
effective JJ 1_o
than IN N
placebo NN 1_i
in IN N
decreasing VBG N
chemotherapy-induced JJ 1_o
peripheral JJ 1_o
neuropathic JJ 1_o
pain NN 1_o
. . 1_o

Pain NNP 1_o
severity NN 1_o
was VBD 1_o
assessed VBN 1_o
using VBG 1_o
the DT 1_o
Brief JJ 1_o
Pain NNP 1_o
Inventory-Short NNP 1_o
Form NNP 1_o
" NNP 1_o
average JJ 1_o
pain NN 1_o
" JJ 1_o
item NN 1_o
with IN 1_o
0 CD 1_o
representing VBG 1_o
no DT 1_o
pain NN 1_o
and CC 1_o
10 CD 1_o
representing VBG 1_o
as RB 1_o
bad JJ 1_o
as IN 1_o
can MD 1_o
be VB 1_o
imagined VBN 1_o
. . 1_o

RESULTS JJ N
Individuals NNS N
receiving VBG N
duloxetine NN 1_i
as IN N
their PRP$ N
initial JJ N
5-week JJ N
treatment NN N
reported VBD N
a DT N
mean JJ N
decrease NN N
in IN N
average JJ 1_o
pain NN 1_o
of IN N
1.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.72-1.40 NNP N
) ) N
vs VBZ N
0.34 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.01-0.66 NNP N
) ) N
among IN N
those DT N
who WP N
received VBD N
placebo NN 1_i
( ( N
P NNP N
= NNP N
.003 NNP N
; : N
effect NN N
size NN N
, , N
0.513 CD N
) ) N
. . N

The DT N
observed JJ N
mean JJ N
difference NN N
in IN N
the DT N
average JJ 1_o
pain NN 1_o
score NN 1_o
between IN N
duloxetine NN 1_i
and CC N
placebo NN 1_i
was VBD N
0.73 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.26-1.20 NN N
) ) N
. . N

Fifty-nine JJ N
percent NN N
of IN N
those DT N
initially RB N
receiving VBG N
duloxetine NN 1_i
vs FW N
38 CD N
% NN N
of IN N
those DT N
initially RB N
receiving VBG N
placebo NN 1_i
reported VBD N
decreased JJ N
pain NN 1_o
of IN N
any DT N
amount NN N
. . N

CONCLUSION NNP N
AND CC N
RELEVANCE NNP N
Among IN N
patients NNS 1_p
with IN 1_p
painful JJ 1_p
chemotherapy-induced JJ 1_o
peripheral JJ 1_o
neuropathy NN 1_o
, , N
the DT N
use NN N
of IN N
duloxetine NN 1_i
compared VBN N
with IN N
placebo NN 1_i
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
a DT N
greater JJR N
reduction NN 1_o
in IN 1_o
pain NN 1_o
. . 1_o

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00489411 NN N
. . N

Effects NNS N
of IN N
mild JJ 1_i
physical JJ 1_i
exercise NN 1_i
on IN N
serum NN 1_o
lipoproteins NNS 1_o
and CC 1_o
metabolites NNS 1_o
of IN 1_o
arachidonic JJ 1_o
acid NN 1_o
: : 1_o
a DT N
controlled VBN N
randomised JJ N
trial NN N
in IN N
middle JJ 1_p
aged VBN 1_p
men NNS 1_p
. . 1_p

To TO N
study VB N
the DT N
effects NNS N
of IN N
physical JJ 1_i
exercise NN 1_i
on IN N
biochemical JJ 1_o
risk NN 1_o
factors NNS 1_o
for IN 1_o
ischaemic JJ 1_o
heart NN 1_o
disease NN 1_o
31 CD 1_p
healthy JJ 1_p
middle NNS 1_p
aged VBN 1_p
men NNS 1_p
undertook IN N
regular JJ 1_i
physical JJ 1_i
exercise NN 1_i
for IN N
two CD N
months NNS N
and CC N
29 CD N
served VBD N
as IN N
controls NNS N
in IN N
a DT N
randomised JJ N
trial NN N
. . N

In IN N
the DT N
men NNS N
taking VBG N
regular JJ 1_i
exercise NN 1_i
serum NN 1_o
cholesterol NN 1_o
concentrations NNS 1_o
increased VBD N
26 CD N
% NN N
more JJR N
in IN N
the DT N
high JJ 1_o
density NN 1_o
lipoprotein VBP 1_o
subfraction NN 1_o
two CD 1_o
( ( 1_o
HDL2 NNP 1_o
) ) 1_o
and CC N
decreased VBD N
31 CD N
% NN N
more JJR N
in IN N
the DT N
subfraction NN 1_o
three CD 1_o
( ( 1_o
HDL3 NNP 1_o
) ) 1_o
and CC N
9 CD N
% NN N
more JJR N
in IN N
the DT N
low JJ 1_o
density NN 1_o
lipoprotein NN 1_o
fraction NN 1_o
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

A DT N
tendency NN N
towards NNS N
increased VBD N
plasma JJ 1_o
6-keto-prostaglandin JJ 1_o
F1 NNP 1_o
alpha NN 1_o
concentration NN 1_o
and CC N
decreased VBD N
serum NN 1_o
thromboxane NN 1_o
B2 NNP 1_o
concentration NN 1_o
was VBD N
found VBN N
during IN N
the DT N
period NN N
of IN N
regular JJ 1_i
exercise NN 1_i
, , N
but CC N
prostaglandin VBP 1_o
E2 NNP 1_o
concentrations NNS 1_o
remained VBD N
unchanged JJ N
. . N

The DT N
increase NN N
in IN N
plasma JJ 1_o
6-keto-prostaglandin JJ 1_o
F1 NNP 1_o
alpha NN 1_o
concentration NN 1_o
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
serum JJ 1_o
HDL2 NNP 1_o
cholesterol NN 1_o
concentration NN 1_o
in IN N
the DT N
group NN N
taking VBG N
regular JJ 1_i
exercise NN 1_i
. . 1_i

Our PRP$ N
data NNS N
suggest VBP N
that IN N
mild JJ 1_i
regular JJ 1_i
physical JJ 1_i
exercise NN 1_i
favourably RB N
influences VBZ N
cholesterol NN N
distribution NN N
in IN N
serum NN 1_o
lipoproteins NNS 1_o
in IN N
healthy JJ 1_p
middle NN 1_p
aged VBN 1_p
men NNS 1_p
and CC N
may MD N
have VB N
beneficial JJ N
effects NNS N
on IN N
circulating VBG 1_o
metabolites NNS 1_o
of IN 1_o
arachidonic JJ 1_o
acid NN 1_o
. . 1_o

Prospective JJ N
study NN N
of IN N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
gonadotropin-releasing JJ 1_i
hormone NN 1_i
agonist NN 1_i
in IN N
an DT N
in IN 1_p
vitro JJ 1_p
fertilization NN 1_p
program NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
usefulness NN 1_o
of IN N
the DT N
ultrashort JJ N
regimen NNS N
of IN N
gonadotropin-releasing JJ 1_i
hormone NN 1_i
agonist NN 1_i
( ( 1_i
GnRH-a NNP 1_i
) ) 1_i
in IN N
ovulation NN N
induction NN N
in IN N
an DT N
in IN 1_p
vitro JJ 1_p
fertilization NN 1_p
( ( 1_p
IVF NNP 1_p
) ) 1_p
program NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
GnRH-a NNP 1_i
. . 1_i

SETTING NN N
Aberdeen NNP 1_p
Assisted NNP 1_p
Reproduction NNP 1_p
Unit NNP 1_p
. . 1_p

PATIENTS NNP N
Forty-eight JJ 1_p
patients NNS 1_p
having VBG 1_p
IVF NNP 1_p
for IN 1_p
the DT 1_p
first JJ 1_p
time NN 1_p
were VBD N
randomized VBN N
between IN N
the DT N
two CD N
protocols NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Response NNP 1_o
to TO 1_o
ovarian JJ 1_o
stimulation NN 1_o
and CC 1_o
occurrence NN 1_o
of IN 1_o
spontaneous JJ 1_o
luteinizing VBG 1_o
hormone NN 1_o
( ( 1_o
LH NNP 1_o
) ) 1_o
surges VBZ 1_o
. . 1_o

RESULTS NNP N
In IN N
ovulation NN 1_o
induction NN 1_o
, , 1_o
fertilization NN 1_o
, , 1_o
and CC 1_o
pregnancy NN 1_o
rates NNS 1_o
the DT N
ultrashort JJ N
regimen NNS N
produces VBZ N
results NNS N
that WDT N
were VBD N
no DT N
different JJ N
to TO N
the DT N
short JJ N
regimen NNS N
but CC N
it PRP N
did VBD N
not RB N
always RB N
prevent VB N
an DT N
LH NNP 1_o
surge NN 1_o
. . 1_o

CONCLUSION VB N
The DT N
ultrashort JJ N
regimen NNS N
can MD N
be VB N
a DT N
useful JJ N
alternative NN N
for IN N
ovarian JJ 1_o
stimulation NN 1_o
of IN N
patients NNS 1_p
undergoing VBG 1_p
IVF NNP 1_p
. . 1_p

Epidemiology NN N
of IN N
stroke NN N
. . N

Importance NN N
of IN N
preventive JJ 1_o
pharmacological JJ 1_o
strategies NNS 1_o
in IN 1_i
elderly JJ 1_i
patients NNS 1_i
and CC N
associated JJ N
costs NNS N
. . N

Stroke NNP N
is VBZ N
a DT N
major JJ N
cause NN N
of IN N
death NN N
and CC N
disability NN N
in IN N
developed JJ N
countries NNS N
. . N

The DT N
incidence NN 1_o
of IN 1_o
stroke NN 1_o
increases NNS N
exponentially RB N
with IN N
age NN N
, , N
yet RB N
, , N
traditionally RB N
, , N
many JJ N
medical JJ N
practitioners NNS N
have VBP N
been VBN N
reluctant JJ N
to TO N
treat VB N
hypertension NN N
in IN 1_p
older JJR 1_p
patients NNS 1_p
. . 1_p

Since IN N
1991 CD N
, , N
the DT N
results NNS N
of IN N
3 CD N
major JJ N
trials NNS N
-- : N
the DT N
British JJ N
Medical NNP N
Research NNP N
Council NNP N
( ( N
MRC NNP N
) ) N
trial NN N
of IN N
treatment NN N
in IN N
older JJR N
adults NNS N
, , N
the DT N
Swedish JJ N
Trial NNP N
in IN N
Old NNP 1_p
Patients NNPS 1_p
with IN 1_p
Hypertension NNP 1_p
( ( N
STOP-Hypertension NNP N
) ) N
and CC N
the DT N
Systolic NNP N
Hypertension NNP N
in IN N
the DT N
Elderly JJ N
Program NNP N
( ( N
SHEP NNP N
) ) N
-- : N
have VBP N
conclusively RB N
established VBN N
the DT N
benefits NNS N
of IN N
treating VBG 1_i
older JJR 1_i
patients NNS 1_i
( ( 1_p
> JJ 1_p
60 CD 1_p
years NNS 1_p
) ) 1_p
with IN 1_p
both DT 1_p
diastolic JJ 1_p
and CC 1_p
isolated JJ 1_p
systolic JJ 1_p
hypertension NN 1_p
. . 1_p

International NNP N
guidelines NNS N
for IN N
the DT N
management NN N
of IN N
hypertension NN N
-- : N
including VBG N
the DT N
Fifth NNP N
Report NNP N
of IN N
the DT N
Joint NNP N
National NNP N
Committee NNP N
, , N
the DT N
1993 CD N
report NN N
of IN N
the DT N
World NNP N
Health NNP N
Organization NNP N
and CC N
the DT N
International NNP N
Society NNP N
of IN N
Hypertension NNP N
and CC N
the DT N
second JJ N
report NN N
of IN N
the DT N
British JJ N
Hypertension NNP N
Society NNP N
Working NNP N
Party NNP N
-- : N
have VBP N
all DT N
been VBN N
modified VBN N
to TO N
reflect VB N
the DT N
emerging VBG N
evidence NN N
concerning VBG N
the DT N
benefits NNS N
of IN N
treating VBG 1_i
older JJR 1_i
patients NNS 1_i
. . 1_i

Cost-effectiveness JJ 1_o
data NNS 1_o
are VBP N
similarly RB N
in IN N
accord NN N
with IN N
giving VBG N
high JJ N
priority NN N
to TO N
the DT N
treatment NN 1_i
of IN 1_i
older JJR 1_i
individuals NNS 1_i
with IN 1_p
hypertension NN 1_p
. . 1_p

A DT N
comparison NN N
of IN N
continuous JJ 1_i
femoral JJ 1_i
nerve NN 1_i
block NN 1_i
( ( 1_i
CFNB NNP 1_i
) ) 1_i
and CC N
continuous JJ 1_i
epidural JJ 1_i
infusion NN 1_i
( ( 1_i
CEI NNP 1_i
) ) 1_i
in IN N
postoperative JJ N
analgesia NN N
and CC N
knee NN N
rehabilitation NN N
after IN 1_p
total JJ 1_p
knee NN 1_p
arthroplasty NN 1_p
( ( 1_p
TKA NNP 1_p
) ) 1_p
. . 1_p

BACKGROUND NNP N
Postoperative NNP N
epidural JJ N
analgesia NN N
( ( N
EA NNP N
) ) N
and CC N
femoral JJ 1_i
nerve NN 1_i
block NN 1_i
( ( 1_i
FNB NNP 1_i
) ) 1_i
provided VBD N
effective JJ N
pain NN 1_o
relief NN 1_o
However RB N
, , N
EA NNP N
has VBZ N
common JJ N
side NN 1_o
effects NNS 1_o
such JJ N
as IN N
nausea NN 1_o
, , 1_o
vomiting VBG 1_o
, , 1_o
pruritus NN 1_o
, , 1_o
dizziness NN 1_o
, , 1_o
and CC 1_o
hypotension NN 1_o
. . 1_o

Some DT N
investigations NNS N
found VBD N
that IN N
those DT N
side JJ N
effects NNS N
were VBD N
less RBR N
in IN N
FNB NNP N
than IN N
in IN N
EA NNP N
. . N

However RB N
the DT N
analgesic JJ N
equivalent NN N
of IN N
both DT N
techniques NNS N
have VBP N
not RB N
been VBN N
confirmed VBN N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
compared VBN N
continuous JJ 1_i
epidural JJ 1_i
infusion NN 1_i
( ( 1_i
CEI NNP 1_i
) ) 1_i
with IN N
continuous JJ 1_i
femoral JJ 1_i
nerve NN 1_i
block NN 1_i
( ( 1_i
CFNB NNP 1_i
) ) 1_i
regarding VBG N
the DT N
postoperative JJ 1_o
analgesic JJ 1_o
efficacy NN 1_o
, , 1_o
side NN 1_o
effects NNS 1_o
, , 1_o
postoperative JJ 1_o
knee NN 1_o
rehabilitation NN 1_o
, , 1_o
and CC 1_o
hospital JJ 1_o
length NN 1_o
of IN 1_o
stay NN 1_o
( ( 1_o
LOS NNP 1_o
) ) 1_o
. . 1_o

MATERIAL NNP N
AND NNP N
METHOD NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
, , N
61 CD 1_p
ASA NNP 1_p
physical JJ 1_p
status NN 1_p
I-III NNP 1_p
patients NNS 1_p
scheduled VBN 1_p
for IN 1_p
elective JJ 1_p
unilateral JJ 1_p
total NN 1_p
knee NN 1_p
arthroplasty NN 1_p
( ( 1_p
TKA NNP 1_p
) ) 1_p
under IN 1_p
spinal JJ 1_p
anesthesia NN 1_p
( ( 1_p
SA NNP 1_p
) ) 1_p
participated VBD N
. . N

The DT N
patients NNS N
were VBD N
allocated VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
the DT N
ward NN N
, , N
patients NNS N
in IN N
Group NNP N
I PRP N
( ( 1_i
CEI NNP 1_i
) ) 1_i
were VBD N
maintained VBN N
by IN N
continuous JJ N
infusion NN N
of IN N
0.125 CD N
% NN N
levobupivacaine NN 1_i
with IN N
morphine JJ 1_i
0.0125 CD N
mg/ml NN N
( ( N
4 CD N
ml/hr NN N
) ) N
, , N
Group NNP N
II NNP N
( ( 1_i
CFNB NNP 1_i
) ) 1_i
were VBD N
maintained VBN N
by IN N
0.125 CD N
% NN N
levobupivacaine NN 1_i
( ( N
8 CD N
ml/hr NN N
) ) N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
CFNB NNP 1_i
group NN N
, , N
the DT N
VAS NNP 1_o
scores NNS 1_o
at IN N
PO6-12 NNP N
hr NN N
and CC N
tramadol NN 1_o
IV NNP 1_o
requirement NN 1_o
were VBD N
significantly RB N
greater JJR N
than IN N
the DT N
CEI NNP 1_i
group NN N
( ( N
VAS NNP N
: : N
PO6 NNP N
hr VBD N
p-value JJ N
= NN N
0.001 CD N
, , N
PO12 NNP N
hr VBD N
p-value JJ N
= NNP N
0.004 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
CEI NNP 1_i
group NN N
experienced VBD N
dizziness NN 1_o
, , 1_o
pruritus NN 1_o
, , 1_o
and CC 1_o
PONV NNP 1_o
more JJR N
than IN N
the DT N
CFNB NNP 1_i
group NN N
significantly RB N
. . N

Patient JJ 1_o
satisfaction NN 1_o
was VBD N
greater JJR N
with IN N
the DT N
CFNB NNP 1_i
group NN N
although IN N
postoperative JJ 1_o
knee NN 1_o
rehabilitation NN 1_o
and CC 1_o
the DT 1_o
hospital NN 1_o
LOS NNP 1_o
were VBD N
not RB N
different JJ N
. . N

CONCLUSION NNP N
CFNB NNP 1_i
represents VBZ N
the DT N
optimal JJ N
analgesia NN N
with IN N
fewer JJR N
side NN 1_o
effects NNS 1_o
and CC N
greater JJR N
patient NN 1_o
, , 1_o
satisfaction NN 1_o
. . 1_o

The DT N
rehabilitation NN 1_o
indices NNS 1_o
and CC 1_o
duration NN 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
are VBP N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

[ JJ N
Double-blind NNP N
placebo-controlled JJ 1_i
study NN N
of IN N
the DT N
effectiveness NN 1_o
and CC N
tolerability NN 1_o
of IN N
10 CD N
and CC N
30 CD N
mg NN N
ketorolac NN 1_i
tromethamine NN 1_i
suppositories NNS N
in IN N
post-cholecystectomy JJ N
pain NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN 1_o
and CC N
tolerability NN 1_o
of IN N
ketorolac NN 1_i
tromethamine NN 1_i
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
in IN N
comparison NN N
to TO N
placebo VB 1_i
, , N
after IN N
single JJ N
dose JJ N
administration NN N
in IN N
patients NNS 1_p
suffering VBG 1_p
from IN 1_p
post-operative JJ 1_p
pain NN 1_p
after IN 1_p
cholecystectomy NN 1_p
. . 1_p

DESIGN NNP N
Double-blind NNP N
, , N
randomized VBD N
, , N
controlled VBD N
study NN N
. . N

SETTING NNP N
Anaesthesia NNP N
Service NNP N
. . N

PATIENTS NNP N
99 CD 1_p
patients NNS 1_p
with IN 1_p
severe JJ 1_p
pain NN 1_p
following VBG 1_p
surgery NN 1_p
. . 1_p

INTERVENTIONS NNP N
Cholecystectomy NNP N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
analgesia JJ 1_o
activity NN 1_o
of IN N
ketorolac NN 1_i
tromethamine NN 1_i
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
were VBD N
evaluated VBN N
after IN N
single JJ N
dose JJ N
administration NN N
by IN N
assessing VBG 1_o
pain NN 1_o
intensity NN 1_o
and CC 1_o
pain NN 1_o
relief NN 1_o
using VBG N
a DT N
4 CD 1_o
point NN 1_o
scale NN 1_o
( ( 1_o
VRS NNP 1_o
) ) 1_o
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
overall JJ N
assessment NN N
of IN N
safety NN 1_o
and CC N
efficacy NN 1_o
were VBD N
recorded VBN N
by IN N
physician JJ N
and CC N
patient JJ N
. . N

The DT N
results NNS N
show VBP N
that IN N
in IN N
both DT N
active JJ N
groups NNS N
after IN N
30 CD N
' POS N
and CC N
until IN N
4 CD N
hours NNS N
, , N
pain VBP 1_o
intensity NN 1_o
decreased VBN N
significantly RB N
with IN N
respect NN N
to TO N
the DT N
baseline NN N
. . N

However RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
groups NNS N
of IN N
p NN N
< NN N
0.02 CD N
, , N
p NN N
< VBD N
0.01 CD N
and CC N
p VB N
< JJ N
0.05 CD N
was VBD N
found VBN N
in IN N
favour NN N
of IN N
the DT N
30 CD N
mg NN N
dose NN N
respectively RB N
at IN N
30 CD N
' '' N
, , N
6 CD N
and CC N
8 CD N
hours NNS N
after IN N
administration NN N
. . N

All PDT N
the DT N
patients NNS N
treated VBN N
with IN N
placebo JJ 1_i
suppositories NNS N
required VBN N
another DT N
rescue NN 1_o
analgesic JJ 1_o
drug NN 1_o
and CC N
withdrew NN N
from IN N
the DT N
trial NN N
. . N

Three CD N
patients NNS N
complained VBD N
adverse JJ 1_o
events NNS 1_o
not RB N
related VBN N
to TO N
treatment NN N
: : N
two CD N
on IN N
placebo NN 1_i
and CC N
one CD N
on IN N
ketorolac NN 1_i
10 CD N
mg NN N
. . N

The DT N
systemic JJ 1_o
and CC 1_o
local JJ 1_o
tolerability NN 1_o
of IN N
the DT N
drug NN N
was VBD N
good JJ N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
ketorolac $ 1_i
30 CD N
mg NN N
suppositories NNS N
are VBP N
effective JJ 1_o
in IN N
clinical JJ N
conditions NNS N
, , N
such JJ N
as IN N
after IN N
surgery NN N
, , N
in IN N
which WDT N
pain NN N
control NN N
must MD N
be VB N
achieved VBN N
within IN N
the DT N
shortest JJ N
time NN N
interval NN N
and CC N
maintained VBD N
or CC N
improved VBN N
by IN N
means NNS N
of IN N
a DT N
single JJ N
route NN N
of IN N
administration NN N
. . N

Amonafide NN 1_i
: : 1_i
An DT N
active JJ N
agent NN N
in IN N
the DT N
treatment NN N
of IN N
previously RB 1_p
untreated VBN 1_p
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
-- : 1_p
a DT 1_p
cancer NN N
and CC N
leukemia NN N
group NN N
B NNP N
study NN N
( ( N
CALGB NNP N
8642 CD N
) ) N
. . N

Amonafide NNP 1_i
is VBZ N
a DT N
new JJ N
imide JJ N
derivative NN N
of IN N
naphthalic JJ N
acid NN N
. . N

The DT N
drug NN N
had VBD N
demonstrated VBN N
significant JJ N
activity NN N
in IN N
preclinical JJ N
studies NNS N
and CC N
some DT N
activity NN N
in IN N
Phase NNP N
I PRP N
trials NNS N
. . N

The DT N
drug NN N
is VBZ N
extensively RB N
metabolized VBN N
and CC N
detected VBN N
in IN N
plasma NN N
and CC N
urine NN N
. . N

Its PRP$ N
toxicity NN N
has VBZ N
previously RB N
been VBN N
correlated VBN N
to TO N
the DT N
formation NN N
of IN N
an DT N
active JJ N
metabolite NN N
, , N
N-acetyl-amonafide NNP N
. . N

Amonafide NNP 1_i
was VBD N
chosen VBN N
for IN N
inclusion NN N
in IN N
the DT N
Cancer NNP N
and CC N
Leukemia NNP N
Group NNP N
B NNP N
( ( N
CALGB NNP N
) ) N
master NN N
metastatic JJ N
breast NN N
cancer NN N
protocol NN N
. . N

CALGB NNP N
8642 CD N
randomizes VBZ N
previously RB 1_p
untreated VBN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
either CC N
to TO N
one CD N
of IN N
several JJ N
Phase NNP N
II NNP N
agents NNS N
given VBN N
for IN N
up IN N
to TO N
four CD N
cycles NNS N
and CC N
then RB N
followed VBN N
by IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN 1_i
, , N
or CC N
to TO N
immediate VB N
treatment NN N
with IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN 1_i
. . 1_i

The DT N
end NN N
point NN N
of IN N
CALGB NNP N
8642 CD N
is VBZ N
to TO N
assess VB 1_o
the DT 1_o
difference NN 1_o
in IN 1_o
survival NN 1_o
, , 1_o
toxicity NN 1_o
, , 1_o
and CC 1_o
overall JJ 1_o
response NN 1_o
when WRB N
limited JJ N
exposure NN N
to TO N
Phase NNP N
II NNP N
agents NNS N
precedes VBZ N
standard JJ N
chemotherapy NN N
. . N

This DT N
report NN N
deals VBZ N
only RB N
with IN N
amonafide RB 1_i
as IN N
a DT N
Phase NNP N
II NNP N
agent NN N
. . N

Comparisons NNS N
with IN N
the DT N
cyclophosphamide-doxorubicin-5-fluorouracil JJ 1_i
arm NN N
will MD N
not RB N
be VB N
addressed VBN N
. . N

Patients NNS 1_p
had VBD 1_p
to TO 1_p
have VB 1_p
histologically RB 1_p
documented VBN 1_p
measurable JJ 1_p
breast NN 1_p
cancer NN 1_p
and CC 1_p
a DT 1_p
performance NN 1_p
status NN 1_p
of IN 1_p
0-1 NNP 1_p
. . 1_p

Patients NNS 1_p
could MD 1_p
not RB 1_p
have VB 1_p
had VBN 1_p
prior JJ 1_p
chemotherapy NN 1_p
for IN 1_p
metastatic JJ 1_p
disease NN 1_p
. . 1_p

Prior NNP 1_p
adjuvant JJ 1_p
chemotherapy NN 1_p
was VBD 1_p
permitted VBN 1_p
. . 1_p

Patients NNS 1_p
could MD 1_p
not RB 1_p
have VB 1_p
visceral JJ 1_p
crisis NN 1_p
. . 1_p

Amonafide NNP 1_i
was VBD N
given VBN N
at IN N
300 CD N
mg/m2/day JJ N
i.v NN N
. . N

for IN N
5 CD N
days NNS N
, , N
and CC N
repeated VBD N
at IN N
21-day JJ N
intervals NNS N
for IN N
a DT N
maximum NN N
of IN N
four CD N
cycles NNS N
. . N

Escalation NN N
and CC N
reduction NN N
in IN N
dose NN N
was VBD N
mandated VBN N
dependent NN N
on IN N
hematotoxicity NN N
or CC N
lack NN N
thereof NN N
. . N

Toxicity NN 1_o
was VBD N
primarily RB N
hematological JJ 1_o
and CC N
bimodal NN N
: : N
32 CD N
% NN N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
leukopenia NN 1_o
and CC N
24 CD N
% NN N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
thrombocytopenia NN 1_o
; : 1_o
22 CD N
% NN N
had VBD N
no DT N
leukopenia NN 1_o
and CC N
44 CD N
% NN N
had VBD N
no DT N
thrombocytopenia NN 1_o
. . 1_o

The DT N
response NN 1_o
rate NN 1_o
was VBD N
18 CD N
% NN N
, , N
including VBG N
one CD N
complete JJ N
response NN N
. . N

When WRB N
response NN N
was VBD N
analyzed VBN N
by IN N
hematological JJ 1_o
toxicity NN 1_o
, , N
there EX N
was VBD N
a DT N
35.7 CD N
% NN N
response NN N
if IN N
patients NNS N
had VBD N
leukopenia VBN 1_o
grade NN N
3/4 CD N
( ( N
versus IN N
8.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.08 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
50 CD N
% NN N
response NN N
if IN N
patients NNS N
had VBD N
thrombocytopenia VBN 1_o
grade NN N
3/4 CD N
( ( N
versus IN N
7.1 CD N
% NN N
, , N
P NNP N
= NNP N
< NNP N
0.01 CD N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
amonafide NN 1_i
is VBZ N
somewhat RB N
active JJ N
in IN N
previously RB N
untreated VBN N
breast NN N
cancer NN N
patients NNS N
. . N

There EX N
may MD N
be VB N
a DT N
steep JJ N
dose-response NN N
curve NN N
, , N
based VBN N
on IN N
the DT N
significant JJ N
correlation NN N
between IN N
myelosuppression NN N
and CC N
response NN N
. . N

Rates NNS 1_o
of IN 1_o
responses NNS 1_o
in IN N
patients NNS N
adequately RB N
dosed VBN N
( ( N
i.e. FW N
, , N
with IN N
significant JJ N
hematotoxicity NN 1_o
) ) 1_o
with IN N
amonafide NN 1_i
ranged VBD N
from IN N
35 CD N
to TO N
50 CD N
% NN N
. . N

Further JJ N
studies NNS N
will MD N
incorporate VB N
individualized JJ N
dosing NN N
based VBN N
on IN N
pretreatment NN N
acetylator NN N
phenotyping NN N
. . N

Effect NN N
of IN N
simvastatin NN 1_i
on IN N
hemostasis NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
isolated JJ 1_p
hypertriglyceridemia NN 1_p
. . 1_p

BACKGROUNDS/AIMS NNP N
Elevated NNP N
triglyceride NN N
levels NNS N
seem VBP N
to TO N
predispose VB N
to TO N
the DT N
earlier JJR N
development NN N
and CC N
accelerated JJ N
progression NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

In IN N
our PRP$ N
study NN N
, , N
we PRP N
assessed VBD N
for IN N
the DT N
first JJ N
time NN N
whether IN N
simvastatin JJ 1_i
treatment NN N
affects NNS N
coagulation NN 1_o
and CC 1_o
fibrinolysis NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
isolated JJ 1_p
hypertriglyceridemia NN 1_p
. . 1_p

METHODS NNP N
The DT N
study NN N
included VBD N
39 CD 1_p
patients NNS 1_p
with IN 1_p
elevated JJ 1_p
triglyceride NN 1_p
levels NNS 1_p
and CC 1_p
peripheral JJ 1_p
artery NN 1_p
sclerosis NN 1_p
, , N
treated VBD N
for IN N
90 CD N
days NNS N
with IN N
either DT N
simvastatin NN 1_i
( ( N
40 CD N
mg NNS N
daily RB N
) ) N
or CC N
placebo NN 1_i
. . 1_i

Plasma NNP 1_o
lipids NNS 1_o
, , 1_o
glucose JJ 1_o
homeostasis NN 1_o
markers NNS 1_o
and CC 1_o
hemostasic JJ 1_o
variables NNS 1_o
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
Simvastatin NNP 1_i
, , N
but CC N
not RB N
placebo VB 1_i
, , N
administered VBN N
to TO N
these DT N
patients NNS N
reduced VBD N
plasma JJ 1_o
levels/activity NN 1_o
of IN 1_o
fibrinogen NN 1_o
( ( N
from IN N
3.5 CD N
± $ N
0.4 CD N
to TO N
2.8 CD N
± NNS N
0.3 CD N
g/l NN N
, , N
p NN N
< NNP N
0.01 CD 1_o
) ) 1_o
, , 1_o
factor NN 1_o
VII NNP 1_o
( ( N
from IN N
144.2 CD N
± $ N
16.9 CD N
to TO N
112.5 CD N
± NNS N
14.0 CD N
% NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
and CC 1_o
plasminogen JJ 1_o
activator NN 1_o
inhibitor-1 NN 1_o
( ( N
from IN N
76.9 CD N
± $ N
13.5 CD N
to TO N
50.2 CD N
± NNS N
9.2 CD N
ng/ml NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
, , N
without IN N
a DT N
significant JJ N
reduction NN 1_o
in IN 1_o
von NN 1_o
Willebrand NNP 1_o
factor NN 1_o
levels NNS 1_o
, , N
and CC N
tended VBD N
to TO N
prolong VB 1_o
the DT 1_o
prothrombin NN 1_o
and CC 1_o
partial JJ 1_o
thromboplastin NN 1_o
times NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP 1_i
that IN 1_i
statin NN 1_i
treatment NN N
produces VBZ N
a DT N
multidirectional JJ N
effect NN 1_o
on IN 1_o
coagulation NN 1_o
and CC 1_o
fibrinolysis NN 1_o
in IN 1_p
patients NNS 1_p
with IN 1_p
isolated JJ 1_p
hypertriglyceridemia NN 1_p
and CC N
that IN N
this DT N
treatment NN N
may MD N
bring VB N
some DT N
benefits NNS 1_p
to TO 1_p
patients NNS 1_p
with IN 1_p
elevated JJ 1_p
triglyceride NN 1_p
levels NNS 1_p
. . N

A DT N
pilot NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
progressive JJ 1_i
muscle NN 1_i
relaxation NN 1_i
training NN 1_i
of IN N
patients NNS 1_p
after IN 1_p
stoma NN 1_p
surgery NN 1_p
. . 1_p

Eighteen JJ 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
undergone JJ 1_p
stoma NN 1_p
surgery NN 1_p
were VBD N
assessed VBN N
with IN N
respect NN N
to TO N
their PRP$ N
anxiety NN 1_o
level NN 1_o
and CC 1_o
self-reported JJ 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
( ( 1_o
QoL NNP 1_o
) ) 1_o
on IN N
three CD N
occasions NNS N
; : N
namely RB N
, , N
immediately RB N
after IN N
surgery NN N
, , N
5 CD N
weeks NNS N
after IN N
surgery NN N
, , N
and CC N
10 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
randomised VBN N
into IN N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
an DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
. . N

A DT N
20-min JJ N
set NN N
of IN N
audiotaped JJ N
instructions NNS N
on IN N
progressive JJ 1_i
muscle NN 1_i
relaxation NN 1_i
training NN 1_i
( ( 1_i
PMRT NNP 1_i
) ) 1_i
was VBD N
given VBN N
to TO N
the DT N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
for IN N
home NN N
practice NN N
. . N

Assessment NNP N
instructions NNS N
included VBD N
the DT N
Chinese JJ 1_o
State-Trait NNP 1_o
Anxiety NNP 1_o
Inventory NNP 1_o
( ( 1_o
C-STAI NNP 1_o
) ) 1_o
, , 1_o
the DT 1_o
Quality NN 1_o
of IN 1_o
Life NNP 1_o
Index NNP 1_o
for IN 1_o
Colostomy NNP 1_o
( ( 1_o
QoL-Colostomy NNP 1_o
) ) 1_o
and CC 1_o
the DT 1_o
Hong NNP 1_o
Kong NNP 1_o
Chinese JJ 1_o
version NN 1_o
of IN 1_o
the DT 1_o
World NNP 1_o
Health NNP 1_o
Organisation NNP 1_o
Quality NNP 1_o
of IN 1_o
Life NNP 1_o
Scale NNP 1_o
( ( 1_o
WHOQoL NNP 1_o
) ) 1_o
. . 1_o

Results NNS N
indicated VBD N
that IN N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
both DT N
the DT N
C-STAI NNP 1_o
score NN 1_o
( ( N
F NNP N
= NNP N
4.66 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
the DT N
WHOQoL NNP 1_o
score NN 1_o
( ( N
F NNP N
= NNP N
4.74 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
. . N

Among IN N
the DT N
domains NNS N
of IN N
WHOQoL NNP 1_o
, , N
a DT N
significant JJ N
difference NN N
was VBD N
shown VBN N
in IN N
physical JJ N
health/independence NN N
and CC N
general JJ N
perception NN N
of IN N
QoL NNP 1_o
, , N
with IN N
the DT N
experimental JJ N
group NN N
demonstrating VBG N
better JJR N
functioning NN N
. . N

For IN N
the DT N
QoL-Colostomy NNP 1_o
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
PMRT NNP 1_i
could MD N
enhance VB N
quality NN 1_o
of IN 1_o
life NN 1_o
and CC N
decrease NN N
state NN N
anxiety NN 1_o
in IN N
patients NNS 1_p
after IN 1_p
stoma NN 1_p
surgery NN 1_p
. . 1_p

A DT N
controlled VBN N
study NN N
of IN N
psychiatric JJ 1_i
hospital NN 1_i
versus NN N
community NN 1_i
treatment NN 1_i
- : N
the DT N
effect NN 1_o
on IN 1_o
relatives NNS 1_o
. . 1_o

One CD 1_p
hundred CD 1_p
and CC 1_p
twenty JJ 1_p
patients NNS 1_p
presenting VBG 1_p
at IN 1_p
Macquarie NNP 1_p
Hospital NNP 1_p
for IN 1_p
admission NN 1_p
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
control NN N
group NN N
patients NNS N
received VBD N
standard JJ 1_i
hospital NN 1_i
care NN 1_i
and CC 1_i
follow-up NN 1_i
. . 1_i

The DT N
project NN N
group NN N
patients NNS N
were VBD N
not RB N
admitted VBN N
if IN N
this DT N
could MD N
be VB N
avoided VBN N
; : N
instead RB N
they PRP N
were VBD N
taken VBN 1_i
back RB 1_i
to TO 1_i
the DT 1_i
community NN 1_i
by IN N
the DT N
project NN N
team NN N
who WP N
provided VBD N
them PRP N
and CC N
their PRP$ N
relatives NNS N
with IN N
comprehensive JJ N
, , N
assertive JJ N
and CC N
prolonged JJ N
follow-up JJ 1_i
treatment NN 1_i
backed VBN N
by IN N
a DT N
24-hour JJ N
crisis NN N
service NN N
. . N

The DT N
majority NN N
( ( N
63 CD N
% NN N
) ) N
of IN N
the DT N
project NN N
group NN N
had VBD N
no DT N
admission NN 1_o
during IN N
the DT N
10 CD N
month NN N
study NN N
period NN N
. . N

Initially RB N
, , N
the DT N
burden NN 1_o
on IN 1_o
the DT 1_o
relatives NNS 1_o
of IN N
the DT N
project NN N
group NN N
was VBD N
higher JJR N
, , N
but CC N
by IN N
one CD N
month NN N
it PRP N
was VBD N
somewhat RB N
lower JJR N
and CC N
by IN N
four CD N
months NNS N
it PRP N
was VBD N
significantly RB N
lower JJR N
than IN N
the DT N
burden NN 1_o
on IN 1_o
the DT 1_o
control NN 1_o
group NN 1_o
relatives VBZ 1_o
. . 1_o

Relatives NNS N
of IN N
the DT N
project NN N
group NN N
patients NNS N
were VBD N
significantly RB N
more RBR N
satisfied JJ 1_o
with IN N
the DT N
treatment NN N
than IN N
control NN N
group NN N
relatives VBZ N
. . N

It PRP N
is VBZ N
clearly RB N
feasible JJ N
to TO N
treat VB N
most JJS N
psychiatric JJ 1_p
patients NNS 1_p
in IN N
the DT N
community NN N
without IN N
increasing VBG N
the DT N
burden NN 1_o
on IN 1_o
their PRP$ 1_o
relatives NNS 1_o
. . 1_o

Cancer NNP 1_i
information NN 1_i
and CC N
anxiety NN 1_o
: : 1_o
applying VBG N
the DT N
extended JJ N
parallel NN N
process NN N
model NN N
. . N

There EX N
is VBZ N
concern NN N
that IN N
public JJ 1_i
education NN 1_i
about IN 1_i
testicular JJ 1_i
cancer NN 1_i
( ( 1_i
TC NNP 1_i
) ) 1_i
may MD N
cause VB N
unnecessary JJ N
anxiety NN 1_o
. . 1_o

Psychological JJ N
theory NN N
suggests VBZ N
that IN N
if IN N
threat NN N
( ( N
eg JJ N
, , N
TC NNP N
) ) N
information NN N
is VBZ N
accompanied VBN N
with IN N
threat NN 1_i
control NN 1_i
strategies NNS 1_i
( ( 1_i
eg NN 1_i
, , 1_i
testicular JJ 1_i
self-examination NN 1_i
; : 1_i
TSE NNP 1_i
) ) 1_i
anxiety NN 1_o
is VBZ N
less RBR N
likely JJ N
. . N

Male JJ 1_p
students NNS 1_p
( ( 1_p
N=443 NNP 1_p
) ) 1_p
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
TC NNP 1_i
or CC N
TC NNP 1_i
+TSE NNP 1_i
information NN N
group NN N
or CC N
a DT N
no DT N
information NN N
control NN N
group NN N
, , N
and CC N
assessed VBD N
at IN N
three CD N
time NN N
points NNS N
. . N

Anxiety NN 1_o
levels NNS 1_o
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
and CC N
exposure NN N
to TO N
TC+TSE NNP 1_i
resulted VBD N
in IN N
greater JJR N
perceived JJ 1_o
message NN 1_o
benefit NN 1_o
, , N
increased VBN N
intention NN 1_o
to TO 1_o
self-examine NN 1_o
and CC N
lower JJR N
message NN 1_o
denigration NN 1_o
. . 1_o

This DT N
suggests VBZ N
TC NNP 1_i
information NN N
is VBZ N
not RB N
anxiogenic JJ 1_o
, , N
but CC N
inclusion NN N
of IN N
TSE NNP 1_i
information NN N
may MD N
improve VB N
acceptance NN 1_o
of IN 1_o
disease NN 1_o
awareness NN 1_o
information NN 1_o
. . 1_o

Conscious JJ N
analgesia/sedation NN N
with IN N
remifentanil NN 1_i
and CC N
propofol NN 1_i
versus NN N
total JJ N
intravenous JJ N
anesthesia NN N
with IN N
fentanyl NN 1_i
, , 1_i
midazolam NN 1_i
, , N
and CC N
propofol NN 1_i
for IN N
outpatient JJ 1_p
colonoscopy NN 1_p
. . 1_p

BACKGROUND NNP N
This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
, , N
for IN 1_p
colonoscopy NN 1_p
, , N
analgesia/sedation NN N
with IN N
remifentanil NN 1_i
and CC N
propofol NN 1_i
might MD N
be VB N
more RBR N
effective JJ 1_o
compared VBN N
with IN N
anesthesia NN N
by IN N
intravenous JJ N
administration NN N
of IN N
midazolam NN 1_i
, , 1_i
fentanyl NN 1_i
, , N
and CC N
propofol NN 1_i
. . 1_i

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
100 CD 1_p
adult NN 1_p
patients NNS 1_p
received VBD N
either RB N
conscious JJ N
analgesia/sedation NN N
( ( N
Sedation NNP N
group NN N
) ) N
or CC N
total JJ N
intravenous JJ N
anesthesia NN N
( ( N
TIVA NNP N
group NN N
) ) N
. . N

Analgesia/sedation NN N
was VBD N
achieved VBN N
by IN N
infusion NN N
of IN N
remifentanil NN 1_i
( ( N
0.20 CD N
to TO N
0.25 CD N
microg/kg/min NN N
) ) N
and CC N
propofol NN 1_i
in IN N
titrated JJ N
doses NNS N
. . N

TIVA NNP N
was VBD N
induced VBN N
by IN N
intravenous JJ N
administration NN N
of IN N
fentanyl NN 1_i
( ( N
2 CD N
microg/kg NN N
) ) N
, , N
midazolam FW 1_i
( ( N
0.05 CD N
mg/kg NN N
) ) N
and CC N
propofol NN 1_i
( ( N
dosage NN N
titrated VBN N
) ) N
. . N

Cardiorespiratory JJ 1_o
parameters NNS 1_o
and CC 1_o
bispectral JJ 1_o
index NN 1_o
were VBD 1_o
monitored VBN 1_o
and CC 1_o
recorded VBN 1_o
. . 1_o

The DT 1_o
quality NN 1_o
of IN 1_o
the DT 1_o
analgesia NN 1_o
was VBD 1_o
assessed VBN 1_o
with IN 1_o
a DT 1_o
Numerical JJ 1_o
Pain NN 1_o
Rating NNP 1_o
Scale NNP 1_o
( ( 1_o
NRS NNP 1_o
) ) 1_o
; : 1_o
recovery NN 1_o
level NN 1_o
and CC 1_o
return NN 1_o
of IN 1_o
psychomotor NN 1_o
efficiency NN 1_o
were VBD 1_o
evaluated VBN 1_o
with IN 1_o
, , 1_o
respectively RB 1_o
, , 1_o
the DT 1_o
Aldrete NNP 1_o
scale NN 1_o
and CC 1_o
a DT 1_o
Modified NNP 1_o
Post NNP 1_o
Anesthesia NNP 1_o
Discharge NNP 1_o
Scoring NNP 1_o
( ( 1_o
MPADS NNP 1_o
) ) 1_o
system NN 1_o
. . 1_o

RESULTS VB N
Both DT N
groups NNS N
of IN N
50 CD N
patients NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
demographic VB N
data NNS N
, , N
initial JJ N
parameters NNS N
, , N
and CC N
duration NN N
of IN N
colonoscopy NN N
. . N

All DT N
patients NNS N
in IN N
the DT N
TIVA NNP N
group NN N
found VBD N
the DT N
colonoscopy NN N
painless NN N
( ( 1_o
NRS NNP 1_o
score RB N
0 CD N
) ) N
. . N

In IN N
the DT N
Sedation NNP N
group NN N
, , N
the DT N
average JJ N
pain NN 1_o
intensity NN 1_o
score NN 1_o
was VBD N
0.4 CD N
( ( N
0.8 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
marked JJ N
difference NN N
between IN N
the DT N
Sedation NNP N
and CC N
TIVA NNP N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
time NN N
from IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
until IN N
the DT N
maximum JJ 1_o
MPADS NNP 1_o
score NN 1_o
was VBD N
reached VBN N
: : N
respectively RB N
, , N
-6.9 NNP N
( ( N
4.0 CD N
) ) N
versus NN N
25.7 CD N
( ( N
8.4 CD N
) ) N
minutes NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
the DT N
TIVA NNP N
group NN N
, , N
changes NNS N
in IN N
mean JJ 1_o
arterial JJ 1_o
pressure NN 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
and CC 1_o
signs NNS 1_o
of IN 1_o
respiratory NN 1_o
depression NN 1_o
were VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Combined NNP N
administration NN N
of IN N
remifentanil NN 1_i
and CC N
propofol NN 1_i
for IN N
colonoscopy NN 1_p
provides VBZ N
sufficient JJ 1_o
analgesia NN 1_o
, , N
satisfactory JJ N
hemodynamic JJ 1_o
stability NN 1_o
, , N
minor JJ N
respiratory NN 1_o
depression NN 1_o
, , N
and CC N
rapid JJ 1_o
recovery NN 1_o
, , N
and CC N
allows VBZ N
patients NNS N
to TO N
be VB N
discharged VBN N
approximately RB N
15 CD N
minutes NNS N
after IN N
the DT N
procedure NN N
. . N

Virtual JJ 1_i
reality NN 1_i
hypnosis NN 1_i
for IN N
pain NN N
associated VBN N
with IN N
recovery NN N
from IN N
physical JJ 1_p
trauma NN 1_p
. . 1_p

Pain VB N
following VBG N
traumatic JJ N
injuries NNS N
is VBZ N
common JJ N
, , N
can MD N
impair VB N
injury JJ N
recovery NN N
and CC N
is VBZ N
often RB N
inadequately RB N
treated VBN N
. . N

In IN N
particular JJ N
, , N
the DT N
role NN N
of IN N
adjunctive JJ N
nonpharmacologic JJ N
analgesic JJ N
techniques NNS N
is VBZ N
unclear JJ N
. . N

The DT N
authors NNS N
report VBP N
a DT N
randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
21 CD 1_p
hospitalized JJ 1_p
trauma NN 1_p
patients NNS 1_p
to TO N
assess VB N
the DT N
analgesic JJ 1_o
efficacy NN 1_o
of IN N
virtual JJ 1_i
reality NN 1_i
hypnosis NN 1_i
( ( 1_i
VRH NNP 1_i
) ) 1_i
-hypnotic JJ 1_i
induction NN 1_i
and CC N
analgesic JJ 1_o
suggestion NN 1_o
delivered VBN N
by IN N
customized JJ N
virtual JJ N
reality NN N
( ( N
VR NNP N
) ) N
hardware/software NN N
. . N

Subjective JJ 1_o
pain NN 1_o
ratings NNS 1_o
were VBD N
obtained VBN N
immediately RB N
and CC N
8 CD N
hours NNS N
after IN N
VRH NNP 1_i
( ( N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
standard VB N
analgesic JJ N
care NN N
) ) N
and CC N
compared VBN N
to TO N
both DT N
adjunctive JJ N
VR NNP 1_i
without IN 1_i
hypnosis NN 1_i
and CC N
standard JJ 1_i
care NN 1_i
alone RB N
. . N

VRH JJ 1_i
patients NNS N
reported VBD N
less RBR N
pain JJ 1_o
intensity NN 1_o
and CC N
less JJR N
pain NN 1_o
unpleasantness JJ 1_o
compared VBN N
to TO N
control VB N
groups NNS N
. . N

These DT N
preliminary JJ N
findings NNS N
suggest VBP N
that IN N
VRH NNP 1_i
analgesia NN N
is VBZ N
a DT N
novel JJ N
technology NN N
worthy NN N
of IN N
further JJ N
study NN N
, , N
both DT N
to TO N
improve VB N
pain NN 1_o
management NN 1_o
and CC N
to TO N
increase VB N
availability NN N
of IN N
hypnotic JJ N
analgesia NN N
to TO N
populations NNS N
without IN N
access NN N
to TO N
therapist-provided JJ N
hypnosis NN N
and CC N
suggestion NN N
. . N

The DT N
treatment NN N
of IN N
asthma NN 1_p
in IN 1_p
adults NNS 1_p
using VBG N
sodium NN 1_i
cromoglycate NN 1_i
pressurized VBN N
aerosol NN N
: : N
a DT N
double-blind NN N
controlled VBN N
trial NN N
. . N

Sodium NN 1_i
cromoglycate NN 1_i
formulated VBN N
as IN N
a DT N
pressurized JJ N
aerosol NN N
( ( N
2 CD N
mg RB N
4-times JJ N
daily JJ N
) ) N
and CC N
placebo NN 1_i
were VBD N
compared VBN N
in IN N
31 CD 1_p
adult NN 1_p
asthmatic JJ 1_p
patients NNS 1_p
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
lasting VBG N
12 CD N
weeks NNS N
. . N

Sodium NNP 1_i
cromoglycate NN 1_i
was VBD N
superior JJ N
to TO N
placebo VB 1_i
in IN N
improving VBG N
breathlessness NN 1_o
at IN 1_o
rest NN 1_o
( ( N
p IN N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
breathlessness NN 1_o
on IN 1_o
exertion NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
the DT N
quality NN 1_o
of IN 1_o
sleep NN 1_o
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
and CC N
also RB N
in IN N
improving VBG N
the DT N
morning NN 1_o
peak NN 1_o
expiratory NN 1_o
flow NN 1_o
rate NN 1_o
value NN 1_o
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Both CC N
the DT N
patients NNS N
' POS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
the DT N
clinicians NNS N
' POS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
treatment NN 1_o
opinions NNS 1_o
, , N
and CC N
their PRP$ N
treatment NN 1_o
preferences NNS 1_o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
favoured VBD N
sodium NN 1_i
cromoglycate NN 1_i
. . 1_i

Moreover RB N
, , N
usage NN N
of IN N
bronchodilators NNS N
( ( N
theophylline NN N
and CC N
aerosol JJ N
beta-stimulants NNS N
combined VBN N
) ) N
declined VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
during IN N
sodium NN 1_i
cromoglycate NN 1_i
treatment NN N
compared VBN N
to TO N
placebo VB 1_i
. . 1_i

No DT N
side-effects NNS 1_o
were VBD N
reported VBN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
sodium NN 1_i
cromoglycate NN 1_i
delivered VBN N
by IN N
pressurized JJ N
aerosol NN N
was VBD N
significantly RB N
superior JJ 1_o
to TO N
placebo VB 1_i
, , N
not RB N
only RB N
in IN N
improving VBG N
asthmatic JJ 1_o
symptoms NNS 1_o
, , N
but CC N
also RB N
in IN N
reducing VBG N
the DT N
amount NN N
of IN N
concomitant JJ N
bronchodilator NN 1_o
therapy NN 1_o
required VBN 1_o
. . 1_o

Raising VBG N
high-density NN 1_o
lipoprotein NN 1_o
in IN N
humans NNS N
through IN N
inhibition NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
: : N
an DT N
initial JJ N
multidose NN N
study NN N
of IN N
torcetrapib NN 1_i
. . 1_i

OBJECTIVE CC N
The DT N
ability NN N
of IN N
the DT N
potent NN N
cholesteryl NN 1_i
ester NN 1_i
transfer NN 1_i
protein NN 1_i
( ( 1_i
CETP NNP 1_i
) ) 1_i
inhibitor NN 1_i
torcetrapib NN 1_i
( ( 1_i
CP-529,414 NNP 1_i
) ) 1_i
to TO N
raise VB N
high-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
( ( 1_o
HDL-C NNP 1_o
) ) 1_o
levels NNS 1_o
in IN N
healthy JJ 1_p
young JJ 1_p
subjects NNS 1_p
was VBD N
tested VBN N
in IN N
this DT N
initial JJ N
phase NN N
1 CD N
multidose NN N
study NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Five NNP 1_p
groups NNS 1_p
of IN 1_p
8 CD 1_p
subjects NNS 1_p
each DT 1_p
were VBD N
randomized VBN N
to TO N
placebo VB 1_i
( ( N
n=2 NN N
) ) N
or CC N
torcetrapib NN 1_i
( ( N
n=6 JJ N
) ) N
at IN N
10 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
120 CD N
mg NNS N
daily RB N
and CC N
120 CD N
mg NN N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Torcetrapib NN 1_i
was VBD N
well RB N
tolerated VBN N
, , N
with IN N
all DT N
treated JJ N
subjects NNS N
completing VBG N
the DT N
study NN N
. . N

The DT N
correlation NN N
of IN N
plasma JJ 1_o
drug NN 1_o
levels NNS 1_o
with IN N
inhibition NN N
( ( N
EC50=43 NNP N
nM RB N
) ) N
was VBD N
as IN N
expected VBN N
based VBN N
on IN N
in IN N
vitro JJ N
potency NN N
( ( N
IC50 NNP N
approximately RB N
50 CD N
nM NNS N
) ) N
, , N
and CC N
increases VBZ N
in IN N
CETP NNP N
mass NN N
were VBD N
consistent JJ N
with IN N
the DT N
proposed VBN N
mechanism NN N
of IN N
inhibition NN N
. . N

CETP NNP N
inhibition NN N
increased VBD N
with IN N
escalating VBG N
dose NN N
, , N
leading VBG N
to TO N
elevations NNS N
of IN N
HDL-C NNP 1_o
of IN N
16 CD N
% NN N
to TO N
91 CD N
% NN N
. . N

Total JJ 1_o
plasma JJ 1_o
cholesterol NN 1_o
did VBD N
not RB N
change VB N
significantly RB N
because IN N
of IN N
a DT N
reduction NN N
in IN N
nonHDL-C JJ 1_o
, , N
including VBG N
a DT N
21 CD N
% NN N
to TO N
42 CD N
% NN N
lowering NN N
of IN N
low-density NN 1_o
lipoprotein NN 1_o
cholesterol NN 1_o
at IN N
the DT N
higher JJR N
doses NNS N
. . N

Apolipoprotein NNP 1_o
A-I NNP 1_o
and CC 1_o
E NNP 1_o
were VBD N
elevated VBN N
27 CD N
% NN N
and CC N
66 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
apoB NN 1_o
was VBD N
reduced VBN N
26 CD N
% NN N
with IN N
120 CD N
mg NNS N
twice RB N
daily RB N
. . N

Cholesteryl NNP 1_o
ester NN 1_o
content NN 1_o
decreased VBN N
and CC N
triglyceride VB 1_o
increased VBN N
in IN N
the DT N
nonHDL JJ 1_o
plasma NN N
fraction NN N
, , N
with IN N
contrasting VBG N
changes NNS N
occurring VBG N
in IN N
HDL NNP 1_o
. . 1_o

CONCLUSIONS NNP N
These DT N
effects NNS N
of IN N
CETP NNP N
inhibition NN N
resemble VBP N
those DT N
observed VBN N
in IN N
partial JJ N
CETP NNP N
deficiency NN N
. . N

This DT N
work NN N
serves VBZ N
as IN N
a DT N
prelude NN N
to TO N
further JJ N
studies NNS N
in IN N
subjects NNS N
with IN N
low JJ N
HDL NNP N
, , N
or CC N
combinations NNS N
of IN N
dyslipidemia NN N
, , N
in IN N
assessing VBG N
the DT N
role NN N
of IN N
CETP NNP N
in IN N
atherosclerosis NN N
. . N

Effects NNS N
of IN N
individualized JJ 1_i
breast NN 1_i
cancer NN 1_i
risk NN 1_o
counseling NN 1_o
: : 1_o
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Studies NNPS N
have VBP N
shown VBN N
that IN N
a DT N
majority NN N
of IN N
women NNS N
with IN N
a DT N
family NN N
history NN N
of IN N
breast NN N
cancer NN N
have VBP N
exaggerated VBN N
perceptions NNS N
of IN N
their PRP$ N
own JJ N
risk NN 1_o
of IN N
this DT N
disease NN N
and CC N
experience NN N
excessive JJ N
anxiety NN N
. . N

In IN N
response NN N
to TO N
the DT N
need NN N
to TO N
communicate VB N
more JJR N
accurate JJ N
risk NN N
information NN N
to TO N
these DT N
women NNS N
, , N
specialized JJ N
programs NNS N
for IN N
breast NN N
cancer NN N
risk NN 1_o
counseling VBG N
have VBP N
been VBN N
initiated VBN N
in IN N
medical JJ N
centers NNS N
across IN N
the DT N
United NNP N
States NNPS N
. . N

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
standardized JJ N
protocol NN N
for IN N
individualized JJ 1_i
breast NN 1_i
cancer NN 1_i
risk NN 1_o
counseling VBG 1_i
on IN N
comprehension NN N
of IN N
personal JJ N
risk NN N
among IN N
first-degree JJ 1_p
relatives NNS 1_p
of IN 1_p
index NN 1_p
breast NN 1_p
cancer NN 1_p
patients NNS 1_p
and CC N
2 CD N
) ) N
to TO N
identify VB N
women NNS N
most RBS N
and CC N
least JJS N
likely JJ N
to TO N
benefit VB 1_o
from IN N
such JJ N
counseling NN 1_i
. . 1_i

METHODS NNP N
This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
individualized VBN 1_i
breast NN 1_i
cancer NN 1_i
risk NN 1_o
counseling VBG 1_i
to TO N
general JJ 1_i
health NN 1_i
counseling NN 1_i
( ( 1_i
control NN 1_i
) ) 1_i
. . 1_i

We PRP N
studied VBD N
200 CD 1_p
women NNS 1_p
aged VBN 1_p
35 CD 1_p
years NNS 1_p
and CC 1_p
older JJR 1_p
who WP 1_p
had VBD 1_p
a DT 1_p
family NN 1_p
history NN 1_p
of IN 1_p
breast NN 1_p
cancer NN 1_p
in IN 1_p
a DT 1_p
first-degree JJ 1_p
relative NN 1_p
. . 1_p

Women NNS 1_p
with IN 1_p
a DT 1_p
personal JJ 1_p
history NN 1_p
of IN 1_p
cancer NN 1_p
were VBD 1_p
excluded VBN 1_p
. . 1_p

Risk NNP 1_o
comprehension NN 1_o
was VBD N
assessed VBN N
as IN N
the DT N
concordance NN 1_o
between IN 1_o
perceived VBN 1_o
" NNP 1_o
subjective JJ 1_o
" NN 1_o
lifetime NN 1_o
breast NN 1_o
cancer NN 1_o
risk NN 1_o
and CC 1_o
estimated VBN 1_o
" NNP 1_o
objective JJ 1_o
" NN 1_o
lifetime NN 1_o
risk NN 1_o
. . 1_o

RESULTS VB N
The DT N
results NNS N
of IN N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
women NNS N
who WP N
received VBD N
risk NN 1_o
counseling NN 1_i
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
improve VB N
their PRP$ N
risk NN 1_o
comprehension NN 1_o
, , N
compared VBN N
with IN N
women NNS N
in IN N
the DT N
control NN N
condition NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
= VBZ N
3.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.3-9.5 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

However RB N
, , N
in IN N
both DT N
groups NNS N
, , N
about RB N
two CD N
thirds NNS N
of IN N
women NNS N
continued VBN N
to TO N
overestimate VB N
their PRP$ N
lifetime NN 1_o
risks NNS 1_o
substantially RB N
following VBG N
counseling VBG 1_i
. . 1_i

Examination NN N
of IN N
subjects NNS N
by IN N
treatment NN N
interaction NN N
effects NNS N
indicated VBD N
that IN N
risk NN 1_o
counseling VBG 1_i
did VBD N
not RB N
produce VB N
improved JJ N
comprehension NN 1_o
among IN N
the DT N
large JJ N
proportion NN N
of IN N
women NNS N
who WP N
had VBD N
high JJ N
levels NNS N
of IN N
anxious JJ N
preoccupation NN N
with IN N
breast NN N
cancer NN N
at IN N
base NN N
line NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
white JJ N
women NNS N
were VBD N
less RBR N
likely JJ N
to TO N
benefit VB N
than IN N
African-American JJ N
women NNS N
( ( N
OR NNP N
= VBZ N
0.34 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.11-0.99 NN N
; : N
P NNP N
= NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Efforts NNPS N
to TO N
counsel NN N
women NNS N
about IN N
their PRP$ N
breast NN N
cancer NN N
risks NNS 1_o
are VBP N
not RB N
likely JJ N
to TO N
be VB N
effective JJ 1_o
unless IN N
their PRP$ N
breast NN N
cancer NN N
anxieties NNS N
are VBP N
also RB N
addressed VBN N
. . N

IMPLICATIONS NNP N
Attention NNP N
to TO N
the DT N
psychological JJ N
aspects NNS N
of IN N
breast NN N
cancer NN N
risk NN 1_o
will MD N
be VB N
critical JJ N
in IN N
the DT N
development NN N
of IN N
risk-counseling JJ 1_o
programs NNS 1_i
that WDT N
incorporate VBP N
testing VBG N
for IN N
the DT N
recently RB N
cloned VBN N
breast NN N
cancer NN N
susceptibility NN N
gene NN N
, , N
BRCA1 NNP N
( ( N
and CC N
BRCA2 NNP N
when WRB N
that DT N
gene NN N
has VBZ N
also RB N
been VBN N
cloned VBN N
) ) N
. . N

[ RB N
Intravenous JJ N
treatment NN N
of IN N
postpartum NN 1_p
anemia NN 1_p
with IN N
trivalent JJ 1_i
ferrum NN 1_i
preparation NN 1_i
] NNP 1_i
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
assess VB N
the DT N
effectivity NN 1_o
and CC N
safeness NN 1_o
of IN N
intravenous JJ N
treatment NN N
of IN N
pospartal JJ 1_p
anemia NN 1_p
with IN N
trivalent JJ 1_i
ferrum NN 1_i
preparation NN 1_i
. . 1_i

TYPE NNP N
OF IN N
THE NNP N
STUDY NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
2nd CD N
Medical NNP N
Faculty NNP N
Charles NNP N
University NNP N
and CC N
Teaching NNP N
Hospital NNP N
Motol NNP N
, , N
Prague NNP 1_p
, , N
and CC N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
1st CD N
Medical NNP N
Faculty NNP N
and CC N
Teaching NNP N
Hospital NNP N
Bulovka NNP N
, , N
Prague NNP 1_p
. . 1_p

METHODS NNP N
500 CD N
mg NN N
of IN N
sacharose JJ 1_i
ferric JJ 1_i
oxide NN 1_i
( ( 1_i
Venofer NNP 1_i
) ) 1_i
was VBD N
intravenously RB N
administered VBN N
in IN N
two CD N
days NNS N
regimen NNS N
to TO N
50 CD 1_p
women NNS 1_p
with IN 1_p
clinical JJ 1_p
and CC 1_p
lab JJ 1_p
signs NNS 1_p
of IN 1_p
postpartal JJ 1_p
anemia NN 1_p
. . 1_p

The DT N
effect NN N
of IN N
administered JJ N
drug NN N
was VBD N
determined VBN N
by IN N
comparsion NN N
of IN N
values NNS 1_o
of IN 1_o
red JJ 1_o
blood NN 1_o
count NN 1_o
recovered VBD N
before IN N
the DT N
treatment NN N
, , N
2nd CD N
or CC N
3rd CD N
day NN N
post NN N
administration NN N
and CC N
two CD N
weeks NNS N
later RB N
. . N

The DT N
serum NN 1_o
values NNS 1_o
of IN 1_o
soluble JJ 1_o
transferrin NN 1_o
receptors NNS 1_o
and CC 1_o
ferritin NNS 1_o
were VBD N
observed VBN N
as IN N
markers NNS N
of IN N
iron NN 1_o
cell NN 1_o
saturation NN 1_o
and CC 1_o
body NN 1_o
iron NN 1_o
reserves NNS 1_o
, , N
too RB N
. . N

Integral JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
monitoring NN N
of IN N
adverse JJ 1_o
events NNS 1_o
during IN N
the DT N
treatment NN N
. . N

RESULTS NNP N
Venofer NNP 1_i
came VBD N
in IN N
sight NN N
as IN N
effective JJ 1_o
drug NN N
in IN N
the DT N
treatment NN N
of IN N
pospartal JJ 1_p
anemia NN 1_p
and CC N
could MD N
become VB N
as IN N
the DT N
alternative NN N
to TO N
blood VB N
transfusion NN N
in IN N
mid-severe JJ N
cases NNS N
. . N

It PRP N
should MD N
be VB N
emphasized VBN N
that IN N
we PRP N
have VBP N
not RB N
encountered VBN N
any DT N
serious JJ 1_o
adverse JJ 1_o
event NN 1_o
with IN N
intravenous JJ N
trivalent NN 1_i
saccharose VBD 1_i
ferric JJ 1_i
oxide JJ 1_i
treatment NN N
. . N

Cryoprobe NNP 1_i
biopsy NN 1_i
increases VBZ N
the DT N
diagnostic JJ 1_o
yield NN 1_o
in IN N
endobronchial JJ 1_p
tumor NN 1_p
lesions NNS 1_p
. . 1_p

OBJECTIVE NNP N
Forceps NNP N
biopsy NN N
is VBZ N
the DT N
standard JJ N
method NN N
to TO N
obtain VB N
specimens NNS N
in IN N
endoscopically RB N
visible JJ N
lesions NNS N
. . N

It PRP N
is VBZ N
common JJ N
to TO N
combine VB N
forceps NNS N
biopsy VB N
with IN N
cytology NN N
methods NNS N
to TO N
increase VB N
the DT N
diagnostic JJ 1_o
yield NN 1_o
. . 1_o

Although IN N
the DT N
flexible JJ N
cryoprobe NN 1_i
has VBZ N
been VBN N
established VBN N
for IN N
bronchoscopic NN N
interventions NNS N
in IN N
malignant JJ N
stenosis NN N
, , N
the DT N
obtained JJ N
biopsies NNS N
, , N
called VBN N
" NN 1_i
cryobiopsies NNS 1_i
, , N
" NNS N
have VBP N
not RB N
been VBN N
investigated VBN N
in IN N
a DT N
large JJ N
cohort NN N
of IN N
patients NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
feasibility NN N
study NN N
was VBD N
to TO N
prospectively RB N
evaluate VB N
the DT N
diagnostic JJ 1_o
yield NN 1_o
and CC N
safety NN 1_o
of IN N
cryobiopsy NN 1_i
and CC N
forceps JJ 1_i
biopsy NN 1_i
. . 1_i

METHODS NNP N
During IN N
a DT N
6-year JJ N
period NN N
, , N
296 CD 1_p
patients NNS 1_p
with IN 1_p
visible JJ 1_p
endoluminal JJ 1_p
tumor NN 1_p
lesions NNS 1_p
were VBD 1_p
included VBN 1_p
in IN N
the DT N
study NN N
at IN N
the DT N
bronchoscopy NN 1_p
unit NN 1_p
of IN 1_p
a DT 1_p
university NN 1_p
hospital NN 1_p
. . 1_p

In IN N
the DT N
first JJ N
consecutively RB N
conducted VBN N
55 CD N
cases NNS N
, , N
both DT N
techniques NNS N
, , N
forceps NNS 1_i
biopsy NN 1_i
and CC 1_i
cryobiopsy NN 1_i
, , N
were VBD N
applied VBN N
simultaneously RB N
. . N

Pathologic NNP 1_o
and CC 1_o
quantitative JJ 1_o
image NN 1_o
analyses NNS 1_o
were VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
size NN 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
the DT 1_o
obtained VBN 1_o
specimens NNS 1_o
. . 1_o

We PRP N
evaluated VBD N
the DT N
safety NN 1_o
and CC N
diagnostic JJ 1_o
yield NN 1_o
to TO N
describe VB N
the DT N
feasibility NN 1_o
of IN N
cryobiopsy NN 1_i
. . 1_i

RESULTS NNP N
Comparative JJ N
analysis NN N
of IN N
the DT N
first JJ N
conducted VBN N
and CC N
randomly RB N
assigned VBD N
55 CD N
cases NNS N
revealed VBD N
a DT N
significantly RB N
higher RBR N
diagnostic JJ 1_o
yield NN 1_o
for IN N
cryobiopsy NN 1_i
compared VBN N
with IN N
forceps NNS 1_i
biopsy NNS 1_i
( ( N
89.1 CD N
% NN N
vs JJ N
65.5 CD N
% NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
this DT N
cohort NN N
, , N
quantitative JJ 1_o
image NN 1_o
analysis NN 1_o
showed VBD N
significantly RB N
larger JJR N
biopsies NNS N
regarding VBG N
size NN 1_o
and CC N
artifact-free JJ N
tissue NN N
sections NNS N
for IN N
cryobiopsy NN 1_i
compared VBN N
with IN N
forceps NNS 1_i
biopsy NN 1_i
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
overall JJ 1_o
diagnostic JJ 1_o
yield NN 1_o
of IN N
cryobiopsy NN 1_i
was VBD N
89.5 CD N
% NN N
. . N

Mild NNP N
bleeding VBG 1_o
occurred VBD N
in IN N
11 CD N
cases NNS N
( ( N
3.7 CD N
% NN N
) ) N
, , N
moderate JJ N
bleeding NN 1_o
occurred VBD N
in IN N
3 CD N
cases NNS N
( ( N
1.0 CD N
% NN N
) ) N
, , N
and CC N
severe JJ N
bleeding NN 1_o
occurred VBD N
in IN N
1 CD N
case NN N
( ( N
0.3 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Cryobiopsy NNP 1_i
is VBZ N
safe JJ 1_o
and CC N
increases VBZ N
the DT N
diagnostic JJ 1_o
yield NN 1_o
in IN N
endobronchial JJ N
tumor NN N
lesions NNS N
. . N

The DT N
method NN N
also RB N
is VBZ N
feasible JJ 1_o
under IN N
routine JJ N
conditions NNS N
. . N

Review NN N
of IN N
the DT N
Multicenter NNP N
Trial NNP N
Committee NNP N
report NN N
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
on IN N
the DT N
prophylaxis NN 1_o
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
. . N

The DT N
etiology NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
( ( N
DVT NNP N
) ) N
is VBZ N
thought VBN N
to TO N
be VB N
due JJ N
to TO N
a DT N
combination NN N
of IN N
factors NNS N
including VBG N
stasis NN 1_o
, , 1_o
a DT 1_o
hypercoagulable JJ 1_o
state NN 1_o
and CC 1_o
venous JJ 1_o
endothelial JJ 1_o
damage NN 1_o
. . 1_o

Methods NNS N
of IN N
prophylaxis NN N
are VBP N
directed VBN N
toward IN N
correcting VBG N
one CD N
or CC N
more JJR N
of IN N
these DT N
pathologic JJ N
events NNS N
. . N

Methods NNS N
counteracting VBG N
more JJR N
than IN N
one CD N
of IN N
these DT N
factors NNS N
can MD N
be VB N
expected VBN N
to TO N
be VB N
even RB N
more RBR N
effective JJ N
. . N

The DT N
combination NN N
of IN N
dihydroergotamine NN 1_i
( ( 1_i
DHE NNP 1_i
) ) 1_i
and CC N
heparin NN 1_i
was VBD N
anticipated VBN N
to TO N
minimize VB N
stasis NN 1_o
and CC 1_o
the DT 1_o
hypercoagulable JJ 1_o
state NN 1_o
respectively RB N
. . N

Based VBN N
upon IN N
current JJ N
experimental JJ N
evidence NN N
and CC N
current JJ N
theory NN N
, , N
an DT N
additional JJ N
benefit NN N
might MD N
include VB N
minimizing VBG N
venous JJ N
endothelial JJ N
injury NN N
by IN N
controlling VBG N
venomotor NN N
tone NN N
. . N

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
was VBD N
designed VBN N
and CC N
performed VBN N
in IN N
the DT N
United NNP 1_p
States NNPS 1_p
evaluating VBG N
the DT N
prophylactic JJ 1_o
efficacy NN 1_o
of IN N
DHE NNP 1_i
0.5 CD N
mg NN N
plus CC N
heparin JJ 1_i
5000 CD N
U NNP N
, , N
DHE NNP 1_i
0.5 CD N
mg NN N
plus CC N
heparin JJ 1_i
2500 CD N
U NNP N
, , N
heparin NN 1_i
5000 CD N
U NNP N
, , N
and CC N
DHE NNP 1_i
0.5 CD N
mg NN N
versus NN N
placebo NN 1_i
. . 1_i

General NNP 1_p
surgical JJ 1_p
patients NNS 1_p
including VBG 1_p
those DT 1_p
undergoing JJ 1_p
noncardiac JJ 1_p
thoracic NN 1_p
and CC 1_p
pelvic JJ 1_p
operations NNS 1_p
who WP 1_p
were VBD 1_p
identified VBN 1_p
at IN 1_p
moderate JJ 1_p
to TO 1_p
high JJ 1_p
risk NN 1_p
for IN 1_p
postop JJ 1_p
DVT NNP 1_p
were VBD 1_p
included VBN 1_p
. . 1_p

Study NNP N
medications NNS N
were VBD N
injected VBN N
subcutaneously RB N
two CD N
hours NNS N
preoperatively RB N
and CC N
every DT N
12 CD N
hours NNS N
postoperatively RB N
for IN N
5-7 JJ N
days NNS N
or CC N
until IN N
the DT N
125I-fibrinogen-uptake JJ N
test NN N
( ( N
RFUT NNP N
) ) N
became VBD N
positive JJ N
. . N

Eight NNP 1_p
hundred VBD 1_p
and CC 1_p
eighty JJ 1_p
eight CD 1_p
patients NNS 1_p
were VBD 1_p
entered VBN 1_p
into IN 1_p
this DT 1_p
trial NN 1_p
and CC 1_p
744 CD 1_p
( ( 1_p
85 CD 1_p
% NN 1_p
) ) 1_p
completed VBD 1_p
the DT 1_p
study NN 1_p
. . 1_p

Results NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
DHE/Hep NNP 1_i
5000 CD N
compared VBN N
to TO N
placebo VB 1_i
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
compared VBN N
to TO N
other JJ N
active JJ N
agents NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

None NN N
of IN N
the DT N
other JJ N
active JJ N
agents NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
prophylactic JJ N
benefit NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
Compensation NN 1_o
in IN N
intergroup JJ N
relations NNS N
: : N
an DT N
investigation NN N
of IN N
its PRP$ N
structural JJ N
and CC N
strategic JJ N
foundations NNS N
. . N

Recent JJ N
work NN N
in IN N
intergroup JJ N
relations NNS N
stresses VBZ N
the DT N
role NN N
of IN N
two CD N
fundamental JJ N
dimensions NNS N
, , N
competence NN N
and CC N
warmth NN N
, , N
which WDT N
organize VBP N
the DT N
perception NN N
of IN N
social JJ N
groups NNS N
. . N

A DT N
pattern NN N
often RB N
encountered VBN N
in IN N
people NNS N
's POS N
ratings NNS N
is VBZ N
one CD N
of IN N
compensation NN N
in IN N
that DT N
a DT N
group NN N
that WDT N
is VBZ N
evaluated VBN N
higher JJR N
than IN N
another DT N
group NN N
on IN N
one CD N
of IN N
the DT N
two CD N
fundamental JJ N
dimensions NNS N
is VBZ N
also RB N
judged VBN N
lower JJR N
on IN N
the DT N
other JJ N
fundamental JJ N
dimension NN N
. . N

Based VBN N
on IN N
Social NNP N
Identity NNP N
Theory NNP N
, , N
the DT N
present JJ N
work NN N
extends VBZ N
previous JJ N
research NN N
on IN N
compensation NN N
by IN N
examining VBG N
boundary JJ 1_o
conditions NNS 1_o
as RB N
well RB N
as IN N
underlying VBG 1_o
psychological JJ 1_o
processes NNS 1_o
. . 1_o

Two CD N
studies NNS N
involving VBG N
experimental JJ N
and CC N
correlational JJ N
evidence NN N
, , N
minimal JJ N
and CC N
real JJ N
groups NNS N
, , N
and CC N
different JJ N
kinds NNS N
of IN N
conflict NN N
, , N
reveal NN N
that IN N
compensation NN N
is VBZ N
more RBR N
likely JJ N
when WRB N
the DT N
groups NNS N
are VBP N
in IN N
asymmetrical JJ N
relation NN N
and CC N
share NN N
a DT N
cooperative JJ N
view NN N
of IN N
the DT N
intergroup NN N
setting NN N
. . N

Our PRP$ N
data NNS N
also RB N
suggest VBP N
that IN N
, , N
among IN N
members NNS N
of IN N
low JJ N
status NN N
groups NNS N
, , N
compensation NN N
is VBZ N
associated VBN N
with IN N
social JJ 1_o
creativity NN 1_o
. . 1_o

In IN N
contrast NN N
, , N
and CC N
in IN N
line NN N
with IN N
the DT N
'noblesse NNP N
oblige NN N
' '' N
effect NN N
, , N
members NNS N
of IN N
the DT N
high JJ N
status NN N
group NN N
would MD N
seem VB N
to TO N
rely VB N
on IN N
compensation NN N
as IN N
a DT N
means NN N
to TO N
appear VB N
non-discriminatory JJ N
. . N

Teacher DT N
and CC N
child JJ N
predictors NNS N
of IN N
achieving VBG N
IEP NNP N
goals NNS N
of IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
. . 1_p

It PRP N
is VBZ N
encouraging VBG N
that IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
show VBP N
a DT N
strong JJ N
response NN N
to TO N
early JJ N
intervention NN N
, , N
yet RB N
more JJR N
research NN N
is VBZ N
needed VBN N
for IN N
understanding VBG N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
specialized JJ N
programs NNS N
. . N

Treatment NNP 1_o
predictor NN 1_o
variables NNS 1_o
from IN N
47 CD 1_p
teachers NNS 1_p
and CC 1_p
children NNS 1_p
who WP N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
COMPASS NNP 1_i
intervention NN 1_i
( ( N
Ruble JJ N
et NN N
al NN N
. . N

in IN N
The DT 1_i
collaborative JJ 1_i
model NN 1_i
for IN 1_i
promoting VBG 1_i
competence NN 1_i
and CC 1_i
success NN 1_i
for IN N
students NNS N
with IN N
ASD NNP N
. . N

Springer NNP N
, , N
New NNP N
York NNP N
, , N
2012a CD N
) ) N
were VBD N
analyzed VBN N
. . N

Predictors NNS 1_o
evaluated VBD N
against IN N
child NN N
IEP NNP N
goal NN N
attainment NN N
included VBD N
child NN 1_o
, , 1_o
teacher NN 1_o
, , 1_o
intervention NN 1_o
practice NN 1_o
, , 1_o
and CC 1_o
implementation NN 1_o
practice NN 1_o
variables NNS 1_o
based VBN 1_o
on IN 1_o
an DT 1_o
implementation NN 1_o
science NN 1_o
framework NN 1_o
( ( N
Dunst NNP N
and CC N
Trivette NNP N
in IN N
J NNP N
Soc NNP N
Sci NNP N
8:143-148 CD N
, , N
2012 CD N
) ) N
. . N

Findings NNS N
revealed VBD N
one CD N
child NN N
( ( N
engagement NN N
) ) N
, , N
one CD N
teacher NN N
( ( N
exhaustion NN N
) ) N
, , N
two CD N
intervention NN 1_o
quality NN 1_o
( ( 1_o
IEP NNP 1_o
quality NN 1_o
for IN 1_o
targeted VBN 1_o
and CC 1_o
not RB 1_o
targeted JJ 1_o
elements NNS 1_o
) ) 1_o
, , N
and CC N
no DT N
implementation NN 1_o
quality NN 1_o
variables NNS 1_o
accounted VBD N
for IN N
variance NN N
in IN N
child NN N
outcomes NNS N
when WRB N
analyzed VBN N
separately RB N
. . N

When WRB N
the DT N
four CD N
significant JJ N
variables NNS N
were VBD N
compared VBN N
against IN N
each DT N
other JJ N
in IN N
a DT N
single JJ N
regression NN N
analysis NN N
, , N
IEP NNP N
quality NN N
accounted VBD N
for IN N
one CD N
quarter NN N
of IN N
the DT N
variance NN N
in IN N
child NN N
outcomes NNS N
. . N

Vibrotactile NNP 1_p
-- : 1_p
auditory JJ 1_p
interactions NNS 1_p
are VBP N
post-perceptual JJ N
. . N

Vibrotactile NNP 1_i
stimuli NN 1_i
can MD N
elicit VB N
compelling VBG 1_o
auditory JJ 1_o
sensations NNS 1_o
, , N
even RB N
when WRB N
sound NN N
energy NN N
levels NNS N
are VBP N
minimal JJ N
and CC N
undetectable JJ N
. . N

It PRP N
has VBZ N
previously RB N
been VBN N
shown VBN N
that IN N
subjects NNS N
judge VBP N
auditory JJ 1_o
tones NNS 1_o
embedded VBN N
in IN N
white JJ N
noise NN N
to TO N
be VB N
louder VBN N
when WRB N
they PRP N
are VBP N
accompanied VBN N
by IN N
a DT N
vibrotactile JJ 1_i
stimulus NN 1_i
of IN N
the DT N
same JJ N
frequency NN N
. . N

A DT N
first JJ N
experiment NN N
replicated VBN N
this DT N
result NN N
at IN N
four CD N
different JJ N
levels NNS N
of IN N
auditory JJ 1_o
stimulation NN 1_o
( ( 1_o
no DT 1_o
tone NN 1_o
, , 1_o
tone NN 1_o
at IN 1_o
detection NN 1_o
threshold NN 1_o
, , 1_o
tone NN 1_o
at IN 1_o
5 CD 1_o
dB NNS 1_o
above IN 1_o
threshold NN 1_o
, , 1_o
and CC 1_o
tone NN 1_o
at IN 1_o
10 CD 1_o
dB NNS 1_o
above IN 1_o
threshold NN 1_o
) ) 1_o
. . 1_o

The DT N
presence NN N
of IN N
a DT N
vibrotactile JJ 1_i
stimulus NN 1_i
induced VBD N
an DT N
increase NN N
in IN N
the DT N
perceived JJ N
loudness NN N
of IN N
auditory NN 1_o
tones NNS 1_o
at IN N
three CD N
of IN N
the DT N
four CD N
values NNS N
in IN N
this DT N
range NN N
. . N

In IN N
two CD N
further JJ N
experiments NNS N
, , N
a DT N
2-interval JJ N
forced-choice JJ N
procedure NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
nature NN 1_o
of IN 1_o
this DT 1_o
cross-modal JJ 1_o
interaction NN 1_o
. . 1_o

Subjects NNS N
were VBD N
biased VBN N
when WRB N
vibrotaction NN 1_i
was VBD N
applied VBN N
in IN N
one CD N
interval NN N
, , N
but CC N
applying VBG N
vibrotaction NN 1_i
in IN N
both DT N
intervals NNS N
produced VBD N
performance NN N
comparable JJ N
to TO N
conditions NNS N
without IN N
vibrotactile NN 1_i
stimuli NN 1_i
. . 1_i

This DT N
demonstrates VBZ N
that IN N
vibrotaction NN 1_i
is VBZ N
sometimes RB N
ignored VBN N
when WRB N
judging VBG N
the DT N
presence NN N
of IN N
an DT N
auditory JJ 1_o
tone NN 1_o
. . 1_o

Hence NNP N
the DT N
interaction NN N
between IN N
vibrotaction NN 1_i
and CC N
audition NN N
does VBZ N
not RB N
appear VB N
to TO N
occur VB N
at IN N
an DT N
early JJ N
perceptual JJ N
level NN N
. . N

Effects NNS N
of IN N
Saccharomyces NNP 1_i
boulardii NN 1_i
in IN N
children NNS 1_p
with IN 1_p
acute JJ 1_p
diarrhoea NN 1_p
. . 1_p

AIM NNP N
Certain NNP N
probiotic JJ N
agents NNS N
, , N
e.g NN N
. . N

Lactobacillus CC N
GG NNP N
, , N
have VBP N
shown VBN N
efficacy NN N
in IN N
clinical JJ N
trials NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ 1_p
childhood NN 1_p
diarrhoea NN 1_p
, , N
but CC N
few JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
Saccharomyces NNP 1_i
boulardii NN 1_i
. . 1_i

We PRP N
evaluated VBD N
the DT N
effect NN 1_o
of IN N
S. NNP 1_i
boulardii NN 1_i
in IN N
children NNS 1_p
with IN 1_p
acute JJ 1_p
diarrhoea NN 1_p
. . 1_p

METHODS NNP N
Two CD 1_p
hundred VBD 1_p
children NNS 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
S. NNP 1_i
boulardii NN 1_i
in IN N
a DT N
granulated JJ N
form NN N
in IN N
a DT N
daily JJ N
dose NN N
of IN N
250 CD N
mg NN N
( ( 1_i
S. NNP 1_i
boulardii NNP 1_i
group NN N
) ) N
or CC N
placebo NN 1_i
( ( 1_i
placebo JJ 1_i
group NN N
) ) N
for IN N
5 CD N
d. JJ N
Clinical NNP N
and CC N
demographic JJ N
characteristics NNS N
on IN N
admission NN N
were VBD N
similar JJ N
between IN N
the DT N
study NN N
groups NNS N
. . N

RESULTS VB N
The DT N
medians NNS N
of IN N
the DT N
average JJ 1_o
stool NN 1_o
frequency NN 1_o
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
S. NNP 1_i
boulardii NN 1_i
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
duration NN 1_o
of IN 1_o
diarrhoea NN 1_o
significantly RB N
reduced VBN N
in IN N
the DT N
S. NNP 1_i
boulardii NN 1_i
group NN N
compared VBN N
with IN N
the DT N
placebo NN 1_i
group NN N
( ( N
4.7 CD N
vs RB N
5.5 CD N
d NN N
, , N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
effect NN 1_o
of IN N
S. NNP 1_i
boulardii NN 1_i
on IN N
watery NN N
diarrhoea NN N
became VBD N
apparent JJ N
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
duration NN 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
was VBD N
shorter JJR N
in IN N
the DT N
S. NNP 1_i
boulardii NN 1_i
group NN N
than IN N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
2.9 CD N
vs RB N
3.9 CD N
d NN N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Four CD N
children NNS N
from IN N
the DT N
placebo NN 1_i
group NN N
versus VBD N
only RB N
one CD N
child NN N
from IN N
the DT N
S. NNP 1_i
boulardii NN 1_i
group NN N
had VBD N
persisting VBG N
diarrhoea NN N
. . N

CONCLUSION VB N
The DT N
placebo-controlled JJ N
study NN N
suggested VBD N
that IN N
S. NNP 1_i
boulardii VBP 1_i
significantly RB N
reduced VBN N
the DT N
duration NN 1_o
of IN 1_o
acute JJ 1_o
diarrhoea NN 1_o
and CC 1_o
the DT 1_o
duration NN 1_o
of IN 1_o
hospital NN 1_o
stay NN 1_o
. . 1_o

S. NNP 1_i
boulardii NN 1_i
seems VBZ N
to TO N
be VB N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
amelioration NN N
of IN N
the DT N
course NN N
of IN N
acute JJ 1_p
diarrhoea NN 1_p
in IN 1_p
children NNS 1_p
when WRB N
used VBN N
therapeutically RB N
. . N

In IN N
school-aged JJ 1_p
children NNS 1_p
a DT N
combination NN N
of IN N
galacto-oligosaccharides NNS 1_i
and CC 1_i
Lactobacillus NNP 1_i
GG NNP 1_i
increases VBZ N
bifidobacteria RB 1_o
more JJR N
than IN N
Lactobacillus NNP 1_i
GG NNP 1_i
on IN N
its PRP$ N
own JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
combination NN N
of IN N
Lactobacillus NNP 1_i
GG NNP 1_i
( ( 1_i
LGG NNP 1_i
) ) 1_i
and CC 1_i
galacto-oligosaccharides NNS 1_i
( ( 1_i
GOS NNP 1_i
) ) 1_i
with IN N
LGG NNP 1_i
on IN N
its PRP$ N
own JJ N
, , N
and CC N
their PRP$ N
effects NNS N
on IN N
the DT N
intestinal JJ 1_o
microbiota NN 1_o
in IN N
school-aged JJ 1_p
children NNS 1_p
. . 1_p

The DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
crossover NN N
study NN N
comprised VBD N
30 CD 1_p
healthy JJ 1_p
children NNS 1_p
. . 1_p

There EX N
were VBD N
two CD N
3-week JJ N
study NN N
periods NNS N
with IN N
a DT N
4-week JJ N
wash-out JJ N
period NN N
in IN N
between IN N
. . N

The DT N
children NNS N
ingested VBD N
daily RB N
65 CD N
ml NN N
of IN N
milk-based JJ N
fruit NN N
juice NN N
containing VBG N
either CC N
LGG NNP 1_i
alone RB N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
CFU NNP N
) ) N
or CC N
LGG NNP 1_i
plus CC N
2 CD N
g NN N
of IN N
GOS NNP 1_i
. . 1_i

Symptom NNP 1_o
diaries NNS N
were VBD N
filled VBN N
during IN N
the DT N
study NN N
periods NNS N
. . N

Fecal JJ 1_o
samples NNS 1_o
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
both DT N
study NN N
periods NNS N
. . N

At IN N
the DT N
end NN N
of IN N
both DT N
study NN N
periods NNS N
, , N
the DT N
amount NN 1_o
of IN 1_o
bifidobacteria NN 1_o
was VBD N
significantly RB N
greater JJR N
after IN N
the DT N
ingestion NN N
of IN N
LGG NNP 1_i
+ NNP 1_i
GOS NNP 1_i
compared VBN N
with IN N
LGG NNP 1_i
alone RB N
( ( N
geometric JJ N
mean VBP N
9.33 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
vs. FW N
4.28 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
CFU/g NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
amount NN N
of IN N
lactobacilli NN 1_o
or CC N
LGG NNP 1_i
, , N
nor CC N
did VBD N
gastrointestinal JJ 1_o
symptoms NNS 1_o
, , 1_o
defecation NN 1_o
frequency NN 1_o
, , 1_o
consistency NN 1_o
of IN 1_o
stools NNS 1_o
or CC 1_o
ease NN 1_o
of IN 1_o
defecation NN 1_o
differ NN N
between IN N
the DT N
two CD N
study NN N
periods NNS N
. . N

Ingestion NN N
of IN N
LGG NNP 1_i
combined VBD N
with IN N
2 CD N
g NN N
of IN N
GOS NNP 1_i
increased VBD N
the DT N
bifidobacteria NN 1_o
more JJR N
than IN N
LGG NNP 1_i
on IN N
its PRP$ N
own JJ N
and CC N
thus RB N
GOS NNP 1_i
clearly RB N
has VBZ N
a DT N
prebiotic JJ 1_o
effect NN 1_o
in IN N
children NNS N
. . N

The DT N
children NNS N
tolerated VBN 1_o
well RB N
a DT N
daily JJ N
intake NN N
of IN N
2 CD N
g NN N
of IN N
GOS NNP 1_i
. . 1_i

The DT N
effect NN 1_o
of IN N
tunnelling VBG 1_i
on IN N
epidural JJ N
catheter NN N
migration NN N
. . N

A DT N
prospective JJ N
, , N
randomised VBD N
study NN N
of IN N
82 CD 1_p
patients NNS 1_p
having VBG 1_p
postoperative JJ 1_p
epidural JJ 1_p
analgesia NN 1_p
was VBD N
performed VBN N
to TO N
determine VB N
whether IN N
the DT N
tunnelling NN 1_i
of IN N
an DT N
epidural JJ N
catheter NN N
influences VBZ N
its PRP$ N
migration NN 1_o
. . 1_o

Tunnelling NN 1_i
of IN N
the DT N
catheter NN N
subcutaneously RB N
for IN N
a DT N
distance NN N
of IN N
5 CD N
cm NN N
reduced VBD N
the DT N
incidence NN 1_o
of IN 1_o
inward JJ 1_o
migration NN 1_o
of IN N
1 CD N
cm NN N
or CC N
more JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
compared VBN N
to TO N
a DT N
standard JJ N
method NN N
of IN N
fixation NN N
with IN N
a DT N
transparent JJ N
adhesive JJ N
dressing NN N
. . N

This DT N
effect NN N
was VBD N
more RBR N
marked JJ N
if IN N
the DT N
epidural JJ N
catheter NN N
was VBD N
sited VBN N
in IN N
the DT N
thoracic NN N
rather RB N
than IN N
the DT N
lumbar JJ N
area NN N
. . N

Sixty CD N
two CD N
percent NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
of IN N
tunnelled JJ 1_i
catheters NNS 1_i
remained VBD N
within IN N
0.5 CD N
cm NNS N
of IN N
their PRP$ N
original JJ N
position NN 1_o
compared VBN N
to TO N
38 CD N
% NN N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
of IN N
non-tunnelled JJ 1_i
catheters NNS 1_i
, , N
although IN N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Outward NNP N
catheter NN 1_o
migration NN 1_o
was VBD N
not RB N
reduced VBN N
by IN N
subcutaneous JJ N
tunnelling NN 1_i
. . 1_i

Comparison NNP N
of IN N
propofol NN 1_i
, , 1_i
droperidol NN 1_i
, , N
and CC N
metoclopramide NN 1_i
for IN N
prophylaxis NN 1_o
of IN 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
after IN N
breast NN 1_p
cancer NN 1_p
surgery NN 1_p
: : 1_p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
Japanese JJ 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
Breast NNP N
cancer NN N
surgery NN N
performed VBN N
with IN N
the DT N
patient NN N
under IN N
general JJ N
anesthesia NN N
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
relatively RB N
high JJ N
incidence NN 1_o
of IN 1_o
postoperative JJ 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
( ( 1_o
PONV NNP 1_o
) ) 1_o
. . 1_o

Between $ N
60 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
who WP N
undergo VBP N
mastectomy NNS N
( ( N
with IN N
axillary JJ N
dissection NN N
) ) N
experience NN N
PONV NNP 1_o
. . 1_o

We PRP N
previously RB N
reported VBD N
that IN N
propofol NN 1_i
at IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
0.5 CD N
mg/kg NN N
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN 1_i
in IN N
preventing VBG N
PONV NNP 1_o
in IN N
women NNS N
who WP N
undergo VBP N
mastectomy NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN 1_o
of IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
propofol NN 1_i
with IN N
the DT N
conventional JJ N
antiemetics NNS N
droperidol NN 1_i
and CC N
metoclopramide NN 1_i
for IN N
the DT N
prophylaxis NN 1_o
of IN 1_o
PONV NNP 1_o
after IN N
breast NN 1_p
cancer NN 1_p
surgery NN 1_p
in IN 1_p
Japanese JJ 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
Japanese JJ 1_p
women NNS 1_p
were VBD N
randomized VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
to TO N
receive VB N
IV NNP N
administration NN N
of IN N
propofol JJ 1_i
0.5 CD N
mg/kg NN N
, , N
droperidol VBZ 1_i
20 CD N
microg/kg NN N
, , N
metoclopramide RB 1_i
0.2 CD N
mg/kg NN N
, , N
or CC N
placebo NN 1_i
( ( 1_i
isotonic JJ 1_i
saline NN 1_i
) ) 1_i
immediately RB N
after IN N
skin JJ N
suture NN N
. . N

A DT N
standard JJ N
general JJ N
anesthetic JJ N
technique NN N
, , N
including VBG N
sevoflurane NN 1_i
and CC N
air NN N
in IN N
oxygen NN 1_i
, , N
was VBD N
used VBN N
. . N

All DT N
episodes NNS 1_o
of IN 1_o
PONV NNP 1_o
during IN 1_o
the DT 1_o
first JJ 1_o
24 CD 1_o
hours NNS 1_o
after IN 1_o
anesthesia JJ 1_o
administration NN 1_o
were VBD N
recorded VBN N
by IN N
an DT N
investigator NN N
who WP N
was VBD N
blinded VBN N
to TO N
treatment NN N
assignment NN N
. . N

The DT N
investigator NN N
questioned VBD N
the DT N
patients NNS N
as IN N
to TO N
whether IN N
they PRP N
experienced VBD N
extrapyramidal NN 1_o
symptoms NNS 1_o
. . 1_o

To TO N
maintain VB N
the DT N
integrity NN N
of IN N
the DT N
study NN N
results NNS N
, , N
none NN N
of IN N
the DT N
patients NNS N
received VBD N
preanesthetic JJ N
medication NN N
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
100 CD 1_p
women NNS 1_p
( ( 1_p
mean JJ 1_p
[ NNP 1_p
SD NNP 1_p
] NNP 1_p
age NN 1_p
, , 1_p
52 CD 1_p
[ NN 1_p
7 CD 1_p
] CD 1_p
years NNS 1_p
; : 1_p
height VBD 1_p
, , 1_p
154 CD 1_p
[ NN 1_p
6 CD 1_p
] NNP 1_p
cm NN 1_p
; : 1_p
weight NN 1_p
, , 1_p
54 CD 1_p
[ NN 1_p
7 CD 1_p
] NNP 1_p
kg NN 1_p
) ) 1_p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Each DT N
study NN N
group NN N
comprised VBD N
25 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
patient VB 1_o
demographics NNS 1_o
, , 1_o
surgery NN 1_o
type NN 1_o
, , 1_o
or CC 1_o
awakening VBG 1_o
time NN 1_o
. . 1_o

The DT N
prevalences NNS 1_o
of IN 1_o
PONV NNP 1_o
0 CD 1_o
to TO 1_o
24 CD 1_o
hours NNS 1_o
after IN N
anesthesia NN N
were VBD N
28 CD N
% NN N
with IN N
propofol NN 1_i
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
32 CD N
% NN N
with IN N
droperidol NN 1_i
( ( N
P NNP N
= NNP N
0.011 CD N
) ) N
, , N
and CC N
60 CD N
% NN N
with IN N
metoclopramide NN 1_i
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
, , N
compared VBN N
with IN N
placebo NN 1_i
( ( N
68 CD N
% NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
in IN N
the DT N
prevalence NN 1_o
of IN 1_o
PONV NNP 1_o
was VBD N
found VBN N
between IN N
patients NNS N
receiving VBG N
propofol NN 1_i
and CC N
those DT N
receiving VBG N
droperidol NN 1_i
, , N
and CC N
propofol NN 1_i
and CC N
droperidol NN 1_i
were VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
prevalences NNS 1_o
of IN 1_o
PONV NNP 1_o
compared VBN N
with IN N
metoclopramide NN 1_i
( ( N
P NNP N
= NNP N
0.022 CD N
and CC N
P NNP N
= NNP N
0.043 CD N
, , N
respectively RB N
) ) N
. . N

Extrapyramidal NNP 1_o
symptoms NNS 1_o
were VBD N
not RB N
reported VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
prevalences NNS 1_o
of IN 1_o
PONV NNP 1_o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
propofol NN 1_i
0.5 CD N
mg/kg NN N
and CC N
droperidol NN 1_i
20 CD N
microg/kg NN N
0 CD N
to TO N
24 CD N
hours NNS N
after IN N
anesthesia NN N
in IN N
this DT N
small JJ N
, , N
select JJ N
group NN N
of IN N
Japanese JJ 1_p
women NNS 1_p
who WP 1_p
underwent VBP 1_p
breast NN 1_p
cancer NN 1_p
surgery NN 1_p
. . 1_p

The DT N
prevalences NNS 1_o
of IN 1_o
PONV NNP 1_o
were VBD N
significantly RB N
lower JJR N
with IN N
propofol NN 1_i
and CC N
droperidol NN 1_i
compared VBN N
with IN N
metoclopramide JJ 1_i
0.2 CD N
mg/kg NN N
and CC N
placebo NN 1_i
. . 1_i

Gastric NNP 1_o
dysrhythmia NN 1_o
in IN N
infants NNS 1_p
with IN 1_p
gastrointestinal JJ 1_p
diseases NNS 1_p
measured VBN N
by IN N
epigastric JJ 1_o
impedance NN 1_o
. . 1_o

BACKGROUND NNP N
Gastrointestinal NNP N
symptoms NNS N
have VBP N
been VBN N
reported VBN N
in IN N
association NN N
with IN N
myoelectrical JJ 1_o
dysrhythmia NN 1_o
, , N
where WRB N
different JJ N
types NNS N
of IN N
gastric JJ 1_o
electrical JJ 1_o
activity NN 1_o
have VBP N
been VBN N
described VBN N
. . N

These DT N
types NNS N
of IN N
gastric JJ 1_o
myoelectrical JJ 1_o
activity NN 1_o
and CC 1_o
dysrhythmia NN 1_o
can MD N
be VB N
measured VBN N
by IN N
electrogastrography NN 1_o
using VBG N
cutaneous JJ N
electrodes NNS N
. . N

Epigastric JJ 1_o
impedance NN 1_o
is VBZ N
a DT N
non-invasive JJ N
method NN N
used VBN N
to TO N
study VB N
gastric JJ 1_o
emptying VBG 1_o
time NN 1_o
and CC 1_o
gastric JJ 1_o
phasic JJ 1_o
activity NN 1_o
. . 1_o

At IN N
present JJ N
no DT N
study NN N
of IN N
gastric JJ 1_o
dysrhythmia NN 1_o
, , N
measured VBN N
with IN N
epigastric JJ 1_o
impedance NN 1_o
, , N
has VBZ N
been VBN N
presented VBN N
, , N
and CC N
the DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
gastric JJ 1_o
rhythms NN 1_o
by IN N
means NNS N
of IN N
impedance NN 1_o
gastrography NN 1_o
in IN N
control NN 1_p
infants NNS 1_p
, , 1_p
compared VBN 1_p
to TO 1_p
infants NNS 1_p
with IN 1_p
different JJ 1_p
gastrointestinal JJ 1_p
diseases NNS 1_p
, , 1_p
before IN 1_p
and CC 1_p
after IN 1_p
treatment NN 1_p
of IN 1_p
their PRP$ 1_p
disease NN 1_p
. . 1_p

METHOD NNP N
21 CD 1_p
patients NNS 1_p
( ( 1_p
age NN 1_p
0-2 CD 1_p
months NNS 1_p
) ) 1_p
and CC 1_p
40 CD 1_p
healthy JJ 1_p
infants NNS 1_p
( ( 1_p
age NN 1_p
0-2 CD 1_p
months NNS 1_p
) ) 1_p
were VBD N
investigated VBN N
. . N

The DT N
patients NNS 1_p
suffered VBD 1_p
from IN 1_p
partial JJ 1_p
or CC 1_p
total JJ 1_p
intestinal JJ 1_p
obstruction NN 1_p
, , 1_p
necrotizing VBG 1_p
enterocolitis NN 1_p
or CC 1_p
pyloric JJ 1_p
stenosis.All NN 1_p
infants NNS 1_p
were VBD 1_p
fasting VBG 1_p
and CC N
studied VBN N
during IN N
periods NNS N
of IN N
at IN N
least JJS N
one CD N
hour NN N
. . N

The DT N
patients NNS N
were VBD N
examined VBN N
in IN N
the DT N
acute NN N
state NN N
and CC N
after IN N
treatment NN N
when WRB N
possible JJ N
. . N

RESULTS VB N
A DT N
pathologic JJ N
result NN N
was VBD N
found VBN N
in IN N
90 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

A DT N
persistent JJ N
phasic JJ 1_o
activity NN 1_o
pattern NN N
was VBD N
found VBN N
in IN N
19 CD N
of IN N
the DT N
21 CD N
patients NNS N
, , N
high JJ N
frequency NN 1_o
phasic JJ 1_o
activity NN 1_o
in IN N
11 CD N
of IN N
the DT N
21 CD N
patients NNS N
. . N

Short-term JJ N
phasic JJ 1_o
activity NN 1_o
was VBD N
only RB N
found VBN N
in IN N
13 CD N
out IN N
of IN N
40 CD N
of IN N
the DT N
normal JJ N
infants NNS N
( ( N
32.5 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Using NNP N
epigastric JJ 1_o
impedance NN 1_o
we PRP N
found VBD N
that IN N
infants NNS 1_p
with IN 1_p
partial JJ 1_p
or CC 1_p
total JJ 1_p
intestinal JJ 1_p
obstruction NN 1_p
had VBD N
gastric JJ N
phasic JJ N
activity NN N
, , N
which WDT N
was VBD N
not RB N
found VBN N
in IN N
the DT N
control NN N
infants NNS N
. . N

The DT N
origin NN N
of IN N
the DT N
gastric JJ 1_o
phasic JJ 1_o
activity NN 1_o
patterns NNS 1_o
is VBZ N
unknown JJ N
, , N
but CC N
they PRP N
may MD N
be VB N
related VBN N
to TO N
electrical JJ N
control NN N
activity NN N
. . N

Paternal NNP 1_o
RHD NNP 1_o
zygosity NN 1_o
determination NN N
in IN N
Tunisians NNS 1_p
: : 1_p
evaluation NN N
of IN N
three CD N
molecular JJ 1_i
tests NNS 1_i
. . 1_i

BACKGROUND IN N
The DT N
choice NN N
of IN N
a DT N
molecular JJ 1_i
test NN 1_i
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ 1_o
RHD NNP 1_o
zygosity NN 1_o
, , N
before IN N
entering VBG N
into IN N
invasive JJ N
diagnostics NNS N
, , N
is VBZ N
important JJ N
for IN N
the DT N
management NN N
of IN N
pregnancies NNS N
at IN N
risk NN N
of IN N
haemolytic JJ N
disease NN N
of IN N
the DT N
foetus NN N
and CC N
newborn RB N
related VBN N
to TO N
anti-RhD JJ N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
RHD NNP 1_o
zygosity NN 1_o
was VBD N
evaluated VBN N
in IN N
370 CD 1_p
RH:1 NNP 1_p
Tunisian JJ 1_p
donors NNS 1_p
by IN N
polymerase NN 1_o
chain NN 1_o
reaction NN 1_o
- : 1_o
sequence-specific JJ 1_o
polymorphism NN 1_o
( ( 1_o
PCR-SSP NNP 1_o
) ) 1_o
analysis NN N
and CC N
polymerase NN 1_o
chain NN 1_o
reaction NN 1_o
- : 1_o
restriction NN 1_o
fragment NN 1_o
length NN 1_o
polymorphism NN 1_o
( ( 1_o
PCR-RFLP NNP 1_o
) ) 1_o
amplification NN 1_o
of IN 1_o
hybrid JJ 1_o
Rhesus NNP 1_o
box NN 1_o
and CC 1_o
by IN 1_o
real JJ 1_o
time NN 1_o
quantitative JJ 1_o
polymerase NN 1_o
chain NN 1_o
reaction NN 1_o
( ( 1_o
RQ-PCR NNP 1_o
) ) 1_o
specific NN 1_o
for IN 1_o
RHD NNP 1_o
exon VBD 1_o
5 CD 1_o
. . 1_o

To TO N
evaluate VB N
the DT N
accuracy NN N
of IN N
molecular JJ 1_i
tests NNS 1_i
in IN N
the DT N
cases NNS N
of IN N
discordant JJ N
results NNS N
, , N
the DT N
ten JJ N
exons NNS N
of IN N
RHD NNP N
and CC N
Rhesus NNP N
boxes NNS N
were VBD N
amplified VBN N
by IN N
PCR NNP 1_i
and CC N
sequenced VBN N
. . N

RESULTS NNP N
Molecular JJ N
investigations NNS N
revealed VBD N
that IN N
our PRP$ N
370 CD 1_p
donors NNS 1_p
comprise VBP N
193 CD N
dizygous JJ N
and CC N
145 CD N
hemizygous JJ N
individuals NNS N
and CC N
32 CD N
subjects NNS N
whose WP$ N
zygosity NN N
remains VBZ N
unknown JJ N
. . N

Positive JJ 1_o
predictive JJ 1_o
values NNS 1_o
were VBD N
higher JJR N
than IN N
99 CD N
% NN N
for IN N
all PDT N
the DT N
methods NNS N
, , N
reaching VBG N
100 CD N
% NN N
for IN N
RQ-PCR NNP 1_i
. . 1_i

Negative NNP 1_o
predictive JJ 1_o
values NNS 1_o
were VBD N
83.24 CD N
% NN N
, , N
87.27 CD N
% NN N
and CC N
98 CD N
% NN N
for IN N
PCR-SSP NNP 1_i
, , 1_i
PCR-RFLP NNP 1_i
and CC 1_i
RQ-PCR NNP 1_i
respectively RB N
. . N

This DT N
study NN N
also RB N
revealed VBD N
19 CD N
novel JJ N
Rhesus NNP 1_o
box NN 1_o
polymorphisms NN 1_o
and CC N
three CD N
novel NN N
RHD NNP 1_o
alleles NNS 1_o
: : 1_o
RHD NNP N
( ( N
Trp185Stop NNP N
) ) N
, , N
RHD NNP N
( ( N
Ala176Thr NNP N
) ) N
and CC N
RHD NNP N
( ( N
Ile342Ile NNP N
) ) N
. . N

DISCUSSION NNP N
RQ-PCR NNP 1_i
is VBZ N
the DT N
most RBS N
convenient JJ N
method NN N
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ 1_o
RHD NNP 1_o
zygosity NN 1_o
in IN N
Tunisians NNPS 1_p
. . 1_p

However RB N
, , N
taking VBG N
into IN N
account NN N
positive JJ N
and CC N
negative JJ N
predictive NN N
values NNS N
, , N
PCR-RFLP NNP 1_o
could MD N
be VB N
an DT N
alternative JJ N
despite IN N
the DT N
heterogeneity NN N
of IN N
Rhesus NNP N
boxes NNS N
and CC N
the DT N
complexity NN N
of IN N
RHD NNP N
. . N

Efficacy NN 1_o
of IN N
intramuscular JJ N
oxytetracycline NN 1_i
as IN N
a DT N
dry JJ N
cow NN N
treatment NN N
for IN N
Staphylococcus NNP 1_p
aureus NN 1_p
mastitis NN 1_p
. . 1_p

To TO N
determine VB N
the DT N
efficacy NN 1_o
of IN N
intramuscular JJ N
oxytetracycline NN 1_i
as IN N
a DT N
supplemental JJ N
dry JJ N
cow NN N
treatment NN N
for IN N
Staphylococcus NNP 1_p
aureus NN 1_p
mastitis NN 1_p
, , 1_p
37 CD 1_p
Holstein NNP 1_p
cows NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
treatment NN N
groups NNS N
: : N
intracisternal JJ N
infusion NN N
with IN N
a DT N
commercial JJ N
preparation NN N
of IN N
cephapirin JJ 1_i
benzathine NN 1_i
at IN N
drying VBG N
off RP N
( ( N
20 CD N
cows NNS N
) ) N
and CC N
infusion NN N
with IN N
cephapirin JJ 1_i
benzathine NN 1_i
at IN N
drying VBG N
off RP N
and CC N
intramuscular JJ N
oxytetracycline NN 1_i
at IN N
11 CD N
mg/kg NNS N
once RB N
daily RB N
on IN N
d NN N
7 CD N
, , N
8 CD N
, , N
9 CD N
, , N
and CC N
10 CD N
after IN N
drying VBG N
off RB N
( ( N
17 CD N
cows NNS N
) ) N
. . N

Milk NN 1_o
samples NNS 1_o
collected VBD N
7 CD N
, , N
14 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
plated VBN N
for IN N
bacterial JJ N
isolation NN N
within IN N
24 CD N
h NN N
after IN N
collection NN N
and CC N
after IN N
24 CD N
to TO N
72 CD N
h NN N
of IN N
storage NN N
at IN N
-20 NNP N
degrees NNS N
C. NNP N
Quarters NNS N
were VBD N
defined VBN N
as IN N
infected JJ 1_o
if IN N
S. NNP N
aureus NN N
was VBD N
isolated VBN N
from IN N
the DT N
fresh JJ N
and CC N
frozen JJ N
cultures NNS N
from IN N
any DT N
one CD N
sample NN N
collected VBD N
before IN N
drying VBG N
off RP N
. . N

An DT N
infected JJ N
quarter NN N
was VBD N
defined VBN N
as IN N
cured JJ N
if IN N
S. NNP N
aureus NN N
was VBD N
not RB N
isolated VBN N
from IN N
the DT N
fresh JJ N
or CC N
frozen JJ N
culture NN N
from IN N
milk NN N
samples NNS N
obtained VBD N
following VBG N
calving NN N
. . N

The DT N
rate NN 1_o
of IN 1_o
cure NN 1_o
by IN N
30 CD N
d NN N
after IN N
calving VBG N
for IN N
systemic JJ N
oxytetracycline NN 1_i
( ( N
in IN N
combination NN N
with IN N
cephapirin JJ 1_i
treatment NN N
) ) N
was VBD N
29.4 CD N
% NN N
for IN N
infected JJ N
quarters NNS N
and CC N
29.4 CD N
% NN N
for IN N
infected JJ N
cows NNS N
, , N
compared VBN N
with IN N
27.5 CD N
and CC N
25.0 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
the DT N
cephapirin NN 1_i
treatment NN N
only RB N
. . N

Results NNS N
including VBG N
the DT N
culture NN 1_o
at IN N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
21.2 CD N
and CC N
22.5 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
combination NN N
therapy NN N
and CC N
cephapirin NN 1_i
therapy NN N
only RB N
. . N

Systemic NNP N
oxytetracycline NN 1_i
, , N
in IN N
combination NN N
with IN N
intramammary JJ N
dry JJ N
cow NN N
treatment NN N
, , N
did VBD N
not RB N
improve VB N
the DT N
rate NN 1_o
of IN 1_o
cure NN 1_o
for IN N
S. NNP N
aureus JJ N
mastitis NN N
. . N

Antioxidant JJ 1_i
supplementation NN 1_i
and CC N
exercise-induced JJ 1_o
oxidative JJ 1_o
stress NN 1_o
in IN N
the DT 1_p
60-year-old JJ 1_p
as IN N
measured VBN N
by IN N
antipyrine NN 1_i
hydroxylates NNS 1_i
. . 1_i

The DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
of IN N
antioxidant JJ 1_i
supplementation NN 1_i
on IN N
exercise-induced JJ 1_o
oxidative JJ 1_o
stress NN 1_o
were VBD N
investigated VBN N
in IN N
older JJR 1_p
adults NNS 1_p
( ( 1_p
60 CD 1_p
( ( 1_p
SE NNP 1_p
1 CD 1_p
) ) 1_p
years NNS 1_p
; : 1_p
BMI NNP 1_p
26 CD 1_p
( ( 1_p
SE NNP 1_p
1 CD 1_p
) ) 1_p
kg/m NN 1_p
( ( 1_p
2 CD 1_p
) ) 1_p
) ) 1_p
. . 1_p

Subjects NNS N
were VBD N
randomly RB N
divided VBN N
in IN N
two CD N
groups NNS N
: : N
supplementation NN N
( ( N
n JJ N
11 CD N
) ) N
with IN N
100 CD N
mg NNS N
dl-alpha-tocopheryl JJ 1_i
acetate NN 1_i
, , N
200 CD N
mg NN N
ascorbic JJ 1_i
acid NN 1_i
, , N
and CC N
2 CD N
mg NN N
beta-carotene NN 1_i
, , N
and CC N
placebo NN 1_i
( ( N
n JJ N
9 CD N
) ) N
. . N

Before IN N
and CC N
after IN N
the DT N
12 CD N
week NN N
supplementation NN N
period NN N
, , N
subjects NNS N
cycled VBD N
for IN N
45 CD N
min NN N
at IN N
submaximal JJ N
intensity NN N
( ( N
50 CD N
% NN N
maximal JJ N
workload NN N
capacity NN N
) ) N
. . N

Antipyrine NNP 1_o
was VBD N
used VBN N
as IN N
marker NN N
for IN N
oxidative JJ 1_o
stress NN 1_o
. . 1_o

Antipyrine NNP 1_o
reacts VBZ N
quickly RB N
with IN N
hydroxyl JJ N
radicals NNS N
to TO N
form VB N
para- JJ 1_o
and CC 1_o
ortho-hydroxyantipyrine JJ 1_o
. . 1_o

The DT N
latter JJ N
metabolite NN N
is VBZ N
not RB N
formed VBN N
in IN N
man NN N
through IN N
the DT N
mono-oxygenase JJ N
pathway NN N
of IN N
cytochrome JJ N
P450 NNP N
. . N

Daily NNP N
supplementation NN N
significantly RB N
increased VBD N
plasma JJ N
concentrations NNS N
of IN N
alpha-tocopherol NN N
and CC N
beta-carotene NN N
in IN N
the DT N
supplemented VBN N
group NN N
( ( N
Delta NNP N
14.4 CD N
( ( N
SE NNP N
3.2 CD N
) ) N
and CC N
0.4 CD N
( ( N
se VB N
0.1 CD N
) ) N
micromol/l NN N
; : N
P NNP N
< VBZ N
0.001 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
, , N
within IN N
and CC N
between IN N
groups NNS N
, , N
were VBD N
observed VBN N
in IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
the DT N
ratios NNS N
para- JJ 1_o
and CC 1_o
ortho-hydroxyantipyrine JJ 1_o
to TO 1_o
antipyrine VB 1_o
. . 1_o

In IN N
addition NN N
, , N
supplementation NN N
did VBD N
not RB N
affect VB N
the DT N
exercise-induced JJ N
increase NN N
in IN N
thiobarbituric JJ 1_o
acid NN 1_o
reactive JJ 1_o
substances NNS 1_o
in IN 1_o
plasma NN 1_o
. . 1_o

In IN N
conclusion NN N
, , N
in IN N
60-year-old JJ 1_p
subjects NNS 1_p
antioxidant JJ 1_i
supplementation NN 1_i
had VBD N
no DT N
effect NN N
on IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
oxidative JJ N
stress NN N
as IN N
measured VBN N
by IN N
free JJ 1_o
radical JJ 1_o
products NNS 1_o
of IN 1_o
antipyrine NN 1_o
. . 1_o

Rapid JJ N
tightening NN N
of IN N
blood NN 1_o
glucose NN 1_o
control NN N
leads VBZ N
to TO N
transient VB 1_o
deterioration NN 1_o
of IN 1_o
retinopathy NN 1_o
in IN N
insulin NN 1_p
dependent NN 1_p
diabetes VBZ 1_p
mellitus NNS 1_p
: : 1_p
the DT N
Oslo NNP N
study NN N
. . N

In IN N
a DT N
study NN N
of IN N
retinopathy NN N
during IN N
one CD N
year NN N
of IN N
tight JJ N
blood NN 1_o
glucose VB 1_o
control NN N
45 CD 1_p
type NN 1_p
I PRP 1_p
( ( 1_p
insulin JJ 1_p
dependent NN 1_p
) ) 1_p
diabetics NNS 1_p
without IN 1_p
proliferative JJ 1_p
retinopathy NN 1_p
were VBD N
randomised VBN N
to TO N
receive VB N
either RB N
continuous JJ N
subcutaneous JJ N
insulin NN 1_i
infusion NN 1_i
, , N
multiple JJ N
insulin NN 1_i
injections NNS 1_i
, , N
or CC N
conventional JJ N
insulin NN 1_i
treatment NN 1_i
( ( N
controls NNS N
) ) N
. . N

Near IN N
normoglycaemia NN N
was VBD N
achieved VBN N
with IN N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
but CC N
not RB N
with IN N
conventional JJ N
treatment NN N
. . N

Blind NNP N
evaluation NN N
of IN N
fluorescein JJ 1_o
angiograms NNS 1_o
performed VBD N
three CD N
monthly JJ N
showed VBD N
progression NN 1_o
of IN 1_o
retinopathy NN 1_o
in IN N
the DT N
control NN N
group NN N
, , N
transient JJ N
deterioration NN N
in IN N
the DT N
continuous JJ N
infusion NN N
group NN N
, , N
and CC N
no DT N
change NN N
in IN N
the DT N
multiple JJ N
injection NN N
group NN N
. . N

Half PDT N
the DT N
patients NNS N
receiving VBG N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
developed VBD N
retinal JJ N
cotton NN N
wool NN N
spots NNS N
after IN N
three CD N
to TO N
six CD N
months NNS N
. . N

These DT N
changes NNS N
regressed VBD N
in IN N
all DT N
but CC N
four CD N
patients NNS N
after IN N
12 CD N
months NNS N
. . N

Control NNP N
patients NNS N
did VBD N
not RB N
develop VB N
cotton NN 1_o
wool NN 1_o
spots NNS 1_o
. . 1_o

Patients NNS N
who WP N
developed VBD N
cotton NN N
wool NN N
spots NNS N
are VBP N
characterised VBN N
by IN N
a DT N
larger JJR N
decrement NN N
in IN N
glycosylated JJ 1_o
haemoglobin NN 1_o
and CC 1_o
blood NN 1_o
glucose NN 1_o
values NNS 1_o
, , N
more RBR N
frequent JJ 1_o
episodes NNS 1_o
of IN 1_o
hypoglycaemia NN 1_o
, , N
a DT N
longer JJR N
duration NN 1_o
of IN 1_o
diabetes NNS 1_o
, , N
and CC N
more RBR N
severe JJ N
retinopathy NN 1_o
at IN 1_o
onset NN 1_o
. . 1_o

A DT N
large JJ N
and CC N
rapid JJ N
fall NN N
in IN N
blood NN 1_o
glucose JJ 1_o
concentration NN 1_o
may MD N
promote VB N
transient JJ N
deterioration NN N
of IN N
diabetic JJ N
retinopathy NN 1_o
. . 1_o

Inhaled VBN N
fluticasone NN 1_i
reduces NNS N
sputum VBP 1_o
inflammatory JJ 1_o
indices NNS 1_o
in IN N
severe JJ 1_p
bronchiectasis NN 1_p
. . 1_p

Although IN N
corticosteroid JJ N
therapy NN N
might MD N
be VB N
clinically RB N
beneficial JJ N
for IN N
bronchiectasis NN N
, , N
very RB N
little JJ N
is VBZ N
known VBN N
of IN N
its PRP$ N
effects NNS N
on IN N
the DT N
inflammatory NN 1_o
and CC 1_o
infective JJ 1_o
markers NNS 1_o
in IN N
bronchiectasis NN N
. . N

We PRP N
have VBP N
therefore RB N
performed VBN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
study NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
4-wk JJ N
administration NN N
of IN N
inhaled JJ N
fluticasone NN 1_i
in IN N
bronchiectasis NN 1_p
. . 1_p

Twenty-four CD 1_p
patients NNS 1_p
( ( 1_p
12 CD 1_p
female NN 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
51 CD 1_p
yr NN 1_p
) ) 1_p
were VBD N
randomized VBN N
into IN N
receiving VBG N
either CC N
inhaled JJ N
fluticasone NN 1_i
( ( N
500 CD N
microgram NN N
twice RB N
daily RB N
) ) N
via IN N
the DT N
Accuhaler NNP N
device NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC N
placebo NN 1_i
. . 1_i

At IN N
each DT N
visit NN N
, , N
spirometry NN 1_o
, , 1_o
24-h JJ 1_o
sputum NN 1_o
volume NN 1_o
, , 1_o
sputum NN 1_o
leukocyte NN 1_o
density NN 1_o
, , 1_o
bacterial JJ 1_o
densities NNS 1_o
, , 1_o
and CC 1_o
concentrations NNS 1_o
of IN 1_o
interleukin NN 1_o
( ( 1_o
IL NNP 1_o
) ) 1_o
-1beta NN 1_o
, , 1_o
IL-8 NNP 1_o
, , 1_o
tumor NN 1_o
necrosis NN 1_o
factor-alpha JJ 1_o
( ( 1_o
TNF-alpha NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
leukotriene JJ 1_o
B4 NNP 1_o
( ( 1_o
LTB4 NNP 1_o
) ) 1_o
were VBD N
determined VBN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
decrease NN N
in IN N
sputum NN 1_o
leukocyte NN 1_o
density NN 1_o
and CC 1_o
IL-1beta NNP 1_o
, , 1_o
IL-8 NNP 1_o
, , 1_o
and CC 1_o
LTB4 NNP 1_o
after IN N
fluticasone NN 1_i
treatment NN N
. . N

The DT N
fluticasone NN 1_i
group NN N
had VBD N
one CD N
and CC N
the DT N
placebo NN 1_i
group NN N
three CD N
episodes NNS N
of IN N
exacerbation NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
spirometry NN 1_o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
or CC N
any DT N
reported JJ 1_o
adverse JJ 1_o
reactions NNS 1_o
in IN N
either DT N
group NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
show VB N
that IN N
high-dose JJ N
fluticasone NN 1_i
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
sputum NN 1_o
inflammatory NN 1_o
indices NNS 1_o
in IN N
bronchiectasis NN 1_p
. . 1_p

Large-scale JJ N
and CC N
long-term JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
inhaled JJ N
steroid JJ 1_i
therapy NN N
on IN N
the DT N
inflammatory JJ 1_o
components NNS 1_o
in IN N
bronchiectasis NN 1_p
. . 1_p

Feasibility NN 1_o
of IN N
two CD N
dose-dense JJ N
FEC NNP 1_i
regimens VBZ N
with IN N
growth NN N
factor NN N
support NN N
for IN N
adjuvant JJ N
therapy NN N
in IN N
patients NNS 1_p
with IN 1_p
early JJ 1_p
breast NN 1_p
cancer NN 1_p
: : 1_p
results NNS N
from IN N
a DT N
randomised JJ N
study NN N
of IN N
the DT N
Central NNP N
European NNP 1_p
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
CECOG NNP N
) ) N
. . N

Addition NN N
of IN N
epirubicin NN 1_i
to TO N
adjuvant VB N
chemotherapy NN N
can MD N
provide VB N
important JJ N
benefits NNS N
for IN N
patients NNS 1_p
with IN 1_p
early JJ 1_p
breast NN 1_p
cancer NN 1_p
, , N
but CC N
the DT N
optimal JJ N
dose NN N
remains VBZ N
unclear JJ N
. . N

Further JJ N
improvements NNS N
can MD N
be VB N
achieved VBN N
with IN N
dose-dense JJ N
regimens NNS N
, , N
but CC N
densification NN N
of IN N
fluorouracil/epirubicin/cyclophosphamide NN 1_i
( ( 1_i
FEC NNP 1_i
) ) 1_i
has VBZ N
proved VBN N
difficult JJ N
, , N
with IN N
FEC NNP 1_i
( ( 1_i
60 CD 1_i
) ) 1_i
providing VBG N
little JJ N
benefit NN N
over IN N
standard JJ N
chemotherapy NN N
and CC N
FEC NNP 1_i
( ( 1_i
100 CD 1_i
) ) 1_i
associated VBN N
with IN N
toxicity NN N
. . N

We PRP N
investigated VBD N
the DT N
feasibility NN 1_o
of IN N
two CD N
intermediate JJ N
dose-dense JJ N
FEC NNP 1_i
regimens NNS N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
six CD N
cycles NNS N
of IN N
FEC NNP 1_i
( ( 1_i
75 CD 1_i
) ) 1_i
or CC N
FEC NNP 1_i
( ( 1_i
90 CD 1_i
) ) 1_i
, , N
with IN N
all DT N
three CD N
drugs NNS N
given VBN N
on IN N
day NN N
1 CD N
of IN N
each DT N
14-day JJ N
cycle NN N
. . N

Patients NNS N
also RB N
received VBD N
pegfilgrastim JJ 1_i
6 CD N
mg NN N
as IN N
a DT N
single JJ N
subcutaneous JJ N
injection NN N
on IN N
day NN N
2 CD N
of IN N
each DT N
cycle NN N
. . N

The DT N
primary JJ N
efficacy NN 1_o
endpoint NN N
was VBD N
the DT N
proportion NN 1_o
of IN 1_o
subjects NNS 1_o
receiving VBG 1_o
> NN 1_o
or CC 1_o
=85 CD 1_o
% NN 1_o
relative JJ 1_o
dose JJ 1_o
intensity NN 1_o
and CC N
was VBD N
achieved VBN N
by IN N
96 CD N
% NN N
and CC N
88 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
FEC NNP 1_i
( ( 1_i
75 CD 1_i
) ) 1_i
and CC N
FEC NNP 1_i
( ( 1_i
90 CD 1_i
) ) 1_i
arms NNS N
, , N
respectively RB N
. . N

Of IN N
147 CD N
FEC NNP 1_i
( ( 1_i
75 CD 1_i
) ) 1_i
infusions NNS N
, , N
4.1 CD N
% NN N
were VBD N
delayed VBN N
, , N
while IN N
9.8 CD N
% NN N
of IN N
143 CD N
FEC NNP 1_i
( ( 1_i
90 CD 1_i
) ) 1_i
infusions NNS N
were VBD N
delayed VBN N
. . N

The DT N
most RBS N
common JJ N
reasons NNS N
for IN N
delay NN N
were VBD N
adverse JJ 1_o
events NNS 1_o
and CC N
personal/logistical JJ N
reasons NNS N
. . N

One CD N
dose JJ N
reduction NN N
occurred VBD N
during IN N
the DT N
study NN N
( ( 1_i
FEC NNP 1_i
( ( 1_i
90 CD 1_i
) ) 1_i
) ) 1_i
, , N
related VBN N
to TO N
diarrhoea VB 1_o
. . 1_o

Grade VB N
3-4 JJ N
haematological JJ 1_o
toxicities NNS 1_o
were VBD N
reported VBN N
in IN N
two CD N
patients NNS N
in IN N
the DT N
FEC NNP 1_i
( ( 1_i
90 CD 1_i
) ) 1_i
arm NN N
. . N

There EX N
were VBD N
no DT N
incidences NNS N
of IN N
febrile JJ 1_o
neutropenia NN 1_o
during IN N
the DT N
study NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ 1_o
events NNS 1_o
were VBD N
increases NNS 1_o
in IN 1_o
liver NN 1_o
enzymes NNS 1_o
and CC 1_o
gastrointestinal JJ 1_o
events NNS 1_o
; : 1_o
no DT N
event NN N
resulted VBD N
in IN N
discontinuation NN N
. . N

Only RB N
one CD N
patient NN N
( ( 1_i
FEC NNP 1_i
( ( 1_i
90 CD 1_i
) ) 1_i
) ) 1_i
experienced VBD N
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
vomiting VBG 1_o
and CC 1_o
throat VB 1_o
oedema NN 1_o
) ) 1_o
. . 1_o

In IN N
conclusion NN N
, , N
dose-dense JJ N
FEC NNP 1_i
( ( 1_i
75 CD 1_i
) ) N
and CC N
FEC NNP 1_i
( ( 1_i
90 CD 1_i
) ) 1_i
are VBP N
feasible JJ 1_o
with IN N
pegfilgrastim JJ 1_i
support NN N
. . N

These DT N
regimens NNS N
are VBP N
associated VBN N
with IN N
a DT N
very RB N
low JJ N
risk NN N
of IN N
Grade NNP N
3-4 JJ N
toxicity NN N
. . N

Effect NN N
of IN N
indomethacin JJ 1_i
phonophoresis NN 1_i
on IN N
the DT N
relief NN N
of IN N
temporomandibular JJ 1_p
joint NN 1_p
pain NN 1_o
. . 1_o

The DT N
pain-relieving JJ 1_o
effect NN N
of IN N
indomethacin JJ 1_i
phonophoresis NN 1_i
on IN N
temporomandibular NN 1_p
( ( 1_p
TMJ NNP 1_p
) ) 1_p
joint NN 1_p
pain NN 1_p
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ 1_i
clinical JJ N
trial NN N
. . N

Twenty NNP 1_p
subjects NNS 1_p
, , 1_p
who WP 1_p
have VBP 1_p
TMJ NNP 1_p
pain NN 1_p
, , 1_p
were VBD 1_p
included VBN 1_p
for IN 1_p
this DT 1_p
study NN 1_p
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Each DT N
treatment NN N
consisted VBN N
of IN N
the DT N
application NN N
of IN N
ultrasound JJ N
massage NN N
( ( N
1.0 CD N
MHz NNP N
, , N
0.8 CD N
to TO N
1.5 CD N
W/cm2 NNP N
continuous JJ N
output NN N
) ) N
for IN N
15 CD N
minutes NNS N
to TO N
the DT N
painful JJ N
temporomandibular JJ N
joint NN N
. . N

As IN N
a DT N
conducting NN N
medium NN N
, , N
1 CD N
% NN N
indomethacin JJ 1_i
cream NN N
was VBD N
used VBN N
for IN N
the DT N
experimental JJ N
group NN N
and CC N
placebo NN 1_i
cream NN N
for IN N
the DT N
control NN N
group NN N
respectively RB N
. . N

Pre- JJ 1_o
and CC 1_o
post-treatment JJ 1_o
pain NN 1_o
levels NNS 1_o
and CC 1_o
pain NN 1_o
sensitivity NN 1_o
were VBD N
assessed VBN N
with IN N
visual JJ 1_o
analogue NN 1_o
scales NNS 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
and CC 1_o
pressure NN 1_o
pain NN 1_o
threshold NN 1_o
( ( 1_o
PPT NNP 1_o
) ) 1_o
. . 1_o

Mean NNP N
data NNS N
indicated VBD N
that IN N
post-treatment JJ 1_o
VAS NNP 1_o
was VBD N
significantly RB N
decreased VBN N
and CC N
post-treatment JJ 1_o
PPT NNP 1_o
was VBD N
significantly RB N
increased VBN N
in IN N
the DT N
experimental JJ N
group NN N
, , N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
indomethacin JJ 1_i
phonophoresis NN 1_i
provides VBZ N
significant JJ N
pain NN 1_o
relieving VBG N
effect NN N
over IN N
the DT N
TMJ NNP N
pain NN N
. . N

[ RB N
Clinical NNP N
study NN N
of IN N
the DT N
efficacy NN 1_o
of IN N
and CC N
tolerance NN 1_o
to TO N
nimesulide VB 1_i
in IN N
suppository JJ N
formulation NN N
in IN N
pain-inflammatory JJ 1_p
pathologies NNS 1_p
of IN 1_p
the DT 1_p
ear NN 1_p
, , 1_p
nose RB 1_p
, , 1_p
and CC 1_p
throat NN 1_p
] NN 1_p
. . N

The DT N
efficacy NN 1_o
and CC N
tolerability NN 1_o
of IN N
a DT N
new JJ N
pharmaceutical JJ N
form NN N
of IN N
the DT N
non-steroid JJ 1_i
anti-inflammatory JJ 1_i
drug NN 1_i
. . 1_i

Nimesulide NNP 1_i
have VBP N
been VBN N
studied VBN N
in IN N
a DT N
double JJ N
blind NN N
study NN N
compared VBN N
with IN N
flurbiprofen NN 1_i
, , N
in IN N
98 CD 1_p
patients NNS 1_p
aged VBN 1_p
between IN 1_p
18 CD 1_p
and CC 1_p
75 CD 1_p
suffering VBG 1_p
from IN 1_p
pain-inflammatory JJ 1_p
pathologies NNS 1_p
of IN 1_p
ENT NNP 1_p
nature NN 1_p
. . 1_p

Both DT N
drugs NNS N
, , N
administered VBN N
in IN N
a DT N
dose NN N
of IN N
one CD N
suppository NN N
twice RB N
a DT N
day NN N
for IN N
7 CD N
days NNS N
, , N
showed VBD N
marked JJ N
anti-inflammatory JJ 1_o
, , 1_o
analgesic JJ 1_o
and CC 1_o
antipyretic JJ 1_o
activity NN 1_o
and CC N
produced VBD N
a DT N
significant JJ N
, , N
progressive JJ N
improvement NN N
in IN N
the DT N
typical JJ N
symptoms NNS 1_o
of IN 1_o
the DT 1_o
inflammatory NN 1_o
state NN 1_o
up IN N
to TO N
their PRP$ N
complete JJ N
remission NN N
. . N

Nimesulide NNP 1_i
evidenced VBD N
greater JJR N
speed NN N
and CC N
duration NN 1_o
of IN N
therapeutic JJ N
action NN N
. . N

Assessment NN N
on IN N
the DT N
effectiveness NN 1_o
and CC N
tolerability NN 1_o
as IN N
expressed VBN N
separately RB N
by IN N
the DT N
physician NN N
and CC N
patient NN N
were VBD N
positive JJ N
in IN N
almost RB N
all DT N
cases NNS N
of IN N
both DT N
treatments NNS N
. . N

The DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN 1_i
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN 1_i
infusion NN N
on IN N
postoperative JJ 1_o
morphine NN 1_o
requirement NN 1_o
in IN N
patients NNS 1_p
undergoing VBG 1_p
laparatomy NN 1_p
. . 1_p

OBJECTIVES NNP N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN 1_i
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN 1_i
infusion NN N
on IN N
postoperative JJ 1_o
morphine NN 1_o
requirement NN 1_o
, , 1_o
adverse JJ 1_o
effects NNS 1_o
, , 1_o
patients NNS 1_o
' POS 1_o
satisfaction NN 1_o
, , 1_o
mobilization NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
first JJ 1_o
defecation NN 1_o
and CC 1_o
time NN 1_o
to TO 1_o
discharge VB 1_o
in IN N
patients NNS 1_p
undergoing VBG 1_p
laparotomy NN 1_p
. . 1_p

METHODS NNP N
Eighty NNP 1_p
patients NNS 1_p
( ( 1_p
18 CD 1_p
to TO 1_p
65 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
) ) 1_p
undergoing VBG 1_p
elective JJ 1_p
laparotomy NN 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
( ( N
n=20 JJ N
in IN N
each DT N
group NN N
) ) N
: : N
group NN N
C NNP N
, , N
placebo NN 1_i
capsules NNS N
and CC N
normal JJ 1_i
saline JJ 1_i
infusion NN 1_i
perioperatively RB N
( ( N
control NN N
) ) N
; : N
group NN N
L NNP N
, , N
placebo NN 1_i
capsules NNS N
and CC N
lidocaine JJ 1_i
1 CD N
mg⁄kg RB N
intravenous JJ N
bolus NN N
dose NN N
followed VBN N
by IN N
2 CD N
mg⁄kg⁄h JJ N
infusion NN N
until IN N
skin JJ N
closure NN N
; : N
group NN N
P NNP N
, , N
150 CD N
mg JJ 1_i
oral JJ 1_i
pregabalin NN 1_i
and CC 1_i
normal JJ 1_i
saline JJ 1_i
infusion NN 1_i
perioperatively RB N
; : N
and CC N
group NN N
PL NNP N
, , N
150 CD 1_i
& CC 1_i
nbsp NN 1_i
; : 1_i
mg CC 1_i
oral JJ 1_i
pregabalin NN 1_i
and CC 1_i
lidocaine NN 1_i
2 CD N
mg⁄kg⁄h NN N
infusion NN N
until IN N
skin JJ 1_o
closure NN 1_o
. . 1_o

Hemodynamic NNP 1_o
parameters NNS 1_o
, , 1_o
visual JJ 1_o
analogue NN 1_o
scale NN 1_o
( ( 1_o
VAS NNP 1_o
) ) 1_o
scores VBZ 1_o
, , 1_o
analgesic JJ 1_o
consumption NN 1_o
, , 1_o
side NN 1_o
effects NNS 1_o
, , 1_o
time NN 1_o
to TO 1_o
mobilization VB 1_o
, , 1_o
time NN 1_o
to TO 1_o
first JJ 1_o
defecation NN 1_o
, , 1_o
time NN 1_o
to TO 1_o
discharge VB 1_o
and CC 1_o
patients NNS 1_o
' POS 1_o
satisfaction NN 1_o
were VBD N
recorded VBN 1_o
. . 1_o

RESULTS NNP 1_o
VAS NNP 1_o
scores NNS N
of IN N
group NN N
L NNP N
, , N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
were VBD N
lower JJR N
than IN N
group NN N
C NNP N
( ( 1_o
P NNP 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
. . 1_o

Morphine NNP 1_o
consumption NN 1_o
of IN N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
was VBD N
lower JJR N
than IN N
group NN N
C NNP N
( ( 1_o
P NNP 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
. . 1_o

Incidence NN 1_o
of IN N
nausea NN N
in IN N
group NN N
C NNP N
was VBD N
higher JJR N
than IN N
group NN N
L NNP N
and CC N
group NN 1_o
PL NNP 1_o
. . 1_o

Time NNP 1_o
to TO 1_o
first VB 1_o
defecation NN 1_o
and CC 1_o
mobilization NN 1_o
were VBD N
shorter JJR N
in IN N
group NN N
L NNP N
and CC N
group NN N
PL NNP N
compared VBN N
with IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Preoperative NNP 1_i
oral JJ 1_i
pregabalin NN 1_i
and CC N
perioperative JJ N
intravenous JJ 1_i
lidocaine NN N
infusion NN N
decreased VBD 1_o
postoperative JJ 1_o
VAS NNP 1_o
scores NNS N
. . N

Preoperative JJ 1_i
oral JJ 1_i
pregabalin NN 1_i
decreased VBD 1_o
morphine JJ 1_o
requirement NN 1_o
and CC N
perioperative JJ N
intravenous JJ 1_i
lidocaine NN N
infusion NN N
hastened VBD N
gastrointestinal JJ N
motility NN N
and CC N
mobilization NN N
, , N
and CC N
decreased VBD 1_o
the DT 1_o
incidence NN 1_o
of IN N
nausea NN 1_p
in IN 1_p
patients NNS 1_p
undergoing VBG 1_p
laparotomy NN 1_p
. . N

Therefore RB N
, , N
preoperative JJ 1_i
pregabalin NN 1_i
with IN N
or CC 1_i
without IN 1_i
lidocaine JJ N
provides VBZ 1_o
superior JJ 1_o
pain NN 1_o
relief NN 1_p
in IN 1_p
patients NNS 1_p
undergoing VBG 1_p
laparatomy NN 1_p
. . N

The DT N
safety NN 1_o
of IN N
whey JJ 1_i
protein NN 1_i
concentrate NN 1_i
derived VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
immunized VBN N
against IN N
Clostridium NNP N
difficile NN N
. . N

A DT N
whey JJ 1_i
protein NN 1_i
concentrate NN 1_i
prepared VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
that WDT N
have VBP N
been VBN N
immunized VBN 1_i
against IN 1_i
Clostridium NNP 1_i
difficile NN 1_i
( ( 1_i
C. NNP 1_i
difficile NN 1_i
) ) 1_i
and CC 1_i
its PRP$ 1_i
toxins NNS 1_i
, , 1_i
toxin NN 1_i
A NNP 1_i
and CC 1_i
toxin NN 1_i
B NNP 1_i
, , N
is VBZ N
produced VBN N
for IN N
use NN N
as IN N
a DT N
medical JJ N
food NN N
for IN N
the DT N
dietary JJ N
management NN N
of IN N
patients NNS 1_p
with IN 1_p
C. NNP 1_p
difficile-associated JJ 1_p
diarrhea NN 1_p
( ( 1_p
CDAD NNP 1_p
) ) 1_p
to TO N
prevent VB N
a DT N
relapse NN N
of IN N
the DT N
infection NN N
. . N

The DT N
safety NN 1_o
of IN N
anti-C. JJ 1_i
difficile NN 1_i
whey NN 1_i
protein VBP 1_i
concentrate NN 1_i
( ( 1_i
anti-CD JJ 1_i
WPC NNP 1_i
) ) 1_i
is VBZ N
supported VBN N
by IN N
analytical JJ N
data NNS N
comparing VBG N
the DT N
composition NN N
of IN N
raw JJ N
milk NN N
from IN N
immunized JJ N
cows NNS N
versus VBP N
that IN N
from IN N
non-immunized JJ N
cows NNS N
, , N
and CC N
the DT N
composition NN N
of IN N
anti-CD JJ 1_i
WPC NNP 1_i
versus NN N
that IN N
of IN N
regular JJ 1_i
whey NN 1_i
protein NN 1_i
concentrate NN 1_i
. . 1_i

Additionally RB N
, , N
a DT N
prospective JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
in IN N
77 CD 1_p
patients NNS 1_p
with IN 1_p
CDAD NNP 1_p
to TO N
demonstrate VB N
the DT N
safety NN 1_o
of IN N
consuming VBG N
anti-CD JJ 1_i
WPC NNP 1_i
to TO N
prevent VB N
relapse NN 1_o
of IN 1_o
the DT 1_o
infection NN 1_o
. . 1_o

This DT N
study NN N
, , N
which WDT N
included VBD N
adverse JJ 1_o
event NN 1_o
monitoring NN 1_o
, , 1_o
physical JJ 1_o
examinations NNS 1_o
, , 1_o
and CC 1_o
extensive JJ 1_o
hematological NN 1_o
and CC 1_o
biochemical JJ 1_o
assessments NNS 1_o
, , N
showed VBD N
that IN N
anti-CD JJ 1_i
WPC NNP 1_i
is VBZ N
safe JJ 1_o
to TO N
consume VB N
by IN N
patients NNS 1_p
with IN 1_p
CDAD NNP 1_p
. . 1_p

The DT N
available JJ N
analytical JJ N
and CC N
clinical JJ N
evidence NN N
demonstrate NN N
that IN N
anti-CD JJ 1_i
WPC NNP 1_i
is VBZ N
safe JJ 1_o
for IN N
use NN N
by IN N
individuals NNS 1_p
with IN 1_p
CDAD NNP 1_p
, , N
under IN N
the DT N
described JJ N
conditions NNS N
of IN N
use NN N
. . N

Therapeutic JJ 1_o
effects NNS 1_o
of IN N
combined JJ N
treatment NN N
using VBG N
tetracycline-immobilized JJ 1_i
collagen NN 1_i
film NN 1_i
and CC 1_i
root NN 1_i
planing NN 1_i
in IN N
periodontal JJ 1_p
furcation NN 1_p
pockets NNS 1_p
. . 1_p

46 CD 1_p
upper JJ 1_p
and CC 1_p
lower JJR 1_p
molars NNS 1_p
with IN 1_p
furcation NN 1_p
grade NN 1_p
II NNP 1_p
involvement NN 1_p
were VBD N
selected VBN N
from IN N
16 CD 1_p
patients NNS 1_p
with IN 1_p
periodontal JJ 1_p
disease NN 1_p
. . 1_p

The DT N
teeth NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
following VBG N
groups NNS N
according VBG N
to TO N
treatment NN N
; : N
( ( N
1 CD N
) ) N
4 CD N
consecutive JJ N
administrations NNS N
of IN N
tetracycline-immobilized JJ 1_i
cross-linked JJ 1_i
collagen NN 1_i
film NN 1_i
( ( 1_i
TC NNP 1_i
film NN 1_i
) ) 1_i
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
( ( N
TC NNP N
group NN N
) ) N
; : N
( ( N
2 CD N
) ) N
1 CD N
root NN 1_i
planing VBG 1_i
treatment NN 1_i
( ( 1_i
RP NNP 1_i
group NN N
) ) N
; : N
( ( N
3 CD N
) ) N
combination NN N
treatment NN N
( ( 1_i
TC NNP 1_i
+ NNP 1_i
RP NNP 1_i
group NN N
) ) N
; : N
( ( N
4 CD N
) ) N
no DT N
treatment NN N
( ( N
control VB N
group NN N
) ) N
. . N

The DT N
therapeutic JJ 1_o
effects NNS 1_o
of IN N
each DT N
treatment NN N
were VBD N
compared VBN N
both DT N
clinically RB N
and CC N
microbiologically RB N
. . N

Records NNS N
of IN N
plaque NN 1_o
index NN 1_o
, , 1_o
gingival NN 1_o
index NN 1_o
, , 1_o
bleeding VBG 1_o
on IN 1_o
probing VBG 1_o
, , 1_o
probing VBG 1_o
depth NN 1_o
, , 1_o
probing VBG 1_o
attachment JJ 1_o
level NN 1_o
and CC 1_o
microscopic NN 1_o
counts NNS 1_o
were VBD N
obtained VBN N
at IN N
0 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
. . N

The DT N
results NNS N
showed VBD N
marked JJ N
decreases NNS N
in IN N
probing VBG 1_o
depth NN 1_o
and CC 1_o
density NN 1_o
of IN 1_o
micro-organisms NN 1_o
in IN N
both CC N
the DT N
RP NNP 1_i
and CC N
TC NNP 1_i
+ NNP 1_i
RP NNP 1_i
groups NNS N
. . N

In IN N
particular JJ N
, , N
the DT N
TC NNP 1_i
+ NNP 1_i
RP NNP 1_i
group NN N
was VBD N
characterized VBN N
by IN N
a DT N
decreased JJ N
rate NN 1_o
of IN 1_o
bleeding VBG 1_o
on IN 1_o
pocket NN 1_o
probing NN 1_o
and CC N
an DT N
increased JJ N
probing NN 1_o
attachment NN 1_o
gain NN 1_o
. . 1_o

The DT N
above JJ N
findings NNS N
demonstrated VBD N
that IN N
root NN 1_i
planning NN 1_i
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
furcation NN N
involvement NN N
and CC N
that IN N
the DT N
effects NNS N
are VBP N
enhanced VBN N
by IN N
the DT N
local JJ N
administration NN N
of IN N
TC NNP 1_i
films NNS 1_i
. . 1_i

Data NNP N
mining NN N
the DT N
ScanBrit NNP N
study NN N
of IN N
a DT N
gluten- JJ 1_i
and CC 1_i
casein-free JJ 1_i
dietary JJ 1_i
intervention NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
behavioural JJ 1_o
and CC 1_o
psychometric JJ 1_o
measures NNS 1_o
of IN 1_o
dietary JJ 1_o
response NN 1_o
. . 1_o

We PRP N
previously RB N
reported VBD N
results NNS N
based VBN N
on IN N
the DT N
examination NN N
of IN N
a DT N
gluten- JJ 1_i
and CC 1_i
casein-free JJ 1_i
diet NN 1_i
as IN N
an DT N
intervention NN N
for IN N
children NNS 1_p
diagnosed VBN 1_p
with IN 1_p
an DT 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
as IN N
part NN N
of IN N
the DT N
ScanBrit NNP N
collaboration NN N
. . N

Analysis NN N
based VBN N
on IN N
grouped JJ N
results NNS N
indicated VBD N
several JJ N
significant JJ N
differences NNS N
between IN N
dietary JJ N
and CC N
non-dietary JJ N
participants NNS N
across IN N
various JJ N
core NN N
and CC N
peripheral JJ N
areas NNS N
of IN N
functioning VBG N
. . N

Results NNP N
also RB N
indicated VBD N
some DT N
disparity NN N
in IN N
individual JJ N
responses NNS 1_o
to TO 1_o
dietary JJ 1_o
modification NN 1_o
potentially RB N
indicative JJ N
of IN N
responder NN N
and CC N
non-responder JJ N
differences NNS N
. . N

Further JJ N
examination NN N
of IN N
the DT N
behavioural JJ 1_o
and CC 1_o
psychometric JJ 1_o
data NNS 1_o
garnered VBN N
from IN N
participants NNS N
was VBD N
undertaken VBN N
, , N
with IN N
a DT N
view NN N
to TO N
determining VBG N
potential JJ N
factors NNS N
pertinent VBP N
to TO N
response NN 1_o
to TO 1_o
dietary JJ 1_o
intervention NN 1_o
. . 1_o

Participants NNS N
with IN N
clinically RB N
significant JJ N
scores NNS N
indicative JJ N
of IN N
inattention NN 1_o
and CC 1_o
hyperactivity NN 1_o
behaviours NNS 1_o
and CC N
who WP N
had VBD N
a DT N
significant JJ N
positive JJ N
changes NNS N
to TO N
said VBD N
scores NNS N
were VBD N
defined VBN N
as IN N
responders NNS 1_o
to TO 1_o
the DT 1_o
dietary JJ 1_o
intervention NN 1_o
. . 1_o

Analyses NNS N
indicated VBD N
several JJ N
factors NNS N
to TO N
be VB N
potentially RB N
pertinent JJ N
to TO N
a DT N
positive JJ N
response NN 1_o
to TO 1_o
dietary JJ 1_o
intervention NN 1_o
in IN N
terms NNS N
of IN N
symptom NN 1_o
presentation NN 1_o
. . 1_o

Chronological JJ 1_o
age NN 1_o
was VBD N
found VBN N
to TO N
be VB N
the DT N
strongest JJS N
predictor NN N
of IN N
response NN N
, , N
where WRB N
those DT N
participants NNS N
aged VBD N
between IN N
7 CD N
and CC N
9 CD N
years NNS N
seemed VBD N
to TO N
derive VB N
most JJS N
benefit NN N
from IN N
dietary JJ 1_o
intervention NN 1_o
. . 1_o

Further CC N
analysis NN N
based VBN N
on IN N
the DT N
criteria NNS N
for IN N
original JJ N
study NN N
inclusion NN N
on IN N
the DT N
presence NN N
of IN N
the DT N
urine JJ 1_o
compound NN 1_o
, , 1_o
trans-indolyl-3-acryloylglycine NN 1_o
may MD N
also RB N
merit VB N
further JJ N
investigation NN N
. . N

These DT N
preliminary JJ N
observations NNS N
on IN N
potential JJ N
best JJS N
responder NN N
characteristics NNS N
to TO N
a DT N
gluten- JJ 1_i
and CC 1_i
casein-free JJ 1_i
diet NN 1_i
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
require VBP N
independent JJ N
replication NN N
. . N

A DT N
novel JJ N
approach NN N
to TO N
the DT N
use NN N
of IN N
subgingival JJ N
controlled-release JJ N
chlorhexidine NN 1_i
delivery NN N
in IN N
chronic JJ 1_p
periodontitis NN 1_p
: : 1_p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND IN N
We PRP N
aimed VBD N
to TO N
analyze VB N
clinical JJ 1_o
, , 1_o
microbiologic JJ 1_o
, , 1_o
and CC 1_o
serologic JJ 1_o
effects NNS 1_o
of IN N
chlorhexidine NN 1_i
( ( 1_i
CHX NNP 1_i
) ) 1_i
chips NNS N
used VBN N
as IN N
a DT N
subgingival JJ N
controlled-release JJ N
delivery NN N
device NN N
before IN N
and CC N
immediately RB N
after IN N
scaling VBG N
and CC N
root NN N
planing NN N
( ( N
SRP NNP N
) ) N
. . N

METHODS NNP N
Twenty-four JJ 1_p
patients NNS 1_p
presenting VBG 1_p
with IN 1_p
≥12 NNP 1_p
teeth NNS 1_p
with IN 1_p
probing VBG 1_p
depth NN 1_p
( ( 1_p
PD NNP 1_p
) ) 1_p
≥5 VBP 1_p
mm NN 1_p
and CC 1_p
bleeding NN 1_p
on IN 1_p
probing VBG 1_p
were VBD N
assigned VBN N
in IN N
test NN N
or CC N
control NN N
groups NNS N
. . N

After IN N
prophylaxis NN 1_i
, , 1_i
CHX NNP 1_i
chips NNS 1_i
( ( 1_i
test NN 1_i
) ) 1_i
or CC 1_i
placebo JJ 1_i
chips NNS N
( ( N
control NN N
) ) N
were VBD N
placed VBN N
in IN N
pockets NNS N
with IN N
PD NNP N
≥5 NNP N
mm NN N
. . N

Ten CD N
days NNS N
later RB N
, , N
SRP NNP N
was VBD N
performed VBN N
in IN N
all DT N
teeth NNS N
with IN N
PD NNP N
≥4 NNP N
mm NN N
in IN N
a DT N
single JJ N
appointment NN N
. . N

Immediately RB N
after IN N
SRP NNP N
, , N
new JJ N
chips NNS N
were VBD N
inserted VBN N
in IN N
all DT N
pockets NNS N
with IN N
PD NNP 1_o
≥5 NNP 1_o
mm NN 1_o
. . 1_o

Parameters NNS 1_o
were VBD N
assessed VBN N
at IN N
baseline NN N
; : N
beginning NN N
of IN N
SRP NNP N
; : N
and CC N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
after IN N
treatment NN 1_o
. . 1_o

Subgingival JJ 1_o
samples NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
; : N
beginning NN N
of IN N
SRP NNP N
; : N
and CC N
at IN N
1 CD N
month NN N
after IN N
treatment NN 1_o
. . 1_o

Periodontal JJ 1_o
pathogens NNS 1_o
Aggregatibacter NNP 1_o
actinomycetemcomitans NNS 1_o
, , 1_o
Porphyromonas NNP 1_o
gingivalis NN 1_o
, , 1_o
Prevotella NNP 1_o
intermedia NN 1_o
, , 1_o
Tannerella NNP 1_o
forsythia NN 1_o
, , 1_o
and CC 1_o
Treponema NNP 1_o
denticola NN N
were VBD N
analyzed VBN 1_o
. . 1_o

Serum NNP 1_o
levels NNS 1_o
of IN 1_o
high JJ 1_o
sensitive JJ 1_o
C-reactive JJ 1_o
and CC 1_o
lipopolysaccharide-binding JJ 1_o
proteins NNS N
were VBD N
measured VBN N
. . N

The DT N
changes NNS 1_o
of IN 1_o
the DT 1_o
parameters NNS 1_o
between IN N
and CC N
within IN N
the DT N
groups NNS N
were VBD N
tested VBN 1_o
by IN 1_o
Mann-Whitney NNP 1_o
U NNP N
test NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP 1_o
All NNP 1_o
clinical JJ 1_o
and CC 1_o
serologic JJ 1_o
parameters NNS 1_o
improved VBN N
in IN N
both DT N
groups NNS N
over IN N
time NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN 1_o
in IN 1_o
clinical JJ 1_o
attachment NN 1_o
level NN 1_o
( ( N
CAL NNP N
) ) N
gain NN N
from IN N
baseline NN N
to TO N
6 CD N
months NNS N
between IN N
groups NNS N
( ( N
1.17 CD N
mm NN N
in IN N
the DT N
test NN N
group NN N
versus VBD N
0.79 CD N
mm NN N
in IN N
the DT N
placebo NN N
group NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
treatment NN 1_i
with IN 1_i
CHX NNP N
chips NNS N
showed VBD N
a DT 1_o
greater JJR 1_o
reduction NN 1_o
of IN 1_o
the DT 1_o
microorganisms NN 1_o
of IN 1_o
the DT 1_o
" NNP 1_o
red VBD 1_o
complex JJ N
" NN N
after IN N
1 CD N
month NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION VB N
The DT 1_i
use NN 1_i
of IN 1_i
CHX NNP N
chips NNS N
before IN N
and CC N
immediately RB N
after IN N
SRP NNP 1_o
improved VBD 1_o
CAL NNP N
and CC N
reduced VBD 1_o
the DT 1_o
subgingival JJ 1_o
microorganisms NN 1_o
of IN 1_o
the DT 1_o
red JJ 1_o
complex NN N
in IN N
the DT N
treatment NN 1_p
of IN 1_p
chronic JJ 1_p
periodontitis NN 1_p
. . N

The DT N
prophylactic JJ 1_o
effect NN 1_o
of IN N
itraconazole JJ 1_i
capsules NNS N
and CC N
fluconazole JJ 1_i
capsules NNS N
for IN N
systemic JJ N
fungal JJ N
infections NNS N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
and CC 1_p
myelodysplastic JJ 1_p
syndromes NNS 1_p
: : 1_p
a DT N
Japanese JJ 1_p
multicenter NN N
randomized VBN N
, , N
controlled VBN N
study NN N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
study NN N
comparing VBG N
the DT N
prophylactic JJ 1_o
effects NNS 1_o
of IN N
capsule NN N
forms NNS N
of IN N
fluconazole NN 1_i
( ( N
n JJ N
= NNP N
110 CD N
) ) N
and CC N
itraconazole JJ 1_i
( ( N
n JJ N
= NNP N
108 CD N
) ) N
in IN N
patients NNS 1_p
with IN 1_p
acute JJ 1_p
myeloid NN 1_p
leukemia NN 1_p
( ( 1_p
AML NNP 1_p
) ) 1_p
or CC 1_p
myelodysplastic JJ 1_p
syndromes NNS 1_p
( ( 1_p
MDS NNP 1_p
) ) 1_p
during IN 1_p
and CC 1_p
after IN 1_p
chemotherapy NN 1_p
. . 1_p

There EX N
were VBD N
4 CD N
cases NNS N
with IN N
possible JJ N
systemic JJ N
fungal JJ N
infection NN N
in IN N
the DT N
itraconazole NN 1_i
group NN N
, , N
and CC N
there EX N
were VBD N
8 CD N
possible JJ N
and CC N
3 CD N
probable JJ N
cases NNS N
in IN N
the DT N
fluconazole JJ 1_i
group NN N
. . N

Adverse JJ 1_o
events NNS 1_o
did VBD N
not RB N
significantly RB N
differ VB N
in IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
patients NNS N
with IN N
MDS NNP N
or CC N
in IN N
the DT N
remission-induction JJ N
phase NN N
of IN N
chemotherapy NN N
, , N
the DT N
numbers NNS N
of IN N
cases NNS 1_o
with IN 1_o
probable JJ 1_o
or CC 1_o
possible JJ 1_o
infections NNS 1_o
were VBD N
lower JJR N
in IN N
the DT N
itraconazole NN 1_i
group NN N
than IN N
in IN N
the DT N
fluconazole NN 1_i
group NN N
, , N
whereas IN N
no DT N
difference NN N
was VBD N
seen VBN N
in IN N
patients NNS N
with IN N
AML NNP N
or CC N
in IN N
the DT N
consolidation NN N
phase NN N
of IN N
therapy NN N
. . N

In IN N
patients NNS N
with IN N
neutrophil JJ N
counts NNS N
of IN N
> $ N
0.1 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
lasting VBG N
for IN N
more JJR N
than IN N
4 CD N
weeks NNS N
, , N
the DT N
frequency NN 1_o
of IN 1_o
infection NN 1_o
in IN N
the DT N
fluconazole JJ 1_i
group NN N
( ( N
5 CD N
of IN N
9 CD N
patients NNS N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
itraconazole JJ 1_i
group NN N
( ( N
0 CD N
of IN N
7 CD N
patients NNS N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN N
in IN N
patients NNS 1_p
with IN 1_p
AML NNP 1_p
or CC 1_p
MDS NNP 1_p
who WP 1_p
received VBD 1_p
chemotherapy NN 1_p
and CC N
that IN N
the DT N
efficacy NN 1_o
of IN N
itraconazole NN 1_i
for IN N
prophylaxis NN N
against IN N
systemic JJ N
fungal JJ N
disease NN N
is VBZ N
not RB N
inferior JJ N
to TO N
that DT N
of IN N
fluconazole NN 1_i
. . 1_i

Protection NN N
of IN N
man NN N
from IN N
natural JJ N
infection NN N
with IN N
influenza JJ N
A2 NNP N
Hong NNP N
Kong NNP N
virus NN N
by IN N
amantadine NN 1_i
: : 1_i
a DT N
controlled JJ N
field NN N
trial NN N
. . N

Prophylactic JJ N
administration NN N
of IN N
amantadine NN 1_i
in IN N
doses NNS N
of IN N
100 CD N
mg. NN N
twice RB N
a DT N
day NN N
offered VBN N
statistically RB N
significant JJ N
protection NN N
against IN N
influenza JJ N
A2 NNP N
infection NN N
in IN N
a DT N
double-blind JJ N
field NN N
trial NN N
involving VBG N
391 CD 1_p
medical JJ 1_p
student NN 1_p
volunteers NNS 1_p
during IN 1_p
the DT 1_p
influenza JJ 1_p
A2 NNP 1_p
Hong NNP 1_p
Kong NNP 1_p
epidemic VBP 1_p
in IN 1_p
Helsinki NNP 1_p
in IN 1_p
the DT 1_p
winter NN 1_p
of IN 1_p
1969 CD 1_p
. . 1_p

Serologically RB 1_o
verified JJ 1_o
influenza NN 1_o
, , N
as IN N
measured VBN N
by IN N
complement JJ 1_o
fixation NN 1_o
and/or NN 1_o
haemagglutination NN 1_o
inhibition NN 1_o
, , N
occurred VBD N
in IN N
27 CD N
out IN N
of IN N
192 CD N
students NNS N
in IN N
the DT N
amantadine NN 1_i
group NN N
against IN N
57 CD N
out IN N
of IN N
199 CD N
in IN N
the DT N
placebo NN 1_i
group NN N
, , N
giving VBG N
a DT N
protection NN N
rate NN N
of IN N
52 CD N
% NN N
. . N

Economic NNP 1_o
burden NN 1_o
of IN N
childhood NN 1_i
autism NN 1_i
spectrum NN 1_i
disorders NNS 1_i
. . 1_i

OBJECTIVE NNP N
To TO N
estimate VB N
the DT N
associations NNS N
between IN N
autism NN 1_i
spectrum NN 1_i
disorder NN 1_i
( ( 1_i
ASD NNP 1_i
) ) 1_i
diagnoses NNS 1_i
and CC N
service NN 1_o
use NN 1_o
, , 1_o
caregiver NN 1_o
time NN 1_o
, , 1_o
and CC 1_o
cost NN 1_o
outcomes NNS 1_o
. . 1_o

METHODS NNP N
We PRP N
used VBD N
national JJ N
data NNS N
from IN N
the DT N
Medical NNP N
Expenditure NNP N
Panel NNP N
Survey NNP N
linked VBD N
to TO N
the DT N
National NNP N
Health NNP N
Interview NNP N
Survey NNP N
and CC N
a DT N
study-specific JJ N
survey NN N
to TO N
estimate VB N
the DT N
annual JJ 1_o
utilization NN 1_o
and CC 1_o
costs NNS 1_o
for IN 1_o
health NN 1_o
care NN 1_o
, , 1_o
school NN 1_o
, , 1_o
ASD-related JJ 1_o
therapy NN 1_o
, , 1_o
family-coordinated JJ 1_o
services NNS 1_o
, , 1_o
as RB 1_o
well RB 1_o
as IN 1_o
caregiver NN 1_o
time NN 1_o
in IN N
children NNS 1_p
aged VBD 1_p
3 CD 1_p
to TO 1_p
17 CD 1_p
years NNS 1_p
, , 1_p
with IN 1_i
and CC 1_i
without IN 1_i
parent-reported JJ 1_i
ASD NNP 1_i
. . 1_i

Regression NNP 1_o
analyses VBZ 1_o
estimated VBN N
the DT N
association NN 1_o
between IN 1_o
ASD NNP 1_o
diagnosis NN 1_o
and CC 1_o
cost NN 1_o
, , 1_o
controlling VBG 1_o
for IN 1_o
child NN 1_o
gender NN 1_o
, , 1_o
age NN 1_o
, , 1_o
race/ethnicity NN 1_o
, , 1_o
insurance NN 1_o
status NN 1_o
, , 1_o
household JJ 1_o
income NN 1_o
, , 1_o
country NN 1_o
region NN 1_o
and CC 1_o
urban/rural JJ 1_o
classification NN 1_o
, , 1_o
and CC 1_o
non-ASD-related JJ 1_o
illnesses NNS 1_o
. . 1_o

RESULTS NNP N
Children NNP 1_i
with IN 1_i
parent-reported JJ 1_i
ASD NNP 1_i
had VBD N
higher JJR N
levels NNS N
of IN N
health NN 1_o
care NN 1_o
office NN 1_o
visits NNS 1_o
and CC 1_o
prescription NN 1_o
drug NN 1_o
use NN 1_o
compared VBN N
with IN N
children NNS 1_i
without IN 1_i
ASD NNP 1_i
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

A DT N
greater JJR N
proportion NN N
of IN N
children NNS 1_i
in IN 1_i
the DT 1_i
ASD NNP 1_i
group NN N
used VBD N
special JJ 1_o
educational JJ 1_o
services NNS 1_o
( ( N
76 CD N
% NN N
vs. FW N
7 CD N
% NN N
in IN N
the DT N
control NN 1_i
group NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

After IN N
adjusting VBG N
for IN N
child JJ N
demographic JJ N
characteristics NNS N
and CC N
non-ASD-associated JJ N
illnesses NNS N
, , N
ASD NNP N
was VBD N
associated VBN N
with IN N
$ $ N
3020 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
$ $ N
1017- CD N
$ $ N
4259 CD N
) ) N
higher JJR N
health NN 1_o
care NN 1_o
costs NNS 1_o
and CC N
$ $ N
14,061 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
$ $ N
4390- JJ N
$ $ N
24,302 CD N
) ) N
higher JJR N
aggregate JJ N
non-health NNS 1_o
care NN 1_o
costs NNS 1_o
, , N
including VBG N
$ $ N
8610 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
$ $ N
6595- JJ N
$ $ N
10,421 CD N
) ) N
higher JJR 1_o
school NN 1_o
costs NNS 1_o
. . 1_o

In IN N
adjusted JJ N
analyses NNS N
, , N
parents NNS 1_i
who WP 1_i
reported VBD 1_i
that IN 1_i
their PRP$ 1_i
child NN 1_i
had VBD 1_i
ASD NNP 1_i
did VBD N
not RB N
have VB N
significantly RB N
higher JJR N
out-of-pocket NN 1_o
costs NNS 1_o
or CC N
spend VB N
more JJR N
time NN 1_o
on IN 1_o
caregiving VBG 1_o
activities NNS 1_o
compared VBN N
with IN N
control NN 1_i
parents NNS N
. . N

CONCLUSIONS VB N
The DT N
economic JJ 1_o
burden NN 1_o
associated VBN N
with IN N
ASD NNP N
is VBZ N
substantial JJ N
and CC N
can MD N
be VB N
measured VBN N
across IN N
multiple JJ N
sectors NNS N
of IN N
our PRP$ N
society NN N
. . N

Previous JJ N
analyses NNS N
that WDT N
focused VBD N
on IN N
health NN N
care NN N
underestimated VBD N
this DT N
economic JJ 1_o
burden NN 1_o
, , N
particularly RB N
for IN N
school NN N
systems NNS N
. . N

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
personalised JJ 1_i
decision NN 1_i
support NN 1_i
delivered VBD N
via IN N
the DT N
internet NN N
for IN N
bowel NN N
cancer NN N
screening VBG N
with IN N
a DT N
faecal JJ 1_o
occult NN 1_o
blood NN 1_o
test NN 1_o
: : 1_o
the DT N
effects NNS N
of IN N
tailoring NN N
of IN N
messages NNS N
according VBG N
to TO N
social JJ N
cognitive JJ N
variables NNS N
on IN N
participation NN N
. . N

BACKGROUND NNP N
In IN N
Australia NNP N
, , N
bowel NN N
cancer NN N
screening VBG N
participation NN N
using VBG N
faecal JJ 1_o
occult NN 1_o
blood NN 1_o
testing NN 1_o
( ( 1_o
FOBT NNP 1_o
) ) 1_o
is VBZ N
low JJ N
. . N

Decision NN N
support NN N
tailored VBD N
to TO N
psychological JJ N
predictors NNS N
of IN N
participation NN N
may MD N
increase VB N
screening VBG N
. . N

The DT N
study NN N
compared VBN N
tailored VBD 1_i
computerised JJ 1_i
decision NN 1_i
support NN 1_i
to TO N
non-tailored JJ 1_i
computer NN 1_i
or CC 1_i
paper NN 1_i
information NN 1_i
. . 1_i

The DT N
primary JJ N
outcome NN N
was VBD N
FOBT NNP 1_o
return NN 1_o
within IN N
12 CD N
weeks NNS N
. . N

Additional JJ N
analyses NNS N
were VBD N
conducted VBN N
on IN 1_o
movement NN 1_o
in IN 1_o
decision NN 1_o
to TO 1_o
screen NN 1_o
and CC N
change NN N
on IN 1_o
psychological JJ 1_o
variables NNS 1_o
. . N

METHODS NNP N
A NNP N
parallel NN N
, , N
randomised VBD N
controlled VBN N
, , N
trial NN 1_p
invited VBD 1_p
25,511 CD 1_p
people NNS 1_p
aged VBN 1_p
50-74 JJ 1_p
years NNS 1_p
to TO N
complete VB N
an DT N
eligibility NN N
questionnaire NN N
. . N

Eligible JJ N
respondents NNS N
( ( N
n JJ N
= NNP N
3,408 CD N
) ) N
were VBD N
assigned VBN 1_i
to TO 1_i
Tailored NNP 1_i
Personalised VBD 1_i
Decision NNP 1_i
Support NNP 1_i
( ( 1_i
TPDS NNP 1_i
) ) 1_i
, , 1_i
Non-Tailored JJ 1_i
PDS NNP 1_i
( ( 1_i
NTPDS NNP 1_i
) ) 1_i
, , 1_i
or CC 1_i
Control NNP 1_i
( ( N
CG NNP N
) ) N
( ( N
intention-to-treat JJ N
, , N
ITT NNP N
sample NN 1_i
) ) 1_i
. . 1_i

TPDS NNP 1_i
and CC 1_i
NTPDS NNP 1_i
groups NNS N
completed VBD N
an DT N
on-line JJ N
baseline NN N
survey NN N
( ( N
BS NNP N
) ) N
and CC N
accessed VBN N
generic JJ N
information NN N
. . 1_i

The DT 1_i
TPDS NNP N
group NN N
additionally RB N
received VBD N
a DT N
tailored VBN N
intervention NN 1_i
. . N

CG JJ N
participants NNS N
completed VBD N
a DT N
paper NN N
BS NNP N
only RB N
. . N

Those DT N
completing VBG N
the DT N
BS NNP N
( ( N
n JJ N
= NN N
2270 CD N
) ) N
were VBD N
mailed VBN N
an DT N
FOBT NNP N
and CC N
requested VBN N
to TO N
complete VB N
an DT N
endpoint NN N
survey NN N
( ( N
ES NNP N
) ) N
that IN N
re-measured JJ N
BS NNP N
variables NNS N
( ( N
per-protocol NN N
, , N
PP NNP N
sample NN N
) ) N
. . 1_o

RESULTS NNP 1_o
FOBT NNP 1_o
return NN N
: : N
In IN N
the DT N
ITT NNP N
sample NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
any DT N
group NN N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
( ( N
2 CD N
) ) N
= NN N
2.57 CD N
, , N
p NN N
= NNP N
.26 NNP N
; : N
TPDS NNP N
, , N
32.5 CD N
% NN N
; : N
NTPDS NNP N
, , N
33 CD N
% NN N
; : N
and CC N
CG NNP N
, , N
34.5 CD N
% NN N
) ) N
. . N

In IN 1_o
the DT 1_o
PP NNP 1_o
sample NN 1_o
, , N
FOBT NNP N
return NN N
in IN N
the DT N
internet NN N
groups NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
the DT N
paper NN N
group NN N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
( ( N
2 CD N
) ) N
= NN N
17.01 CD N
, , N
p NN N
< NNP N
.001 NNP N
; : N
TPDS NNP N
, , N
80 CD 1_o
% NN 1_o
; : 1_o
NTPDS NNP 1_o
, , N
83 CD N
% NN N
; : N
and CC N
CG NNP 1_i
, , 1_i
74 CD 1_i
% NN 1_i
) ) 1_i
. . N

FOBT NNP 1_i
completion NN 1_i
by IN N
TPDS NNP N
and CC N
NTPDS NNP N
did VBD N
not RB N
differ VB N
( ( N
χ NNP N
( ( N
2 CD N
) ) N
( ( N
1 CD N
) ) N
= NN N
2.23 CD N
, , N
p NN N
= NNP N
.13 NNP N
) ) N
. . N

Age NNP N
was VBD N
positively RB N
associated VBN N
with IN N
kit JJ N
return NN N
. . N

Decision NN N
to TO N
screen NN N
: : N
2227/2270 CD N
of IN N
the DT N
PP NNP N
sample NN N
provided VBD N
complete JJ N
BS NNP N
data NN N
. . N

Participants NNS N
not RB N
wanting VBG N
to TO N
screen VB N
at IN N
baseline NN 1_i
( ( 1_i
1083/2227 CD 1_i
) ) 1_i
and CC N
allocated VBN N
to TO N
TPDS NNP N
and CC N
NTPDS NNP N
were VBD N
significantly RB N
more RBR 1_o
likely JJ 1_o
to TO 1_o
decide VB N
to TO N
screen VB N
and CC N
return VB N
an DT N
FOBT NNP 1_o
than IN 1_o
those DT 1_o
assigned VBN 1_i
to TO 1_i
the DT 1_i
CG NNP N
. . N

FOBT NNP N
return NN N
by IN N
TPDS NNP N
and CC N
NTPDS NNP N
did VBD N
not RB N
differ VB N
from IN N
one CD N
another DT 1_o
( ( 1_o
OR NNP 1_o
= VBZ 1_o
1.16 CD 1_o
, , 1_o
p NN 1_o
= NNP 1_o
.42 NNP 1_o
) ) 1_o
. . N

Change NN N
on IN N
psychosocial JJ N
predictors NNS 1_o
: : 1_o
Analysis NN 1_o
of IN 1_o
change NN 1_o
indicated VBD 1_o
that IN 1_o
salience NN 1_o
and CC 1_o
coherence NN N
of IN N
screening VBG N
and CC N
self-efficacy NN N
were VBD N
improved VBN N
and CC N
faecal JJ N
aversion NN N
decreased VBN N
by IN N
tailored JJ N
messaging NN N
. . N

CONCLUSIONS NNP N
Online NNP N
information NN N
resources NNS N
may MD N
have VB N
a DT N
role NN N
in IN N
encouraging VBG N
internet-enabled JJ N
people NNS N
who WP N
are VBP N
uncommitted VBN N
to TO N
screening VBG N
to TO N
change VB N
their PRP$ N
attitudes NNS N
, , N
perceptions NNS N
and CC N
behaviour NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
ACTRN12610000095066 NNP N
. . N

The DT N
immediate JJ 1_o
efficacy NN 1_o
of IN N
adjunctive JJ N
doxycycline NN 1_i
in IN N
treatment NN N
of IN N
localized VBN 1_p
juvenile NN 1_p
periodontitis NN 1_p
. . 1_p

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
on IN N
the DT N
immediate JJ 1_o
clinical JJ 1_o
and CC 1_o
microbiological JJ 1_o
efficacy NN 1_o
of IN N
doxycycline NN 1_i
( ( N
100 CD N
mg NN N
for IN N
14 CD N
days NNS N
) ) N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
benefit NN N
of IN N
adjunctive JJ N
medication NN N
in IN N
16 CD 1_p
patients NNS 1_p
with IN 1_p
localized JJ 1_p
juvenile NN 1_p
periodontitis NN 1_p
. . 1_p

Measurements NNS N
of IN N
gingival NN 1_o
fluid NN 1_o
flow NN 1_o
, , 1_o
probing VBG 1_o
depths NNS 1_o
, , 1_o
bleeding VBG 1_o
on IN 1_o
probing VBG 1_o
and CC 1_o
suppuration NN 1_o
were VBD N
determined VBN N
at IN N
2 CD N
periodontal JJ N
sites NNS N
with IN N
and CC N
2 CD N
without IN N
radiographic JJ 1_o
attachment JJ 1_o
loss NN 1_o
, , N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
3 CD N
and CC N
8 CD N
. . N

Subgingival JJ 1_o
bacterial JJ 1_o
samples NNS 1_o
were VBD N
taken VBN N
with IN N
curettes NNS N
from IN N
the DT N
same JJ N
sites NNS N
. . N

Spirochaetes NNS 1_o
were VBD N
searched VBN N
for IN N
by IN N
dark-field JJ 1_o
microscopy NN 1_o
. . 1_o

Actinobacillus CC 1_o
actinomycetemcomitans NNS 1_o
, , 1_o
pigmented VBN 1_o
and CC 1_o
non-pigmented JJ 1_o
Bacteroides NNP 1_o
spp. NN 1_o
, , N
Capnocytophaga NNP 1_o
, , 1_o
Fusobacterium NNP 1_o
and CC 1_o
Actinomyces NNP 1_o
spp NN 1_o
. . 1_o

were VBD N
cultured VBN N
on IN N
various JJ N
selective JJ N
and CC N
non-selective JJ N
media NNS N
. . N

Bacterial JJ 1_o
species NNS 1_o
found VBN N
at IN N
least JJS N
in IN N
50 CD N
% NN N
of IN N
the DT N
patients NNS N
and CC N
comprising VBG N
on IN N
average JJ N
5 CD N
% NN N
or CC N
more JJR N
of IN N
the DT N
cultivable JJ N
flora NNS N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

Neither CC N
short-term JJ 1_o
clinical JJ 1_o
nor CC 1_o
microbiological JJ 1_o
efficacy NN 1_o
beyond IN N
that DT N
of IN N
a DT N
course NN N
of IN N
mechanical JJ N
debridement NN N
alone RB N
was VBD N
found VBN N
by IN N
using VBG N
systemic JJ N
medication NN N
with IN N
doxycycline NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
localized JJ 1_p
juvenile NN 1_p
periodontitis NN 1_p
. . 1_p

Intervention NN 1_i
pilot NN N
for IN N
parents NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
autistic JJ 1_p
spectrum NN 1_p
disorder NN 1_p
. . 1_p

Parents NNS 1_p
of IN 1_p
children NNS 1_p
who WP 1_p
receive VBP 1_p
the DT 1_p
diagnosis NN 1_p
of IN 1_p
autistic JJ 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
experience NN N
a DT N
situational JJ N
crisis NN N
related VBN N
to TO N
receiving VBG N
the DT N
diagnosis NN N
, , N
which WDT N
causes VBZ N
feelings NNS N
of IN N
distress NN N
and CC N
urgency NN N
to TO N
access NN N
services NNS N
for IN N
the DT N
affected JJ N
child NN N
. . N

This DT N
paper NN N
describes VBZ N
a DT N
randomized JJ N
trial NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
that WDT N
was VBD N
conducted VBN N
at IN N
a DT N
regional JJ N
diagnostic JJ N
center NN N
of IN N
a DT N
large JJ N
metropolitan JJ N
children NNS N
's POS N
hospital NN N
to TO N
( ( N
a DT N
) ) N
refine NN N
a DT N
nursing NN 1_i
intervention NN 1_i
designed VBN N
for IN N
parents NNS 1_p
of IN 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
and CC N
( ( N
b NN N
) ) N
to TO N
identify VB N
methodological JJ N
revisions NNS N
for IN N
a DT N
larger JJR N
study NN N
. . N

A DT N
secondary JJ N
purpose NN N
was VBD N
to TO N
test VB N
the DT N
effects NNS 1_o
of IN N
a DT N
post-diagnosis JJ 1_i
nursing NN 1_i
intervention NN 1_i
on IN N
parents NNS 1_o
' POS 1_o
reports NNS 1_o
of IN 1_o
stress NN 1_o
, , 1_o
impact NN 1_o
of IN 1_o
event NN 1_o
( ( 1_o
diagnosis NN 1_o
) ) 1_o
, , 1_o
and CC 1_o
use NN 1_o
of IN 1_o
services NNS 1_o
after IN N
a DT N
child NN N
is VBZ N
newly RB N
diagnosed VBN N
with IN N
ASD NNP N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
usual JJ 1_i
care NN 1_i
plus CC N
3 CD N
hours NNS N
contact NN 1_i
with IN 1_i
a DT 1_i
pediatric JJ 1_i
nurse NN 1_i
practitioner NN 1_i
( ( 1_i
PNP NNP 1_i
) ) 1_i
for IN 1_i
counseling NN 1_i
, , 1_i
instruction NN 1_i
, , 1_i
and CC 1_i
assistance NN 1_i
with IN 1_i
implementation NN 1_i
of IN 1_i
the DT 1_i
recommended VBN 1_i
treatment NN 1_i
plan NN 1_i
. . 1_i

The DT N
control NN N
group NN N
received VBD N
only RB N
the DT N
usual JJ 1_i
care NN 1_i
post-diagnosis NN N
, , N
which WDT N
consisted VBD N
of IN N
a DT N
1-hour JJ N
consultation NN 1_i
session NN 1_i
to TO 1_i
receive VB 1_i
the DT 1_i
results NNS 1_i
of IN 1_i
diagnostic JJ 1_i
tests NNS 1_i
and CC 1_i
a DT 1_i
written VBN 1_i
copy NN 1_i
of IN 1_i
the DT 1_i
recommended VBN 1_i
treatment NN 1_i
plan NN 1_i
provided VBN N
by IN N
a DT N
developmental JJ N
pediatrician JJ N
and/or NN N
PNP NNP N
. . N

Between NNP N
group NN N
differences NNS N
in IN N
measures NNS N
of IN N
" NNP 1_o
impact NN 1_o
of IN 1_o
event NN 1_o
" NN 1_o
and CC N
" NNP 1_o
perceived VBD 1_o
stress JJ 1_o
" NNS 1_o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

This DT N
was VBD N
attributed VBN N
to TO N
a DT N
small JJ N
sample NN N
size NN N
. . N

A NNP N
larger JJR N
study NN N
is VBZ N
feasible JJ N
and CC N
recommended VBD N
with IN N
an DT N
expanded JJ N
nursing NN 1_i
intervention NN 1_i
and CC N
a DT N
significantly RB N
larger JJR N
sample NN N
recruited VBD N
from IN N
an DT N
additional JJ N
recruitment NN N
site NN N
. . N

Nurses NNS N
working VBG N
with IN N
this DT N
special JJ N
population NN N
must MD N
recognize VB N
that IN N
parents NNS N
have VBP N
information NN N
and CC N
counseling NN N
needs NNS N
that WDT N
begin VBP N
after IN N
they PRP N
receive VBP N
the DT N
diagnosis NN N
of IN N
ASD NNP N
for IN N
their PRP$ N
child NN N
and CC N
can MD N
address VB N
these DT N
needs NNS N
with IN N
a DT N
standardized JJ N
nursing NN 1_i
intervention NN 1_i
. . 1_i

The DT N
course NN N
of IN N
depression NN N
in IN N
recent JJ 1_p
onset NN 1_p
rheumatoid NN 1_p
arthritis NN 1_p
: : 1_p
the DT N
predictive JJ N
role NN 1_o
of IN N
disability NN 1_o
, , 1_o
illness JJ 1_o
perceptions NNS 1_o
, , 1_o
pain NN 1_o
and CC 1_o
coping NN 1_o
. . 1_o

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
course NN N
of IN N
depression NN N
for IN N
patients NNS 1_p
with IN 1_p
recently RB 1_p
diagnosed VBN 1_p
rheumatoid NN 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
and CC N
to TO N
investigate VB N
predictors NNS 1_o
of IN 1_o
depression NN 1_o
. . 1_o

METHODS NNP N
Twenty-two JJ 1_p
patients NNS 1_p
with IN 1_p
a DT 1_p
history NN 1_p
of IN 1_p
recently RB 1_p
diagnosed VBN 1_p
RA NNP 1_p
of IN 1_p
less JJR 1_p
than IN 1_p
2 CD 1_p
years NNS 1_p
were VBD N
assessed VBN N
on IN N
a DT N
variety NN N
of IN N
clinical JJ 1_o
outcome NN 1_o
and CC 1_o
process NN 1_o
measures NNS 1_o
on IN N
six CD N
assessment JJ N
occasions NNS N
over IN N
a DT N
21-month JJ N
period NN N
. . N

These DT N
22 CD 1_p
patients NNS 1_p
constituted VBD N
the DT N
control NN N
group NN N
of IN N
a DT N
controlled VBN N
trial NN N
and CC N
received VBN N
standard JJ 1_i
outpatient NN 1_i
clinic JJ 1_i
treatment NN 1_i
during IN N
follow-up JJ N
. . N

RESULTS JJ N
Patients NNPS N
became VBD N
significantly RB N
more RBR N
depressed JJ N
over IN N
time NN N
. . N

A DT N
set NN N
of IN N
five CD N
factors NNS N
were VBD N
found VBN N
to TO N
consistently RB N
predict VB 1_o
depression NN 1_o
at IN N
the DT N
following JJ N
assessment NN N
. . N

These DT N
were VBD N
initial JJ 1_o
level NN 1_o
of IN 1_o
depression NN 1_o
, , 1_o
disability NN 1_o
, , 1_o
pain NN 1_o
, , 1_o
beliefs VB 1_o
about IN 1_o
the DT 1_o
consequences NNS 1_o
of IN 1_o
arthritis NN 1_o
and CC 1_o
coping VBG 1_o
strategies NNS 1_o
. . 1_o

CONCLUSIONS VB N
The DT N
results NNS N
confirm VBP N
the DT N
importance NN N
of IN N
psychological JJ N
factors NNS N
in IN N
early JJ N
RA NNP N
and CC N
their PRP$ N
relative JJ N
independence NN N
from IN N
physical JJ N
findings NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
document VB N
the DT N
importance NN N
of IN N
illness JJ N
perceptions NNS N
in IN N
recent JJ 1_p
onset NN 1_p
RA NNP 1_p
. . 1_p

Is VBZ N
a DT N
2-week JJ N
duration NN 1_o
sufficient NN N
for IN N
stenting VBG 1_i
in IN N
endopyelotomy NN 1_i
? . N
PURPOSE NNP N
Internal NNP 1_i
stenting NN 1_i
is VBZ N
an DT N
integral JJ N
part NN N
of IN N
endopyelotomy NN N
. . N

Studies NNS N
in IN N
animals NNS N
show VBP N
good JJ N
healing NN N
after IN N
1 CD N
to TO N
2 CD N
weeks NNS N
of IN N
ureterotomy JJ N
. . N

Inherent JJ N
stent NN 1_i
related VBN N
problems NNS N
warrant VBP N
a DT N
minimum JJ N
possible JJ N
duration NN N
of IN N
stenting VBG N
without IN N
compromising VBG N
the DT N
results NNS N
of IN N
endopyelotomy JJ N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
optimum JJ 1_o
duration NN 1_o
of IN 1_o
stenting VBG 1_o
after IN N
endopyelotomy NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP 1_p
total NN 1_p
of IN 1_p
57 CD 1_p
consecutive JJ 1_p
patients NNS 1_p
with IN 1_p
primary JJ 1_p
ureteropelvic JJ 1_p
junction NN 1_p
obstruction NN 1_p
were VBD N
randomized VBN N
to TO N
undergo VB N
7/14Fr CD 1_i
internal JJ 1_i
endopyelotomy NN 1_i
stent JJ 1_i
placement NN 1_i
for IN N
2 CD N
( ( N
group NN N
1 CD N
) ) N
and CC N
4 CD N
( ( N
group NN N
2 CD N
) ) N
weeks NNS N
. . N

A DT N
symptom NN 1_o
based VBN 1_o
questionnaire NN 1_o
was VBD N
administered VBN N
to TO N
all DT N
patients NNS N
at IN N
stent JJ N
removal NN N
. . N

Followup NNP N
was VBD N
done VBN N
with IN N
diuretic JJ 1_o
scanning NN 1_o
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
and CC N
12 CD N
months NNS N
and CC N
then RB N
yearly RB N
, , N
and CC N
thereafter RB N
with IN N
diuretic JJ 1_o
renography NN 1_o
. . 1_o

RESULTS NNP N
In IN N
each DT N
group NN N
26 CD N
patients NNS N
were VBD N
available JJ N
for IN N
evaluation NN N
. . N

The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
sex NN N
, , N
symptoms NNS 1_o
and CC 1_o
ipsilateral JJ 1_o
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
. . 1_o

Mean NNP N
followup NN N
was VBD N
22.3 CD N
( ( N
range NN N
12 CD N
to TO N
36 CD N
) ) N
and CC N
21.3 CD N
months NNS N
( ( N
range VB N
12 CD N
to TO N
35 CD N
) ) N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
. . N

At IN N
the DT N
end NN N
of IN N
1 CD N
year NN N
24 CD N
group NN N
1 CD N
( ( N
92.3 CD N
% NN N
) ) N
and CC N
23 CD N
group NN N
2 CD N
( ( N
90.3 CD N
% NN N
) ) N
patients NNS N
had VBD N
an DT N
improved JJ N
drainage NN 1_o
pattern NN 1_o
. . 1_o

This DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Stent NNP 1_o
related JJ 1_o
symptoms NNS 1_o
were VBD N
present JJ N
in IN N
a DT N
good JJ N
proportion NN N
of IN N
patients NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
but CC N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
urinary JJ 1_o
tract NN 1_o
infections NNS 1_o
( ( N
11.5 CD N
% NN N
versus IN N
38.1 CD N
% NN N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Of IN N
the DT N
group NN N
2 CD N
patients NNS N
64 CD N
% NN N
preferred JJ N
2 CD N
weeks NNS N
of IN N
stenting VBG N
. . N

CONCLUSIONS NNP N
Two CD N
weeks NNS N
seems VBZ N
to TO N
be VB N
a DT N
sufficient JJ N
duration NN 1_o
to TO N
allow VB N
functional JJ N
restoration NN N
across IN N
the DT N
ureteropelvic JJ N
junction NN N
after IN N
endopyelotomy NN 1_p
and CC N
decrease NN N
stent NN 1_o
related JJ 1_o
complications NNS 1_o
. . 1_o

The DT N
effect NN N
of IN N
weight NN 1_i
training NN 1_i
on IN N
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
and CC 1_o
bone NN 1_o
turnover NN 1_o
in IN N
postmenopausal JJ 1_p
breast NN 1_p
cancer NN 1_p
survivors NNS 1_p
with IN 1_p
bone JJ 1_p
loss NN 1_p
: : 1_p
a DT N
24-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

SUMMARY VB N
This DT N
study NN N
examined VBD N
whether IN N
24 CD N
months NNS N
of IN N
weight JJ 1_i
training NN 1_i
exercises NNS 1_i
enhanced VBD N
the DT N
effectiveness NN 1_o
of IN N
risedronate NN N
, , N
calcium NN N
, , N
and CC N
vitamin NN N
D NNP N
in IN N
maintaining VBG N
or CC N
improving VBG N
bone JJ 1_o
mineral JJ 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
in IN N
223 CD 1_p
postmenopausal NN 1_p
breast NN 1_p
cancer NN 1_p
survivors NNS 1_p
. . 1_p

Subjects NNS N
who WP N
were VBD N
> NNP N
or CC N
=50 CD N
% NN N
adherent NN N
to TO N
exercise VB N
had VBN N
no DT N
improvement NN N
in IN N
BMD NNP 1_o
but CC N
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP 1_o
. . 1_o

INTRODUCTION NNP N
This DT N
study NN N
examined VBD N
whether IN N
( ( N
1 CD N
) ) N
postmenopausal NN 1_p
breast NN 1_p
cancer NN 1_p
survivors NNS 1_p
( ( 1_p
BCS NNP 1_p
) ) 1_p
with IN 1_p
bone NN 1_p
loss NN 1_p
taking VBG N
24 CD N
months NNS N
of IN N
risedronate NN 1_i
, , 1_i
calcium NN 1_i
, , N
and CC N
vitamin NN 1_i
D NNP 1_i
had VBD N
increased VBN N
bone RB 1_o
mineral JJ 1_o
density NN 1_o
( ( 1_o
BMD NNP 1_o
) ) 1_o
at IN 1_o
the DT 1_o
total JJ 1_o
hip NN 1_o
, , 1_o
femoral JJ 1_o
neck NN 1_o
, , 1_o
L1-L4 NNP 1_o
spine NN 1_o
, , 1_o
total JJ 1_o
radius NN 1_o
and CC N
33 CD N
% NN N
radius NN N
, , N
and CC N
decreased VBD N
bone NN 1_o
turnover NN 1_o
; : 1_o
( ( N
2 CD N
) ) N
subjects NNS N
who WP N
also RB N
participated VBD N
in IN N
strength/weight JJ 1_i
training NN 1_i
( ( 1_i
ST NNP 1_i
) ) 1_i
exercises NNS 1_i
had VBD N
greater JJR N
increases NNS N
in IN N
BMD NNP 1_o
and CC N
greater JJR N
decreases NNS N
in IN N
bone NN 1_o
turnover NN 1_o
; : 1_o
and CC N
( ( N
3 CD N
) ) N
subjects NNS N
who WP N
also RB N
exercised VBD N
were VBD N
more RBR N
likely JJ N
to TO N
preserve VB N
( ( N
at IN N
least JJS N
maintain NN N
) ) N
BMD NNP 1_o
. . 1_o

METHODS NNP N
Postmenopausal NNP 1_p
BCS NNP 1_p
( ( 1_p
223 CD 1_p
) ) 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
exercise VB 1_i
plus JJ 1_i
medication NN 1_i
or CC N
medication NN 1_i
only RB N
groups NNS N
. . N

Both DT N
groups NNS N
received VBD N
24 CD N
months NNS N
of IN N
1,200 CD N
mg NN N
of IN N
calcium NN 1_i
and CC N
400 CD N
IU NNP N
of IN N
vitamin NNP 1_i
D NNP 1_i
daily RB N
and CC N
35 CD N
mg NN N
of IN N
risedronate JJ 1_i
weekly JJ N
, , N
and CC N
the DT N
exercise NN 1_i
group NN N
additionally RB N
had VBD N
ST NNP 1_i
exercises NNS 1_i
twice RB N
weekly RB N
. . N

RESULTS NNP N
After IN N
24 CD N
months NNS N
, , N
women NNS N
who WP N
took VBD N
medications NNS 1_i
without IN N
exercising VBG 1_i
had VBD N
significant JJ N
improvements NNS N
in IN N
BMD NNP 1_o
at IN N
the DT N
total JJ N
hip NN N
( ( N
+1.81 CD N
% NN N
) ) N
and CC N
spine NN N
( ( N
+2.85 CD N
% NN N
) ) N
and CC N
significant JJ N
decreases NNS N
in IN N
Alkphase NNP 1_o
B NNP 1_o
( ( N
-8.7 NNP N
% NN N
) ) N
and CC N
serum JJ 1_o
NTx NNP 1_o
( ( N
-16.7 NNP N
% NN N
) ) N
. . N

Women NNS N
who WP N
also RB N
exercised VBD 1_i
had VBD N
additional JJ N
increases NNS N
in IN N
BMD NNP 1_o
at IN N
the DT N
femoral JJ N
neck NN N
( ( N
+0.29 CD N
% NN N
) ) N
, , N
total JJ N
hip NN N
( ( N
+0.34 CD N
% NN N
) ) N
, , N
spine NN N
( ( N
+0.23 CD N
% NN N
) ) N
, , N
total JJ N
radius NN N
( ( N
+0.30 CD N
% NN N
) ) N
, , N
and CC N
additional JJ N
decreases NNS N
in IN N
Alkphase NNP 1_o
B NNP 1_o
( ( N
-2.4 NNP N
% NN N
) ) N
and CC N
Serum NNP 1_o
NTx NNP 1_o
( ( N
-6.5 NNP N
% NN N
) ) N
. . N

Additional JJ N
changes NNS 1_o
in IN 1_o
BMD NNP 1_o
and CC 1_o
bone NN 1_o
turnover NN 1_o
with IN N
exercise NN 1_i
were VBD N
not RB N
significant JJ N
. . N

Subjects NNS N
who WP N
were VBD N
> NNP N
or CC N
=50 CD N
% NN N
adherent NN N
to TO N
exercise VB 1_i
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP 1_o
at IN N
the DT N
total JJ N
hip NN N
( ( N
chi-square JJ N
[ NN N
1 CD N
] NNP N
= NNP N
4.66 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
femoral JJ N
neck NN N
( ( N
chi-square JJ N
[ NN N
1 CD N
] NNP N
= NNP N
4.63 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSION NNP N
Strength/weight NNP 1_i
training NN 1_i
exercises NNS 1_i
may MD N
prevent VB N
loss NN N
of IN N
BMD NNP 1_o
in IN N
postmenopausal NN 1_p
BCS NNP 1_p
at IN 1_p
risk NN 1_p
for IN 1_p
bone NN 1_p
loss NN 1_p
. . 1_p

Psychological JJ 1_o
mediators NNS 1_o
of IN N
bupropion NN 1_i
sustained-release NN 1_i
treatment NN N
for IN N
smoking VBG 1_p
cessation NN 1_p
. . 1_p

AIM IN N
The DT N
study NN N
aimed VBN N
to TO N
test VB N
simultaneously RB N
our PRP$ N
understanding NN N
of IN N
the DT N
effects NNS N
of IN N
bupropion NN 1_i
sustained-release NN 1_i
( ( 1_i
SR NNP 1_i
) ) 1_i
treatment NN N
on IN N
putative JJ 1_o
mediators NNS 1_o
and CC N
our PRP$ N
understanding NN N
of IN N
determinants NNS N
of IN N
post-quit NN 1_o
abstinence NN 1_o
, , 1_o
including VBG 1_o
withdrawal NN 1_o
distress NN 1_o
, , 1_o
cigarette NN 1_o
craving NN 1_o
, , 1_o
positive JJ 1_o
affect NN 1_o
and CC 1_o
subjective JJ 1_o
reactions NNS 1_o
to TO 1_o
cigarettes NNS 1_o
smoked VBN 1_o
during IN 1_o
a DT 1_o
lapse NN 1_o
. . 1_o

The DT N
specificity NN 1_o
of IN N
bupropion NN 1_i
SR NNP 1_i
effects NNS N
was VBD N
also RB N
tested VBN N
in IN N
exploratory JJ N
analyses NNS N
. . N

DESIGN NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
bupropion NN 1_i
SR NNP 1_i
were VBD N
submitted VBN N
to TO N
mediation NN N
analyses NNS N
. . N

SETTING NN N
Center NNP N
for IN N
Tobacco NNP N
Research NNP N
and CC N
Intervention NNP N
, , N
Madison NNP 1_p
, , 1_p
WI NNP 1_p
, , 1_p
USA NNP 1_p
. . 1_p

PARTICIPANTS VB N
A DT N
total NN N
of IN N
403 CD 1_p
adult NN 1_p
, , 1_p
daily JJ 1_p
smokers NNS 1_p
without IN 1_p
contraindications NNS 1_p
to TO 1_p
bupropion VB 1_i
SR NNP 1_i
use NN 1_p
. . 1_p

INTERVENTION NN N
Participants NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
a DT N
9-week JJ N
course NN N
of IN N
bupropion NN 1_i
SR NNP 1_i
or CC N
placebo NN 1_i
pill NN N
and CC N
to TO N
receive VB N
eight CD N
brief JJ N
individual JJ N
counseling NN N
sessions NNS N
or CC N
no DT N
counseling NN N
. . N

MEASUREMENTS NNP N
Ecological NNP 1_o
momentary JJ 1_o
assessment NN 1_o
ratings NNS 1_o
of IN 1_o
smoking VBG 1_o
behavior NN 1_o
and CC 1_o
putative JJ 1_o
mediators NNS 1_o
were VBD N
collected VBN N
pre- JJ N
and CC N
post-quit NN N
. . N

FINDINGS NNP N
Results NNP N
of IN N
structural JJ N
equation NN N
and CC N
hierarchical JJ N
linear JJ N
models NNS N
did VBD N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
bupropion NN 1_i
SR NNP 1_i
treatment NN N
improves VBZ N
short-term JJ 1_o
abstinence NN 1_o
by IN N
reducing VBG N
withdrawal NN 1_o
distress NN 1_o
or CC N
affecting VBG N
the DT N
subjective JJ 1_o
effects NNS 1_o
of IN 1_o
a DT 1_o
lapse NN 1_o
cigarette NN 1_o
, , N
but CC N
provided VBD N
partial JJ N
support NN N
for IN N
mediation NN N
by IN N
cigarette NN 1_o
craving VBG 1_o
reduction NN 1_o
and CC N
enhanced VBD N
positive JJ 1_o
affect NN 1_o
. . 1_o

Bupropion NNP 1_i
SR NNP 1_i
effects NNS N
on IN N
point-prevalence NN 1_o
abstinence NN 1_o
at IN N
1 CD N
month NN N
post-quit NN N
were VBD N
also RB N
mediated VBN N
partially RB N
by IN N
enhanced JJ N
motivation NN 1_o
to TO N
quit VB N
and CC N
self-efficacy NN 1_o
. . 1_o

CONCLUSIONS NNP N
Results NNP N
provided VBD N
some DT N
support NN N
for IN N
models NNS N
of IN N
bupropion NN 1_i
SR NNP 1_i
treatment NN N
and CC N
relapse NN N
and CC N
suggested VBD N
that IN N
motivational JJ N
processes NNS N
may MD N
partially RB N
account VB N
for IN N
bupropion NN 1_i
SR NNP 1_i
efficacy NN 1_o
. . 1_o

A DT N
multi-component JJ 1_i
social JJ 1_i
skills NNS 1_i
intervention NN 1_i
for IN N
children NNS 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
: : 1_p
the DT N
Junior NNP 1_i
Detective NNP 1_i
Training NNP 1_i
Program NNP 1_i
. . 1_i

BACKGROUND NNP N
The DT N
study NN N
aimed VBN N
to TO N
investigate VB N
the DT N
effectiveness NN 1_o
of IN N
a DT N
new JJ N
multi-component JJ 1_i
social JJ 1_i
skills NNS 1_i
intervention NN 1_i
for IN N
children NNS 1_p
with IN 1_p
Asperger NNP 1_p
syndrome NN 1_p
( ( 1_p
AS IN 1_p
) ) 1_p
: : 1_p
The DT N
Junior NNP N
Detective NNP N
Training NNP N
Program NNP N
. . N

This DT N
7-week JJ N
program NN N
included VBD N
a DT N
computer NN N
game NN N
, , N
small JJ 1_i
group NN 1_i
sessions NNS 1_i
, , 1_i
parent NN 1_i
training NN 1_i
sessions NNS 1_i
and CC N
teacher NN 1_i
handouts NNS 1_i
. . 1_i

METHOD NNP N
Forty-nine JJ 1_p
children NNS 1_p
with IN 1_p
AS NNP 1_p
were VBD N
recruited VBN N
to TO N
participate VB N
and CC N
randomly VB N
assigned VBN N
to TO N
intervention NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
or CC N
wait-list JJ N
control NN N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
conditions NNS N
. . N

RESULTS NNP N
Relative NNP N
to TO N
children NNS N
in IN N
the DT N
wait-list JJ N
group NN N
, , N
program NN N
participants NNS N
showed VBD N
greater JJR N
improvements NNS 1_o
in IN 1_o
social JJ 1_o
skills NNS 1_o
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
, , N
as IN N
indicated VBN N
by IN N
parent-report JJ 1_o
measures NNS 1_o
. . 1_o

Teacher-report NNP 1_o
data NNS 1_o
also RB N
confirmed VBD N
that IN N
children NNS N
receiving VBG N
the DT N
intervention NN N
made VBD N
significant JJ N
improvements NNS N
in IN N
social JJ 1_o
functioning NN 1_o
from IN N
pre- JJ N
to TO N
post-treatment JJ N
. . N

Treatment NNP N
group NN N
participants NNS N
were VBD N
better RBR N
able JJ N
to TO N
suggest VB N
appropriate JJ N
emotion-management JJ 1_o
strategies NNS 1_o
for IN N
story NN N
characters NNS N
at IN N
post-intervention NN N
than IN N
at IN N
pre-intervention NN N
, , N
whereas NNS N
control VBP N
participants NNS N
were VBD N
not RB N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
improvements NNS N
made VBN N
by IN N
children NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
conditions NNS N
on IN N
facial JJ 1_o
expression NN 1_o
and CC 1_o
body-posture NN 1_o
recognition NN 1_o
measures NNS 1_o
. . 1_o

Follow-up NNP N
data NN N
suggested VBD N
that IN N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
by IN N
children NNS N
at IN N
5-months JJ N
post-intervention NN N
. . N

CONCLUSIONS VB N
The DT N
Junior NNP 1_i
Detective NNP 1_i
Training NNP 1_i
Program NNP 1_i
appeared VBD N
to TO N
be VB N
effective JJ 1_o
in IN N
enhancing VBG N
the DT N
social JJ 1_o
skills NNS 1_o
and CC 1_o
emotional JJ 1_o
understanding NN 1_o
of IN N
children NNS 1_p
with IN 1_p
AS NNP 1_p
. . 1_p

Limitations NNS N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

Safety NN 1_o
and CC N
preliminary JJ 1_o
immunogenicity NN 1_o
of IN N
Cuban NNP 1_i
pneumococcal JJ 1_i
conjugate NN 1_i
vaccine NN 1_i
candidate NN 1_p
in IN 1_p
healthy JJ 1_p
children NNS 1_p
: : 1_p
a DT N
randomized JJ N
phase NN N
I PRP N
clinical JJ N
trial NN N
. . N

A DT N
new JJ N
heptavalent NN 1_i
conjugate NN 1_i
vaccine NN 1_i
( ( 1_i
PCV7-TT NNP 1_i
) ) 1_i
is VBZ N
under IN N
development NN N
in IN N
Cuba NNP N
. . N

PCV7-TT NNP 1_i
contains VBZ N
2 CD N
μg NN N
of IN N
serotypes NNS N
1 CD N
, , N
5 CD N
, , N
14 CD N
, , N
18C CD N
, , N
19F CD N
, , N
23F CD N
and CC N
4 CD N
μg NN N
of IN N
6B CD N
, , N
each DT N
one CD N
conjugated VBN N
to TO N
tetanus VB N
toxoid NN N
( ( N
TT NNP N
) ) N
. . N

This DT N
vaccine NN N
was VBD N
designed VBN N
with IN N
the DT N
serotypes NNS N
that WDT N
cause VBP N
most RBS N
invasive JJ N
pneumococcal JJ N
diseases NNS N
( ( N
IPD NNP N
) ) N
worldwide NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
the DT 1_o
safety NN 1_o
and CC N
explored VBD N
the DT 1_o
immunogenicity NN 1_o
of IN 1_i
PCV7-TT NNP 1_i
during IN N
a DT N
controlled VBN N
, , N
randomized VBN N
and CC N
double JJ N
blind NN N
clinical JJ N
trial NN N
phase NN N
I PRP N
in IN 1_p
4-5-year-old JJ 1_p
children NNS 1_i
. . 1_i

PCV7-TT NN 1_i
was VBD N
well RB 1_o
tolerated JJ 1_o
and CC N
as RB 1_o
safe JJ 1_o
as IN 1_i
Synflorix NNP 1_i
used VBD N
as IN N
control NN N
vaccine NN N
. . N

Following VBG N
a DT N
single-dose JJ N
vaccination NN N
, , N
all DT N
individual JJ N
serotypes NNS N
included VBN N
in IN 1_i
PCV7-TT NNP 1_i
induced VBD N
statistically RB N
significant JJ N
increase NN N
of IN 1_o
IgG NNP 1_o
GMC NNP 1_o
and CC 1_o
OPA NNP 1_o
GMT NNP 1_o
. . N

These DT N
are VBP N
the DT N
first JJ N
clinical JJ N
results NNS N
of IN 1_i
PCV7-TT NNP 1_i
in IN N
children NNS N
and CC N
they PRP N
pave VBP N
the DT N
way NN N
toward IN N
next JJ N
clinical JJ N
trials NNS N
in IN N
children NNS N
and CC N
infants NNS N
. . N

This DT N
clinical JJ N
trial NN N
was VBD N
published VBN N
in IN N
the DT N
Cuban NNP N
Public NNP N
Register NNP N
of IN N
Clinical NNP N
Trials NNP N
with IN N
code NN N
RPCEC00000173 NNP N
. . N

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
fluvoxamine NN 1_i
in IN N
adults NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

BACKGROUND NNP N
Autistic NNP N
disorder NN N
is VBZ N
characterized VBN N
by IN N
a DT N
fundamental JJ N
disturbance NN N
in IN N
social JJ 1_o
interaction NN 1_o
, , 1_o
impairments NNS 1_o
in IN 1_o
communication NN 1_o
, , N
and CC N
a DT N
markedly RB N
restricted JJ 1_o
repertoire NN 1_o
of IN 1_o
activities NNS 1_o
and CC 1_o
interests NNS 1_o
. . 1_o

Abnormalities NNS N
in IN N
the DT N
serotonin NN N
neurotransmitter NN N
system NN N
have VBP N
been VBN N
identified VBN N
in IN N
some DT N
persons NNS N
with IN N
autism NN N
. . N

No DT N
consistently RB N
effective JJ N
and CC N
safe JJ N
drugs NNS N
have VBP N
been VBN N
developed VBN N
for IN N
treating VBG N
the DT N
symptoms NNS 1_o
of IN N
autism NN N
. . N

METHODS NNP N
Thirty NNP 1_p
adults NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
completed VBD N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ 1_i
trial NN N
of IN N
the DT N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitor NN N
fluvoxamine NN 1_i
maleate NN 1_i
. . 1_i

Behavioral JJ 1_o
ratings NNS 1_o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
Eight NNP N
( ( N
53 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
in IN N
the DT N
fluvoxamine-treated JJ 1_i
group NN N
were VBD N
categorized VBN N
as IN N
responders NNS N
compared VBN N
with IN N
none NN N
of IN N
15 CD N
in IN N
the DT N
placebo NN 1_i
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Fluvoxamine NNP 1_i
was VBD N
superior JJ N
to TO N
placebo VB 1_i
in IN N
reducing VBG N
repetitive JJ 1_o
thoughts NNS 1_o
and CC 1_o
behavior NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
maladaptive JJ 1_o
behavior NN 1_o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
aggression NN 1_o
( ( N
P NNP N
< NNP N
.03 NNP N
) ) N
, , N
and CC N
in IN N
improving VBG N
some DT N
aspects NNS N
of IN N
social JJ 1_o
relatedness NN 1_o
( ( N
P NNP N
< NNP N
.04 NNP N
) ) N
, , N
especially RB N
language NN 1_o
usage NN 1_o
( ( N
P NNP N
< NNP N
.008 NNP N
) ) N
. . N

Treatment JJ 1_o
response NN 1_o
was VBD N
not RB N
correlated VBN N
with IN N
age NN 1_o
level NN 1_o
of IN 1_o
autistic JJ 1_o
behavior NN 1_o
, , N
or CC N
full-scale JJ 1_o
IQ NNP 1_o
. . 1_o

Other JJ N
than IN N
mild JJ 1_o
sedation NN 1_o
and CC 1_o
nausea NN 1_o
in IN N
a DT N
few JJ N
patients NNS N
, , N
fluvoxamine NN 1_i
was VBD N
well RB N
tolerated VBN N
. . N

No DT N
dyskinesias NN 1_o
, , 1_o
adverse JJ 1_o
cardiovascular JJ 1_o
events NNS 1_o
, , 1_o
or CC 1_o
seizures NNS 1_o
occurred VBD N
. . N

CONCLUSIONS NNP N
Fluvoxamine NNP 1_i
is VBZ N
more RBR N
effective JJ 1_o
than IN N
placebo NN 1_i
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
the DT N
symptoms NNS 1_o
of IN N
autistic JJ 1_p
disorder NN 1_p
in IN 1_p
adults NNS 1_p
. . 1_p

Controlled JJ N
studies NNS N
of IN N
fluvoxamine NN 1_i
and CC N
other JJ N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitors NNS N
seem VBP N
warranted VBN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
. . N

Time-varying JJ N
smoking NN N
abstinence NN N
predicts VBZ N
lower JJR N
depressive JJ 1_o
symptoms NNS 1_o
following VBG N
smoking VBG N
cessation NN N
treatment NN N
. . N

INTRODUCTION NNP N
The DT N
question NN N
of IN N
whether IN N
abstinence NN N
during IN N
the DT N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
exacerbates VBZ N
or CC N
improves VBZ N
depressive JJ 1_o
symptoms NNS 1_o
is VBZ N
an DT N
important JJ N
clinical JJ N
issue NN N
. . N

Extant NNP N
research NN N
has VBZ N
primarily RB N
modeled VBN N
between-person JJ N
covariation NN N
between IN N
postquit NN N
abstinence NN 1_o
and CC 1_o
depressive JJ 1_o
symptom NN 1_o
trajectories NNS N
. . N

However RB N
, , N
this DT N
approach NN N
can MD N
not RB N
account VB N
for IN N
potential JJ N
third JJ N
variables NNS N
between IN N
participants NNS N
that WDT N
may MD N
affect VB N
both DT N
smoking NN N
and CC N
depression NN N
. . N

Accordingly RB N
, , N
the DT N
current JJ N
study NN N
examined VBD N
within-person JJ N
covariation NN N
between IN N
time-varying JJ 1_o
abstinence NN 1_o
and CC 1_o
depressive JJ 1_o
symptom NN 1_o
in IN N
a DT N
multilevel NN N
model NN N
( ( N
MLM NNP N
) ) N
, , N
which WDT N
allowed VBD N
for IN N
transitions NNS N
between IN N
smoking VBG N
statuses NNS N
within IN N
a DT N
participant NN N
. . N

METHODS JJ N
Participants NNS 1_p
were VBD 1_p
236 CD 1_p
heavy JJ 1_p
drinking NN 1_p
smokers NNS 1_p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
testing VBG N
the DT N
efficacy NN 1_o
of IN N
incorporating VBG N
brief JJ N
alcohol NN 1_i
intervention NN 1_i
into IN N
smoking VBG N
cessation NN N
treatment NN N
. . N

Depressive NNP 1_o
symptoms NNS 1_o
and CC 1_o
biochemically RB 1_o
verified JJ 1_o
abstinence NN 1_o
were VBD N
assessed VBN N
1 CD N
week NN N
prior RB N
to TO N
and CC N
2 CD N
, , N
8 CD N
, , N
16 CD N
, , N
and CC N
26 CD N
weeks NNS N
after IN N
quit NN N
date NN N
. . N

RESULTS NNP N
MLMs NNP N
indicated VBD N
a DT N
slight JJ N
increase NN N
in IN N
depressive JJ 1_o
symptoms NNS 1_o
over IN N
time NN N
in IN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
. . N

However RB N
, , N
there EX N
was VBD N
an DT N
inverse JJ N
relation NN N
between IN N
time-varying JJ 1_o
abstinence NN 1_o
( ( 1_o
vs. IN 1_o
smoking NN 1_o
) ) 1_o
and CC N
concurrent JJ N
level NN 1_o
of IN 1_o
depressive JJ 1_o
symptoms NNS 1_o
, , N
indicating VBG N
that IN N
transitions NNS N
from IN N
smoking VBG N
to TO N
abstinence VB N
within IN N
individuals NNS N
were VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
depressive JJ 1_o
symptoms NNS 1_o
. . 1_o

CONCLUSIONS NNP N
During IN N
the DT N
first JJ N
6 CD N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
, , N
being VBG N
abstinent NN N
in IN N
a DT N
particular JJ N
week NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
lower JJR N
levels NNS N
of IN N
concurrent NN N
depressive NN 1_o
symptoms NNS 1_o
. . 1_o

These DT N
results NNS N
are VBP N
not RB N
concordant JJ N
with IN N
the DT N
view NN N
that IN N
intentional JJ N
smoking NN N
abstinence NN N
exacerbates VBZ N
depressive JJ 1_o
symptoms NNS 1_o
. . 1_o

Efforts NNS N
to TO N
promote VB N
smoking VBG N
cessation NN N
should MD N
highlight VB N
that IN N
individuals NNS N
are VBP N
likely JJ N
to TO N
feel VB N
more RBR N
rather RB N
than IN N
less JJR N
psychologically RB N
healthy JJ N
when WRB N
they PRP N
successfully RB N
quit VBP N
smoking NN N
. . N

Safety NN 1_o
, , 1_o
tolerability NN 1_o
, , 1_o
and CC 1_o
immunogenicity NN 1_o
after IN N
1 CD N
and CC N
2 CD N
doses NNS N
of IN N
zoster NN 1_i
vaccine NN 1_i
in IN N
healthy JJ 1_p
adults NNS 1_p
≥60 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . N

BACKGROUND NNP N
Incidence NNP N
and CC N
severity NN N
of IN N
herpes NNS N
zoster NNP N
( ( N
HZ NNP N
) ) N
and CC N
postherpetic JJ N
neuralgia JJ N
increase NN N
with IN N
age NN N
, , N
associated VBN N
with IN N
age-related JJ N
decrease NN N
in IN N
immunity NN N
to TO N
varicella-zoster JJ N
virus NN N
( ( N
VZV NNP N
) ) N
. . N

One CD N
dose NN N
of IN 1_i
zoster NN 1_i
vaccine NN 1_i
( ( 1_i
ZV NNP 1_i
) ) 1_i
has VBZ N
demonstrated VBN N
substantial JJ N
protection NN N
against IN N
HZ NNP N
; : N
this DT N
study NN N
examined VBD N
impact NN N
of IN N
a DT N
second JJ N
dose NN N
of IN 1_i
ZV NNP 1_i
. . N

METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
multicenter NN N
study NN N
with IN 1_p
210 CD 1_p
subjects NNS 1_p
≥60 CD 1_p
years NNS 1_p
old JJ N
compared VBN 1_o
immunity NN 1_o
and CC 1_o
safety NN 1_o
profiles NNS 1_o
after IN N
one CD N
and CC N
two CD N
doses NNS 1_i
of IN 1_i
ZV NNP N
, , N
separated VBN N
by IN N
6 CD N
weeks NNS N
, , N
vs. FW 1_i
placebo NN 1_o
. . 1_o

Immunogenicity NNP 1_o
was VBD 1_o
evaluated VBN 1_o
using VBG 1_o
VZV NNP 1_o
interferon-gamma JJ 1_o
( ( 1_o
IFN-γ NNP 1_o
) ) 1_o
enzyme-linked JJ 1_o
immunospot NN 1_o
( ( 1_o
ELISPOT NNP 1_o
) ) 1_o
assay NN 1_o
and CC 1_o
VZV NNP 1_o
glycoprotein VBD 1_o
enzyme-linked JJ 1_o
immunosorbent NN 1_o
antibody NN 1_o
( ( 1_o
gpELISA NN 1_o
) ) 1_o
assay NN 1_o
. . 1_o

Adverse JJ 1_o
experiences NNS 1_o
( ( 1_o
AEs NNP 1_o
) ) 1_o
were VBD N
recorded VBN N
on IN 1_o
a DT 1_o
standardized JJ 1_o
Vaccination NNP 1_o
Report NNP 1_o
Card NNP N
. . N

RESULTS NNP 1_o
No NNP 1_o
serious JJ 1_o
vaccine-related JJ 1_o
AEs NNP N
occurred VBD 1_o
. . 1_o

VZV NNP 1_o
IFN-γ NNP 1_o
ELISPOT NNP 1_o
geometric JJ 1_o
mean NN 1_o
count NN 1_o
( ( 1_o
GMC NNP 1_o
) ) 1_o
of IN 1_o
spot-forming JJ 1_o
cells NNS 1_o
per IN 1_o
10 CD 1_o
( ( 1_o
6 CD 1_o
) ) 1_o
peripheral JJ 1_o
blood NN 1_o
mononuclear JJ 1_o
cells NNS N
increased VBN N
in IN 1_i
the DT 1_i
ZV NNP N
group NN N
from IN N
16.9 CD N
prevaccination NN N
to TO N
49.5 CD N
and CC N
32.8 CD N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postdose RB N
1 CD N
, , N
respectively RB N
. . N

Two CD N
weeks NNS N
, , N
6 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
postdose RB N
2 CD N
, , N
GMC NNP N
was VBD N
44.3 CD N
, , N
42.9 CD N
, , N
and CC N
36.5 CD N
, , N
respectively RB 1_o
. . N

GMC NNP N
in IN 1_i
the DT 1_i
placebo NN 1_i
group NN N
did VBD N
not RB N
change NN N
during IN N
the DT N
study NN 1_o
. . 1_o

The DT 1_o
peak JJ 1_o
ELISPOT NNP 1_o
response NN 1_o
occurred VBD N
∼2 NNP N
weeks NNS N
after IN 1_i
each DT N
ZV NNP N
dose NN 1_o
. . 1_o

The DT 1_o
gpELISA NN 1_o
geometric JJ 1_o
mean NN 1_o
titers NNS 1_o
( ( 1_i
GMTs NNP 1_i
) ) 1_i
in IN 1_i
the DT N
ZV NNP N
group NN N
were VBD N
higher JJR N
than IN 1_i
in IN 1_i
the DT 1_i
placebo NN N
group NN N
at IN N
6 CD N
weeks NNS N
after IN N
each DT N
dose NN N
. . N

Correlation NN N
between IN 1_o
the DT 1_o
IFN-γ NNP 1_o
ELISPOT NNP 1_o
and CC 1_o
gpELISA NN 1_o
assays NNS N
was VBD N
poor JJ N
. . N

CONCLUSIONS NNP 1_i
ZV NNP N
was VBD N
generally RB N
well-tolerated JJ N
and CC N
immunogenic JJ 1_p
in IN 1_p
adults NNS 1_p
≥60 CD 1_p
years NNS N
old JJ N
. . N

A DT N
second JJ 1_i
dose NN N
of IN N
ZV NNP N
was VBD 1_o
generally RB 1_o
safe JJ N
, , N
but CC N
did VBD N
not RB N
boost VB N
VZV-specific NNP 1_o
immunity NN N
beyond IN N
levels NNS N
achieved VBN N
postdose RB N
1 CD N
. . N

[ JJ N
Effect NNP N
of IN N
transcranial JJ 1_i
electrostimulation NN 1_i
on IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
in IN N
patients NNS 1_p
with IN 1_p
gastric JJ 1_p
ulcer JJ 1_p
] NN 1_p
. . N

The DT N
study NN N
included VBD N
100 CD 1_p
patients NNS 1_p
with IN 1_p
gastric JJ 1_p
ulcer NNS 1_p
aged VBN 1_p
from IN 1_p
16 CD 1_p
to TO 1_p
60 CD 1_p
years NNS 1_p
. . 1_p

In IN N
58 CD N
patients NNS N
, , N
traditional JJ 1_i
treatment NN 1_i
was VBD N
supplemented VBN N
by IN N
transcranial JJ 1_i
electrotherapy NN 1_i
using VBG N
a DT N
TRANSAIR-02 JJ N
apparatus NN N
. . N

Laboratory NNP 1_o
studies NNS 1_o
included VBD N
measurements NNS 1_o
of IN 1_o
lactoferrin NN 1_o
( ( 1_o
LF NNP 1_o
) ) 1_o
and CC 1_o
tumour JJ 1_o
necrosis NN 1_o
factor-alpha NN 1_o
( ( 1_o
TNF-alpha NNP 1_o
) ) 1_o
, , 1_o
besides VBZ 1_o
standard JJ 1_o
analyses NNS 1_o
. . 1_o

Combined VBN N
treatment NN N
( ( 1_i
traditional JJ 1_i
therapy NN 1_i
plus CC 1_i
electrostimulation NN 1_i
) ) 1_i
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
duration NN 1_o
of IN 1_o
the DT 1_o
main JJ 1_o
symptoms NNS 1_o
of IN 1_o
the DT 1_o
gastric JJ 1_o
ulcer NN 1_o
depending VBG N
on IN N
the DT N
severity NN N
of IN N
ulceration NN N
process NN N
, , N
patients NNS 1_o
' POS 1_o
age NN 1_o
and CC 1_o
sex NN 1_o
. . 1_o

Moreover RB N
, , N
it PRP N
facilitated VBD N
ulcer JJ 1_o
scarring NN 1_o
and CC N
had VBD N
beneficial JJ N
effect NN N
on IN N
dynamics NNS N
of IN N
serum NN 1_o
LF NNP 1_o
and CC 1_o
TNF-alpha NNP 1_o
levels NNS 1_o
. . 1_o

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
multicenter NN N
safety NN 1_o
and CC N
immunogenicity NN 1_o
study NN N
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP 1_i
. . 1_i

The DT N
vaccine NN N
Zostavax NNP 1_i
has VBZ N
been VBN N
shown VBN N
to TO N
prevent VB N
herpes NNS N
zoster NNP N
( ( N
HZ NNP N
) ) N
and CC N
postherpetic JJ N
neuralgia NN N
and CC N
is VBZ N
recommended VBN N
for IN N
individuals NNS N
> CD N
or CC N
=60 CD N
years NNS N
of IN N
age NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
safety NN 1_o
and CC N
the DT N
immunogenicity NN 1_o
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
( ( 1_i
Zostavax NNP 1_i
refrigerated VBD N
) ) N
with IN N
those DT N
of IN N
the DT N
current JJ N
formulation NN N
( ( 1_i
Zostavax NNP 1_i
frozen RB N
) ) N
in IN N
subjects NNS 1_p
> VBP 1_p
or CC 1_p
=50 CD 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
. . 1_p

Subjects VBZ 1_p
with IN 1_p
a DT 1_p
negative JJ 1_p
history NN 1_p
for IN 1_p
HZ NNP 1_p
were VBD N
randomized VBN N
1:1 CD N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
formulation NN N
. . N

Enrollment NN 1_p
was VBD 1_p
stratified VBN 1_p
1:2 CD 1_p
by IN 1_p
age NN 1_p
( ( 1_p
50 CD 1_p
to TO 1_p
59 CD 1_p
years NNS 1_p
and CC 1_p
> NN 1_p
or CC 1_p
=60 CD 1_p
years NNS 1_p
) ) 1_p
. . N

Safety NN 1_o
was VBD N
evaluated VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Varicella-zoster JJ 1_o
virus NN 1_o
( ( 1_o
VZV NNP 1_o
) ) 1_o
antibody NN 1_o
responses NNS 1_o
were VBD N
measured VBN N
by IN N
a DT N
glycoprotein JJ 1_o
enzyme-linked JJ 1_o
immunosorbent NN 1_o
assay NN 1_o
( ( 1_o
gpELISA NN 1_o
) ) 1_o
. . 1_o

The DT N
primary JJ N
endpoints NNS N
were VBD N
the DT N
VZV NNP 1_o
antibody NN 1_o
geometric JJ 1_o
mean NN 1_o
titer NN 1_o
( ( 1_o
GMT NNP 1_o
; : 1_o
day NN N
28 CD N
) ) N
, , N
the DT N
VZV NNP 1_o
antibody NN 1_o
geometric JJ 1_o
mean NN 1_o
rise NN 1_o
( ( 1_o
GMR NNP 1_o
; : 1_o
days NNS N
1 CD N
to TO N
28 CD N
) ) N
, , N
and CC N
the DT N
incidence NN 1_o
of IN 1_o
vaccine-related JJ 1_o
serious JJ 1_o
adverse JJ 1_o
experiences NNS 1_o
( ( 1_o
AEs NNP 1_o
) ) 1_o
over IN N
28 CD N
days NNS N
. . N

The DT N
refrigerated JJ N
( ( N
n JJ N
= NNP N
182 CD N
) ) N
and CC N
frozen JJ N
( ( N
n JJ N
= NNP N
185 CD N
) ) N
formulations NNS N
induced VBD N
similar JJ N
GMTs NNP 1_o
( ( N
727.4 CD N
and CC N
834.4 CD N
gpELISA NN 1_o
units/ml NN N
, , N
respectively RB N
) ) N
; : N
the DT N
estimated VBN N
GMT NNP 1_o
ratio NN N
( ( N
refrigerated VBN N
formulation/frozen RB N
formulation NN N
) ) N
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.71 CD N
to TO N
1.07 CD N
) ) N
. . N

The DT N
GMRs NNPS 1_o
were VBD N
2.6- JJ N
and CC N
2.9-fold JJ N
, , N
respectively RB N
. . N

No DT N
vaccine-related JJ 1_o
serious JJ 1_o
AEs NNP 1_o
were VBD N
reported VBN N
in IN N
either DT N
group NN N
, , N
and CC N
the DT N
safety NN 1_o
profiles NNS N
of IN N
the DT N
formulations NNS N
were VBD N
generally RB N
similar JJ N
. . N

The DT N
frequencies NNS N
of IN N
injection-site JJ 1_o
AEs NNP 1_o
during IN N
follow-up JJ N
were VBD N
35.6 CD N
% NN N
and CC N
46.4 CD N
% NN N
in IN N
the DT N
refrigerated JJ N
and CC N
the DT N
frozen JJ N
formulation NN N
groups NNS N
, , N
respectively RB N
, , N
and CC N
were VBD N
generally RB N
mild VBN N
. . N

The DT N
frequencies NNS N
of IN N
systemic JJ 1_o
AEs NNP 1_o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
and CC N
those DT N
of IN N
vaccine-related JJ 1_o
AEs NNP 1_o
were VBD N
approximately RB N
6 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP 1_i
has VBZ N
an DT N
acceptable JJ N
safety NN 1_o
profile NN N
and CC N
is VBZ N
as RB N
immunogenic JJ 1_o
as IN N
the DT N
frozen JJ N
formulation NN N
; : N
thus RB N
, , N
the DT N
vaccine NN N
may MD N
be VB N
used VBN N
in IN N
clinical JJ N
settings NNS N
where WRB N
freezer NN N
availability NN N
is VBZ N
limited VBN N
. . N

The DT N
effect NN N
of IN N
two CD N
types NNS N
of IN N
teacher NN 1_i
training NN 1_i
on IN N
implementation NN 1_o
of IN 1_o
Smart NNP 1_o
Choices NNPS 1_o
: : 1_o
a DT N
tobacco NN N
prevention NN N
curriculum NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
implementation NN N
phase NN N
of IN N
a DT N
four-year JJ N
research NN N
project NN N
to TO N
test VB N
the DT N
effectiveness NN 1_o
of IN N
strategies NNS N
to TO N
increase VB N
diffusion NN 1_o
of IN 1_o
Smart NNP 1_o
Choices NNP 1_o
, , N
a DT N
school-based JJ N
tobacco NN N
prevention NN N
program NN N
. . N

The DT N
impact NN 1_o
on IN N
curriculum JJ N
implementation NN N
of IN N
two CD N
approaches NNS N
to TO N
teacher VB 1_i
training NN 1_i
are VBP N
compared VBN N
. . N

School JJ 1_p
districts NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
live JJ 1_i
workshop NN 1_i
training NN 1_i
or CC N
video NN 1_i
training NN 1_i
condition NN 1_i
. . 1_i

The DT N
outcome NN N
of IN N
the DT N
evaluation NN N
was VBD N
teachers NNS 1_o
' POS 1_o
implementation NN 1_o
of IN 1_o
Smart NNP 1_o
Choices NNP 1_o
. . 1_o

Results NNP N
show VBP N
a DT N
lower JJR N
proportion NN N
of IN N
video-trained JJ 1_i
teachers NNS 1_i
implemented VBD N
the DT N
curriculum NN N
, , N
but CC N
overall JJ N
completeness NN 1_o
and CC 1_o
fidelity NN 1_o
of IN 1_o
implementation NN 1_o
for IN N
those DT N
teachers NNS N
who WP N
did VBD N
teach VB N
the DT N
curriculum NN N
were VBD N
comparable JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

Video-trained JJ 1_i
teachers NNS 1_i
, , N
however RB N
, , N
were VBD N
less RBR N
likely JJ N
to TO N
use VB N
brainstorming NN N
and CC N
student NN N
presentations/role NN N
plays NNS N
, , N
two CD N
of IN N
the DT N
methods NNS N
prescribed VBN N
by IN N
the DT N
curriculum NN N
. . N

Implications NNS N
of IN N
the DT N
results NNS N
for IN N
teacher JJ 1_i
training NN 1_i
are VBP N
discussed VBN N
. . N

Effectiveness NN 1_o
of IN N
hygienic-dietary JJ 1_i
recommendations NNS 1_i
as IN N
enhancers NNS N
of IN N
antidepressant JJ N
treatment NN N
in IN N
patients NNS 1_p
with IN 1_p
depression NN 1_p
: : 1_p
study NN N
protocol NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
In IN N
recent JJ N
years NNS N
some DT N
studies NNS N
have VBP N
been VBN N
published VBN N
supporting VBG N
the DT N
efficacy NN 1_o
of IN N
light JJ N
exposure NN N
, , N
physical JJ N
activity NN N
, , N
sleep VB N
control NN N
and CC N
a DT N
Mediterranean NNP N
diet JJ N
pattern NN N
on IN N
the DT N
improvement NN N
or CC N
prevention NN N
of IN N
depression NN N
. . N

However RB N
, , N
to TO N
our PRP$ N
knowledge NN N
, , N
there EX N
have VBP N
been VBN N
no DT N
studies NNS N
using VBG N
all PDT N
these DT N
measures NNS N
together RB N
as IN N
an DT N
adjuvant JJ N
antidepressant NN N
strategy NN N
. . N

METHODS NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
controlled VBN N
, , N
two CD N
arm-parallel JJ N
, , N
clinical JJ N
trial NN N
. . N

Eighty NNP 1_p
depressed VBD 1_p
patients NNS 1_p
undergoing VBG 1_p
standard JJ 1_p
antidepressant JJ 1_i
treatment NN 1_p
will MD N
be VB N
advised VBN N
to TO N
follow VB N
four CD N
additional JJ N
hygienic-dietary JJ 1_i
recommendations NNS 1_i
about IN N
exercise NN N
, , N
diet JJ N
, , N
sunlight JJ N
exposure NN N
and CC N
sleep NN N
. . N

Outcome NNP 1_o
measures NNS 1_o
will MD N
be VB N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
6 CD N
month NN N
intervention NN N
period NN N
. . N

DISCUSSION NNP N
We PRP N
expect VBP N
the DT N
patients NNS N
in IN N
the DT N
active JJ N
recommendations NNS N
group NN N
to TO N
experience VB N
a DT N
greater JJR N
improvement NN N
in IN N
their PRP$ N
depressive NN 1_o
symptoms NNS 1_o
. . 1_o

If IN N
so RB N
, , N
this DT N
would MD N
be VB N
a DT N
great JJ N
support NN N
for IN N
doctors NNS N
who WP N
might MD N
systematically RB N
recommend VB N
these DT N
simple JJ N
and CC N
costless JJ N
measures NNS N
, , N
especially RB N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN59506583 NNP N
. . N

Inference-Based JJ 1_i
Approach NNP 1_i
versus NN N
Cognitive NNP 1_i
Behavioral NNP 1_i
Therapy NNP 1_i
in IN N
the DT N
Treatment NNP N
of IN N
Obsessive-Compulsive NNP 1_p
Disorder NNP 1_p
with IN 1_p
Poor NNP 1_p
Insight NNP 1_p
: : 1_p
A DT N
24-Session JJ N
Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

OBJECTIVE NNP N
Obsessive-compulsive JJ N
disorder NN N
( ( N
OCD NNP N
) ) N
with IN N
poor JJ N
insight NN N
has VBZ N
severe JJ N
consequences NNS N
for IN N
patients NNS N
; : N
nonetheless RB N
, , N
no DT N
randomized VBN N
controlled VBN N
trial NN N
has VBZ N
ever RB N
been VBN N
performed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN 1_o
of IN N
any DT N
treatment NN N
specifically RB N
for IN N
poor-insight JJ 1_p
OCD NNP 1_p
. . 1_p

A DT N
new JJ N
psychotherapy NN N
for IN N
OCD NNP N
, , N
the DT N
inference-based JJ 1_i
approach NN 1_i
( ( 1_i
IBA NNP 1_i
) ) 1_i
, , N
targets NNS N
insight VBP N
in IN N
OCD NNP N
by IN N
strengthening VBG N
normal JJ N
sensory-driven JJ N
reality NN N
testing VBG N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
effectiveness NN 1_o
of IN N
this DT N
new JJ N
treatment NN N
to TO N
the DT N
effectiveness NN 1_o
of IN N
cognitive JJ 1_i
behavior NN 1_i
therapy NN 1_i
( ( 1_i
CBT NNP 1_i
) ) 1_i
for IN N
patients NNS 1_p
with IN 1_p
OCD NNP 1_p
with IN 1_p
poor JJ 1_p
insight NN 1_p
. . 1_p

METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
, , N
in IN N
which WDT N
90 CD 1_p
patients NNS 1_p
with IN 1_p
OCD NNP 1_p
with IN 1_p
poor JJ 1_p
insight NN 1_p
received VBD N
either RB N
24 CD N
CBT NNP 1_i
sessions NNS N
or CC N
24 CD N
IBA JJ 1_i
sessions NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Yale-Brown JJ 1_o
Obsessive NNP 1_o
Compulsive NNP 1_o
Scale NNP 1_o
( ( 1_o
YBOCS NNP 1_o
) ) 1_o
. . 1_o

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
level NN 1_o
of IN 1_o
insight NN 1_o
, , 1_o
anxiety NN 1_o
and CC 1_o
depressive JJ 1_o
symptoms NNS 1_o
, , 1_o
and CC 1_o
quality NN 1_o
of IN 1_o
life NN 1_o
. . 1_o

Mixed-effects NNS 1_o
models NNS 1_o
were VBD N
used VBN N
to TO N
determine VB N
the DT N
treatment NN N
effect NN N
. . N

RESULTS NN N
In IN N
both DT N
conditions NNS N
, , N
a DT N
significant JJ N
OCD NNP 1_o
symptom NN 1_o
reduction NN 1_o
was VBD N
reached VBN N
, , N
but CC N
no DT N
condition NN 1_o
effects NNS 1_o
were VBD N
established VBN N
. . N

Post NNP N
hoc NN N
, , N
in IN N
a DT N
small JJ N
subgroup NN N
of IN N
patients NNS N
with IN N
the DT N
worst JJS N
insight NN N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
, , N
it PRP N
was VBD N
found VBN N
that IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
IBA NNP 1_i
reached VBD N
a DT N
significantly RB N
higher JJR N
OCD NNP 1_o
symptom VBZ 1_o
reduction NN 1_o
than IN N
the DT N
patients NNS N
treated VBN N
with IN N
CBT NNP 1_i
[ NNP N
estimated VBD N
marginal JJ N
mean NN N
= NNP N
-7.77 NNP N
, , N
t NN N
( ( N
219.45 CD N
) ) N
= NN N
-2.4 NN N
, , N
p NN N
= VBD N
0.017 CD N
] NN N
. . N

CONCLUSION NNP N
Patients NNPS 1_p
with IN 1_p
OCD NNP 1_p
with IN 1_p
poor JJ 1_p
insight JJ 1_p
improve VB N
significantly RB N
after IN N
psychological JJ N
treatment NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
both DT N
CBT NNP 1_i
and CC N
the DT N
IBA NNP 1_i
are VBP N
effective JJ 1_o
treatments NNS N
for IN N
OCD NNP N
with IN N
poor JJ N
insight NN N
. . N

The DT N
IBA NNP 1_i
might MD N
be VB N
more RBR N
promising JJ N
than IN N
CBT NNP 1_i
for IN N
patients NNS 1_p
with IN 1_p
more RBR 1_p
extreme JJ 1_p
poor JJ 1_p
insight NN 1_p
. . 1_p

Identifying VBG 1_o
patients NNS 1_o
at IN 1_o
high JJ 1_o
risk NN 1_o
for IN 1_o
neutropenic JJ 1_o
complications NNS 1_o
during IN N
chemotherapy NN N
for IN N
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
with IN N
doxorubicin NN 1_i
or CC N
pegylated VBN 1_i
liposomal JJ 1_i
doxorubicin NN 1_i
: : 1_i
the DT N
development NN N
of IN N
a DT N
prediction NN N
model NN N
. . N

OBJECTIVE UH N
To TO N
develop VB N
a DT N
cycle-based JJ 1_o
risk NN 1_o
prediction NN 1_o
model NN 1_o
for IN 1_o
neutropenic JJ 1_o
complications NNS 1_o
( ( 1_o
NC NNP 1_o
) ) 1_o
during IN N
chemotherapy NN N
with IN N
doxorubicin NN 1_i
( ( 1_i
DOX NNP 1_i
) ) 1_i
or CC N
a DT N
pegylated JJ 1_i
liposomal JJ 1_i
formulation NN 1_i
( ( 1_i
PLD NNP 1_i
) ) 1_i
for IN N
patients NNS 1_p
with IN 1_p
metastatic JJ 1_p
breast NN 1_p
cancer NN 1_p
( ( 1_p
MBC NNP 1_p
) ) 1_p
. . 1_p

METHODS NNP N
Data NNP N
analyzed VBD N
was VBD N
from IN N
a DT N
phase NN N
III NNP N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
DOX NNP 1_i
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
weeks NNS N
) ) N
or CC N
PLD NNP 1_i
( ( N
50 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
4 CD N
weeks NNS N
) ) N
for IN N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
MBC NNP 1_p
( ( 1_p
n JJ 1_p
= NNP 1_p
509 CD 1_p
) ) 1_p
( ( N
O'Brien NNP N
et RB N
al RB N
, , N
Ann NNP N
Oncol NNP N
. . N

2004 CD N
; : N
15:440-449 JJ N
) ) N
. . N

NC NNP 1_o
were VBD N
defined VBN N
as IN N
an DT N
absolute NN 1_o
neutrophil NN 1_o
count NN 1_o
< NNP 1_o
or CC 1_o
=1.5 NNP 1_o
x VBP 1_o
10 CD 1_o
( ( 1_o
9 CD 1_o
) ) 1_o
cells/L NN 1_o
( ( 1_o
ie JJ 1_o
, , 1_o
> JJ 1_o
or CC 1_o
=grade JJ 1_o
II NNP 1_o
) ) 1_o
before IN 1_o
the DT 1_o
next JJ 1_o
cycle NN 1_o
, , 1_o
febrile JJ 1_o
neutropenia NN 1_o
or CC 1_o
neutropenia NN 1_o
with IN 1_o
a DT 1_o
documented JJ 1_o
infection NN 1_o
. . 1_o

Patient NNP 1_o
and CC 1_o
hematologic JJ 1_o
factors NNS 1_o
potentially RB 1_o
associated VBN 1_o
with IN 1_o
NC NNP 1_o
were VBD N
evaluated VBN N
. . N

Factors NNS N
with IN N
a DT N
P NNP N
value NN N
of IN N
< NNP N
or CC N
=0.25 NNP N
within IN N
a DT N
cycle NN N
were VBD N
included VBN N
in IN N
a DT N
generalized JJ N
estimating NN N
equations NNS N
regression NN N
model NN N
. . N

Using VBG N
backward JJ N
elimination NN N
, , N
we PRP N
derived VBD N
a DT N
risk NN 1_o
scoring VBG 1_o
algorithm NN 1_o
( ( N
range VB N
0-63 NN N
) ) N
from IN N
the DT N
final JJ N
reduced VBN N
model NN N
. . N

RESULTS NNP N
Risk NNP 1_o
factors NNS 1_o
retained VBD N
in IN N
the DT N
model NN N
included VBD N
poor JJ 1_o
performance NN 1_o
status NN 1_o
, , 1_o
absolute VB 1_o
neutrophil JJ 1_o
count NN 1_o
< NN 1_o
or CC 1_o
=2.0 VB 1_o
x JJ 1_o
10 CD 1_o
( ( 1_o
9 CD 1_o
) ) 1_o
cells/L NN 1_o
in IN N
the DT N
previous JJ N
cycle NN N
, , N
the DT N
first JJ N
cycle NN N
of IN N
chemotherapy NN N
, , N
DOX NNP 1_i
versus NN N
PLD NNP 1_i
and CC N
advanced JJ N
age NN 1_o
. . 1_o

A DT N
precycle NN 1_o
risk NN 1_o
score NN 1_o
from IN N
> NN N
or CC N
=25 NN N
to TO N
< VB N
40 CD N
for IN N
a DT N
given VBN N
patient NN N
was VBD N
identified VBN N
as IN N
being VBG N
the DT N
optimal JJ N
threshold NN N
for IN N
sensitivity NN N
( ( N
58.0 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
78.7 CD N
% NN N
) ) N
. . N

Patients NNS N
with IN N
a DT N
score NN N
at IN N
or CC N
beyond IN N
this DT N
threshold NN N
would MD N
be VB N
considered VBN N
at IN N
high JJ N
risk NN 1_o
for IN N
developing VBG N
NC NNP 1_o
in IN N
later JJ N
cycles NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
this DT N
model NN N
may MD N
enhance VB N
patient NN N
care NN N
by IN N
targeting VBG N
preventative JJ N
therapies NNS N
( ( N
eg NN N
, , N
granulocyte NN N
colony NN N
stimulating VBG N
factor NN N
or CC N
PLD NNP 1_i
) ) 1_i
to TO N
those DT N
MBC NNP 1_p
patients NNS 1_p
most RBS N
likely JJ N
to TO N
experience VB N
NC NNP 1_o
during IN N
anthracycline-based JJ N
chemotherapy NN N
. . N

Long-term JJ 1_o
survival NN 1_o
in IN N
a DT N
phase NN N
III NNP N
, , N
randomised VBD N
study NN N
of IN N
topotecan JJ 1_i
versus NN N
paclitaxel NN 1_i
in IN N
advanced JJ 1_p
epithelial JJ 1_p
ovarian JJ 1_p
carcinoma NN 1_p
. . 1_p

BACKGROUND IN N
We PRP N
have VBP N
continued VBN N
to TO N
monitor VB N
the DT N
survival NN 1_o
of IN N
patients NNS N
randomised VBN N
in IN N
a DT N
previously RB N
reported VBN N
multicentre JJ N
phase NN N
III NNP N
study NN N
of IN N
topotecan JJ 1_i
versus NN N
paclitaxel NN 1_i
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
epithelial JJ 1_p
ovarian JJ 1_p
cancer NN 1_p
who WP 1_p
had VBD 1_p
failed VBN 1_p
one CD 1_p
prior JJ 1_p
platinum-based JJ 1_p
regimen NNS 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS 1_p
with IN 1_p
bidimensionally RB 1_p
measurable JJ 1_p
disease NN 1_p
were VBD N
randomised VBN N
to TO N
topotecan VB 1_i
( ( N
1.5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
for IN N
5 CD N
days NNS N
) ) N
or CC N
paclitaxel NN 1_i
( ( N
175 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
as IN N
a DT N
3-h JJ N
infusion NN N
) ) N
every DT N
21 CD N
days NNS N
. . N

Patients NNS N
were VBD N
eligible JJ N
for IN N
treatment NN N
with IN N
the DT N
alternate NN N
therapy NN N
at IN N
third JJ N
line NN N
. . N

The DT 1_o
European JJ 1_o
Organisation NNP 1_o
for IN 1_o
Research NNP 1_o
and CC 1_o
Treatment NNP 1_o
of IN 1_o
Cancer NNP 1_o
Quality NNP 1_o
of IN 1_o
Life NNP 1_o
( ( 1_o
EORTC NNP 1_o
QOL NNP 1_o
) ) 1_o
-C30 VBP 1_o
questionnaire NN 1_o
was VBD N
also RB N
used VBN N
to TO N
measure VB N
eight CD N
symptoms NNS N
at IN N
baseline NN N
and CC N
during IN N
each DT N
course NN N
( ( 1_o
pain NN 1_o
, , 1_o
anorexia NN 1_o
, , 1_o
diarrhoea NN 1_o
, , 1_o
fatigue NN 1_o
, , 1_o
nausea NN 1_o
and CC 1_o
vomiting NN 1_o
, , 1_o
dyspnea NN 1_o
, , 1_o
constipation NN 1_o
and CC 1_o
insomnia NN 1_o
) ) 1_o
. . N

RESULTS VB N
A DT 1_p
total NN 1_p
of IN 1_p
226 CD 1_p
patients NNS 1_p
were VBD 1_p
evaluable JJ 1_p
for IN 1_p
response NN 1_p
. . 1_p

Demographic JJ N
characteristics NNS N
were VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
as IN N
were VBD N
results NNS N
of IN N
the DT N
EORTC NNP 1_o
QOL-30 NNP 1_o
questionnaire NN 1_o
. . 1_o

For IN N
the DT N
topotecan JJ 1_i
group NN N
, , N
median JJ N
time NN N
to TO N
progression NN 1_o
was VBD N
18.9 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
92.6+ CD N
weeks NNS N
; : N
25 CD N
% NN N
censored VBN N
) ) N
, , N
and CC N
, , N
for IN N
paclitaxel NN 1_i
, , N
14.7 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
137.3+ CD N
weeks NNS N
; : N
12.3 CD N
% NN N
censored VBN N
) ) N
; : N
P NNP N
= VBD N
0.076 CD N
. . N

At IN N
4 CD N
years NNS N
post-randomisation NN N
, , N
median JJ 1_o
survival NN 1_o
in IN N
the DT N
topotecan JJ 1_i
group NN N
was VBD N
63.0 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
238.4+ CD N
weeks NNS N
; : N
20.5 CD N
% NN N
censored VBN N
) ) N
and CC N
, , N
for IN N
paclitaxel NN 1_i
, , N
53.0 CD N
weeks NNS N
( ( N
range NN N
< RB N
1 CD N
to TO N
226.3+ CD N
weeks NNS N
; : N
12.3 CD N
% NN N
censored VBN N
) ) N
; : N
P NNP N
= VBD N
0.44 CD N
. . N

CONCLUSION NNP N
Topotecan NNP 1_i
continues VBZ N
to TO N
demonstrate VB N
comparable JJ N
efficacy NN 1_o
and CC N
survival NN 1_o
to TO N
paclitaxel VB 1_i
with IN N
manageable JJ N
and CC N
non-cumulative JJ N
haematological JJ 1_o
toxicity NN 1_o
. . 1_o

Non-haematological JJ 1_o
toxicity NN 1_o
was VBD N
generally RB N
mild VBN N
for IN N
both DT N
groups NNS N
. . N

The DT N
long-term JJ 1_o
survival NN 1_o
rate NN 1_o
indicates VBZ N
substantial JJ N
therapeutic JJ N
benefit NN N
for IN N
this DT N
group NN N
of IN N
patients NNS N
receiving VBG N
topotecan JJ 1_i
at IN N
relapse NN N
of IN N
ovarian JJ 1_p
cancer NN 1_p
. . 1_p

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
a DT N
social JJ 1_i
skills NNS 1_i
training VBG 1_i
for IN N
preadolescent JJ 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
: : 1_p
generalization NN N
of IN N
skills NNS N
by IN N
training VBG N
parents NNS N
and CC N
teachers NNS N
? . N
BACKGROUND NNP N
Social NNP 1_i
skills NNS 1_i
training VBG 1_i
( ( 1_i
SST NNP 1_i
) ) 1_i
is VBZ N
a DT N
common JJ N
intervention NN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
( ( 1_p
ASDs NNP 1_p
) ) 1_p
to TO N
improve VB N
their PRP$ N
social JJ 1_o
and CC 1_o
communication NN 1_o
skills NNS 1_o
. . 1_o

Despite IN N
the DT N
fact NN N
that IN N
SSTs NNP 1_i
are VBP N
often RB N
applied VBN N
in IN N
clinical JJ N
practice NN N
, , N
the DT N
evidence NN N
for IN N
the DT N
effectiveness NN 1_o
of IN N
these DT N
trainings NNS N
for IN N
children NNS 1_p
with IN 1_p
ASD NNP 1_p
is VBZ N
inconclusive JJ N
. . N

Moreover RB N
, , N
long JJ 1_o
term NN 1_o
outcome NN 1_o
and CC N
generalization NN 1_o
of IN 1_o
learned JJ 1_o
skills NNS 1_o
are VBP N
little JJ N
evaluated JJ N
. . N

Additionally RB N
, , N
there EX N
is VBZ N
no DT N
research NN N
on IN N
the DT N
influence NN N
of IN N
involvement NN N
of IN N
parents NNS N
and CC N
teachers NNS N
on IN N
effectiveness NN 1_o
of IN N
SST NNP 1_i
and CC N
on IN N
the DT N
generalization NN 1_o
of IN 1_o
learned VBN 1_o
social JJ 1_o
skills NNS 1_o
to TO 1_o
daily JJ 1_o
life NN 1_o
. . 1_o

We PRP N
expect VBP N
parent NN N
and CC N
teacher NN N
involvement NN N
in IN N
SST NNP 1_i
to TO N
enhance VB N
treatment NN 1_o
efficacy NN 1_o
and CC N
to TO N
facilitate VB N
generalization NN 1_o
of IN 1_o
learned JJ 1_o
skills NNS 1_o
to TO 1_o
daily JJ 1_o
life NN 1_o
. . 1_o

METHOD/DESIGN NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
with IN N
three CD N
conditions NNS N
, , N
120 CD 1_p
participants NNS 1_p
with IN 1_p
ASD NNP 1_p
at IN 1_p
the DT 1_p
end NN 1_p
of IN 1_p
primary JJ 1_p
school NN 1_p
( ( 1_p
10-12 CD 1_p
years NNS 1_p
of IN 1_p
calendar NN 1_p
age NN 1_p
) ) 1_p
have VBP N
been VBN N
randomized VBN N
to TO N
SST NNP 1_i
, , 1_i
SST-PTI NNP 1_i
( ( 1_i
SST NNP 1_i
with IN 1_i
Parent NNP 1_i
& CC 1_i
Teacher NNP 1_i
Involvement NNP 1_i
) ) 1_i
, , N
or CC N
care-as-usual JJ 1_i
. . 1_i

The DT N
SST NNP 1_i
consists VBZ N
of IN N
18 CD N
group NN N
sessions NNS N
of IN N
1.5 CD N
hours NNS N
for IN N
the DT N
children NNS N
. . N

In IN N
the DT N
SST-PTI JJ 1_i
condition NN N
, , N
parents NNS N
additionally RB N
participate VBP N
in IN N
8 CD N
parent NN N
sessions NNS N
and CC N
parents NNS N
and CC N
teachers NNS N
are VBP N
actively RB N
involved VBN N
in IN N
homework NN N
assignments NNS N
. . N

Assessment NNP N
takes VBZ N
place NN N
at IN N
three CD N
moments NNS N
: : N
before RB N
and CC N
immediately RB N
after IN N
the DT N
intervention NN N
period NN N
and CC N
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

Primary JJ N
outcome NN N
is VBZ N
socialization NN 1_o
, , N
as IN N
an DT N
aspect NN N
of IN N
adaptive JJ 1_o
functioning NN 1_o
. . 1_o

Secondary JJ N
outcomes NNS N
focus VBP N
on IN N
specific JJ 1_o
social JJ 1_o
skills NNS 1_o
children NNS N
learn VBP N
during IN N
SST NNP 1_i
and CC N
on IN N
more JJR N
general JJ 1_o
social JJ 1_o
skills NNS 1_o
pertaining VBG N
to TO N
home NN N
and CC N
community NN N
settings NNS N
from IN N
a DT N
multi-informant JJ N
perspective NN N
. . N

Additionally RB N
, , N
possible JJ 1_o
predictors NNS 1_o
of IN 1_o
treatment NN 1_o
outcome NN 1_o
will MD N
be VB N
assessed VBN N
. . N

DISCUSSION VB N
The DT N
current JJ N
study NN N
is VBZ N
an DT N
RCT NNP N
study NN N
evaluating VBG N
SST NNP 1_i
in IN N
a DT N
large JJ N
sample NN N
of IN N
Dutch NNP 1_p
children NNS 1_p
with IN 1_p
ASD NNP 1_p
in IN 1_p
a DT 1_p
specific JJ 1_p
age NN 1_p
range NN 1_p
( ( 1_p
10-12 CD 1_p
years NNS 1_p
) ) 1_p
. . 1_p

Strengths NNP N
of IN N
the DT N
study NN N
are VBP N
the DT N
use NN N
of IN N
one CD N
manualized VBN N
protocol NN N
, , N
application NN N
of IN N
standardized JJ N
and CC N
internationally RB N
used VBD N
rating NN N
instruments NNS N
, , N
use NN N
of IN N
multiple JJ N
raters NNS N
, , N
investigation NN N
of IN N
generalization NN 1_o
of IN N
learned JJ N
skills NNS N
to TO N
daily JJ N
life NN N
, , N
and CC N
the DT N
evaluation NN N
of IN N
efficacy NN 1_o
in IN N
the DT N
longer JJR N
term NN N
by IN N
follow-up JJ N
measures NNS N
at IN N
6 CD N
months NNS N
after IN N
the DT N
end NN N
of IN N
training NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NTR2405 NNP N
. . N

Local JJ N
immunotherapy NN N
by IN N
inhalation NN N
of IN N
a DT N
powder NN N
extract NN N
in IN N
asthma NN 1_p
due JJ 1_p
to TO 1_p
house NN 1_p
dust NN 1_p
mite NN 1_p
Dermatophagoides NNP 1_p
pteronyssinus NN 1_p
: : 1_p
a DT N
double-blind JJ N
comparison NN N
with IN N
parenteral JJ N
immunotherapy NN N
. . N

To TO N
verify VB N
the DT N
efficacy NN 1_o
and CC N
the DT N
tolerability NN 1_o
of IN N
local JJ 1_i
immunotherapy NN 1_i
( ( N
LI NNP N
) ) N
by IN N
inhalation NN N
of IN N
a DT N
powder NN 1_i
extract NN 1_i
of IN 1_i
house NN 1_i
dust NN 1_i
mite NN 1_i
( ( 1_i
HDM NNP 1_i
) ) 1_i
, , N
in IN N
comparison NN N
with IN N
parenteral JJ 1_i
immunotherapy NN 1_i
( ( 1_i
PI NNP 1_i
) ) 1_i
by IN N
injection NN N
, , N
10 CD 1_p
patients NNS 1_p
with IN 1_p
asthma NNS 1_p
due JJ 1_p
to TO 1_p
HDM NNP 1_p
were VBD N
studied VBN N
in IN N
a DT N
blind JJ N
fashion NN N
. . N

5 CD N
patients NNS N
( ( N
Group NNP N
A NNP N
) ) N
underwent NN N
LI NNP N
and CC N
subcutaneous JJ N
injections NNS N
of IN N
placebo NN 1_i
, , N
5 CD N
patients NNS N
( ( N
Group NNP N
B NNP N
) ) N
underwent NN N
PI NNP N
and CC N
inhalation NN N
of IN N
lactose NN 1_i
for IN N
6 CD N
months NNS N
. . N

In IN N
both DT N
groups NNS N
each DT N
inhalation NN N
was VBD N
preceded VBN N
by IN N
premedication NN N
with IN N
disodium NN 1_i
cromoglycate NN 1_i
( ( 1_i
DSCG NNP 1_i
) ) 1_i
( ( N
40 CD N
mg NN N
) ) N
. . N

In IN N
Group NNP N
A NNP N
a DT N
significant JJ N
decrease NN N
in IN N
symptoms NNS 1_o
score NN 1_o
and CC N
in IN N
peak JJ 1_o
expiratory NN 1_o
flow NN 1_o
( ( 1_o
PEF NNP 1_o
) ) 1_o
-derived VBD 1_o
parameters NNS 1_o
was VBD N
observed VBN N
already RB N
after IN N
3 CD N
months NNS N
of IN N
treatment NN N
, , N
and CC N
2 CD N
patients NNS N
lost VBD N
the DT N
late JJ N
component NN N
of IN N
the DT N
bronchial JJ 1_o
response NN 1_o
to TO N
the DT N
challenge NN N
with IN N
HDM NNP N
. . N

No NNP N
significant JJ N
variation NN N
was VBD N
found VBN N
in IN N
bronchial JJ 1_o
responsiveness NN 1_o
to TO N
methacholine VB N
and CC N
ultrasonically RB N
nebulized VBN N
distilled JJ N
water NN N
( ( N
UNDW NNP N
) ) N
and CC N
in IN N
immunologic JJ 1_o
humoral JJ 1_o
and CC 1_o
cellular JJ 1_o
parameters NNS 1_o
in IN 1_o
peripheral JJ 1_o
blood NN 1_o
after IN N
treatment NN N
in IN N
either DT N
group NN N
. . N

No DT N
local JJ 1_o
important JJ 1_o
adverse JJ 1_o
reactions NNS 1_o
were VBD N
observed VBN N
in IN N
Group NNP N
A NNP N
and CC N
no DT N
systemic JJ 1_o
side NN 1_o
effects NNS 1_o
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
LI NNP N
is VBZ N
as RB N
effective JJ 1_o
as IN N
PI NNP N
, , N
but CC N
more RBR N
rapid JJ N
in IN N
its PRP$ N
action NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
asthma NNS 1_p
due JJ 1_p
to TO 1_p
HDM NNP 1_p
. . 1_p

Moreover RB N
, , N
LI NNP N
is VBZ N
locally RB N
well RB N
tolerated VBN 1_o
, , N
providing VBG N
DSCG NNP 1_i
is VBZ N
inhaled VBN N
before IN N
each DT N
therapeutic JJ N
inhalation NN N
, , N
and CC N
does VBZ N
not RB N
induce VB N
systemic JJ 1_o
side NN 1_o
effects NNS 1_o
. . 1_o

Influence NN N
of IN N
diets NNS N
rich JJ N
in IN N
Maillard NNP 1_i
reaction NN 1_i
products NNS 1_i
on IN N
calcium NN 1_o
bioavailability NN 1_o
. . 1_o

Assays NNS N
in IN N
male JJ 1_p
adolescents NNS 1_p
and CC N
in IN N
Caco-2 NNP N
cells NNS N
. . N

The DT N
effects NNS N
of IN N
the DT N
high JJ N
intake NN N
of IN N
Maillard NNP 1_i
reaction NN 1_i
products NNS 1_i
( ( 1_i
MRP NNP 1_i
) ) 1_i
on IN N
calcium NN 1_o
availability NN 1_o
in IN N
adolescents NNS 1_p
and CC N
across IN N
Caco-2 NNP N
cell NN N
monolayers NNS N
were VBD N
examined VBN N
. . N

In IN N
a DT N
2 CD N
week NN N
randomized VBN N
two-period JJ N
crossover NN N
trial NN N
, , N
18 CD 1_p
male NN 1_p
adolescents NNS 1_p
consumed VBD N
two CD N
diets NNS N
, , N
named VBN N
white JJ 1_i
diet NN 1_i
( ( 1_i
WD NNP 1_i
) ) 1_i
and CC N
brown JJ 1_i
diet NN 1_i
( ( 1_i
BD NNP 1_i
) ) 1_i
, , N
which WDT N
were VBD N
poor JJ N
and CC N
rich JJ N
in IN N
MRP NNP 1_i
, , N
respectively RB N
. . N

A DT N
3 CD N
day NN N
balance NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
, , N
and CC N
fasting VBG 1_o
blood NN 1_o
samples NNS 1_o
were VBD N
collected VBN N
. . N

Calcium NNP 1_o
solubility NN 1_o
and CC 1_o
absorption NN 1_o
across IN 1_o
Caco-2 NNP 1_o
cells NNS 1_o
were VBD N
studied VBN N
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
of IN N
the DT N
diets NNS N
. . N

The DT N
in IN N
vitro NN N
assay NN N
showed VBD N
similar JJ N
solubility NN 1_o
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
and CC N
similar JJ N
transport NN N
across IN N
Caco-2 NNP N
cells NNS N
. . N

In IN N
accordance NN N
, , N
calcium NN 1_o
bioavailability NN 1_o
in IN N
adolescents NNS N
did VBD N
not RB N
vary JJ N
between IN N
the DT N
diets NNS N
( ( N
% NN N
WD NNP N
= VBZ N
40.4 CD N
+/- JJ N
5.1 CD N
, , N
% NN N
BD NNP N
= VBZ N
38.2 CD N
+/- JJ N
3.6 CD N
) ) N
. . N

Serum NNP 1_o
and CC 1_o
urine JJ 1_o
biochemical JJ 1_o
parameters NNS 1_o
related VBN 1_o
to TO 1_o
calcium NN 1_o
status NN 1_o
and CC 1_o
bone NN 1_o
metabolism NN 1_o
remained VBD N
unaltered JJ N
. . N

Only RB N
deoxypyridinoline JJ 1_o
values NNS N
were VBD N
significantly RB N
lower JJR N
after IN N
consumption NN N
of IN N
the DT N
BD NNP N
( ( N
13.0 CD N
+/- JJ N
1.1 CD N
compared VBN N
to TO N
18.3 CD N
+/- JJ N
2.1 CD N
nM/Mm JJ N
Cr NNP N
in IN N
the DT N
WD NNP N
) ) N
, , N
possibly RB N
indicative JJ N
of IN N
less RBR N
efficient JJ N
bone NN 1_o
turnover NN 1_o
during IN N
this DT N
period NN N
. . N

As IN N
calcium NN N
acquired VBD N
during IN N
adolescence NN N
is VBZ N
essential JJ N
to TO N
maximize VB N
peak JJ N
bone NN N
mass NN N
and CC N
to TO N
prevent VB N
osteoporosis NN N
, , N
possible JJ N
long-term JJ N
effects NNS N
of IN N
excessive JJ N
MRP NNP 1_i
intake NN N
during IN N
this DT N
period NN N
warrant JJ N
attention NN N
. . N

Effects NNS N
of IN N
low-dose JJ N
aspirin NN 1_i
on IN N
clinic NN 1_o
and CC 1_o
ambulatory JJ 1_o
blood NN 1_o
pressure NN 1_o
in IN N
treated JJ 1_p
hypertensive JJ 1_p
patients NNS 1_p
. . 1_p

Collaborative NNP N
Group NNP N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
( ( N
PPP NNP N
) ) N
-- : N
Hypertension NNP N
study NN N
. . N

Nonsteroidal NNP N
antiinflammatory JJ N
drugs NNS N
may MD N
affect VB N
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
control NN 1_o
in IN N
hypertensive JJ 1_p
patients NNS 1_p
receiving VBG 1_p
drug NN 1_p
treatment NN 1_p
, , N
but CC N
data NNS N
on IN N
the DT N
effects NNS N
of IN N
low-dose JJ N
aspirin NNS 1_i
are VBP N
scanty RB N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
chronic JJ N
treatment NN N
with IN N
low JJ N
doses NNS N
of IN N
aspirin NN 1_i
( ( N
100 CD N
mg/day NN N
) ) N
on IN N
clinic NN 1_o
and CC 1_o
ambulatory JJ 1_o
systolic NN 1_o
( ( 1_o
SBP NNP 1_o
) ) 1_o
and CC 1_o
diastolic JJ 1_o
( ( 1_o
DBP NNP 1_o
) ) 1_o
BP NNP 1_o
in IN N
hypertensives NNS 1_p
on IN 1_p
chronic NN 1_p
, , 1_p
stable JJ 1_p
antihypertensive JJ 1_p
therapy NN 1_p
. . 1_p

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
framework NN N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
( ( N
PPP NNP N
) ) N
, , N
a DT N
randomized VBN N
, , N
controlled VBN N
factorial JJ N
trial NN N
on IN N
the DT N
preventive JJ N
effect NN N
of IN N
aspirin NN 1_i
or CC N
vitamin NN 1_i
E NN 1_i
in IN N
people NNS 1_p
with IN 1_p
one CD 1_p
or CC 1_p
more JJR 1_p
cardiovascular JJ 1_p
risk NN 1_p
factors NNS 1_p
. . 1_p

Fifteen NNP 1_p
Italian JJ 1_p
hypertension NN 1_p
units NNS 1_p
studied VBD 1_p
142 CD 1_p
hypertensive JJ 1_p
patients NNS 1_p
( ( 1_p
76 CD 1_p
men NNS 1_p
, , 1_p
66 CD 1_p
women NNS 1_p
; : 1_p
mean JJ 1_p
age NN 1_p
59 CD 1_p
+/- JJ 1_p
5.9 CD 1_p
years NNS 1_p
) ) 1_p
treated VBD 1_p
with IN 1_p
different JJ 1_p
antihypertensive JJ 1_p
drugs NNS 1_p
: : 1_p
71 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
aspirin VB 1_i
and CC N
71 CD N
served VBD N
as IN N
controls NNS N
. . N

All DT N
patients NNS N
underwent VBD N
a DT N
clinic JJ 1_o
BP NNP 1_o
evaluation NN N
with IN N
an DT N
automatic JJ N
sphygmomanometer NN N
and CC N
a DT N
24-h JJ 1_o
ambulatory NN 1_o
BP NNP 1_o
monitoring NN 1_o
, , N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ 1_i
treatment NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
changes NNS N
in IN N
clinic JJ 1_o
SBP NNP 1_o
and CC 1_o
DBP NNP 1_o
were VBD N
not RB N
statistically RB N
different JJ N
in IN N
treated JJ N
and CC N
untreated JJ N
subjects NNS N
. . N

Ambulatory NNP 1_o
SBP NNP 1_o
and CC 1_o
DBP NNP 1_o
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ 1_i
treatment NN N
were VBD N
similar JJ N
to TO N
baseline VB N
: : N
deltaSBP NN N
-0.5 NN N
mmHg NN N
( ( N
95 CD N
% NN N
confidence NN N
intervals NNS N
[ VBP N
CI NNP N
] NN N
from IN N
-1.9 NN N
to TO N
+2.9 VB N
mm JJ N
Hg NNP N
) ) N
and CC N
deltaDBP JJ N
-1.1 NNP N
mm NN N
Hg NNP N
( ( N
95 CD N
% NN N
CI NNP N
from IN N
-2.5 NNP N
to TO N
+0.3 VB N
mm JJ N
Hg NNP N
) ) N
. . N

The DT N
pattern NN N
was VBD N
similar JJ N
in IN N
the DT N
control NN N
group NN N
. . N

No DT N
interaction NN N
was VBD N
found VBN N
between IN N
aspirin NN 1_i
and CC N
the DT N
most RBS N
used JJ N
antihypertensive JJ N
drug NN N
classes NNS N
( ( N
angiotensin IN N
converting VBG N
enzyme JJ N
inhibitors NNS N
and CC N
calcium NN N
antagonists NNS N
) ) N
. . N

Despite IN N
the DT N
relatively RB N
small JJ N
sample NN N
size NN N
our PRP$ N
results NNS N
seem VBP N
to TO N
exclude VB N
any DT N
significant JJ N
influence NN N
of IN N
low-dose JJ N
aspirin NN 1_i
on IN N
BP NNP 1_o
control NN N
in IN N
hypertensives NNS 1_p
under IN 1_p
treatment NN 1_p
. . 1_p

To TO N
compare VB N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
nifedipine NN 1_i
sustained VBN 1_i
release NN 1_i
with IN N
Ginkgo NNP 1_i
biloba NN 1_i
extract NN 1_i
to TO N
treat VB N
patients NNS 1_p
with IN 1_p
primary JJ 1_p
Raynaud NNP 1_p
's POS 1_p
phenomenon NN 1_p
in IN 1_p
South NNP 1_p
Korea NNP 1_p
; : 1_p
Korean NNP N
Raynaud NNP N
study NN N
( ( N
KOARA NNP N
study NN N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
efficacy NN 1_o
and CC N
safety NN 1_o
of IN N
nifedipine NN 1_i
sustained VBN 1_i
release NN 1_i
( ( 1_i
nifedipine JJ 1_i
SR NNP 1_i
) ) 1_i
compared VBN N
with IN N
Ginkgo NNP 1_i
biloba NN 1_i
extract NN 1_i
as IN N
treatment NN N
for IN N
primary JJ 1_p
Raynaud NNP 1_p
's POS 1_p
phenomenon NN 1_p
( ( 1_p
RP NNP 1_p
) ) 1_p
in IN 1_p
Korea NNP 1_p
. . 1_p

Primary NNP N
RP NNP N
were VBD N
screened VBN N
and CC N
assigned VBN N
to TO N
either CC N
the DT N
nifedipine JJ 1_i
SR NNP 1_i
group NN N
( ( N
Group NNP N
N NNP N
) ) N
or CC N
the DT N
Ginkgo NNP 1_i
biloba NN 1_i
extract NN 1_i
group NN N
( ( N
Group NNP N
G NNP N
) ) N
in IN N
the DT N
ratio NN N
of IN N
2:1 CD N
. . N

After IN N
a DT N
run-in JJ N
period NN N
of IN N
2 CD N
weeks NNS N
, , N
patients NNS N
received VBD N
treatment NN N
for IN N
8 CD N
weeks NNS N
. . N

We PRP N
observed VBD N
the DT N
percent NN 1_o
improvement NN 1_o
of IN 1_o
the DT 1_o
RP NNP 1_o
attack NN 1_o
rate NN 1_o
between IN 1_o
before IN 1_o
and CC 1_o
after IN 1_o
the DT 1_o
8-week JJ 1_o
treatment NN 1_o
. . 1_o

Ninety-three JJ 1_p
subjects NNS 1_p
were VBD N
randomly RB N
assigned VBN N
. . N

The DT N
percent NN 1_o
improvement NN 1_o
in IN N
Group NNP N
N NNP N
was VBD N
50.1 CD N
% NN N
at IN N
8 CD N
weeks NNS N
after IN N
treatment NN N
, , N
while IN N
it PRP N
was VBD N
31.0 CD N
% NN N
in IN N
Group NNP N
G NNP N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

No DT N
serious JJ 1_o
adverse JJ 1_o
events NNS 1_o
occurred VBD N
, , N
and CC N
almost RB N
adverse JJ 1_o
events NNS 1_o
were VBD N
mild JJ N
and CC N
improved VBN N
without IN N
specific JJ N
treatment NN N
. . N

nifedipine JJ 1_i
SR NNP 1_i
was VBD N
more RBR N
effective JJ 1_o
than IN N
Ginkgo NNP 1_i
biloba NN 1_i
extract NN 1_i
for IN N
treatment NN N
of IN N
primary JJ 1_p
RP NNP 1_p
in IN 1_p
Korean JJ 1_p
patients NNS 1_p
. . 1_p

Both DT N
drugs NNS N
were VBD N
tolerable JJ 1_o
with IN N
primary JJ 1_p
RP NNP 1_p
patients NNS 1_p
. . 1_p

Preschoolers NNS 1_p
acquire VB N
general JJ 1_o
knowledge NN 1_o
by IN N
sharing VBG N
in IN N
pretense NN 1_i
. . 1_i

Children NNP N
acquire VB N
general JJ 1_o
knowledge NN 1_o
about IN N
many JJ N
kinds NNS N
of IN N
things NNS N
, , N
but CC N
there EX N
are VBP N
few JJ N
known VBN N
means NNS N
by IN N
which WDT N
this DT N
knowledge NN N
is VBZ N
acquired VBN N
. . N

In IN N
this DT N
article NN N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
children NNS 1_p
acquire VB N
generic JJ 1_o
knowledge NN 1_o
by IN N
sharing VBG N
in IN N
pretend JJ 1_i
play NN 1_i
. . 1_i

In IN N
Experiment JJ N
1 CD N
, , N
twenty-two JJ 1_p
3- JJ 1_p
to TO 1_p
4-year-olds NNS 1_p
watched VBN N
pretense NN 1_i
in IN N
which WDT N
a DT N
puppet NN N
represented VBD N
a DT N
" JJ N
nerp NN N
" NNP N
( ( N
an DT N
unfamiliar JJ N
kind NN N
of IN N
animal NN N
) ) N
. . N

For IN N
instance NN N
, , N
in IN N
one CD N
scenario NN N
, , N
the DT N
nerp JJ N
ate NN N
and CC N
disliked VBD N
a DT N
carrot NN N
. . N

When WRB N
subsequently RB N
asked VBD N
generic JJ N
questions NNS N
about IN N
real JJ N
nerps NNS N
, , N
children NNS 1_o
's POS 1_o
responses NNS 1_o
suggested VBD N
that IN N
they PRP N
had VBD N
learned VBN N
general JJ N
facts NNS N
( ( N
e.g. NN N
, , N
nerps RB N
dislike JJ N
carrots NNS N
) ) N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
thirty-two JJ 1_p
4- JJ 1_p
to TO 1_p
5-year-olds NNS 1_p
learned VBN N
from IN N
scenarios NNS 1_i
lacking VBG 1_i
pretend JJ 1_i
speech NN 1_i
or CC 1_i
sound JJ 1_i
effects NNS 1_i
. . 1_i

The DT N
findings NNS N
reveal VBP N
a DT N
long JJ N
overlooked JJ N
means NNS N
by IN N
which WDT N
children NNS N
can MD N
acquire VB N
generic JJ 1_o
knowledge NN 1_o
. . 1_o

[ JJ 1_o
Efficacy NNP 1_o
of IN N
paliperidone NN 1_i
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ 1_o
functions NNS 1_o
in IN N
schizophrenics NNS 1_p
: : 1_p
a DT N
randomized NN N
and CC N
controlled VBD N
study NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
efficacy NN 1_o
of IN N
paliperidone NN 1_i
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ 1_o
functions NNS 1_o
in IN N
schizophrenics NNS 1_p
. . 1_p

METHODS NNP N
A NNP N
total NN 1_p
of IN 1_p
81 CD 1_p
schizophrenics NNS 1_p
were VBD N
randomly RB N
divided VBN N
into IN N
study NN N
group NN N
with IN N
paliperidone NN 1_i
extended-release JJ N
tablets NNS N
and CC N
control NN N
group NN N
with IN N
risperidone NN 1_i
for IN N
a DT N
12-week JJ N
treatment NN N
. . N

They PRP N
were VBD N
assessed VBN N
and CC N
analyzed VBN N
by IN N
positive JJ 1_o
and CC 1_o
negative JJ 1_o
symptoms NNS 1_o
scales NNS 1_o
( ( 1_o
PANSS NNP 1_o
) ) 1_o
, , 1_o
social JJ 1_o
disability NN 1_o
screening VBG 1_o
schedule NN 1_o
( ( 1_o
SDSS NNP 1_o
) ) 1_o
and CC 1_o
treatment NN 1_o
emergent NN 1_o
symptom NN 1_o
scale NN 1_o
( ( 1_o
TESS NNP 1_o
) ) 1_o
at IN N
baseline NN N
, , N
6 CD N
( ( N
th NN N
) ) N
weekend NN N
and CC N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
. . N

RESULTS NNP N
In IN N
study NN N
group NN N
, , N
the DT N
factors NNS 1_o
and CC 1_o
total JJ 1_o
scores NNS 1_o
of IN 1_o
PANSS NNP 1_o
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
[ NNP N
( ( N
12.0 CD N
± RB N
2.8 CD N
) ) N
, , N
( ( N
12.1 CD N
± RB N
3.6 CD N
) ) N
, , N
( ( N
26.2 CD N
± RB N
5.0 CD N
) ) N
, , N
( ( N
50.2 CD N
± RB N
8.7 CD N
) ) N
] NN N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline JJ N
[ NNP N
( ( N
24.7 CD N
± RB N
5.3 CD N
) ) N
, , N
( ( N
23.8 CD N
± RB N
3.6 CD N
) ) N
, , N
( ( N
45.0 CD N
± RB N
2.9 CD N
) ) N
, , N
( ( N
93.5 CD N
± RB N
6.8 CD N
) ) N
] NN N
( ( N
t JJ N
= NNP N
9.60-16.78 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
study NN N
group NN 1_o
, , 1_o
the DT 1_o
positive JJ 1_o
factor NN 1_o
, , 1_o
negative JJ 1_o
factor NN 1_o
and CC 1_o
total JJ 1_o
scores NNS 1_o
of IN 1_o
PANSS NNP N
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
[ NNP N
( ( N
12.0 CD N
± RB N
2.8 CD N
) ) N
, , N
( ( N
12.1 CD N
± RB N
3.6 CD N
) ) N
, , N
( ( N
50.2 CD N
± RB N
8.7 CD N
) ) N
] NN N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
[ NNP N
( ( N
14.2 CD N
± RB N
1.8 CD N
) ) N
, , N
( ( N
14.6 CD N
± RB N
2.4 CD N
) ) N
, , N
( ( N
56.5 CD N
± RB N
6.4 CD N
) ) N
] NN N
( ( N
t JJ N
= NNP N
2.58-4.26 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN 1_o
, , 1_o
the DT 1_o
factors NNS 1_o
and CC 1_o
total JJ 1_o
scores NNS 1_o
of IN N
PANSS NNP N
in IN N
study NN N
group NN N
[ NNP N
( ( N
12.0 CD N
± RB N
2.8 CD N
) ) N
, , N
( ( N
12.1 CD N
± RB N
3.6 CD N
) ) N
, , N
( ( N
26.2 CD N
± RB N
5.0 CD N
) ) N
, , N
( ( N
50.2 CD N
± RB N
8.7 CD N
) ) N
] NN N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
[ NNP N
( ( N
16.9 CD N
± RB N
4.9 CD N
) ) N
, , N
( ( N
18.7 CD N
± RB N
5.3 CD N
) ) N
, , N
( ( N
32.5 CD N
± RB N
5.1 CD N
) ) N
, , N
( ( N
68.1 CD N
± RB N
13.0 CD N
) ) N
] NN N
( ( N
t JJ N
= NNP N
-4.28 NNP N
-- : N
5.67 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
study NN 1_o
group NN 1_o
, , 1_o
the DT 1_o
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
( ( N
5.93 CD N
± RB N
2.78 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline NN N
( ( N
13.9 CD N
± RB N
3.4 CD N
) ) N
( ( N
t JJ N
= NN N
10.83 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN 1_o
study NN 1_o
group NN 1_o
, , 1_o
the DT 1_o
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
( ( N
5.9 CD N
± RB N
2.8 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6 CD N
( ( N
th NN N
) ) N
weekend NN N
of IN N
treatment NN N
( ( N
7.6 CD N
± RB N
2.9 CD N
) ) N
( ( N
t JJ N
= NN N
5.21 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

But CC N
there EX N
was VBD N
no DT N
significant JJ N
improvement NN N
in IN N
control NN N
group NN N
( ( N
t JJ N
= NN N
1.88 CD N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
12 CD N
( ( N
th NN N
) ) N
weekend NN 1_o
of IN 1_o
treatment NN 1_o
, , N
the DT N
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
study NN N
group NN N
( ( N
5.9 CD N
± RB N
2.8 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
( ( N
8.8 CD N
± RB N
2.9 CD 1_o
) ) 1_o
( ( 1_o
t JJ 1_o
= NNP 1_o
-4.49 NNP 1_o
, , 1_o
P NNP 1_o
< NNP 1_o
0.05 CD 1_o
) ) 1_o
. . N

No UH N
severe JJ N
adverse JJ N
effect NN N
was VBD N
reported VBN N
in IN 1_i
either DT 1_i
group NN 1_i
. . N

CONCLUSION NNP N
Paliperidone NNP N
extended-release JJ 1_o
tablets NNS 1_o
are VBP 1_o
effective JJ 1_o
to TO N
improve VB 1_o
social JJ 1_o
functions NNS 1_o
and CC 1_p
psychiatric JJ 1_p
symptoms NNS N
of IN N
schizophrenics NNS N
. . N

Intrathecal JJ N
morphine NN 1_i
suppresses NNS N
NK NNP 1_o
cell NN 1_o
activity NN 1_o
following VBG N
abdominal JJ 1_p
surgery NN 1_p
. . 1_p

PURPOSE VB N
The DT N
effects NNS N
of IN N
morphine NN 1_i
on IN N
natural JJ 1_o
killer NN 1_o
( ( 1_o
NK NNP 1_o
) ) 1_o
cell NN 1_o
activity NN 1_o
were VBD N
investigated VBN N
in IN N
patients NNS 1_p
who WP 1_p
underwent JJ 1_p
hysterectomy NN 1_p
. . 1_p

METHODS NNP N
Forty NNP 1_p
patients NNS 1_p
were VBD 1_p
divided VBN 1_p
into IN 1_p
four CD 1_p
groups NNS 1_p
of IN 1_p
ten NN 1_p
. . 1_p

The DT N
groups NNS N
received VBD N
intrathecal JJ N
0.5 CD N
mg NN N
morphine NN 1_i
( ( N
Group NNP N
IT0.5 NNP N
) ) N
, , N
intrathecal JJ N
0.1 CD N
mg NN N
morphine NN 1_i
( ( N
Group NNP N
IT0.1 NNP N
) ) N
or CC N
10 CD N
mg NNS N
morphine JJ 1_i
i.v NN N
. . N

( ( N
Group NNP N
IV NNP N
) ) N
. . N

The DT N
remaining VBG N
ten JJ N
patients NNS N
served VBD N
as IN N
controls NNS N
and CC N
received VBN N
inhalation NN N
anesthesia NN N
alone RB N
( ( N
Group NNP N
C NNP N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
withdrawn VBN N
before RB N
and CC N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
days NNS N
one CD N
and CC N
two CD N
to TO N
determine VB N
the DT N
blood NN 1_o
NK NNP 1_o
cell NN 1_o
activity NN 1_o
using VBG N
a DT N
chromium NN 1_o
release NN 1_o
assay VBP 1_o
with IN 1_o
K562 NNP 1_o
cells NNS 1_o
as IN 1_o
targets NNS 1_o
, , 1_o
plasma JJ 1_o
catecholamines NNS 1_o
and CC 1_o
cortisol NN 1_o
levels NNS 1_o
. . 1_o

The DT N
postoperative JJ 1_o
pain NN 1_o
score NN 1_o
and CC 1_o
side NN 1_o
effects NNS 1_o
were VBD N
studied VBN N
in IN N
the DT N
four CD N
groups NNS N
. . N

RESULTS NNP N
In IN N
Group NNP N
IT0.5 NNP N
, , N
the DT N
NK NNP 1_o
cell NN 1_o
activity NN 1_o
was VBD N
lower JJR N
on IN N
postoperative JJ N
day NN N
1 CD N
( ( N
23.9 CD N
+/- JJ N
8.4 CD N
% NN N
) ) N
than IN N
the DT N
baseline NN N
level NN N
( ( N
45.7 CD N
+/- JJ N
13 CD N
% NN N
) ) N
before IN N
surgery NN N
, , N
and CC N
recovered VBD N
on IN N
postoperative JJ N
day NN N
2 CD N
. . N

In IN N
Groups NNP N
IT0.1 NNP N
, , N
C NNP N
and CC N
IV NNP N
, , N
the DT N
NK NNP 1_o
cell NN 1_o
activities NNS 1_o
showed VBD N
no DT N
significant JJ N
changes NNS N
. . N

In IN N
all DT N
four CD N
groups NNS N
, , N
neither CC N
plasma JJ 1_o
adrenaline NN 1_o
nor CC N
noradrenaline JJ 1_o
concentrations NNS 1_o
changed VBD N
. . N

In IN N
all DT N
four CD N
groups NNS N
, , N
the DT N
plasma NN 1_o
cortisol NN 1_o
levels NNS 1_o
increased VBN N
after IN N
surgery NN N
, , N
on IN N
postoperative JJ N
days NNS N
1 CD N
and CC N
2 CD N
. . N

The DT N
pain NN 1_o
score NN 1_o
was VBD N
lower JJR N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
day NN N
1 CD N
in IN N
Group NNP N
IT0.5 NNP N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
long-lasting JJ N
analgesic JJ N
effects NNS N
of IN N
intrathecal JJ N
0.5 CD N
mg JJ N
morphine NN 1_i
suppress NN N
the DT N
immune JJ N
response NN N
following VBG N
abdominal JJ 1_p
surgery NN 1_p
. . 1_p

Plasma NNP 1_o
AGE-peptides NNP 1_o
and CC 1_o
C-peptide NNP 1_o
in IN N
early-stage JJ 1_p
diabetic JJ 1_p
nephropathy JJ 1_p
patients NNS 1_p
on IN N
thiamine NN 1_i
and CC N
pyridoxine NN 1_i
therapy NN N
. . N

AIM IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
circulatory JJ 1_o
AGE-peptide JJ 1_o
levels NNS 1_o
in IN N
diabetic JJ 1_p
nephropathy NN 1_p
and CC N
to TO N
observe VB N
the DT N
effects NNS N
of IN N
thiamine NN 1_i
( ( 1_i
vitamin JJ 1_i
B1 NNP 1_i
) ) 1_i
and CC N
pyridoxine NN 1_i
( ( 1_i
vitamin JJ 1_i
B6 NNP 1_i
) ) 1_i
therapy NN N
. . N

METHODS NNP N
Type NNP 1_p
2 CD 1_p
diabetic JJ 1_p
patients NNS 1_p
( ( 1_p
N.=57 NNP 1_p
) ) 1_p
were VBD 1_p
divided VBN 1_p
into IN N
two CD N
groups NNS N
as IN N
" NN N
with IN N
nephropathy JJ N
" NNP N
( ( N
N.=27 NNP N
) ) N
and CC N
" $ N
without IN N
nephropathy JJ N
" NN N
( ( N
N.=30 NNP N
) ) N
. . N

Diabetic NNP 1_p
nephropathy JJ 1_p
patients NNS 1_p
were VBD N
treated VBN N
with IN N
either DT N
B6 NNP 1_i
( ( N
N.=12 NNP N
) ) N
( ( N
250 CD N
mg/day NN N
) ) N
or CC N
B1+B6 NNP 1_i
( ( N
N.=15 NNP N
) ) N
( ( N
250 CD N
mg/day NN N
, , N
each DT N
) ) N
for IN N
five CD N
months NNS N
. . N

At IN N
the DT N
beginning NN N
and CC N
the DT N
end NN N
of IN N
the DT N
experimentation NN N
period NN N
, , N
glucose NN 1_o
, , 1_o
HbA1c NNP 1_o
, , 1_o
triglyceride NN 1_o
, , 1_o
cholesterol NN 1_o
, , 1_o
insulin NN 1_o
, , 1_o
C-peptide NNP 1_o
, , 1_o
thiamine NN 1_o
pyrophosphate NN 1_o
, , 1_o
pyridoxal JJ 1_o
phosphate NN 1_o
and CC 1_o
AGE- NNP 1_o
peptides NNS 1_o
were VBD N
measured VBN N
. . N

RESULTS JJ N
AGE-peptides NNS 1_o
were VBD N
higher JJR N
in IN N
the DT N
diabetic JJ N
group NN N
with IN N
nephropathy JJ N
than IN N
without IN N
nephropathy JJ N
( ( N
P=0.005 NNP N
) ) N
. . N

Within IN N
five CD N
months NNS N
AGE-peptides NNS 1_o
increased VBD N
in IN N
the DT N
diabetic JJ N
group NN N
without IN N
nephropathy JJ N
( ( N
P=0.042 NNP N
) ) N
but CC N
not RB N
in IN N
the DT N
group NN N
with IN N
nephropathy JJ N
treated VBN N
either RB N
with IN N
B1+B6 NNP 1_i
or CC N
B6 NNP 1_i
. . 1_i

In IN N
B6 NNP 1_i
treated VBD N
group NN N
a DT N
substantial JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
HbA1c NNP 1_o
( ( N
P=0.033 NNP N
) ) N
. . N

B1+B6 NNP 1_i
or CC N
B6 NNP 1_i
treatment NN N
both DT N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP 1_o
( ( N
P=0.006 NNP N
, , N
P=0.004 NNP N
) ) N
. . N

CONCLUSION NNP N
Among IN N
the DT N
parameters NNS N
measured VBD N
, , N
plasma JJ 1_o
AGE-peptides NNP 1_o
was VBD N
the DT N
only JJ N
parameter NN N
found VBD N
to TO N
be VB N
higher JJR N
in IN N
type NN 1_p
2 CD 1_p
diabetes NNS 1_p
mellitus JJ 1_p
patients NNS 1_p
" VBP 1_p
with IN 1_p
nephropathy JJ 1_p
" NN 1_p
than IN N
" NN N
without IN N
nephropathy JJ N
" NN N
. . N

However RB N
, , N
patients NNS 1_p
with IN 1_p
nephropathy JJ 1_p
treated VBN N
with IN N
B1+B6 NNP 1_i
or CC N
B6 NNP 1_i
did VBD N
not RB N
display VB N
any DT N
further JJ N
increase NN N
in IN N
AGE-peptides NNP 1_o
within IN N
five CD N
months NNS N
. . N

Both DT N
of IN N
the DT N
treatments NNS N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP 1_o
. . 1_o

Effect NN N
of IN N
different JJ N
rates NNS N
of IN N
infusion NN N
of IN N
propofol NN 1_i
for IN N
induction NN N
of IN N
anaesthesia NN N
in IN N
elderly JJ 1_p
patients NNS 1_p
. . 1_p

The DT N
effect NN N
of IN N
changing VBG N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
propofol NN 1_i
for IN N
induction NN N
of IN N
anaesthesia NN N
was VBD N
studied VBN N
in IN N
60 CD 1_p
elderly JJ 1_p
patients NNS 1_p
. . 1_p

Propofol NNP 1_i
was VBD N
administered VBN N
at IN N
300 CD N
, , N
600 CD N
or CC N
1200 CD N
ml JJ N
h-1 JJ N
until IN N
loss NN 1_o
of IN 1_o
consciousness NN 1_o
( ( 1_o
as IN 1_o
judged VBN 1_o
by IN 1_o
loss NN 1_o
of IN 1_o
verbal JJ 1_o
contact NN 1_o
with IN 1_o
the DT 1_o
patient NN 1_o
) ) 1_o
had VBD N
been VBN N
achieved VBN N
. . N

The DT N
duration NN 1_o
of IN 1_o
induction NN 1_o
was VBD N
significantly RB N
longer JJR N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
with IN N
the DT N
slower JJR N
infusion NN 1_o
rates NNS 1_o
( ( N
104 CD N
, , N
68 CD N
and CC N
51 CD N
s NN N
) ) N
, , N
but CC N
the DT N
total JJ 1_o
dose NN 1_o
used VBN N
was VBD N
significantly RB N
less JJR N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
in IN N
these DT N
patients NNS N
( ( N
1.2 CD N
, , N
1.6 CD N
and CC N
2.5 CD N
mg NN N
kg-1 NN N
, , N
respectively RB N
) ) N
. . N

The DT N
decrease NN N
in IN N
systolic JJ 1_o
and CC 1_o
diastolic JJ 1_o
arterial JJ 1_o
pressure NN 1_o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
300-ml JJ N
h-1 JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
induction NN N
and CC N
immediately RB N
after IN N
induction NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
incidence NN 1_o
of IN 1_o
apnoea NN 1_o
was VBD N
also RB N
significantly RB N
less RBR N
in IN N
the DT N
slower JJR N
infusion NN N
group NN N
. . N

Prevention NN N
of IN N
spinal JJ N
anesthesia-induced JJ N
hypotension NN N
in IN 1_p
the DT 1_p
elderly JJ 1_p
: : 1_p
comparison NN N
between IN N
preanesthetic JJ N
administration NN N
of IN N
crystalloids NNS 1_i
, , 1_i
colloids NNS 1_i
, , N
and CC N
no DT 1_i
prehydration NN 1_i
. . 1_i

The DT N
practice NN N
of IN N
routinely RB N
prehydrating VBG N
patients NNS N
by IN N
infusing VBG N
a DT N
crystalloid NN 1_i
or CC N
colloid JJ 1_i
solution NN 1_i
( ( N
up IN N
to TO N
1.0 CD N
L/70 NNP N
kg NN N
) ) N
for IN N
prevention NN N
of IN N
spinal JJ N
anesthesia-induced JJ N
hypotension NN N
has VBZ N
been VBN N
challenged VBN N
recently RB N
, , N
after IN N
several JJ N
reports NNS N
of IN N
failure NN N
to TO N
demonstrate VB N
its PRP$ N
efficacy NN 1_o
in IN N
young JJ N
women NNS N
. . N

We PRP N
compared VBN N
the DT N
incidence NN 1_o
and CC 1_o
frequency NN 1_o
of IN 1_o
hypotension NN 1_o
and CC 1_o
vasopressor NN 1_o
therapy NN 1_o
after IN N
spinal JJ N
anesthesia NN N
and CC N
no DT 1_i
prehydration NN 1_i
with IN N
crystalloid NN 1_i
and CC N
colloid JJ 1_i
prehydration NN 1_i
in IN 1_p
elderly JJ 1_p
patients NNS 1_p
. . 1_p

Eighty-five JJ 1_p
ASA NNP 1_p
grade NN 1_p
I PRP 1_p
or CC 1_p
II NNP 1_p
patients NNS 1_p
( ( 1_p
aged VBN 1_p
60-89 CD 1_p
yr NN 1_p
) ) 1_p
for IN 1_p
elective JJ 1_p
total JJ 1_p
hip NN 1_p
replacement NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
500 CD N
mL NN N
crystalloid JJ 1_i
solution NN 1_i
( ( 1_i
Hartmanns NNP 1_i
, , N
n JJ N
= NNP N
29 CD N
) ) N
, , N
500 CD N
mL NN N
colloid NN 1_i
( ( 1_i
Haemaccel NNP 1_i
, , N
n JJ N
= NNP N
28 CD N
) ) N
, , N
or CC N
no DT 1_i
prehydration NN 1_i
( ( N
n JJ N
= NNP N
28 CD N
) ) N
over IN N
10 CD N
min NNS N
prior RB N
to TO N
spinal JJ N
anesthesia NN N
. . N

Hypotension NNP 1_o
was VBD N
defined VBN N
as IN N
a DT N
30 CD 1_o
% NN 1_o
decrease NN 1_o
from IN 1_o
baseline JJ 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
( ( 1_o
BP NNP 1_o
) ) 1_o
or CC N
systolic JJ 1_o
< $ 1_o
90 CD 1_o
mm NN 1_o
Hg NNP 1_o
, , N
and CC N
was VBD N
treated VBN N
with IN N
ephedrine JJ N
3-mg JJ N
boluses NNS N
. . N

Although IN N
absolute JJ 1_o
systolic JJ 1_o
BP NNP 1_o
readings NNS 1_o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
colloid NN 1_i
group NN N
between IN N
6 CD N
and CC N
30 CD N
min NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
the DT N
incidence NN 1_o
of IN 1_o
hypotension NN 1_o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

The DT N
incidence NN 1_o
of IN 1_o
ephedrine NN 1_o
use NN 1_o
, , 1_o
incidence NN 1_o
of IN 1_o
nausea/vomiting NN 1_o
, , 1_o
and CC 1_o
median JJ 1_o
total NN 1_o
dose NN 1_o
of IN 1_o
ephedrine NN 1_o
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
, , N
in IN N
elderly JJ 1_p
patients NNS 1_p
undergoing VBG 1_p
elective JJ 1_p
procedures NNS 1_p
, , N
withholding VBG N
prehydration NN 1_i
is VBZ N
not RB N
associated VBN N
with IN N
any DT N
greater JJR N
degree NN 1_o
of IN 1_o
hypotension NN 1_o
or CC 1_o
need NN 1_o
for IN 1_o
vasopressor NN 1_o
therapy NN 1_o
compared VBN N
with IN N
crystalloid NN 1_i
or CC N
colloid JJ 1_i
prehydration NN 1_i
. . 1_i

Assessment NN N
of IN N
acute JJ N
bronchodilator NN 1_i
effects NNS 1_o
from IN N
specific JJ N
airway NN N
resistance NN N
changes NNS N
in IN N
stable JJ 1_p
COPD NNP 1_p
patients NNS 1_p
. . 1_p

BACKGROUND NNP N
In IN N
COPD NNP 1_p
patients NNS 1_p
, , N
reversibility NN N
is VBZ N
currently RB N
evaluated VBN N
from IN N
the DT N
changes NNS N
of IN N
forced JJ 1_o
expiratory NN 1_o
volume NN 1_o
at IN 1_o
1s CD 1_o
( ( 1_o
ΔFEV1 NN 1_o
) ) 1_o
and CC 1_o
forced VBN 1_o
vital JJ 1_o
capacity NN 1_o
( ( 1_o
ΔFVC NNP 1_o
) ) 1_o
. . N

By IN N
lowering VBG N
peripheral JJ N
airway RB N
smooth JJ N
muscle NN N
tone NN 1_i
, , 1_i
bronchodilators NNS 1_i
should MD N
decrease VB 1_o
dynamic JJ 1_o
hyperinflation NN 1_o
, , 1_o
gas NN 1_o
trapping NN 1_o
, , N
and CC N
possibly RB 1_o
dyspnea VB 1_o
at IN 1_o
rest NN 1_o
. . N

Hence NNP N
, , N
we PRP N
hypothesize VBP N
that IN 1_o
specific JJ 1_o
airway NN 1_o
resistance NN 1_o
changes NNS 1_o
( ( 1_o
ΔsRAW NN 1_o
) ) 1_o
should MD N
better RBR N
characterize VB N
the DT N
acute JJ N
response NN N
to TO 1_i
bronchodilators NNS 1_i
. . N

METHODS NNP N
On IN N
two CD N
days NNS 1_p
, , 1_p
60 CD 1_p
COPD NNP 1_p
patients NNS 1_p
underwent JJ 1_o
dyspnea JJ 1_o
evaluation NN 1_o
( ( 1_o
VAS NNP 1_o
score NN 1_o
) ) 1_o
and CC 1_o
pulmonary JJ 1_o
function NN 1_o
testing VBG 1_o
at IN N
baseline NN N
and CC N
one CD N
hour NN N
after IN 1_i
placebo NN 1_i
or CC N
300μg CD 1_i
indacaterol JJ 1_i
administration NN N
. . N

RESULTS NNP 1_o
Spirographic NNP 1_o
and CC 1_o
ΔsRAW-based JJ 1_o
criteria NNS 1_o
identified VBN N
as IN N
responders NNS N
24 CD N
and CC N
45 CD N
patients NNS N
, , N
respectively RB N
. . N

ΔsRAW NN N
correlated VBD N
with IN N
changes NNS 1_o
of IN 1_o
intrathoracic NN 1_o
gas NN 1_o
volume NN 1_o
( ( 1_o
ΔITGV NN 1_o
) ) 1_o
( ( N
r=0.61 NN N
; : N
p CC 1_o
< VB 1_o
0.001 CD 1_o
) ) 1_o
, , 1_o
residual JJ 1_o
volume NN 1_o
( ( N
ΔRV NN N
) ) N
( ( N
r=0.60 NN N
; : N
p CC 1_o
< VB 1_o
0.001 CD 1_o
) ) 1_o
, , N
ΔFVC NNP N
( ( N
r=0.44 NN N
; : N
p=0.001 NN 1_o
) ) 1_o
, , N
and CC N
ΔVAS NNP N
( ( N
r=0.73 NN N
; : N
p CC 1_o
< VB 1_o
0.001 CD 1_o
) ) 1_o
, , 1_o
while IN 1_o
ΔFEV1 NN N
correlated VBD 1_o
only RB 1_o
with IN N
ΔFVC NNP N
( ( N
r=0.34 NN N
; : N
p=0.008 NN N
) ) N
. . N

Significant JJ N
differences NNS N
in IN 1_o
terms NNS 1_o
of IN N
ΔITGV NN 1_o
( ( 1_o
p=0.002 NN 1_o
) ) 1_o
, , N
ΔRV NNP N
( ( 1_o
p=0.023 NN 1_o
) ) 1_o
, , N
and CC N
ΔVAS NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
occurred VBD N
only RB N
if IN N
patients NNS N
were VBD N
stratified VBN 1_o
according VBG 1_o
to TO N
ΔsRAW NNP N
. . N

CONCLUSIONS NNP N
In IN N
assessing VBG N
the DT N
acute JJ N
functional JJ 1_i
effect NN 1_i
of IN 1_i
bronchodilators NNS N
, , N
ΔsRAW-based JJ N
criterion NN N
is VBZ N
preferable JJ N
to TO N
FEV1-FVC-based JJ N
criteria NNS N
, , N
being VBG N
more RBR N
closely RB 1_i
related VBN 1_i
to TO 1_i
bronchodilator-induced JJ 1_o
improvements NNS 1_o
of IN 1_o
lung NN 1_o
mechanics NNS 1_o
and CC 1_o
dyspnea NN N
at IN N
rest NN N
. . N

Double-blind NNP N
randomized JJ N
evaluation NN N
of IN N
intercostal JJ 1_i
nerve NN 1_i
blocks NNS 1_i
as IN N
an DT N
adjuvant NN N
to TO N
subarachnoid VB N
administered JJ N
morphine NN 1_i
for IN N
post-thoracotomy JJ 1_p
analgesia NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Thoracotomy NNP N
is VBZ N
associated VBN N
with IN N
pain NN 1_o
and CC N
compromised VBD N
pulmonary JJ 1_o
function NN 1_o
. . 1_o

Intercostal NNP 1_i
nerve NN 1_i
blocks NNS 1_i
( ( 1_i
INB NNP 1_i
) ) 1_i
and CC N
subarachnoid JJ 1_i
morphine NN 1_i
( ( 1_i
SM NNP 1_i
) ) 1_i
act NN N
on IN N
different JJ N
portions NNS N
of IN N
the DT N
pain NN N
pathway RB N
. . N

Each DT N
is VBZ N
effective JJ N
for IN N
post-thoracotomy JJ N
pain NN 1_o
relief NN N
. . N

The DT N
combination NN N
of IN N
these DT N
two CD N
modalities NNS N
in IN N
relieving VBG N
post-thoracotomy JJ 1_o
pain NN 1_o
and CC N
improving VBG N
postoperative JJ 1_o
pulmonary JJ 1_o
function NN 1_o
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
study NN N
, , N
20 CD 1_p
patients NNS 1_p
undergoing JJ 1_p
lateral JJ 1_p
thoracotomy NN 1_p
for IN 1_p
lung NN 1_p
resection NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
0.5 CD N
mg NN N
SM NNP 1_i
preoperatively RB N
and CC N
INB NNP 1_i
with IN N
bupivacaine NN 1_i
( ( N
INB+ NNP N
) ) N
prior RB N
to TO N
wound VB N
closure NN N
or CC N
0.5 CD N
mg NNS N
SM NNP 1_i
with IN N
INB NNP 1_i
using VBG N
saline NN 1_i
( ( 1_i
INB- NNP 1_i
) ) 1_i
. . N

Visual JJ 1_o
analog NN 1_o
scale NN 1_o
pain NN 1_o
scores NNS 1_o
at IN 1_o
rest NN 1_o
, , 1_o
with IN 1_o
cough NN 1_o
, , 1_o
and CC 1_o
with IN 1_o
movement NN 1_o
of IN 1_o
the DT 1_o
ipsilateral JJ 1_o
arm NN 1_o
, , 1_o
forced VBD 1_o
expiratory JJ 1_o
volume NN 1_o
in IN 1_o
1 CD 1_o
second JJ 1_o
( ( 1_o
FEV1 NNP 1_o
) ) 1_o
, , 1_o
and CC 1_o
forced VBD 1_o
vital JJ 1_o
capacity NN 1_o
( ( 1_o
FVC NNP 1_o
) ) 1_o
were VBD N
measured VBN N
at IN N
4 CD N
, , N
24 CD N
, , N
48 CD N
, , N
and CC N
72 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

Opioid NNP 1_o
use NN 1_o
was VBD N
measured VBN N
during IN N
the DT N
initial JJ N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

RESULTS NNP N
At IN N
4 CD N
hours NNS N
, , N
the DT N
INB+ NNP 1_i
group NN N
demonstrated VBD N
better JJR N
FEV1 NNP 1_o
( ( N
56.6 CD N
% NN N
vs. FW N
40.4 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
FVC NNP 1_o
values NNS N
( ( N
54.6 CD N
% NN N
vs. FW N
39.6 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
less RBR N
resting VBG 1_o
and CC 1_o
cough JJ 1_o
pain NN 1_o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
FEV1 NNP 1_o
continued VBD N
to TO N
decline VB N
in IN N
the DT N
INB+ NNP 1_i
group NN N
at IN N
24 CD N
hours NNS N
to TO N
lower JJR N
than IN N
the DT N
INB- NNP 1_i
group NN N
although IN N
pain NN 1_o
scores NNS 1_o
were VBD N
similar JJ N
beyond IN N
4 CD N
hours NNS N
. . N

Opioid JJ 1_o
usage NN 1_o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
was VBD N
similar JJ N
( ( 1_i
INB- NNP 1_i
, , N
16.7 CD N
mg NN N
vs. FW N
INB+ NNP 1_i
, , N
13.2 CD N
mg NN N
, , N
P NNP N
= NNP N
.7 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
postoperative JJ N
INB NNP 1_i
provided VBD N
modest JJ N
improvements NNS N
in IN N
pain NN 1_o
and CC 1_o
pulmonary JJ 1_o
function NN 1_o
when WRB N
used VBN N
as IN N
an DT N
adjuvant NN N
to TO N
0.5 CD N
mg NNS N
SM NNP 1_i
for IN N
post-thoracotomy JJ N
analgesia NN N
, , N
the DT N
benefits NNS N
were VBD N
transient JJ N
. . N

The DT N
authors NNS N
do VBP N
not RB N
recommend VB N
adding VBG N
INB NNP 1_i
for IN N
patients NNS 1_p
undergoing JJ 1_p
lateral JJ 1_p
thoracotomy NN 1_p
who WP N
receive VBP N
0.5 CD N
mg NN N
SM NNP 1_i
. . 1_i

Salmeterol NNP 1_i
plus CC N
fluticasone JJ 1_i
propionate NN 1_i
versus IN N
fluticasone NN 1_i
propionate NN 1_i
plus CC N
montelukast NN 1_i
: : 1_i
a DT N
randomised JJ N
controlled VBN N
trial NN N
investigating VBG N
the DT N
effects NNS 1_o
on IN 1_o
airway JJ 1_o
inflammation NN 1_o
in IN N
asthma NN 1_p
. . 1_p

BACKGROUND NNP N
Few NNP N
studies NNS N
have VBP N
compared VBN N
treatment NN N
strategies NNS N
in IN N
patients NNS 1_p
with IN 1_p
asthma JJ 1_p
poorly RB 1_p
controlled VBN 1_p
on IN 1_p
low JJ 1_p
dose NN 1_p
inhaled JJ 1_p
corticosteroids NNS 1_i
, , N
and CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
different JJ N
treatments NNS N
on IN N
airway JJ N
inflammation NN N
. . N

In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
, , N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
salmeterol NN 1_i
plus CC N
fluticasone NN 1_i
propionate NN 1_i
( ( 1_i
FP NNP 1_i
) ) 1_i
( ( 1_i
Seretide NNP 1_i
; : 1_i
SFC NNP 1_i
) ) 1_i
and CC N
FP NNP 1_i
plus CC N
montelukast NN 1_i
( ( 1_i
FP/M NNP 1_i
) ) 1_i
on IN N
sputum NN 1_o
inflammatory NN 1_o
markers NNS 1_o
, , 1_o
airway RB 1_o
responsiveness NN 1_o
, , 1_o
lung NN 1_o
function NN 1_o
, , 1_o
and CC 1_o
symptoms NNS 1_o
in IN N
adult NN 1_p
asthmatics NNS 1_p
. . 1_p

METHODS NNP N
Sixty-six JJ 1_p
subjects NNS 1_p
were VBD N
randomised VBN N
to TO N
SFC NNP 1_i
or CC N
FP/M NNP 1_i
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
changes NNS 1_o
in IN 1_o
neutrophil NN 1_o
, , 1_o
eosinophil NN 1_o
, , 1_o
macrophage NN 1_o
, , 1_o
lymphocyte NN 1_o
, , 1_o
and CC 1_o
epithelial JJ 1_o
cell NN 1_o
levels NNS 1_o
in IN 1_o
induced JJ 1_o
sputum NN 1_o
. . 1_o

Additional NNP N
outcomes NNS N
included VBD N
the DT N
change NN 1_o
in IN 1_o
other JJ 1_o
sputum JJ 1_o
markers NNS 1_o
of IN 1_o
airway JJ 1_o
inflammation NN 1_o
, , 1_o
airway RB 1_o
responsiveness NN 1_o
, , 1_o
symptom NN 1_o
control NN 1_o
, , 1_o
and CC 1_o
lung NN 1_o
function NN 1_o
. . 1_o

RESULTS NNP N
Both NNP N
treatments NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
induced JJ 1_o
sputum NN 1_o
inflammatory NN 1_o
cells NNS 1_o
, , N
although IN N
there EX N
was VBD N
a DT N
trend NN N
for IN N
a DT N
reduction NN N
in IN N
sputum NN 1_o
eosinophils NNS 1_o
. . 1_o

Both DT N
treatments NNS N
significantly RB N
improved VBN N
airway RB 1_o
responsiveness NN 1_o
, , N
whereas WP N
SFC NNP 1_i
generally RB N
led VBD N
to TO N
greater JJR N
improvements NNS N
in IN N
symptom JJ 1_o
control NN 1_o
and CC 1_o
lung NN 1_o
function NN 1_o
than IN N
FP/M NNP 1_i
. . 1_i

FP/M NNP 1_i
led VBD N
to TO N
significantly RB N
greater JJR N
reductions NNS N
in IN N
sputum NN 1_o
cysteinyl NN 1_o
leukotrienes NNS 1_o
than IN N
SFC NNP 1_i
( ( N
treatment NN N
ratio NN N
1.80 CD N
; : N
95 CD N
% NN N
CI NNP N
1.09 CD N
, , N
2.94 CD N
) ) N
. . N

CONCLUSION NNP N
Both DT N
treatments NNS N
led VBD N
to TO N
similar JJ N
control NN N
of IN N
eosinophilic JJ 1_o
airway NN 1_o
inflammation NN 1_o
, , N
although IN N
PEF NNP N
and CC N
symptom VB 1_o
control NN 1_o
were VBD N
better JJR N
with IN N
SFC NNP 1_i
. . 1_i

STUDY NNP N
NUMBER NNP N
: : N
SAM40030 NNP N
( ( N
SOLTA NNP N
) ) N
. . N

Phase NNP N
III NNP N
study NN N
of IN N
concurrent JJ 1_i
chemoradiotherapy NN 1_i
versus NN N
radiotherapy NN 1_i
alone RB N
for IN N
advanced JJ 1_p
nasopharyngeal JJ 1_p
carcinoma NN 1_p
: : 1_p
positive JJ N
effect NN 1_o
on IN N
overall JJ 1_o
and CC 1_o
progression-free JJ 1_o
survival NN 1_o
. . 1_o

PURPOSE NNP N
Nasopharyngeal NNP N
carcinoma NN N
( ( N
NPC NNP N
) ) N
is VBZ N
a DT N
radiosensitive JJ N
and CC N
chemosensitive JJ N
tumor NN N
. . N

This DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
compared VBN N
concurrent JJ 1_i
chemoradiotherapy NN 1_i
( ( 1_i
CCRT NNP 1_i
) ) 1_i
versus NN N
radiotherapy NN 1_i
( ( 1_i
RT NNP 1_i
) ) 1_i
alone RB N
in IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
NPC NNP 1_p
. . 1_p

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP 1_p
December NNP 1_p
1993 CD 1_p
to TO 1_p
April NNP 1_p
1999 CD 1_p
, , 1_p
284 CD 1_p
patients NNS 1_p
with IN 1_p
1992 CD 1_p
American NNP 1_p
Joint NNP 1_p
Committee NNP 1_p
on IN 1_p
Cancer NNP 1_p
stage NN 1_p
III NNP 1_p
to TO 1_p
IV NNP 1_p
( ( 1_p
M0 NNP 1_p
) ) 1_p
NPC NNP 1_p
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
arms NNS N
. . N

Similar JJ N
dosage NN N
and CC N
fractionation NN N
of IN N
RT NNP 1_i
was VBD N
administered VBN N
in IN N
both DT N
arms NNS N
. . N

The DT N
investigational JJ N
arm NN N
received VBD N
two CD N
cycles NNS N
of IN N
concurrent JJ N
chemotherapy NN 1_i
with IN N
cisplatin NN 1_i
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
plus CC N
fluorouracil JJ 1_i
400 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
by IN N
96-hour CD N
continuous JJ N
infusion NN N
during IN N
the DT N
weeks NNS N
1 CD N
and CC N
5 CD N
of IN N
RT NNP 1_i
. . 1_i

Survival NNP 1_o
analysis NN 1_o
was VBD 1_o
estimated VBN 1_o
by IN 1_o
the DT 1_o
Kaplan-Meier NNP 1_o
method NN 1_o
and CC 1_o
compared VBN 1_o
by IN 1_o
the DT 1_o
log-rank JJ 1_o
test NN 1_o
. . 1_o

RESULTS NNP N
Baseline NNP N
patient JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
65 CD N
months NNS N
, , N
26.2 CD N
% NN N
( ( N
37 CD N
of IN N
141 CD N
) ) N
and CC N
46.2 CD N
% NN N
( ( N
66 CD N
of IN N
143 CD N
) ) N
of IN N
patients NNS N
developed JJ N
tumor NN 1_o
relapse NN 1_o
in IN N
the DT N
CCRT NNP 1_i
and CC N
RT-alone NNP 1_i
groups NNS N
, , N
respectively RB N
. . N

The DT N
5-year JJ 1_o
overall JJ 1_o
survival NN 1_o
rates NNS 1_o
were VBD N
72.3 CD N
% NN N
for IN N
the DT N
CCRT NNP 1_i
arm NN N
and CC N
54.2 CD N
% NN N
for IN N
the DT N
RT-only JJ 1_i
arm NN N
( ( N
P NNP N
=.0022 NNP N
) ) N
. . N

The DT N
5-year JJ 1_o
progression-free JJ 1_o
survival NN 1_o
rates NNS 1_o
were VBD N
71.6 CD N
% NN N
for IN N
the DT N
CCRT NNP 1_i
group NN N
compared VBN N
with IN N
53.0 CD N
% NN N
for IN N
the DT N
RT-only JJ 1_i
group NN N
( ( N
P NNP N
=.0012 NNP N
) ) N
. . N

Although IN N
significantly RB N
more JJR N
toxicity NN 1_o
was VBD N
noted VBN N
in IN N
the DT N
CCRT NNP 1_i
arm NN N
, , N
including VBG N
leukopenia NN 1_o
and CC 1_o
emesis NN 1_o
, , N
compliance NN N
with IN N
the DT N
combined JJ N
treatment NN N
was VBD N
good JJ N
. . N

The DT N
second JJ N
cycle NN N
of IN N
concurrent JJ 1_i
chemotherapy NN 1_i
was VBD N
refused VBN N
by IN N
nine CD N
patients NNS N
and CC N
was VBD N
delayed VBN N
for IN N
> NN N
or CC N
= $ N
1 CD N
week NN N
for IN N
another DT N
nine CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ 1_o
deaths NNS 1_o
in IN N
either DT N
arm NN N
. . N

CONCLUSION NN N
We PRP N
conclude VBP N
that DT N
CCRT NNP 1_i
is VBZ N
superior JJ N
to TO N
RT VB 1_i
alone RB N
for IN N
patients NNS 1_p
with IN 1_p
advanced JJ 1_p
NPC NNP 1_p
in IN 1_p
endemic JJ 1_p
areas NNS 1_p
. . 1_p

[ IN N
The DT N
chemotherapy NN 1_i
of IN N
advanced JJ 1_p
breast NN 1_p
cancer NN 1_p
. . 1_p

A DT N
report NN N
on IN N
the DT N
first JJ N
600 CD 1_p
cases NNS 1_p
in IN N
a DT N
cooperative JJ N
programme NN N
to TO N
carry VB N
out RP N
a DT N
systematic JJ N
study NN N
( ( N
1974-1977 JJ N
) ) N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

The DT N
authors NNS N
explain VBP N
the DT N
objectives NNS N
and CC N
the DT N
structure NN N
of IN N
a DT N
programme NN N
evolved VBN N
for IN N
the DT N
methodic JJ N
study NN N
of IN N
advanced JJ 1_p
breast NN 1_p
cancers NNS 1_p
which WDT N
they PRP N
have VBP N
worked VBN N
out RP N
and CC N
carried VBD N
out RP N
in IN N
cooperation NN N
with IN N
the DT N
departments NNS N
of IN N
medicine NN N
in IN 1_p
eight CD 1_p
French JJ 1_p
anticancer NN 1_p
centres NNS 1_p
. . 1_p

They PRP N
analyse VBP N
the DT N
initial JJ N
phases NNS N
, , N
which WDT N
correspond NN N
to TO N
the DT N
three CD N
first JJ N
years NNS N
of IN N
work NN N
. . N

They PRP N
give VBP N
the DT N
state NN N
of IN N
the DT N
results NNS N
that WDT N
have VBP N
been VBN N
obtained VBN N
in IN N
603 CD 1_p
patients NNS 1_p
using VBG N
three CD N
protocols NNS N
for IN N
treatment NN N
. . N

These DT N
consisted VBN N
of IN N
the DT N
administration NN N
in IN N
interrupted JJ N
doses NNS N
of IN N
chemotherapy NN 1_i
which WDT N
consisted VBD N
of IN N
vincristine NN 1_i
associated VBN N
for IN N
the DT N
one CD N
part NN N
with IN N
cyclophosphamide NN 1_i
and CC N
5-fluoro-uracil JJ 1_i
and CC N
on IN N
the DT N
other JJ N
hand NN N
with IN N
doxorubicine NN 1_i
or/and NN N
with IN N
methotrexate NN 1_i
. . 1_i

From IN N
this DT N
study NN N
there RB N
emerged VBD N
the DT N
value NN N
of IN N
combined JJ N
therapy NN N
using VBG N
doxorubicine NN 1_i
as IN N
much JJ N
because IN N
of IN N
the DT N
frequency NN N
with IN N
which WDT N
results NNS 1_o
better JJR N
than IN N
50 CD N
% NN N
were VBD N
obtained VBN N
( ( N
in IN N
a DT N
randomised JJ N
trial NN N
) ) N
as IN N
by IN N
their PRP$ N
quality NN 1_o
, , N
which WDT N
was VBD N
made VBN N
clear JJ N
in IN N
an DT N
important JJ N
series NN N
of IN N
240 CD N
cases NNS N
. . N

They PRP N
point VBP N
out RP N
the DT N
conditions NNS N
required VBN N
to TO N
initiate VB N
the DT N
place NN N
of IN N
such PDT N
a DT N
scheme NN N
in IN N
all DT N
complex JJ N
therapy NN N
which WDT N
aims VBZ N
as RB N
much JJ N
at IN N
palliation NN N
as IN N
at IN N
cure NN N
, , N
and CC N
point VB N
out RP N
how WRB N
important JJ N
it PRP N
is VBZ N
to TO N
be VB N
methodical JJ N
in IN N
the DT N
application NN N
of IN N
chemotherapy NN 1_i
in IN N
order NN N
to TO N
ensure VB N
its PRP$ N
development NN N
as IN N
an DT N
anticancer NN N
therapy NN N
. . N

Serum NNP 1_o
biochemical JJ 1_o
characteristics NNS 1_o
of IN N
Beluga NNP 1_p
, , 1_p
Huso NNP 1_p
huso NN 1_p
( ( 1_p
L. NNP 1_p
) ) 1_p
, , N
in IN N
response NN N
to TO N
blood NN N
sampling NN N
after IN N
clove NN N
powder NN N
solution NN N
exposure NN N
. . N

In IN N
order NN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
anesthesia NN 1_i
on IN N
serum NN 1_o
parameters NNS 1_o
, , N
Beluga NNP 1_p
, , 1_p
Huso NNP 1_p
huso NN 1_p
( ( 1_p
L. NNP 1_p
) ) 1_p
were VBD N
blood-sampled JJ N
immediately RB N
without IN N
anesthesia NN 1_i
( ( N
control NN N
) ) N
or CC N
subjected VBN N
to TO N
following VBG N
anesthesia JJ 1_i
procedure NN N
: : N
40 CD N
, , N
120 CD N
, , N
and CC N
240 CD N
s NN N
exposure NN N
to TO N
3,000 CD N
, , N
700 CD N
, , N
and CC N
500 CD N
mg NN N
l⁻¹ NN 1_i
clove NN 1_i
solution NN 1_i
, , N
respectively RB 1_o
. . 1_o

Blood NN 1_o
samples NNS 1_o
were VBD N
collected VBN N
after IN N
these DT N
periods NNS N
, , N
when WRB N
fish NN N
were VBD N
immobile JJ N
and CC N
reached VBD N
stage NN N
4 CD N
anesthesia NN N
. . N

Results NNS N
showed VBD N
that IN 1_o
cortisol NN 1_o
and CC 1_o
glucose JJ 1_o
levels NNS 1_o
were VBD N
significantly RB N
high JJ N
in IN N
700 CD N
and CC N
500 CD N
but CC N
not RB N
3,000 CD N
mg NNS N
l⁻¹ JJ N
group NN N
compared VBN N
to TO N
control VB 1_o
. . 1_o

Serum NNP 1_o
lactate NN 1_o
levels NNS 1_o
were VBD N
significantly RB N
high JJ N
in IN N
500 CD N
mg NNS N
l⁻¹ JJ N
group NN N
compared VBN N
to TO N
control VB 1_o
group NN 1_o
. . 1_o

Lactate NNP 1_o
levels NNS N
were VBD N
not RB N
significantly RB N
differed VBN N
between IN N
control NN N
, , N
3,000 CD N
, , N
and CC N
700 CD N
mg NN N
l⁻¹ NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS 1_o
in IN 1_o
serum NN 1_o
levels NNS 1_o
of IN 1_o
cholesterol NN 1_o
, , 1_o
total JJ 1_o
protein NN 1_o
, , 1_o
lactate JJ 1_o
dehydrogenase NN 1_o
, , 1_o
aspartate JJ 1_o
aminotransferase NN 1_o
, , 1_o
alanine JJ 1_o
aminotransferase NN 1_o
, , 1_o
Na⁺ NNP 1_o
, , 1_o
Cl⁻ NNP 1_o
, , N
K⁺ NNP N
, , N
and CC N
Ca²⁺ NNP N
. . N

Results NNP 1_i
suggest VBP 1_i
that IN 1_i
rapid JJ N
anesthesia NN N
with IN N
higher JJR N
dose NN 1_i
is VBZ 1_i
better JJR 1_i
than IN N
slow JJ N
anesthesia NN 1_o
with IN 1_o
lower JJR 1_o
dose NN 1_o
for IN 1_p
blood NN 1_p
sampling NN N
in IN N
Beluga NNP N
. . N

Effects NNS N
of IN N
soy JJ 1_i
intake NN N
on IN N
sex NN 1_o
hormone NN 1_o
metabolism NN 1_o
in IN N
premenopausal JJ 1_p
women NNS 1_p
. . 1_p

Studies NNS N
suggest VBP N
that IN N
phytoestrogens NNS N
in IN N
soy JJ 1_i
products NNS N
may MD N
impart VB N
hormonal JJ 1_o
effects NNS 1_o
that WDT N
protect VBP N
women NNS N
against IN N
breast NN N
cancer NN N
. . N

Limited VBN N
research NN N
suggests VBZ N
that IN N
intake NN N
of IN N
soy NN 1_i
products NNS N
high JJ N
in IN N
isoflavonoid JJ N
phytoestrogens NNS N
affects VBZ N
sex NN 1_o
hormone NN 1_o
metabolism NN 1_o
, , N
but CC N
it PRP N
is VBZ N
unknown JJ N
whether IN N
phytoestrogens NNS N
in IN N
soy NNS 1_i
have VBP N
any DT N
effect NN N
on IN N
menstrual JJ 1_o
function NN 1_o
or CC 1_o
serum VB 1_o
sex NN 1_o
hormones NNS 1_o
in IN N
women NNS N
on IN N
common JJ N
hormone NN N
therapies NNS N
, , N
such JJ N
as IN N
oral JJ N
contraceptives NNS N
( ( N
OC NNP N
) ) N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
soy NN 1_i
in IN N
36 CD 1_p
premenopausal JJ 1_p
women NNS 1_p
, , 1_p
20 CD 1_p
of IN 1_p
whom WP 1_p
used VBD 1_p
OC NNP 1_p
. . 1_p

Subjects NNS N
consumed VBD N
their PRP$ N
normal JJ 1_i
diet NNS 1_i
for IN N
two CD N
menstrual JJ N
cycles NNS N
and CC N
added VBD N
a DT N
soy JJ 1_i
beverage NN 1_i
containing VBG N
20 CD N
g NN N
of IN N
protein NN N
and CC N
38 CD N
mg NN N
of IN N
total JJ N
isoflavones NNS N
to TO N
their PRP$ N
usual JJ N
diet NN N
for IN N
another DT N
two CD N
menstrual JJ N
cycles NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
serum NN 1_o
estrone NN 1_o
, , 1_o
estradiol NN 1_o
, , 1_o
sex NN 1_o
hormone-binding JJ 1_o
globulin NN 1_o
, , 1_o
dehydroepiandrosterone NN 1_o
sulfate NN 1_o
, , 1_o
prolactin NN 1_o
, , 1_o
or CC 1_o
progesterone NN 1_o
concentrations NNS 1_o
with IN N
soy JJ 1_i
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
. . N

No DT N
changes NNS N
in IN N
menstrual JJ 1_o
cycle NN 1_o
length NN 1_o
or CC 1_o
the DT 1_o
urinary JJ 1_o
estrogen NN 1_o
metabolite NNS 1_o
ratio NN 1_o
of IN 1_o
2-hydroxyestrone CD 1_o
to TO 1_o
16 CD 1_o
alpha-hydroxyestrone NN 1_o
were VBD N
seen VBN N
with IN N
soy JJ N
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
. . N

Levels NNP N
of IN N
urinary JJ 1_o
estrogen NN 1_o
metabolites NNS 1_o
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
non-OC JJ N
and CC N
the DT N
OC NNP N
group NN N
. . N

Thus RB N
soy JJ 1_i
consumption NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
menstrual JJ 1_o
cycle NN 1_o
, , 1_o
serum JJ 1_o
sex NN 1_o
hormones NNS 1_o
, , 1_o
or CC 1_o
urinary JJ 1_o
estrogen NN 1_o
metabolite NN 1_o
ratio NN 1_o
in IN N
premenopausal NN 1_p
OC NNP 1_p
or CC 1_p
non-OC JJ 1_p
users NNS 1_p
. . 1_p

Sedation NN N
during IN N
endoscopic NN N
retrograde NN 1_p
cholangiopancreatography NN 1_p
: : 1_p
a DT N
randomized NN N
controlled VBN N
study NN N
of IN N
patient-controlled JJ N
propofol NN 1_i
sedation NN N
and CC N
that IN N
given VBN N
by IN N
a DT N
nurse JJ N
anesthetist NN N
. . N

OBJECTIVE CC N
Different JJ N
regimens NNS N
are VBP N
used VBN N
for IN N
sedation NN N
during IN N
endoscopic NN N
retrograde NN N
cholangiopancreatography NN N
( ( N
ERCP NNP N
) ) N
. . N

Our PRP$ N
objectives NNS N
were VBD N
to TO N
compare VB N
safety NN 1_o
, , 1_o
ease NN 1_o
of IN 1_o
treatment NN 1_o
, , 1_o
recovery NN 1_o
, , 1_o
and CC 1_o
patients NNS 1_o
' POS 1_o
experiences NNS 1_o
using VBG N
patient-controlled JJ 1_i
sedation NN 1_i
( ( N
PCS NNP N
) ) N
with IN N
propofol NN 1_i
, , N
nurse JJ N
anesthetist-controlled JJ 1_i
sedation NN 1_i
( ( N
ACS NNP N
) ) N
, , N
or CC N
the DT N
department NN N
's POS N
standard NN 1_i
of IN 1_i
care NN 1_i
, , 1_i
midazolam VB 1_i
given VBN N
by IN N
the DT N
procedure NN N
team NN N
( ( N
control VB N
group NN N
) ) N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN 1_p
included VBD 1_p
281 CD 1_p
adults NNS 1_p
in IN 1_p
301 CD 1_p
procedures NNS 1_p
. . 1_p

The DT N
PCS NNP N
group NN N
( ( N
n JJ N
= NNP N
101 CD N
) ) N
delivered VBN N
bolus JJ N
doses NNS N
of IN N
5 CD N
mg NN N
of IN N
propofol NN 1_i
according VBG N
to TO N
their PRP$ N
need NN N
for IN N
sedation NN N
. . N

The DT N
ACS NNP N
group NN N
( ( N
n JJ N
= NNP N
100 CD N
) ) N
had VBD N
2-8 JJ N
mg/kg/h NN N
of IN N
propofol NN 1_i
infused VBN N
, , N
with IN N
the DT N
target NN N
for IN N
sedation NN N
being VBG N
level JJ N
3 CD N
of IN N
the DT N
Observer NNP 1_o
's POS 1_o
Assessment NNP 1_o
of IN 1_o
Alertness/Sedation NNP 1_o
( ( 1_o
OAA/S NNP 1_o
) ) 1_o
scale NN 1_o
. . 1_o

The DT N
control NN N
group NN N
was VBD N
given VBN N
2-3 JJ N
mg NN N
of IN N
midazolam NN 1_i
for IN N
induction NN N
and CC N
additional JJ N
1 CD N
mg NN N
if IN N
required VBN N
. . N

RESULTS NNP N
PCS NNP N
and CC N
ACS NNP N
increased VBD N
the DT N
ease NN 1_o
of IN 1_o
the DT 1_o
procedure NN 1_o
and CC N
reduced VBD N
the DT N
number NN 1_o
of IN 1_o
sedation NN 1_o
failures NNS 1_o
compared VBN N
to TO N
midazolam VB 1_i
sedation NN N
( ( N
ACS NNP N
n RB N
= VBZ N
0 CD N
; : N
PCS NNP N
n VBD N
= JJ N
4 CD N
; : N
midazolam NN 1_i
n IN N
= $ N
20 CD N
) ) N
. . N

The DT N
ACS NNP N
group NN N
had VBD N
more RBR N
deeply RB N
sedated JJ N
patients NNS N
( ( N
OAA/S NNP N
level RB N
2 CD N
) ) N
, , N
desaturation NN N
, , N
and CC N
obstructed VBD N
airways NNS N
than IN N
the DT N
PCS NNP N
and CC N
midazolam NN 1_i
groups NNS N
. . N

Time NN 1_o
to TO 1_o
full JJ 1_o
recovery NN 1_o
( ( 1_o
Aldrete NNP 1_o
score RB 1_o
≥9 VBD N
) ) N
was VBD N
shortest JJS N
following VBG N
PCS NNP N
. . N

PCS NNP N
resulted VBD N
in IN N
the DT N
least JJS 1_o
fatigue NN 1_o
and CC 1_o
pain NN 1_o
after IN N
the DT N
procedure NN 1_o
. . 1_o

Patients NNS 1_o
' POS 1_o
preference NN 1_o
for IN N
PCS NNP N
and CC N
ACS NNP N
was VBD N
the DT N
same JJ N
. . N

CONCLUSION NNP N
PCS NNP N
with IN 1_i
propofol NN 1_i
is VBZ N
superior JJ N
to TO 1_i
midazolam VB 1_i
and CC N
comparable VB N
to TO N
ACS NNP N
. . N

PCS NNP N
resulted VBD N
in IN N
a DT 1_o
rapid JJ 1_o
recovery NN 1_o
, , 1_o
fewer JJR 1_o
respiratory NN 1_o
events NNS 1_o
, , N
and CC N
was VBD N
almost RB N
as RB 1_o
effective JJ 1_o
as IN N
ACS NNP N
in IN N
ensuring VBG N
a DT N
successful JJ N
examination NN N
. . N

[ JJ N
Effects NNS N
of IN N
auditory JJ 1_i
integrative JJ 1_i
training NN 1_i
on IN N
autistic JJ 1_p
children NNS 1_p
] VBP 1_p
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
short-term JJ N
treatment NN N
effect NN 1_o
of IN N
the DT N
auditory JJ 1_i
integrative JJ 1_i
training NN 1_i
on IN N
autistic JJ 1_p
children NNS 1_p
and CC N
provide VB N
them PRP N
with IN N
clinical JJ N
support NN N
for IN N
rehabilitative JJ N
treatment NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
81 CD 1_p
cases NNS 1_p
of IN 1_p
autistic JJ 1_p
children NNS 1_p
were VBD 1_p
selected VBN 1_p
through IN N
the DT N
standard NN N
of IN N
DSM-4 NNP N
and CC N
clinical JJ N
case NN N
study NN N
was VBD N
used VBN N
. . N

They PRP N
were VBD N
divided VBN N
randomly RB N
into IN N
experimental JJ N
group NN N
and CC N
control VB N
one CD N
, , N
and CC N
respectively RB N
received VBD N
auditory JJ 1_i
integrative JJ 1_i
training NN 1_i
and CC N
no DT N
training NN N
based VBN N
on IN N
the DT N
multiple JJ N
therapies NNS N
. . N

The DT N
patients NNS N
were VBD N
investigated VBN N
using VBG N
clinical JJ 1_o
manifestation NN 1_o
and CC 1_o
Autism NNP 1_o
Behavior NNP 1_o
Checklist NNP 1_o
( ( 1_o
ABC NNP 1_o
) ) 1_o
and CC 1_o
intelligence NN 1_o
quotient NN 1_o
( ( 1_o
IQ NNP 1_o
) ) 1_o
before IN N
and CC N
after IN N
six CD N
months NNS N
of IN N
treatment NN N
. . N

The DT N
effect NN N
was VBD N
evaluated VBN N
through IN N
the DT N
changes NNS 1_o
of IN 1_o
clinical JJ 1_o
manifestations NNS 1_o
and CC 1_o
scores NNS 1_o
of IN 1_o
ABC NNP 1_o
and CC 1_o
IQ NNP 1_o
. . 1_o

The DT N
changes NNS 1_o
of IN 1_o
scores NNS 1_o
of IN 1_o
IQ NNP 1_o
were VBD 1_o
determined VBN 1_o
with IN 1_o
Gesell NNP 1_o
and CC 1_o
WPPSI NNP 1_o
or CC 1_o
WISC-R NNP 1_o
. . 1_o

RESULTS NNP N
Compared VBD N
with IN N
40 CD N
patients NNS N
of IN N
the DT N
control NN N
group NN N
after IN N
the DT N
six CD N
months NNS N
of IN N
the DT N
auditory JJ 1_i
integrative JJ 1_i
training NN 1_i
, , N
41 CD N
of IN N
the DT N
experimental JJ N
group NN N
had VBD N
greatly RB N
improved VBN N
in IN N
many JJ N
aspects NNS N
, , N
such JJ N
as IN N
the DT N
disorders NNS 1_o
of IN 1_o
their PRP$ 1_o
language NN 1_o
, , 1_o
social JJ 1_o
interactions NNS 1_o
and CC 1_o
typical JJ 1_o
behavior NN 1_o
symptoms NNS 1_o
while IN N
they PRP N
had VBD N
not RB N
changed VBN N
in IN N
their PRP$ N
abnormal JJ 1_o
behaviors NNS 1_o
. . 1_o

The DT N
scores NNS 1_o
of IN 1_o
IQ NNP 1_o
or CC 1_o
DQ NNP 1_o
had VBD N
increased VBN N
and CC N
scores NNS 1_o
of IN 1_o
ABC NNP 1_o
had VBD N
dropped VBN N
. . N

The DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
greatly RB N
significant JJ N
in IN N
statistics NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
decreasing VBG N
level NN N
of IN N
both DT N
ABC NNP 1_o
scores NNS 1_o
and CC N
the DT N
increasing VBG N
level NN N
of IN N
the DT N
IQ NNP 1_o
scores NNS 1_o
were VBD N
negatively RB N
correlated VBN N
with IN N
age NN N
, , N
and CC N
the DT N
decreasing VBG N
level NN N
of IN N
ABC NNP 1_o
scores NNS 1_o
was VBD N
in IN N
line NN N
regression NN N
( ( N
positive JJ N
correlation NN N
) ) N
with IN N
base NN N
IQ NNP N
. . N

CONCLUSION NNP N
The DT N
treatment NN N
of IN N
auditory JJ 1_i
integrative JJ 1_i
training NN 1_i
( ( 1_i
AIT NNP 1_i
) ) 1_i
could MD N
greatly RB N
improve VB N
on IN N
language NN 1_o
disorders NNS 1_o
, , 1_o
the DT 1_o
difficulties NNS 1_o
of IN 1_o
social JJ 1_o
interactions NNS 1_o
, , 1_o
typical JJ 1_o
behavior NN 1_o
symptoms NNS 1_o
and CC 1_o
developmental JJ 1_o
levels NNS 1_o
, , N
therefore IN N
it PRP N
is VBZ N
positive JJ N
to TO N
the DT N
autistic JJ 1_p
children NNS 1_p
in IN N
its PRP$ N
short-term JJ N
treatment NN N
effect NN 1_o
. . 1_o

Anti-emetic JJ 1_o
efficacy NN 1_o
of IN N
prophylactic JJ N
granisetron NNS 1_i
compared VBN N
with IN N
perphenazine NN 1_i
for IN N
the DT N
prevention NN 1_o
of IN N
post-operative JJ N
vomiting NN N
in IN N
children NNS 1_p
. . 1_p

We PRP N
have VBP N
compared VBN N
the DT N
efficacy NN 1_o
of IN N
granisetron NN 1_i
with IN N
perphenazine NN 1_i
in IN N
the DT N
prevention NN N
of IN N
vomiting VBG N
after IN N
tonsillectomy NN 1_p
with IN 1_p
or CC 1_p
without IN 1_p
adenoidectomy NN 1_p
in IN 1_p
children NNS 1_p
. . 1_p

In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
, , N
90 CD 1_p
paediatric JJ 1_p
patients NNS 1_p
, , 1_p
ASA NNP 1_p
I PRP 1_p
, , 1_p
aged VBN 1_p
4-10 CD 1_p
years NNS 1_p
, , N
received VBD N
granisetron NN 1_i
40 CD N
mg JJ N
kg-1 NN N
or CC N
perphenazine VB 1_i
70 CD N
mg JJ N
kg-1 NN N
( ( N
n JJ N
= RB N
45 CD N
each DT N
) ) N
intravenously RB N
immediately RB N
after IN N
an DT N
inhalation NN N
induction NN N
of IN N
anaesthesia NN N
. . N

A DT N
standard JJ N
general JJ N
anaesthetic JJ N
technique NN N
was VBD N
employed VBN N
throughout IN N
. . N

A DT N
complete JJ 1_o
response NN 1_o
, , 1_o
defined VBD 1_o
as IN 1_o
no DT 1_o
emesis NN 1_o
with IN 1_o
no DT 1_o
need NN 1_o
for IN 1_o
another DT 1_o
rescue NN 1_o
antiemetic JJ 1_o
, , N
during IN N
the DT N
first JJ N
3 CD N
h NN N
( ( N
0-3 JJ N
h NN N
) ) N
after IN N
anesthesia NN N
was VBD N
87 CD N
% NN N
with IN N
granisetron NN 1_i
and CC N
78 CD N
% NN N
with IN N
perphenazine NN 1_i
( ( N
P NNP N
= NNP N
0.204 CD N
) ) N
. . N

The DT N
corresponding JJ 1_o
incidence NN 1_o
during IN N
the DT N
next JJ N
21 CD N
h NN N
( ( N
3-24 JJ N
h NN N
) ) N
after IN N
anaesthesia NN N
was VBD N
87 CD N
% NN N
and CC N
62 CD N
% NN N
( ( N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

No UH N
clinically RB N
serious JJ N
adverse JJ 1_o
events NNS 1_o
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
granisetron NN 1_i
is VBZ N
a DT N
better JJR N
anti-emetic JJ N
than IN N
perphenazine NN 1_i
for IN N
the DT N
long-term JJ 1_o
prevention NN 1_o
of IN 1_o
post-operative JJ 1_o
vomiting NN 1_o
in IN N
children NNS 1_p
undergoing VBG 1_p
general JJ 1_p
anaesthesia NN 1_p
for IN 1_p
tonsillectomy NN 1_p
. . 1_p

A DT N
pooled JJ N
analysis NN N
of IN N
eastern JJ N
cooperative JJ N
oncology NN N
group NN N
and CC N
intergroup NN N
trials NNS N
of IN N
adjuvant JJ N
high-dose JJ N
interferon NN 1_i
for IN N
melanoma NN N
. . N

PURPOSE NNP N
Nearly RB 1_p
2000 CD 1_p
patients NNS 1_p
with IN 1_p
stage NN 1_p
IIB NNP 1_p
and CC 1_p
III NNP 1_p
melanoma NNS 1_p
have VBP N
participated VBN N
in IN N
four CD N
multicenter NN N
, , N
randomized VBN N
trials NNS N
, , N
conducted VBN N
by IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
and CC N
the DT N
Intergroup NNP N
, , N
investigating VBG N
adjuvant JJ N
high-dose JJ N
IFN-alpha JJ 1_i
2b CD 1_i
therapy NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
update VB N
the DT N
analyses NNS N
of IN N
each DT N
individual JJ N
trial NN N
and CC N
to TO N
analyze VB N
prognostic JJ 1_o
factors NNS 1_o
and CC 1_o
treatment NN 1_o
effects NNS 1_o
based VBN N
on IN N
pooled JJ N
data NNS N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Survival NNP N
and CC N
disease NN N
status NN N
were VBD N
updated VBN N
to TO N
April NNP N
2001 CD N
. . N

Analysis NN N
of IN N
prognostic JJ 1_o
factors NNS 1_o
using VBG 1_o
optimized JJ 1_o
statistical JJ 1_o
models NNS 1_o
was VBD N
based VBN N
on IN N
data NNS N
from IN N
patients NNS N
in IN N
E1684 NNP N
, , N
E1690 NNP N
, , N
E1694 NNP N
, , N
and CC N
E2696 NNP N
. . N

Analysis NN N
of IN N
treatment NN 1_o
effects NNS 1_o
versus VBP 1_o
observation NN 1_o
( ( 1_o
Obs NNP 1_o
) ) 1_o
was VBD N
based VBN N
on IN N
data NNS N
from IN N
713 CD N
patients NNS N
randomized VBN N
to TO N
high-dose JJ N
IFN-alpha JJ 1_i
2b CD 1_i
( ( 1_i
HDI NNP 1_i
) ) 1_i
or CC N
Obs NNP 1_i
in IN N
Trials NNP N
E1684 NNP N
and CC N
E1690 NNP N
. . N

RESULTS NNP N
Updated VBD N
analysis NN N
of IN N
E1684 NNP N
, , N
E1690 NNP N
, , N
and CC N
E1694 NNP N
confirmed VBD N
their PRP$ N
original JJ N
conclusions NNS N
, , N
now RB N
at IN N
median JJ N
follow-up JJ N
intervals NNS N
of IN N
2.1-12.6 JJ N
years NNS N
. . N

Based VBN N
on IN N
two-sided JJ N
univariate JJ N
log-rank JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
E1684 NNP N
and CC N
E1690 NNP N
( ( N
median JJ N
follow-up NN N
, , N
7.2 CD N
years NNS N
) ) N
, , N
relapse-free JJ 1_o
survival NN 1_o
( ( 1_o
RFS NNP 1_o
) ) 1_o
-but VBZ 1_o
not RB N
overall JJ 1_o
survival NN 1_o
( ( 1_o
OS NNP 1_o
) ) 1_o
-was VBP 1_o
significantly RB N
prolonged VBN N
( ( N
two-sided JJ N
log-rank NN N
P NNP N
value NN N
= NNP N
0.006 CD N
) ) N
for IN N
patients NNS N
treated VBN N
with IN N
HDI NNP 1_i
versus NN N
Obs NNP 1_i
. . 1_i

Among IN N
all DT N
patients NNS N
, , N
prognostic JJ 1_o
factors NNS 1_o
that WDT N
significantly RB N
negatively RB N
impacted JJ N
RFS NNP N
and CC N
OS NNP N
included VBD N
ulceration NN 1_o
, , 1_o
recurrent JJ 1_o
disease NN 1_o
at IN 1_o
entry NN 1_o
, , N
enrollment NN N
in IN N
E1684 NNP N
, , N
and CC N
age NN 1_o
> VBP N
49 CD N
years NNS N
. . N

Multivariate NNP N
statistical JJ N
models NNS N
adjusting VBG N
for IN N
these DT N
factors NNS N
confirmed VBD N
the DT N
statistically RB N
significant JJ N
RFS NNP 1_o
benefit NN N
of IN N
HDI NNP 1_i
versus NN N
Obs NNP 1_i
but CC N
did VBD N
not RB N
demonstrate VB N
a DT N
significant JJ N
OS NNP 1_o
benefit NN N
in IN N
the DT N
pooled JJ N
populations NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS 1_p
with IN 1_p
high-risk JJ 1_p
resected JJ 1_p
melanoma NN 1_p
, , N
HDI NNP N
is VBZ N
effective JJ N
adjuvant JJ N
therapy NN N
with IN N
strong JJ N
evidence NN N
for IN N
improved JJ N
RFS NNP 1_o
and CC N
evidence NN N
for IN N
moderate JJ N
improvement NN N
in IN N
OS NNP 1_o
based VBN N
on IN N
two CD N
prospective JJ N
randomized VBN N
studies NNS N
but CC N
not RB N
the DT N
pooled JJ N
analysis NN N
. . N

Analyses NNS N
of IN N
predictors NNS 1_o
of IN 1_o
relapse NN 1_o
and CC 1_o
response NN 1_o
are VBP N
now RB N
needed VBN N
to TO N
improve VB N
the DT N
therapeutic JJ N
value NN N
of IN N
this DT N
modality NN N
. . N

Bayesian JJ 1_i
adaptive JJ 1_i
trials NNS 1_i
offer VBP N
advantages NNS N
in IN N
comparative JJ N
effectiveness NN 1_o
trials NNS N
: : N
an DT N
example NN N
in IN N
status NN 1_p
epilepticus NN 1_p
. . 1_p

OBJECTIVE IN N
We PRP N
present VBP N
a DT N
novel JJ N
Bayesian JJ 1_i
adaptive JJ 1_i
comparative NN 1_i
effectiveness NN 1_o
trial NN 1_i
comparing VBG N
three CD N
treatments NNS N
for IN N
status NN 1_p
epilepticus NN 1_p
that WDT N
uses VBZ N
adaptive JJ N
randomization NN N
with IN N
potential JJ N
early JJ N
stopping NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
The DT N
trial NN N
will MD N
enroll VB N
720 CD 1_p
unique JJ 1_p
patients NNS 1_p
in IN 1_p
emergency NN 1_p
departments NNS 1_p
and CC 1_p
uses VBZ 1_p
a DT 1_p
Bayesian JJ 1_i
adaptive JJ 1_i
design NN 1_i
. . 1_i

RESULTS VB N
The DT N
trial NN N
design NN N
is VBZ N
compared VBN N
to TO N
a DT N
trial NN 1_i
without IN 1_i
adaptive JJ 1_i
randomization NN 1_i
and CC N
produces VBZ N
an DT N
efficient JJ N
trial NN N
in IN N
which WDT N
a DT N
higher JJR N
proportion NN 1_o
of IN 1_o
patients NNS 1_o
are VBP N
likely JJ N
to TO N
be VB N
randomized VBN N
to TO N
the DT N
most RBS N
effective JJ N
treatment NN N
arm NN N
while IN N
generally RB N
using VBG N
fewer JJR N
total JJ 1_o
patients NNS 1_o
and CC N
offers VBZ N
higher JJR N
power NN N
than IN N
an DT N
analogous JJ N
trial NN N
with IN N
fixed JJ N
randomization NN N
when WRB N
identifying VBG N
a DT N
superior JJ N
treatment NN N
. . N

CONCLUSION NN N
When WRB N
one CD N
treatment NN N
is VBZ N
superior JJ N
to TO N
the DT N
other JJ N
two CD N
, , N
the DT N
trial NN N
design NN N
provides VBZ N
better RBR N
patient NN 1_o
care NN 1_o
, , N
higher JJR N
power NN 1_o
, , N
and CC N
a DT N
lower JJR N
expected VBN 1_o
sample JJ 1_o
size NN 1_o
. . 1_o

Parent-implemented JJ N
enhanced VBD 1_i
milieu NNS 1_i
teaching VBG 1_i
with IN N
preschool JJ 1_p
children NNS 1_p
who WP 1_p
have VBP 1_p
intellectual JJ 1_p
disabilities NNS 1_p
. . 1_p

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
enhanced JJ 1_i
milieu NN 1_i
teaching NN 1_i
( ( 1_i
EMT NNP 1_i
) ) 1_i
implemented VBN N
by IN N
parents NNS N
and CC N
therapists NNS N
versus VBP N
therapists VBZ N
only RB N
on IN N
the DT N
language NN 1_o
skills NNS 1_o
of IN N
preschool NN 1_p
children NNS 1_p
with IN 1_p
intellectual JJ 1_p
disabilities NNS 1_p
( ( 1_p
IDs NNP 1_p
) ) 1_p
, , 1_p
including VBG 1_p
children NNS 1_p
with IN 1_p
Down NNP 1_p
syndrome NN 1_p
and CC 1_p
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorders NNS 1_p
. . 1_p

METHOD NNP N
Seventy-seven JJ 1_p
children NNS 1_p
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
treatments NNS N
( ( 1_i
parent NN 1_i
+ NNP 1_i
therapist NN 1_i
EMT NNP 1_i
or CC N
therapist-only RB 1_i
EMT NNP 1_i
) ) 1_i
and CC N
received VBD N
36 CD N
intervention NN N
sessions NNS N
. . N

Children NNP N
were VBD N
assessed VBN N
before RB N
, , N
immediately RB N
after IN N
, , N
6 CD N
months NNS N
after IN N
, , N
and CC N
12 CD N
months NNS N
after IN N
intervention NN N
. . N

Separate JJ N
linear JJ N
regressions NNS N
were VBD N
conducted VBN N
for IN N
each DT N
standardized JJ 1_o
and CC 1_o
observational JJ 1_o
measure NN 1_o
at IN N
each DT N
time NN N
point NN N
. . N

RESULTS JJ N
Parents NNS N
in IN N
the DT N
parent NN N
+ NNP N
therapist NN N
group NN N
demonstrated VBD N
greater JJR N
use NN 1_o
of IN 1_o
EMT NNP 1_o
strategies NNS 1_o
at IN N
home NN N
than IN N
untrained JJ N
parents NNS N
in IN N
the DT N
therapist-only JJ N
group NN N
, , N
and CC N
these DT N
effects NNS N
maintained VBD N
over IN N
time NN N
. . N

Effect JJ N
sizes NN N
for IN N
observational JJ 1_o
measures NNS 1_o
ranged VBD N
from IN N
d NN N
= $ N
0.10 CD N
to TO N
d VB N
= JJ N
1.32 CD N
favoring VBG N
the DT N
parent NN N
+ NNP N
therapist NN N
group NN N
, , N
with IN N
the DT N
largest JJS N
effect NN N
sizes VBZ N
found VBD N
12 CD N
months NNS N
after IN N
intervention NN N
. . N

CONCLUSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
indicate VBP N
generally RB N
that IN N
there EX N
are VBP N
benefits NNS N
to TO N
training VBG N
parents NNS N
to TO N
implement VB N
naturalistic JJ N
language NN N
intervention NN N
strategies NNS N
with IN N
preschool JJ 1_p
children NNS 1_p
who WP 1_p
have VBP 1_p
ID NNP 1_p
and CC 1_p
significant JJ 1_p
language NN 1_p
impairments NNS 1_p
. . 1_p

Levobunolol NNP 1_i
compared VBN N
with IN N
timolol NN 1_i
: : 1_i
a DT N
four-year JJ N
study NN N
. . N

Fifty-one CD 1_p
patients NNS 1_p
with IN 1_p
raised VBN 1_p
intraocular JJ 1_o
pressure NN 1_o
( ( 1_o
IOP NNP 1_o
) ) 1_o
were VBD N
treated VBN N
for IN N
up IN N
to TO N
four CD N
years NNS N
with IN N
one CD N
of IN N
three CD N
ophthalmic JJ N
solutions NNS N
: : N
0.5 CD N
% NN N
levobunolol NN 1_i
, , N
1 CD N
% NN N
levobunolol NN 1_i
, , N
or CC N
0.5 CD N
% NN N
timolol NN 1_i
. . 1_i

The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
double-masked JJ N
, , N
randomised JJ N
trial NN N
in IN N
which WDT N
medications NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
to TO N
both DT N
eyes NNS N
. . N

Levobunolol NNP 1_i
and CC N
timolol NN 1_i
were VBD N
equally RB N
effective JJ 1_o
in IN N
reducing VBG N
overall JJ 1_o
mean JJ 1_o
IOP NNP 1_o
; : 1_o
reductions NNS N
were VBD N
greater JJR N
than IN N
8.8 CD N
mmHg NNS N
in IN N
all DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
study NN N
showed VBD N
levobunolol NNS 1_i
to TO N
be VB N
as IN N
safe JJ N
and CC N
effective JJ 1_o
as IN N
timolol NN 1_i
in IN N
the DT N
long-term JJ N
control NN N
of IN N
raised VBN N
IOP NNP N
. . N

[ VB 1_o
The DT 1_o
sympatho-adrenergic JJ 1_o
stress NN 1_o
reaction NN 1_o
in IN N
ear JJ 1_p
surgery NN 1_p
using VBG N
various JJ N
anesthesia JJ N
technics NNS N
] VBP N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
various JJ N
anaesthetic JJ N
procedures NNS N
on IN N
the DT N
endocrine NN 1_o
stress NN 1_o
responses NNS 1_o
during IN N
ear JJ 1_p
microsurgical JJ 1_p
operations NNS 1_p
. . 1_p

Simple JJ 1_p
mastoidectomies NNS 1_p
, , 1_p
radical JJ 1_p
mastoidectomies NNS 1_p
and CC 1_p
tympano NN 1_p
plastics NNS 1_p
were VBD 1_p
carried VBN 1_p
out IN 1_p
in IN 1_p
49 CD 1_p
patients NNS 1_p
under IN N
the DT N
following VBG N
randomised VBD N
anaesthetic JJ N
procedures NNS N
: : N
Group NNP N
1 CD N
halothane NN 1_i
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN 1_i
and CC N
ornipressin NN 1_i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
, , N
Group NNP N
2 CD N
fentanyl NN 1_i
anaesthesia NN N
and CC N
retroauricular JJ N
anaesthesia NN N
with IN N
lidocaine NN 1_i
and CC N
ornipressin NN 1_i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
, , N
Group NNP N
3 CD N
fentanyl NN 1_i
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN 1_i
and CC N
epinephrine NN 1_i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
, , N
and CC N
Group NNP N
4 CD N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
prilocaine NN 1_i
and CC N
epinephrine NN 1_i
( ( N
n JJ N
= NNP N
14 CD N
) ) N
. . N

The DT N
plasma NN 1_o
levels NNS 1_o
of IN 1_o
epinephrine NN 1_o
, , 1_o
norepinephrine NN 1_o
, , 1_o
glucose NN 1_o
, , 1_o
lactate NN 1_o
and CC 1_o
free JJ 1_o
glycerol NN 1_o
were VBD N
measured VBN N
in IN N
addition NN N
to TO N
mean VB 1_o
arterial JJ 1_o
pressure NN 1_o
( ( 1_o
MAP NNP 1_o
) ) 1_o
and CC 1_o
heart NN 1_o
rate NN 1_o
( ( 1_o
HR NNP 1_o
) ) 1_o
immediately RB N
before IN N
anaesthesia NN N
, , N
10 CD N
minutes NNS N
after IN N
skin JJ N
incision NN N
, , N
10 CD N
minutes NNS N
after IN N
having VBG N
started VBD N
bone CD N
drilling NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
and CC N
3 CD N
hours NNS N
after IN N
operation NN N
. . N

All DT N
data NNS N
were VBD N
subjected VBN N
to TO N
covariance VB N
analysis NN N
including VBG N
the DT N
age NN N
factor NN N
. . N

Plasma NNP 1_o
catecholamine JJ 1_o
concentrations NNS 1_o
remained VBD N
within IN N
the DT N
normal JJ N
range NN N
during IN N
the DT N
investigation NN N
in IN N
patients NNS N
subjected VBN N
to TO N
general JJ N
anaesthesia NN N
( ( N
Groups NNP N
1-3 CD N
) ) N
. . N

Plasma NNP 1_o
catecholamines NNS 1_o
( ( 1_o
epinephrine NN 1_o
and CC 1_o
norepinephrine NN 1_o
) ) 1_o
increased VBD N
significantly RB N
in IN N
Group NNP N
4 CD N
( ( N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
) ) N
. . N

There EX N
were VBD N
no DT N
group NN N
variabilities VBZ N
with IN N
regard NN N
to TO N
MAP NNP 1_o
and CC N
HR NNP 1_o
. . 1_o

The DT N
plasma NN 1_o
levels NNS 1_o
of IN 1_o
epinephrine NN 1_o
and CC 1_o
norepinephrine JJ 1_o
demonstrate NN N
a DT N
direct JJ N
response NN N
to TO N
stress NN N
followed VBN N
by IN N
a DT N
secondary JJ N
change NN N
in IN N
glucose NN 1_o
, , 1_o
lactate NN 1_o
and CC 1_o
free JJ 1_o
glycerol NN 1_o
. . 1_o

The DT N
beneficial JJ N
effect NN N
of IN N
general JJ N
anaesthesia NN N
is VBZ N
documented VBN N
by IN N
normal JJ N
plasma NN N
levels NNS N
of IN N
epinephrine NN N
and CC N
norepinephrine NN N
throughout IN N
the DT N
operation NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
[ JJ N
Effect NNP N
of IN N
branch NN 1_i
chain NN 1_i
amino NN 1_i
acid NN 1_i
enriched VBD 1_i
formula NN 1_i
on IN N
postoperative JJ 1_o
fatigue NN 1_o
and CC 1_o
nutritional JJ 1_o
status NN 1_o
after IN 1_p
digestive JJ 1_p
surgery NN 1_p
] NN 1_p
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
branch NN 1_i
chain NN 1_i
amino NN 1_i
acid NN 1_i
( ( 1_i
BCAA NNP 1_i
) ) 1_i
enriched VBD 1_i
formula NN 1_i
on IN N
nutritional JJ 1_o
status NN 1_o
and CC N
postoperative JJ 1_o
fatigue NN 1_o
for IN N
digestive JJ 1_p
surgery NN 1_p
patients NNS 1_p
. . 1_p

METHODS NNP N
Forty NNP 1_p
patients NNS 1_p
who WP 1_p
underwent VBP 1_p
digestive JJ 1_p
surgery NN 1_p
were VBD N
randomly RB N
received VBN N
parenteral JJ N
nutrition NN N
with IN N
either DT N
BCAA NNP 1_i
enriched VBD 1_i
( ( N
study NN N
group NN N
, , N
n=20 RB N
) ) N
or CC N
routine JJ 1_i
amino NN 1_i
acid NN 1_i
( ( N
control NN N
group NN N
, , N
n=20 RB N
) ) N
for IN N
seven CD N
consecutive JJ N
days NNS N
. . N

Nitrogen NNP 1_o
balance NN 1_o
, , 1_o
serum JJ 1_o
total NN 1_o
protein NN 1_o
, , 1_o
albumin NN 1_o
, , 1_o
prealbumin NN 1_o
, , 1_o
transferrin NN 1_o
, , 1_o
retinol NN 1_o
binding NN 1_o
protein NN 1_o
and CC 1_o
postoperative JJ 1_o
fatigue NN 1_o
score NN 1_o
were VBD N
monitored VBN N
during IN N
the DT N
postoperative JJ N
period NN N
. . N

RESULTS VB N
The DT N
cumulative JJ 1_o
postoperative JJ 1_o
fatigue NN 1_o
scores NNS 1_o
were VBD N
lower JJR N
in IN N
BCAA NNP 1_i
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
at IN N
the DT N
4th CD N
, , N
5th CD N
and CC N
7th CD N
day NN N
after IN N
operation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNS N
achieved VBD N
positive JJ N
nitrogen NN 1_o
balance NN 1_o
2 CD N
days NNS N
earlier RBR N
in IN N
the DT N
study NN N
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cumulative JJ 1_o
nitrogen NN 1_o
balance NN 1_o
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
elevation NN N
of IN N
serum JJ 1_o
total JJ 1_o
protein NN 1_o
, , 1_o
albumin NN 1_o
, , 1_o
prealbumin NN 1_o
, , 1_o
transferrin NN 1_o
at IN N
the DT N
7th CD N
day NN N
after IN N
operation NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
compared VBN N
with IN N
those DT N
at IN N
the DT N
first JJ N
day NN N
after IN N
operation NN N
. . N

The DT N
serum JJ 1_o
level NN 1_o
of IN 1_o
retinol NN 1_o
binding VBG 1_o
protein NN 1_o
was VBD N
higher JJR N
in IN N
BCAA-enriched NNP 1_i
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P=0.004 NNP N
) ) N
. . N

CONCLUSION NNP N
TPN NNP N
with IN N
BCAA NNP 1_i
enriched VBD 1_i
formula NN 1_i
can MD N
reduce VB N
postoperative JJ 1_o
fatigue NN 1_o
score NN 1_o
and CC N
improve VB N
the DT N
nutritional JJ 1_o
status NN 1_o
for IN N
digestive JJ 1_p
surgery NN 1_p
patients NNS 1_p
. . 1_p

Regional JJ N
ventricular JJ N
performance NN N
and CC N
exercise NN 1_i
training NN 1_i
in IN N
children NNS 1_p
and CC 1_p
young JJ 1_p
adults NNS 1_p
after IN 1_p
repair NN 1_p
of IN 1_p
tetralogy NN 1_p
of IN 1_p
Fallot NN 1_p
: : 1_p
randomized VBN N
controlled VBD N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Public-health NNP N
guidelines NNS N
recommend VBP N
patients NNS N
with IN N
congenital JJ N
heart NN N
disease NN N
to TO N
exercise VB N
. . N

Studies NNS N
have VBP N
shown VBN N
that IN N
patients NNS N
with IN N
congenital JJ N
heart NN N
disease NN N
can MD N
improve VB N
physical JJ N
exercise NN N
capacity NN N
. . N

The DT N
effect NN N
of IN N
training VBG 1_i
on IN N
regional JJ 1_o
ventricular JJ 1_o
performance NN 1_o
has VBZ N
hardly RB N
been VBN N
studied VBN N
. . N

We PRP N
performed VBD N
a DT N
pilot NN N
study NN N
to TO N
assess VB N
whether IN N
an DT N
exercise NN 1_i
training NN 1_i
program NN 1_i
would MD N
result VB N
in IN N
adverse JJ 1_o
changes NNS 1_o
of IN 1_o
regional JJ 1_o
ventricular JJ 1_o
performance NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
corrected JJ 1_p
tetralogy NN 1_p
of IN 1_p
Fallot NNP 1_p
. . 1_p

METHODS NNP N
AND CC N
RESULTS NNP N
Multicenter NNP N
prospective JJ N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
in IN N
patients NNS 1_p
with IN 1_p
tetralogy NN 1_p
of IN 1_p
Fallot NNP 1_p
aged VBD 1_p
10 CD 1_p
to TO 1_p
25 CD 1_p
years NNS 1_p
. . 1_p

A DT N
12-week JJ N
standardized JJ N
aerobic JJ N
dynamic JJ N
exercise NN 1_i
training NN 1_i
program NN 1_i
( ( N
3 CD N
one-hour JJ N
sessions NNS N
per IN N
week NN N
) ) N
was VBD N
used VBN N
. . N

Pre- JJ N
and CC N
post-training JJ N
cardiopulmonary JJ 1_o
exercise NN 1_o
tests NNS 1_o
, , 1_o
MRI NNP 1_o
, , 1_o
and CC 1_o
echocardiography NN 1_o
, , 1_o
including VBG 1_o
tissue-Doppler NN 1_o
imaging NN 1_o
, , N
were VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
exercise NN 1_i
group NN N
( ( N
n=28 JJ N
) ) N
or CC N
control VB 1_i
group NN N
( ( N
n=20 RB N
) ) N
. . N

One CD N
patient NN N
in IN N
the DT N
exercise NN 1_i
group NN N
dropped VBD N
out RP N
. . N

Change VB 1_o
in IN 1_o
tissue-Doppler NN 1_o
imaging NN 1_o
parameters NNS 1_o
was VBD N
similar JJ N
in IN N
the DT N
exercise NN 1_i
group NN N
and CC N
control NN 1_i
group NN N
( ( N
change NN N
in IN N
right JJ N
ventricle NN N
free JJ N
wall NN N
peak NN N
velocity NN N
E NNP N
' POS N
exercise NN 1_i
group NN N
, , N
0.8±2.6 CD N
cm/s NN 1_i
; : 1_i
control NN 1_i
group NN N
, , N
0.9±4.1 CD N
; : N
peak JJ N
velocity NN N
A NNP 1_i
' POS 1_i
exercise NN 1_i
group NN N
, , N
0.4±2.4 CD N
m/s NN 1_i
; : 1_i
control NN 1_i
group NN N
4.6±18.1 CD N
cm/s NN N
) ) N
. . N

CONCLUSIONS VB N
This DT N
randomized VBN N
controlled VBD N
pilot NN N
study NN N
provides VBZ N
preliminary JJ N
data NNS N
suggesting VBG N
that IN 1_o
regional JJ 1_o
ventricular JJ 1_o
performance NN 1_o
is VBZ N
well RB N
maintained VBN N
during IN N
3-month JJ N
aerobic JJ N
dynamic JJ 1_i
exercise NN 1_i
training NN 1_i
in IN 1_p
children NNS 1_p
and CC 1_p
young JJ 1_p
adults NNS 1_p
with IN 1_p
repaired JJ 1_p
tetralogy NN 1_p
of IN 1_p
Fallot NNP 1_p
. . N

This DT N
information NN N
might MD N
help VB N
patients NNS N
adhere VB N
to TO N
current JJ N
public-health NN N
guidelines NNS N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http// NN N
: : N
www.trialregister.nl NN N
. . N

Unique NNP N
identifier NN N
: : N
NTR2731 NNP N
. . N

Chronic NNP N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN 1_i
in IN N
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
long-term JJ 1_o
effect NN 1_o
of IN N
flosequinan NN 1_i
, , N
a DT N
new JJ N
orally RB N
administered VBN N
arterial JJ N
and CC N
venous JJ N
dilator NN N
, , N
on IN N
the DT N
clinical JJ 1_o
course NN 1_o
of IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
congestive JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

Seventeen JJ 1_p
patients NNS 1_p
on IN 1_p
chronic JJ 1_p
digitalis NN 1_p
and CC 1_p
diuretic JJ 1_p
therapy NN 1_p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
flosequinan NN 1_i
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
placebo NN 1_i
( ( N
n JJ N
= NNP N
8 CD N
) ) N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

Changes NNS 1_o
in IN 1_o
symptomatology NN 1_o
, , 1_o
exercise NN 1_o
performance NN 1_o
, , 1_o
and CC 1_o
left VBD 1_o
ventricular JJ 1_o
function NN 1_o
were VBD N
assessed VBN N
serially RB N
during IN N
the DT N
two-month JJ N
treatment NN N
period NN N
. . N

During IN N
the DT N
course NN N
of IN N
therapy NN N
, , N
a DT N
modest JJ N
improvement NN N
in IN N
the DT N
symptom NN 1_o
scores NNS 1_o
and CC 1_o
functional JJ 1_o
classification NN 1_o
of IN N
the DT N
flosequinan-treated JJ 1_i
patients NNS N
was VBD N
observed VBN N
. . N

Flosequinan NNP 1_i
evoked VBD N
a DT N
significant JJ N
increase NN N
in IN N
maximal JJ 1_o
exercise NN 1_o
capacity NN 1_o
. . 1_o

While IN N
long-term JJ N
flosequinan JJ 1_i
administration NN N
also RB N
effected VBD N
a DT N
progressive JJ N
increase NN N
in IN N
resting VBG 1_o
heart NN 1_o
rate NN 1_o
, , N
it PRP N
did VBD N
not RB N
consistently RB N
improve VB N
indices NNS N
of IN N
left JJ 1_o
ventricular JJ 1_o
systolic JJ 1_o
function NN 1_o
. . 1_o

The DT N
addition NN N
of IN N
chronic JJ N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN 1_i
to TO N
standard VB N
digitalis-diuretic JJ N
regimens NNS N
is VBZ N
capable JJ N
of IN N
inducing VBG N
clinical JJ N
improvement NN N
in IN N
patients NNS 1_p
with IN 1_p
moderate JJ 1_p
to TO 1_p
severe VB 1_p
chronic JJ 1_p
heart NN 1_p
failure NN 1_p
. . 1_p

Trials NNS N
involving VBG N
larger JJR N
patient JJ N
populations NNS N
will MD N
be VB N
necessary JJ N
to TO N
confirm VB N
the DT N
results NNS N
of IN N
this DT N
preliminary JJ N
study NN N
and CC N
to TO N
determine VB N
the DT N
extent NN N
of IN N
clinical JJ N
improvement NN N
, , N
subpopulations NNS N
benefited VBD N
, , N
role NN N
in IN N
heart NN N
failure NN N
therapeutics NNS N
, , N
and CC N
so RB N
forth JJ N
. . N

An DT N
open-label JJ N
extension NN N
study NN N
of IN N
the DT N
safety NN 1_o
and CC N
efficacy NN 1_o
of IN N
risperidone NN 1_i
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autistic JJ 1_p
disorder NN 1_p
. . 1_p

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
long-term JJ 1_o
safety NN 1_o
and CC 1_o
efficacy NN 1_o
of IN N
risperidone NN 1_i
in IN N
treating VBG N
irritability NN N
and CC N
related JJ N
behaviors NNS N
in IN N
children NNS 1_p
and CC 1_p
adolescents NNS 1_p
with IN 1_p
autistic JJ 1_p
disorders NNS 1_p
. . 1_p

METHODS NNP N
In IN N
this DT N
6 CD N
month NN N
( ( N
26 CD N
week NN N
) ) N
open-label NN N
extension NN N
( ( N
OLE NNP N
) ) N
study NN N
, , N
patients NNS 1_p
( ( 1_p
5-17 JJ 1_p
years NNS 1_p
of IN 1_p
age NN 1_p
, , 1_p
who WP 1_p
completed VBD 1_p
the DT 1_p
previous JJ 1_p
fixed-dose JJ 1_p
, , 1_p
6 CD 1_p
week NN 1_p
, , 1_p
double-blind JJ 1_p
[ NNP 1_p
DB NNP 1_p
] NNP 1_p
phase NN 1_p
) ) 1_p
were VBD N
flexibly RB N
dosed VBN N
with IN N
risperidone NN 1_i
based VBN N
on IN N
body NN N
weight NN N
. . N

The DT N
maximum JJ N
allowed VBD N
dose NN N
was VBD N
1.25 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
20 CD N
to TO N
< VB N
45 CD N
kg NN N
, , N
and CC N
1.75 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
≥ JJ N
45 CD N
kg NN N
. . N

The DT N
study NN N
primarily RB N
assessed VBD 1_i
risperidone NN 1_o
's POS 1_o
safety NN 1_o
; : 1_o
efficacy NN 1_o
was VBD N
assessed VBN N
as IN N
a DT N
secondary JJ N
end-point NN N
. . N

RESULTS VB 1_p
Fifty-six NNP 1_p
( ( 1_p
71 CD 1_p
% NN 1_p
) ) 1_p
out IN 1_p
of IN 1_p
79 CD 1_p
enrolled JJ 1_p
patients NNS 1_p
completed VBD 1_p
the DT 1_p
OLE NNP 1_p
; : 1_p
the DT N
most RBS N
common JJ N
discontinuations NNS N
were VBD N
for IN N
insufficient JJ N
response NN N
( ( N
7 CD N
[ RB N
9 CD N
% NN N
] NN N
) ) N
or CC 1_o
adverse JJ 1_o
events NNS 1_o
( ( 1_o
AE NNP 1_o
) ) 1_o
( ( N
5 CD N
[ RB N
6 CD N
% NN N
] NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
( ( N
≥ JJ N
5 CD N
% NN N
frequency NN N
in IN N
the DT N
total JJ N
group NN 1_o
) ) 1_o
AEs NNP N
were VBD 1_o
increased VBN 1_o
appetite RB 1_o
( ( N
11 CD N
% NN N
[ JJ 1_o
n=9 JJ 1_o
] NN 1_o
) ) 1_o
; : 1_o
increased VBN 1_o
weight NN 1_o
and CC 1_o
vomiting NN 1_o
( ( N
9 CD N
% NN N
[ JJ N
n=7 JJ N
] NNP N
each DT 1_o
) ) 1_o
; : 1_o
sedation NN 1_o
, , 1_o
pyrexia NN 1_o
, , 1_o
and CC 1_o
upper JJ 1_o
respiratory NN 1_o
tract NN 1_o
infection NN 1_o
( ( N
8 CD N
% NN N
[ JJ N
n=6 JJ N
] NNP N
each DT 1_o
) ) 1_o
; : 1_o
nasopharyngitis NN 1_o
( ( N
6 CD N
% NN N
[ JJ N
n=5 JJ N
] NN N
) ) N
; : N
and CC 1_o
somnolence NN 1_o
and CC 1_o
fatigue NN 1_o
( ( N
5 CD N
% NN N
[ JJ N
n=4 JJ N
] NNP N
each DT 1_o
) ) 1_o
. . 1_o

Extrapyramidal JJ 1_o
AEs NNP N
were VBD N
reported VBN N
in IN N
6 CD N
( ( N
8 CD N
% NN N
) ) N
patients NNS 1_o
. . 1_o

Increase NNP 1_o
in IN 1_o
mean JJ 1_o
weight NN 1_o
( ( N
11-15 CD N
% NN N
) ) N
and CC 1_o
body NN 1_o
mass NN 1_o
index NN 1_o
( ( N
5-10 CD N
% NN N
) ) N
occurred VBD N
; : N
one CD N
patient NN N
discontinued VBN N
because IN 1_o
of IN 1_o
weight JJ 1_o
increase NN 1_o
. . N

One CD N
potentially RB 1_o
prolactin-related JJ 1_o
AE NNP 1_o
( ( 1_o
irregular JJ 1_o
menstruation NN 1_o
) ) 1_o
was VBD N
reported VBN N
. . N

The DT 1_i
risperidone NN 1_i
high-dose JJ N
group NN N
had VBD N
the DT N
greatest JJS 1_o
mean JJ 1_o
improvement NN 1_o
in IN 1_o
sleep JJ 1_o
visual JJ 1_o
analog NN 1_o
scale NN 1_o
( ( N
24.6 CD N
) ) N
. . N

All DT N
groups NNS N
showed VBD N
additional JJ N
improvement NN 1_o
in IN 1_o
efficacy NN 1_o
scale JJ 1_o
scores NNS 1_o
during IN N
the DT N
OLE NNP N
. . N

CONCLUSIONS NNP N
During IN N
this DT N
OLE NNP 1_o
, , 1_o
safety NN 1_o
findings NNS N
with IN 1_i
risperidone NN 1_i
treatment NN N
( ( N
maximum JJ N
weight-based JJ N
dose NN N
of IN N
1.25 CD N
mg/day NN N
or CC N
1.75 CD N
mg/day NN N
) ) N
were VBD N
consistent JJ N
with IN N
those DT N
observed VBN N
in IN N
the DT N
DB NNP N
phase NN N
, , N
and CC N
with IN N
the DT N
current JJ 1_o
safety NN 1_o
information NN N
for IN 1_i
risperidone NN 1_i
in IN N
autistic JJ N
, , N
psychiatric JJ N
, , N
and CC N
behavioral JJ N
disorders NNS N
. . N

Patients NNS N
experienced VBD N
some DT N
additional JJ N
improvement NN 1_o
in IN 1_o
irritability NN 1_o
and CC 1_o
related JJ 1_o
behaviors NNS 1_o
. . N

CLINICAL JJ N
TRIALS NNP N
REGISTRY NNP N
This DT N
phase-4 JJ N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
( ( N
NCT00576732 NNP N
) ) N
. . N

[ NN 1_o
Improving VBG 1_o
wound IN 1_o
healing VBG 1_o
after IN 1_p
nose JJ 1_p
surgery NN 1_p
by IN N
combined JJ N
administration NN N
of IN N
xylometazoline NNP 1_i
and CC N
dexpanthenol JJ 1_i
] NNP 1_i
. . N

BACKGROUND NNP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
examination NN N
of IN N
efficacy NN 1_o
and CC N
tolerability NN 1_o
of IN N
an DT N
application-form NN N
of IN N
the DT N
new JJ N
combination NN N
of IN N
Xylometazoline NN 1_i
with IN N
Dexpanthenol NNP 1_i
( ( 1_i
Nasic NNP 1_i
) ) 1_i
versus FW N
Xylometazoline NNP 1_i
alone RB 1_i
. . 1_i

PATIENTS NNP N
AND CC N
METHODS NNP N
Randomized NNP N
verum NN N
controlled VBD N
parallel-group-comparison NN N
of IN N
two CD N
weeks NNS N
treatment NN N
of IN N
a DT N
nasal-spray JJ N
. . N

61 CD 1_p
inpatients NNS 1_p
with IN 1_p
the DT 1_p
diagnosis NN 1_p
Rhinitis NNP 1_p
following VBG 1_p
nasal JJ 1_p
operation NN 1_p
were VBD N
included VBN N
in IN N
this DT N
study NN N
and CC N
30 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
verum NN 1_i
and CC N
placebo NN 1_i
each DT N
. . N

The DT N
assessment NN N
of IN N
nasal-breathing-resistance NN 1_o
according VBG 1_o
to TO 1_o
scores NNS 1_o
was VBD 1_o
defined VBN 1_o
as IN 1_o
target-parameter NN 1_o
. . 1_o

Confirmatory NNP N
statistical JJ N
analysis NN N
was VBD N
carried VBN N
out RP N
according VBG N
to TO N
Wilcoxon-Mann-Whitney-U JJ N
two-sided JJ N
at IN N
alpha JJ N
< NN N
or CC N
= $ N
0.05 CD N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
superiority NN 1_o
of IN N
the DT N
combination NN N
of IN N
Xylometazoline-Dexpanthenol JJ 1_i
nasal-spray JJ N
versus NN N
Xylometazoline NNP 1_i
nasal NN N
spray NN N
could MD N
be VB N
proven VBN N
for IN N
the DT N
target-parameter NN 1_o
as IN N
clinically RB N
relevant JJ N
and CC N
statistically RB N
significant JJ N
. . N

The DT N
clinically RB N
proven JJ N
efficacy NN 1_o
is VBZ N
emphasized VBN N
by IN N
good JJ N
tolerability NN 1_o
of IN N
both DT N
treatments NNS N
. . N

Due NNP N
to TO N
easy VB N
handling NN N
of IN N
the DT N
nasal-spray JJ N
a DT N
good JJ N
compliance NN 1_o
was VBD N
confirmed VBN N
. . N

CONCLUSION NNP N
Distinct NNP N
improvement NN 1_o
of IN N
symptoms NNS N
in IN N
patients NNS 1_p
following VBG 1_p
nasal JJ 1_p
operations NNS 1_p
underlines VBP N
the DT N
efficacy NN 1_o
of IN N
both DT N
medications NNS N
. . N

With IN N
respect NN N
to TO N
the DT N
tolerability NN 1_o
therapy NN N
with IN N
the DT N
combination NN N
is VBZ N
more RBR N
beneficial JJ N
in IN N
comparison NN N
to TO N
the DT N
alternative JJ N
therapy NN N
. . N

The DT N
result NN N
of IN N
this DT N
controlled VBN N
clinical JJ N
study NN N
confirms VBZ N
that IN N
the DT N
combination NN N
Xylometazoline-Dexpanthenol NNP 1_i
is VBZ N
an DT N
enlargement NN N
and CC N
improvement NN N
of IN N
effective JJ N
medicinal JJ N
treatment NN N
of IN N
rhinitis NN 1_p
following VBG 1_p
nasal JJ 1_p
operation NN 1_p
in IN N
comparison NN N
to TO N
therapy VB N
with IN N
Xylometazoline NNP 1_i
alone RB N
. . N

Effects NNS N
of IN N
cuff NN N
inflation NN N
on IN N
self-recorded JJ 1_o
blood NN 1_o
pressure NN 1_o
. . 1_o

Changes NNS N
in IN N
continuously RB 1_o
recorded VBN 1_o
'Finapres NNS 1_o
' POS 1_o
finger NN 1_o
blood NN 1_o
pressure NN 1_o
in IN N
ten JJ 1_p
normotensive JJ 1_p
and CC 1_p
seven CD 1_p
hypertensive JJ 1_p
subjects NNS 1_p
induced VBN N
by IN N
self-inflation NN 1_i
of IN 1_i
the DT 1_i
cuff NN 1_i
or CC N
just RB 1_i
wearing VBG 1_i
the DT 1_i
inflated JJ 1_i
cuff NN 1_i
were VBD N
studied VBN N
. . N

Inflating VBG 1_i
the DT 1_i
cuff NN 1_i
caused VBD N
an DT N
instantaneous JJ N
rise NN N
in IN N
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
of IN N
13 CD N
and CC N
12 CD N
mm NN N
Hg NNP N
( ( 1_p
hypertensive JJ 1_p
and CC 1_p
normotensive JJ 1_p
subjects NNS 1_p
, , N
respectively RB N
) ) N
. . N

Wearing VBG N
the DT N
inflated JJ 1_i
cuff NN 1_i
did VBD N
not RB N
change VB N
blood NN 1_o
pressure NN 1_o
. . 1_o

Thus VB N
the DT N
rise NN N
in IN N
pressure NN 1_o
was VBD N
related VBN N
to TO N
the DT N
muscular JJ N
activity NN N
required VBN N
for IN N
cuff NN 1_i
inflation NN 1_i
. . 1_i

Systolic NNP 1_o
blood NN 1_o
pressure NN 1_o
took VBD N
on IN N
average JJ N
7 CD N
s NN N
and CC N
at IN N
most JJS N
21 CD N
s NN N
to TO N
return VB N
to TO N
baseline VB N
level NN N
after IN N
stopping VBG N
cuff NN 1_i
inflation NN 1_i
. . 1_i

Since IN N
first JJ N
Korotkoff NNP N
sounds NNS N
may MD N
already RB N
be VB N
heard VBN N
after IN N
10-15 JJ N
s NN N
when WRB N
following VBG N
recommended VBD N
procedures NNS N
, , N
self-recorded JJ 1_o
systolic JJ 1_o
blood NN 1_o
pressure NN 1_o
may MD N
be VB N
recorded VBN N
as IN N
too RB N
high JJ N
when WRB N
subjects NNS N
inflate VBP 1_i
their PRP$ 1_i
cuff NN 1_i
at IN N
too RB N
low JJ N
a DT N
pressure NN N
or CC N
deflate VB N
it PRP N
too RB N
fast RB N
. . N

Prediction NN N
of IN N
creatinine JJ 1_o
clearance NN 1_o
from IN 1_o
serum JJ 1_o
creatinine NN 1_o
in IN N
patients NNS 1_p
with IN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
: : 1_p
comparison NN N
of IN N
six CD N
formulae NNS N
and CC N
one CD N
nomogram NN N
. . N

The DT N
estimation NN N
of IN N
glomerular JJ 1_o
filtration NN 1_o
rate NN 1_o
is VBZ N
important JJ N
for IN N
the DT N
medical JJ N
treatment NN N
of IN N
patients NNS 1_p
with IN 1_p
rheumatoid JJ 1_p
arthritis NN 1_p
( ( 1_p
RA NNP 1_p
) ) 1_p
. . 1_p

However RB N
, , N
the DT N
determination NN N
of IN N
endogenous JJ N
creatinine JJ N
clearance NN N
( ( N
Clcr NNP N
) ) N
from IN N
a DT N
24-h JJ N
urine JJ N
collection NN N
is VBZ N
an DT N
unreliable JJ N
and CC N
time-consuming JJ N
procedure NN N
. . N

We PRP N
therefore RB N
tested VBD N
the DT N
accuracy NN 1_o
of IN N
six CD N
equations NNS N
and CC N
one CD N
nomogram NN N
for IN N
the DT N
prediction NN 1_o
of IN 1_o
Clcr NNP 1_o
from IN 1_o
serum JJ 1_o
creatinine NN 1_o
( ( 1_o
Scr NNP 1_o
) ) 1_o
in IN N
38 CD 1_p
patients NNS 1_p
with IN 1_p
RA NNP 1_p
and CC 1_p
20 CD 1_p
controls NNS 1_p
. . 1_p

A DT N
positive JJ N
correlation NN 1_o
was VBD N
found VBN N
for IN N
all DT N
methods NNS N
in IN N
the DT N
controls NNS 1_p
( ( N
r VB N
= NNP N
0.83-0.94 NN N
) ) N
and CC N
RA NNP 1_p
patients NNS 1_p
( ( N
r JJ N
= NNP N
0.51-0.69 NN N
) ) N
. . N

The DT N
methods NNS N
did VBD N
not RB N
overestimate VB N
Clcr NNP N
in IN 1_p
RA NNP 1_p
. . 1_p

In IN N
the DT N
RA NNP 1_p
group NN 1_p
the DT N
simple JJ N
formula NN N
published VBN N
by IN N
Cockcroft NNP N
[ NNP N
Clcr NNP N
= NNP N
( ( N
( ( N
140 CD N
- : N
age NN N
) ) N
x VBZ N
body NN N
weight NN N
) ) N
/ NN N
( ( N
72 CD N
x NNP N
Scr NNP N
) ) N
, , N
x $ N
0.85 CD N
for IN N
females NNS N
] VBP N
showed VBD N
the DT N
best JJS N
correlation NN 1_o
with IN N
the DT N
measured VBN N
Clcr NNP N
. . N

In IN N
RA NNP 1_p
the DT N
Cockroft NNP N
formula NN N
can MD N
reliably RB N
be VB N
used VBN N
to TO N
predict VB 1_o
Clcr NNP 1_o
from IN 1_o
Scr NNP 1_o
. . 1_o

Experimental JJ N
hyaline NN N
membrane NN N
disease NN N
in IN N
the DT 1_p
premature NN 1_p
monkey NN 1_p
: : 1_p
effects NNS N
of IN N
antenatal JJ N
dexamethasone NN 1_i
. . 1_i

A DT N
blind NN N
, , N
randomized VBN N
trial NN N
of IN N
antenatal JJ N
glucocorticoid NN 1_i
treatment NN N
was VBD N
conducted VBN N
using VBG N
the DT N
premature NN 1_p
monkey NN 1_p
( ( 1_p
Macaca NNP 1_p
nemestrina RB 1_p
) ) 1_p
model NN 1_p
of IN 1_p
hyaline JJ 1_p
membrane NN 1_p
disease NN 1_p
( ( 1_p
HMD NNP 1_p
) ) 1_p
. . 1_p

Twelve NNP 1_p
dams VBZ 1_p
received VBN N
dexamethasone NN 1_i
( ( N
2 CD N
mg/dose NN N
) ) N
72 CD N
, , N
48 CD N
, , N
and CC N
24 CD N
h NN N
before IN N
abdominal JJ N
delivery NN N
at IN N
135 CD N
+/- JJ N
1 CD N
days NNS N
of IN N
gestation NN N
. . N

Twelve VB 1_p
control NN 1_p
animals NNS 1_p
received VBD N
saline JJ 1_i
. . 1_i

Infants NNS N
of IN N
dexamethasone-treated JJ 1_i
dams NNS N
had VBD N
significantly RB N
lower JJR N
incidence NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
HMD NNP 1_o
than IN N
did VBD N
infants NNS N
of IN N
control NN N
animals NNS N
( ( N
50 CD N
versus RB N
92 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Improvement JJ N
with IN N
treatment NN N
was VBD N
markedly RB N
greater JJR N
for IN N
males NNS N
than IN N
for IN N
females NNS N
. . N

Differences NNS N
in IN N
volume-pressure JJ 1_o
behavior NN 1_o
of IN N
the DT N
excised JJ N
lungs NNS N
included VBD N
greater JJR N
distensibility NN 1_o
in IN N
the DT N
infants NNS N
from IN N
dexamethasone-treated JJ 1_i
dams NNS N
( ( N
20.6 CD N
+/- JJ N
7.1 CD N
ml/g NN N
dry JJ N
lung NN N
versus IN N
14.7 CD N
+/- JJ N
6.1 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
enhanced JJ N
deflation NN 1_o
stability NN 1_o
with IN N
treatment NN N
. . N

Accelerated JJ N
production NN 1_o
of IN 1_o
surface NN 1_o
active JJ 1_o
material NN 1_o
( ( 1_o
SAM NNP 1_o
) ) 1_o
phospholipids NNS 1_o
in IN N
infants NNS N
from IN N
dexamethasone-treated JJ 1_i
dams NNS N
was VBD N
indicated VBN N
by IN N
increases NNS N
in IN N
total JJ 1_o
lung NN 1_o
phospholipid NN 1_o
( ( N
84.5 CD N
+/- JJ N
8.1 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
75.1 CD N
+/- JJ N
9.9 CD N
, , N
p NN N
less JJR N
than IN N
0.025 CD N
) ) N
, , N
alveolar JJ 1_o
lavage NN 1_o
fluid NN 1_o
phospholipid NN 1_o
( ( N
5.65 CD N
+/- JJ N
3.33 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
3.01 CD N
+/- JJ N
1.84 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
and CC N
alveolar JJ 1_o
lavage NN 1_o
fluid NN 1_o
disaturated VBN 1_o
phosphatidylcholine NN 1_o
( ( N
DPC NNP N
) ) N
( ( N
2.47 CD N
+/- JJ N
1.84 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
1.06 CD N
+/- JJ N
1.05 CD N
, , N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Incorporation NN N
of IN N
14C-palmitate JJ 1_o
into IN N
lung NN 1_o
lipid NN 1_o
was VBD N
not RB N
influenced VBN N
by IN N
dexamethasone NN 1_i
, , N
but CC N
a DT N
significantly RB N
greater JJR N
portion NN N
of IN N
the DT N
label NN N
appeared VBD N
in IN N
the DT N
DPC NNP 1_o
fraction NN 1_o
with IN N
treatment NN N
. . N

Antenatal NNP N
dexamethasone NN 1_i
treatment NN N
was VBD N
successful JJ N
in IN N
reducing VBG N
the DT N
incidence NN 1_o
and CC 1_o
severity NN 1_o
of IN 1_o
experimental JJ 1_o
HMD NNP 1_o
in IN 1_p
this DT 1_p
animal JJ 1_p
model NN 1_p
; : 1_p
the DT N
beneficial JJ N
effects NNS 1_o
of IN N
treatment NN N
were VBD N
associated VBN N
with IN N
accelerated JJ N
maturation NN N
of IN N
fetal JJ 1_o
pulmonary JJ 1_o
functions NNS 1_o
, , N
including VBG N
, , N
but CC N
not RB N
limited JJ N
to TO N
, , N
synthetic JJ N
metabolism NN N
of IN N
SAM NNP N
phospholipid NN N
. . N

Sensory NNP 1_i
Adapted NNP 1_i
Dental NNP 1_i
Environments NNP 1_i
to TO N
Enhance VB N
Oral NNP N
Care NNP N
for IN N
Children NNP 1_p
with IN 1_p
Autism NNP 1_p
Spectrum NNP 1_p
Disorders NNPS 1_p
: : 1_p
A DT N
Randomized NNP N
Controlled NNP N
Pilot NNP N
Study NNP N
. . N

This DT N
pilot NN N
and CC N
feasibility NN N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
a DT N
sensory JJ 1_i
adapted JJ 1_i
dental NN 1_i
environment NN 1_i
( ( 1_i
SADE NNP 1_i
) ) 1_i
to TO N
reduce VB N
distress NN 1_o
, , 1_o
sensory JJ 1_o
discomfort NN 1_o
, , 1_o
and CC 1_o
perception NN 1_o
of IN 1_o
pain NN 1_o
during IN N
oral JJ N
prophylaxis NN N
for IN N
children NNS 1_p
with IN 1_p
autism NN 1_p
spectrum NN 1_p
disorder NN 1_p
( ( 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

Participants NNS 1_p
were VBD 1_p
44 CD 1_p
children NNS 1_p
ages VBZ 1_p
6-12 NN 1_p
( ( 1_p
n JJ 1_p
= $ 1_p
22 CD 1_p
typical JJ 1_p
, , 1_p
n JJ 1_p
= FW 1_p
22 CD 1_p
ASD NNP 1_p
) ) 1_p
. . 1_p

In IN N
an DT N
experimental JJ N
crossover NN N
design NN N
, , N
each DT N
participant JJ N
underwent JJ N
two CD N
professional JJ N
dental JJ N
cleanings NNS N
, , N
one CD N
in IN N
a DT N
regular JJ 1_i
dental NN 1_i
environment NN 1_i
( ( 1_i
RDE NNP 1_i
) ) 1_i
and CC N
one CD N
in IN N
a DT N
SADE NNP 1_i
, , N
administered VBN N
in IN N
a DT N
randomized JJ N
and CC N
counterbalanced JJ N
order NN N
3-4 JJ N
months NNS N
apart RB N
. . N

Outcomes NNP N
included VBD N
measures NNS N
of IN N
physiological JJ 1_o
anxiety NN 1_o
, , 1_o
behavioral JJ 1_o
distress NN 1_o
, , 1_o
pain NN 1_o
intensity NN 1_o
, , 1_o
and CC 1_o
sensory JJ 1_o
discomfort NN 1_o
. . 1_o

Both DT N
groups NNS N
exhibited VBD N
decreased JJ N
physiological JJ 1_o
anxiety NN 1_o
and CC N
reported VBD N
lower JJR N
pain NN 1_o
and CC 1_o
sensory JJ 1_o
discomfort NN 1_o
in IN N
the DT N
SADE NNP 1_i
condition NN N
compared VBN N
to TO N
RDE NNP 1_i
, , N
indicating VBG N
a DT N
beneficial JJ N
effect NN N
of IN N
the DT N
SADE NNP 1_i
. . 1_i

Fluoroscopic NNP 1_o
functional JJ 1_o
evaluation NN 1_o
of IN N
bileaflet NN 1_i
prostheses NNS 1_i
: : 1_i
effect NN N
of IN N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
. . N

Fluoroscopy NNP N
is VBZ N
a DT N
reliable JJ N
, , N
easy JJ N
, , N
and CC N
readily RB N
available JJ N
technique NN N
to TO N
follow-up JJ N
prosthesis NN N
functioning NN N
after IN N
heart NN N
valve NN N
surgery NN N
. . N

The DT N
different JJ N
orientation NN N
given VBN N
to TO N
the DT N
prosthesis NN 1_i
may MD N
represent VB N
a DT N
limitation NN N
of IN N
the DT N
technique NN N
accounting NN N
for IN N
unsatisfactory JJ N
results NNS N
in IN N
10 CD N
% NN N
to TO N
40 CD N
% NN N
of IN N
the DT N
cases NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
and CC N
to TO N
what WP N
extent VB N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
influence NN N
feasibility NN 1_o
and CC N
accuracy NN 1_o
of IN N
postoperative JJ 1_o
fluoroscopic JJ 1_o
evaluation NN 1_o
of IN N
bileaflet NN 1_i
prostheses NNS 1_i
. . 1_i

We PRP N
prospectively RB N
evaluated VBD N
90 CD 1_p
patients NNS 1_p
who WP 1_p
had VBD 1_p
aortic JJ 1_p
, , 1_p
mitral JJ 1_p
, , 1_p
and/or JJ 1_p
tricuspid JJ 1_p
valve FW 1_p
replacement NN 1_p
with IN 1_p
Sorin NNP 1_i
Bicarbon NNP 1_i
or CC 1_i
CarboMedics NNPS 1_i
bileaflet NN 1_i
prostheses NNS 1_i
. . 1_i

Fifty NNP N
percent NN N
of IN N
the DT N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
prostheses NNS 1_i
oriented VBN N
in IN N
a DT N
perpendicular NN N
or CC N
a DT N
parallel JJ N
position NN N
with IN N
respect NN N
to TO N
the DT N
ventricular JJ N
septum NN N
. . N

Fluoroscopic NNP 1_o
evaluation NN 1_o
was VBD N
considered VBN N
appropriate JJ N
when WRB N
the DT N
prosthesis NN 1_i
' POS 1_i
" JJ N
tilting VBG N
disk NN N
" NNP N
projection NN N
was VBD N
obtained VBN N
. . N

The DT N
valve NN 1_o
's POS 1_o
hemodynamic JJ 1_o
performance NN 1_o
was VBD 1_o
investigated VBN 1_o
through IN 1_o
Doppler NNP 1_o
study NN 1_o
. . 1_o

A DT N
proper JJ N
fluoroscopic NN 1_o
evaluation NN 1_o
was VBD N
rapidly RB N
( ( N
15 CD N
+/- JJ N
5 CD N
seconds NNS N
) ) N
achieved VBN N
in IN N
all DT N
patients NNS N
with IN N
the DT N
former JJ N
orientation NN N
, , N
whereas IN N
it PRP N
was VBD N
impossible JJ N
to TO N
obtain VB N
it PRP N
in IN N
8 CD N
of IN N
20 CD N
( ( N
40 CD N
% NN N
) ) N
, , N
19 CD N
of IN N
20 CD N
( ( N
95 CD N
% NN N
) ) N
, , N
and CC N
4 CD N
of IN N
5 CD N
( ( N
80 CD N
% NN N
) ) N
of IN N
patients NNS N
with IN N
the DT N
latter JJ N
orientation NN N
. . N

In IN N
the DT N
remaining VBG N
patients NNS N
extremely RB N
angulated VBN N
, , N
uneasy JJ N
projection NN N
was VBD N
often RB N
required VBN N
to TO N
get VB N
a DT N
correct JJ N
fluoroscopic NN N
image NN N
. . N

The DT N
Doppler NNP N
study NN N
showed VBD N
a DT N
similarly RB N
favorable JJ N
hemodynamic JJ 1_o
performance NN 1_o
regardless NN N
of IN N
valve JJ N
orientation NN N
. . N

Prosthesis NNP 1_i
orientation NN N
crucially RB N
affects VBZ N
the DT N
rate NN 1_o
of IN 1_o
success NN 1_o
of IN 1_o
the DT 1_o
fluoroscopic JJ 1_o
evaluation NN 1_o
. . 1_o

The DT N
orientation NN N
perpendicular NN N
to TO N
the DT N
ventricular JJ N
septum NN N
greatly RB N
facilitates VBZ N
the DT N
postoperative JJ N
feasibility NN 1_o
and CC 1_o
accuracy NN 1_o
of IN 1_o
fluoroscopy NN 1_o
, , N
and CC N
it PRP N
is VBZ N
not RB N
detrimental JJ N
to TO N
the DT N
valve NN 1_o
's POS 1_o
hemodynamic JJ 1_o
performance NN 1_o
. . 1_o

This DT N
valve JJ N
orientation NN N
may MD N
provide VB N
a DT N
better JJR N
fluoroscopic NN 1_o
window NN N
whenever WRB N
a DT N
valve NN N
dysfunction NN N
is VBZ N
suspected VBN N
. . N

